{"docstore/data": {"47c5a99a-eb44-46ea-ac60-14415645b32e": {"__data__": {"id_": "47c5a99a-eb44-46ea-ac60-14415645b32e", "embedding": null, "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded. ", "original_text": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "690cb2ea-4aa0-4966-ac82-c080e8951c0a", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran. ", "original_text": "Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc. "}, "hash": "3399a657ea27f0c28c2dde924a8beeb366f4cf0b16417aded474809e10ba755f", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "690cb2ea-4aa0-4966-ac82-c080e8951c0a": {"__data__": {"id_": "690cb2ea-4aa0-4966-ac82-c080e8951c0a", "embedding": null, "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran. ", "original_text": "Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47c5a99a-eb44-46ea-ac60-14415645b32e", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded. ", "original_text": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a03f69c792074093642c2d54b062f1089271cb9b7daf0b718461876bd19d328", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e59078f-2bfe-4211-a07a-fad3fb6ac28a", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n", "original_text": "Third Quarter Fiscal Year 2020 \nEarnings  Conference Call. "}, "hash": "9b478e173cab0dcf7e857d29db27d339dec375c2d37f28807432153d20a1d365", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc. ", "start_char_idx": 48, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e59078f-2bfe-4211-a07a-fad3fb6ac28a": {"__data__": {"id_": "8e59078f-2bfe-4211-a07a-fad3fb6ac28a", "embedding": null, "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n", "original_text": "Third Quarter Fiscal Year 2020 \nEarnings  Conference Call. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "690cb2ea-4aa0-4966-ac82-c080e8951c0a", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran. ", "original_text": "Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1cb8720fca82247380983d9c97aa248e15f894b25d342e3ee4751cc7b469d7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff1ed46f-c758-4be5-9c81-9be58ae9827f", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning. ", "original_text": "Today's conference is being recorded. "}, "hash": "ec143b399057d5144f8d9025962e8e5f3b03ff807d3ba79be8906b75cbeea7d4", "class_name": "RelatedNodeInfo"}}, "text": "Third Quarter Fiscal Year 2020 \nEarnings  Conference Call. ", "start_char_idx": 174, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff1ed46f-c758-4be5-9c81-9be58ae9827f": {"__data__": {"id_": "ff1ed46f-c758-4be5-9c81-9be58ae9827f", "embedding": null, "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e59078f-2bfe-4211-a07a-fad3fb6ac28a", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n", "original_text": "Third Quarter Fiscal Year 2020 \nEarnings  Conference Call. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd6844e6ab5d544a2afed0fbf69bc76ac302af5ae60991c9c255ef8b269813eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "846764b5-7124-4336-b239-b506e1d38ee1", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations. ", "original_text": "At this time, I would like to turn the \nconference over to  Kevin Moran. "}, "hash": "4df813f5357d3b1b3413cfeea5cc2ed2cc8259c8a4abe65065a95bbbabb99373", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 233, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "846764b5-7124-4336-b239-b506e1d38ee1": {"__data__": {"id_": "846764b5-7124-4336-b239-b506e1d38ee1", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations. ", "original_text": "At this time, I would like to turn the \nconference over to  Kevin Moran. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff1ed46f-c758-4be5-9c81-9be58ae9827f", "node_type": "1", "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d3987d617d6cdbbb5beb490c1940218c133ba346398866c3cc18d3bc7eea51b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "711bf7b3-b259-486f-a475-6f5f76afe506", "node_type": "1", "metadata": {"window": "Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n", "original_text": "Please go ahead.  \n \n"}, "hash": "09b2343b54254674d893ef78b4252acf66497f6bc798df6e771cf62c81aa82b5", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the \nconference over to  Kevin Moran. ", "start_char_idx": 271, "end_char_idx": 344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "711bf7b3-b259-486f-a475-6f5f76afe506": {"__data__": {"id_": "711bf7b3-b259-486f-a475-6f5f76afe506", "embedding": null, "metadata": {"window": "Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "846764b5-7124-4336-b239-b506e1d38ee1", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations. ", "original_text": "At this time, I would like to turn the \nconference over to  Kevin Moran. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db129dcbefc451cb23c345bd517f4b53dc20ff0c77f38e5403c0c583c5ecf6b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52be385d-b5a3-42e8-a979-3ae8790f7bfd", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer. ", "original_text": "Kevin Moran:  \nGood morning. "}, "hash": "ec8e7718fd7764cfe1e33150dca2fd21b173a2dff6f2ec00c36432b37a4461cf", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 344, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52be385d-b5a3-42e8-a979-3ae8790f7bfd": {"__data__": {"id_": "52be385d-b5a3-42e8-a979-3ae8790f7bfd", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer. ", "original_text": "Kevin Moran:  \nGood morning. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "711bf7b3-b259-486f-a475-6f5f76afe506", "node_type": "1", "metadata": {"window": "Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d83c21a370b84e5409be4394bf7ee50931fcc87add215def34ff9c0a20cfa3c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a1e5e52-3282-49be-9335-dca9c048d947", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n", "original_text": "This is Kevin Moran, Vice President of Investor Relations. "}, "hash": "b53ff0197b8cfd9782826f1d5edffc533841959bf3af62a229dd3ba5f1c84887", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nGood morning. ", "start_char_idx": 365, "end_char_idx": 394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a1e5e52-3282-49be-9335-dca9c048d947": {"__data__": {"id_": "5a1e5e52-3282-49be-9335-dca9c048d947", "embedding": null, "metadata": {"window": "At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n", "original_text": "This is Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52be385d-b5a3-42e8-a979-3ae8790f7bfd", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer. ", "original_text": "Kevin Moran:  \nGood morning. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b254d771a40f93c89fc1840b88001912cd3f140a7713c98506a3000ae903e2b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccf7ff9f-485f-4413-a386-121b695907c7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements. ", "original_text": "We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n"}, "hash": "4e33b88adefab4a886f46d9b0e1913f7335c85ba7f9830af57ade20d9e59db95", "class_name": "RelatedNodeInfo"}}, "text": "This is Kevin Moran, Vice President of Investor Relations. ", "start_char_idx": 394, "end_char_idx": 453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccf7ff9f-485f-4413-a386-121b695907c7": {"__data__": {"id_": "ccf7ff9f-485f-4413-a386-121b695907c7", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements. ", "original_text": "We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a1e5e52-3282-49be-9335-dca9c048d947", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the \nconference over to  Kevin Moran.  Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n", "original_text": "This is Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92e3cb2772f1f93a48987bf00481a526698797d4478032f7f6516adc6372682b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b69904dc-6f3c-45f0-b520-87c090fffd81", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied. ", "original_text": "Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer. "}, "hash": "7118198e3842bff8d7f06ecc33d1df80edf7a87c2d948bbe2d3e6916eea8d9b2", "class_name": "RelatedNodeInfo"}}, "text": "We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n", "start_char_idx": 453, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b69904dc-6f3c-45f0-b520-87c090fffd81": {"__data__": {"id_": "b69904dc-6f3c-45f0-b520-87c090fffd81", "embedding": null, "metadata": {"window": "Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied. ", "original_text": "Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccf7ff9f-485f-4413-a386-121b695907c7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements. ", "original_text": "We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff207533d2a14074d19ded80ad70b747e16ad1825a91790441be6d8736ba834e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c97f1a92-7662-4a4c-8806-6d479f641aed", "node_type": "1", "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n", "original_text": "You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n"}, "hash": "4d59daa5f027d4b0a574676af0a4f628ddb7d4d964b951630d71f78646fbeaa6", "class_name": "RelatedNodeInfo"}}, "text": "Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer. ", "start_char_idx": 672, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c97f1a92-7662-4a4c-8806-6d479f641aed": {"__data__": {"id_": "c97f1a92-7662-4a4c-8806-6d479f641aed", "embedding": null, "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n", "original_text": "You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b69904dc-6f3c-45f0-b520-87c090fffd81", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nGood morning.  This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied. ", "original_text": "Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abf4cf002edc93fa561640fa33e1eb1bf24034f7196ae9ebf7eef1f6d2bcfdc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e53f4588-d725-437c-b0b4-7a03999a1a0f", "node_type": "1", "metadata": {"window": "We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. "}, "hash": "f1966b8e5d9fd656e076055e805228351e1fb70f86aa6ed37a192a59db48ac89", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n", "start_char_idx": 848, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e53f4588-d725-437c-b0b4-7a03999a1a0f": {"__data__": {"id_": "e53f4588-d725-437c-b0b4-7a03999a1a0f", "embedding": null, "metadata": {"window": "We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c97f1a92-7662-4a4c-8806-6d479f641aed", "node_type": "1", "metadata": {"window": "This is Kevin Moran, Vice President of Investor Relations.  We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n", "original_text": "You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "700bf56d7f2b64f763f88987912250362ca92cf49691162cd2856e9d5d56d4b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "829525ed-a150-4bf8-8a40-690985afc94c", "node_type": "1", "metadata": {"window": "Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n", "original_text": "The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied. "}, "hash": "723f91ce21c639d7421fe8d47bcbdba52f2ea90b96d3b2b7eaf799cdce543503", "class_name": "RelatedNodeInfo"}}, "text": "During the call, we will be making forward -looking statements. ", "start_char_idx": 963, "end_char_idx": 1027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "829525ed-a150-4bf8-8a40-690985afc94c": {"__data__": {"id_": "829525ed-a150-4bf8-8a40-690985afc94c", "embedding": null, "metadata": {"window": "Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n", "original_text": "The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e53f4588-d725-437c-b0b4-7a03999a1a0f", "node_type": "1", "metadata": {"window": "We hope that you and your \nloved ones  are healthy and safe, and we thank  you for joining us as we discuss Cardinal Health's \nthird quarter fiscal 2020  results and expectations for the remainder of the fiscal year.  \n Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c419bb7ce7307c9c914d33f2ac96047ed03c2104f34b4f071578f449408f7ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aede73da-2713-45b4-ac7b-bd7b4d482f32", "node_type": "1", "metadata": {"window": "You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials. ", "original_text": "Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n"}, "hash": "0433846a103c301b03349ce0ab7dbd2fa78146da5bc739f251dca34c53af8206", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied. ", "start_char_idx": 1027, "end_char_idx": 1201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aede73da-2713-45b4-ac7b-bd7b4d482f32": {"__data__": {"id_": "aede73da-2713-45b4-ac7b-bd7b4d482f32", "embedding": null, "metadata": {"window": "You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials. ", "original_text": "Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "829525ed-a150-4bf8-8a40-690985afc94c", "node_type": "1", "metadata": {"window": "Joining me on the call today are Mike Kaufmann, Chief Executive Officer, Dave Evans, Interim Chief \nFinancial  Office r and Jason Hollar, our Incoming Chief Financial Officer.  You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n", "original_text": "The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be24707443c6b2b219ce53571328ce6b75d07949c928938e151c5d58363464dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c85ef088-5d3c-4786-ab59-831cf32fb740", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change. ", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP. "}, "hash": "f1c296b87f43177ef084bdf3ee826dff9b69fe88e38267744653b7e096cce229", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n", "start_char_idx": 1201, "end_char_idx": 1369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c85ef088-5d3c-4786-ab59-831cf32fb740": {"__data__": {"id_": "c85ef088-5d3c-4786-ab59-831cf32fb740", "embedding": null, "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change. ", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aede73da-2713-45b4-ac7b-bd7b4d482f32", "node_type": "1", "metadata": {"window": "You can find today's press \nrelease and  presentation on the IR section of our website at ir.cardinalhealth.com.  \n During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials. ", "original_text": "Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50ca68165a49a538dd1250432de8b90ed0b4199f9a9b39fb283bf472b9ff6570", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b147ee21-1125-42d9-9a6a-05f027b4eb28", "node_type": "1", "metadata": {"window": "The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n"}, "hash": "e77c71f08402b96bf9b3b4c978407eef5cdd64e661106b48bd58f3767e07df38", "class_name": "RelatedNodeInfo"}}, "text": "Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP. ", "start_char_idx": 1369, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b147ee21-1125-42d9-9a6a-05f027b4eb28": {"__data__": {"id_": "b147ee21-1125-42d9-9a6a-05f027b4eb28", "embedding": null, "metadata": {"window": "The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c85ef088-5d3c-4786-ab59-831cf32fb740", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change. ", "original_text": "Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb8f6d5e830ff4b2b4f611fc438980834bb27f2934789efe68c62fea00eaac5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7bec4fc-bcfe-4225-907e-67b54d91a775", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials. "}, "hash": "c2bbfe42b99f6b4edda86aee67340500999bd295b7ece53e357734796726740e", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n", "start_char_idx": 1509, "end_char_idx": 1634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7bec4fc-bcfe-4225-907e-67b54d91a775": {"__data__": {"id_": "a7bec4fc-bcfe-4225-907e-67b54d91a775", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b147ee21-1125-42d9-9a6a-05f027b4eb28", "node_type": "1", "metadata": {"window": "The matters addressed in  the \nstatements are  subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or  implied.  Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9613915f9154cc624cdcaa2511c215e8a3cf2ff76f4319060036e50a26a58fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc8c5def-8e00-47a3-bb82-4417b92bdd25", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change. "}, "hash": "f527bde1b6ea773fa36b68988f7068a3716c0d78a8b4d8d0e1dceb710185bc0c", "class_name": "RelatedNodeInfo"}}, "text": "As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials. ", "start_char_idx": 1634, "end_char_idx": 1820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc8c5def-8e00-47a3-bb82-4417b92bdd25": {"__data__": {"id_": "dc8c5def-8e00-47a3-bb82-4417b92bdd25", "embedding": null, "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7bec4fc-bcfe-4225-907e-67b54d91a775", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statements \nslide at the beginning of our  presentation f or a description of these risks and uncertainties.  \n Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "193d091e0cb0ba2f2e5cfa6d6ec31653e570d3062a59491745717d8a697596c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "829e6ccb-219e-46c9-9210-bebb656a458f", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "The remaining time will be available for "}, "hash": "13a612236c8c4f554d57b02386f4e06a3941505b282ddbbf4fc875ff622c89ba", "class_name": "RelatedNodeInfo"}}, "text": "Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change. ", "start_char_idx": 1820, "end_char_idx": 1993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "829e6ccb-219e-46c9-9210-bebb656a458f": {"__data__": {"id_": "829e6ccb-219e-46c9-9210-bebb656a458f", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "The remaining time will be available for ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efdaacc1f8366966cf3acd9f892c037d6a97bdfbed663d9ea5006b046ad24c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc8c5def-8e00-47a3-bb82-4417b92bdd25", "node_type": "1", "metadata": {"window": "Please note that during the discussion today, our comments will be on a non -GAAP basis, unless \nthey are  specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11021bcf40eb026eeee6c4c1215a454d7771551bf5fa662f7ab1e0b5c4647188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26a36ef8-9269-49a2-8276-9e68c12a6dc4", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin. ", "original_text": " \nPage 2 of 31 \n \nyour questions. "}, "hash": "a2adf2fa8b8a3cc7651f81676f0140dfe0fe60fb693471c8301a7b228cd0ad7e", "class_name": "RelatedNodeInfo"}}, "text": "The remaining time will be available for ", "start_char_idx": 1993, "end_char_idx": 2034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26a36ef8-9269-49a2-8276-9e68c12a6dc4": {"__data__": {"id_": "26a36ef8-9269-49a2-8276-9e68c12a6dc4", "embedding": null, "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin. ", "original_text": " \nPage 2 of 31 \n \nyour questions. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "829e6ccb-219e-46c9-9210-bebb656a458f", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be fou nd in the  schedules attached to our press release.  \n As far as the agenda for today, Mike will start off by sharing Cardinal Health's response to the \nCOVID -19 pandemic before turning the call over to Dave, who will cover the financials.  Jason will \nbriefly in troduce himself  and then Mike will share some perspectives on our mid - and longer -term \nstrategies as we navigate this time of  tremendous change.  The remaining time will be available for ", "original_text": "The remaining time will be available for ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0c8c2f5b66525037d78475bb41365dde0b6c58f089d7617925c0294e47fddd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9adda905-9082-4ad4-895b-307be315f9d1", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us. ", "original_text": "During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n"}, "hash": "6d03eb810bef3a7d24b2a534ba51befefe1f46abc8854b152335408a5c6182a0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 31 \n \nyour questions. ", "start_char_idx": 0, "end_char_idx": 34, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9adda905-9082-4ad4-895b-307be315f9d1": {"__data__": {"id_": "9adda905-9082-4ad4-895b-307be315f9d1", "embedding": null, "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us. ", "original_text": "During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26a36ef8-9269-49a2-8276-9e68c12a6dc4", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin. ", "original_text": " \nPage 2 of 31 \n \nyour questions. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bc0646630845ea0125e544ba3b858340d59a2ab6d3390fc61fff515218ebfcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "578a5c69-c3ac-4b4b-b6de-035d7c802a5e", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n", "original_text": "With that, I'll now turn the call over to Mike.  \n  \n"}, "hash": "0ace65364db4f59a4f3b0b65be43cd765ebff02432378362bb4576c9c2ee8bbe", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n", "start_char_idx": 34, "end_char_idx": 171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "578a5c69-c3ac-4b4b-b6de-035d7c802a5e": {"__data__": {"id_": "578a5c69-c3ac-4b4b-b6de-035d7c802a5e", "embedding": null, "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n", "original_text": "With that, I'll now turn the call over to Mike.  \n  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9adda905-9082-4ad4-895b-307be315f9d1", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us. ", "original_text": "During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52c7664826b5416e8124d892a8bac43bc9729a66c463fc9e045ff478b8d4850b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa852383-154e-4103-8aec-9250751934dd", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers . ", "original_text": "Michael C. Kaufmann:  \nThanks, Kevin. "}, "hash": "a38775b16be678241d230f18dce2d6c69ec55503375d7325c04b4cafba37c875", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll now turn the call over to Mike.  \n  \n", "start_char_idx": 171, "end_char_idx": 224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa852383-154e-4103-8aec-9250751934dd": {"__data__": {"id_": "aa852383-154e-4103-8aec-9250751934dd", "embedding": null, "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers . ", "original_text": "Michael C. Kaufmann:  \nThanks, Kevin. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "578a5c69-c3ac-4b4b-b6de-035d7c802a5e", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n", "original_text": "With that, I'll now turn the call over to Mike.  \n  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a9d94794c5beec10e3b67920f46b7ff14740fa28cd71caf4c836a0c16b41aba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f2e560a-3b20-44aa-87ae-3dc576fef4c4", "node_type": "1", "metadata": {"window": "During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n", "original_text": "Good morning to everyone joining us. "}, "hash": "8699811a703f027cdf1162c5de6141ce19342329c3eb83c50939ff8466d1dc0d", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nThanks, Kevin. ", "start_char_idx": 224, "end_char_idx": 262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f2e560a-3b20-44aa-87ae-3dc576fef4c4": {"__data__": {"id_": "9f2e560a-3b20-44aa-87ae-3dc576fef4c4", "embedding": null, "metadata": {"window": "During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n", "original_text": "Good morning to everyone joining us. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa852383-154e-4103-8aec-9250751934dd", "node_type": "1", "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers . ", "original_text": "Michael C. Kaufmann:  \nThanks, Kevin. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0869626e35c3399e4898c67b430177e0f3b4ffaee2f6eede57cfa5094570a58e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa3158aa-2327-4d81-9765-545930f325c1", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority. ", "original_text": "I hope you and your families are safe and well.  \n"}, "hash": "bebb0ff7516b797bbb447f7094bad5a823b366a778c6f27dc667bda7f9aabcbf", "class_name": "RelatedNodeInfo"}}, "text": "Good morning to everyone joining us. ", "start_char_idx": 262, "end_char_idx": 299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa3158aa-2327-4d81-9765-545930f325c1": {"__data__": {"id_": "fa3158aa-2327-4d81-9765-545930f325c1", "embedding": null, "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority. ", "original_text": "I hope you and your families are safe and well.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f2e560a-3b20-44aa-87ae-3dc576fef4c4", "node_type": "1", "metadata": {"window": "During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n", "original_text": "Good morning to everyone joining us. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02fe48edaaa3c9821753a9e8e383e43106eccd1f2a4f40255c131a905ad4b7ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25465d55-1aaf-4e1a-a402-d046f474555b", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations. ", "original_text": "These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers . "}, "hash": "c34ac3c19be010b18ca0e31bfe6ffad63fb34ecf98205dfe1b786b1f2749d5d5", "class_name": "RelatedNodeInfo"}}, "text": "I hope you and your families are safe and well.  \n", "start_char_idx": 299, "end_char_idx": 349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25465d55-1aaf-4e1a-a402-d046f474555b": {"__data__": {"id_": "25465d55-1aaf-4e1a-a402-d046f474555b", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations. ", "original_text": "These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers . ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa3158aa-2327-4d81-9765-545930f325c1", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority. ", "original_text": "I hope you and your families are safe and well.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dad528543fe40b84242a00f1d5eff7fbd673d38645b381ab93e1b820b3352b4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d70d74e5-3107-4c2d-9446-7ac770a55bd7", "node_type": "1", "metadata": {"window": "Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n", "original_text": "As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n"}, "hash": "05a06cc1017b492b8736f511067fa0ada1d2040cdb15da602d75a7cd710ef793", "class_name": "RelatedNodeInfo"}}, "text": "These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers . ", "start_char_idx": 349, "end_char_idx": 510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d70d74e5-3107-4c2d-9446-7ac770a55bd7": {"__data__": {"id_": "d70d74e5-3107-4c2d-9446-7ac770a55bd7", "embedding": null, "metadata": {"window": "Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n", "original_text": "As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25465d55-1aaf-4e1a-a402-d046f474555b", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nThanks, Kevin.  Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations. ", "original_text": "These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers . ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce389dd08e175a8b9215811510f592908f138ef4daf8e88e5895bd03d7087ba1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da97ab2b-20bb-43b3-8c62-9fad83a36a12", "node_type": "1", "metadata": {"window": "I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity. ", "original_text": "Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority. "}, "hash": "63c6eeb7438cf3514f11ea62b3914a7c9c887b0eded80ae47f32835e736bb3fd", "class_name": "RelatedNodeInfo"}}, "text": "As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n", "start_char_idx": 510, "end_char_idx": 716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da97ab2b-20bb-43b3-8c62-9fad83a36a12": {"__data__": {"id_": "da97ab2b-20bb-43b3-8c62-9fad83a36a12", "embedding": null, "metadata": {"window": "I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity. ", "original_text": "Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d70d74e5-3107-4c2d-9446-7ac770a55bd7", "node_type": "1", "metadata": {"window": "Good morning to everyone joining us.  I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n", "original_text": "As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e8ae634b7e0b1e79a98a68c81cabbbf45682f5e00ddd3066e0f9285b2d6e4fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de6748f0-1b20-45db-90be-6c6872dc0e4f", "node_type": "1", "metadata": {"window": "These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products. ", "original_text": "To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations. "}, "hash": "9686b6b6f9b00dac398c162534c7e59130d525953b5d6fb23c6c59344e8098de", "class_name": "RelatedNodeInfo"}}, "text": "Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority. ", "start_char_idx": 716, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de6748f0-1b20-45db-90be-6c6872dc0e4f": {"__data__": {"id_": "de6748f0-1b20-45db-90be-6c6872dc0e4f", "embedding": null, "metadata": {"window": "These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products. ", "original_text": "To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da97ab2b-20bb-43b3-8c62-9fad83a36a12", "node_type": "1", "metadata": {"window": "I hope you and your families are safe and well.  \n These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity. ", "original_text": "Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5e768155d955684da32cd0fa37184ba2091a25bebe300370dd25f0de73513d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9affa75-974a-4844-a58d-cb7b6c6bd627", "node_type": "1", "metadata": {"window": "As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n", "original_text": "And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n"}, "hash": "98e5522f5f7fa356d98dca012d4185831aae84782d8a061cecff0b41b20a0ffc", "class_name": "RelatedNodeInfo"}}, "text": "To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations. ", "start_char_idx": 815, "end_char_idx": 951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9affa75-974a-4844-a58d-cb7b6c6bd627": {"__data__": {"id_": "e9affa75-974a-4844-a58d-cb7b6c6bd627", "embedding": null, "metadata": {"window": "As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n", "original_text": "And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de6748f0-1b20-45db-90be-6c6872dc0e4f", "node_type": "1", "metadata": {"window": "These past  several weeks, we've had a heightened focus on both keeping our Cardinal Health family \nhealthy and safe and on  effectively serving our customers .  As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products. ", "original_text": "To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d2769ee77afb0c1cbf933ae46da15f3b269e53ecd9f20e8d3a0673da1de3d61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "207a37e8-a96e-4e47-810c-fa232779d0dc", "node_type": "1", "metadata": {"window": "Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities. ", "original_text": "As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity. "}, "hash": "803bf1bd1c15c602fbea90f3731743c53e67348392378ef74827adaf739423e3", "class_name": "RelatedNodeInfo"}}, "text": "And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n", "start_char_idx": 951, "end_char_idx": 1055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "207a37e8-a96e-4e47-810c-fa232779d0dc": {"__data__": {"id_": "207a37e8-a96e-4e47-810c-fa232779d0dc", "embedding": null, "metadata": {"window": "Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities. ", "original_text": "As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9affa75-974a-4844-a58d-cb7b6c6bd627", "node_type": "1", "metadata": {"window": "As one of the largest suppliers of medical \nand pharmaceutical products, now,  more than ever, we are committed to fulfilling our mission of \nsupporting healthcare providers and the patients they  serve.  \n Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n", "original_text": "And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea77e235bc95b1f290fcef0fe2c27b7170726e7b5187c8d9267f4943c43dacf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e61107d1-d8a3-4908-aa57-1604cff2243c", "node_type": "1", "metadata": {"window": "To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities. ", "original_text": "Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products. "}, "hash": "246ed37bd2328a2e4abb913da0927243c28572c34adc68d72feddabc13f5fcb7", "class_name": "RelatedNodeInfo"}}, "text": "As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity. ", "start_char_idx": 1055, "end_char_idx": 1301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e61107d1-d8a3-4908-aa57-1604cff2243c": {"__data__": {"id_": "e61107d1-d8a3-4908-aa57-1604cff2243c", "embedding": null, "metadata": {"window": "To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities. ", "original_text": "Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "207a37e8-a96e-4e47-810c-fa232779d0dc", "node_type": "1", "metadata": {"window": "Keeping our distribution and manufacturing facilities functioning smoothly remains a key priority.  To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities. ", "original_text": "As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27c952bc3cb13d5bef1a30a63e540984b0aee66b2d3bcb4aa936f8373a540bee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5aad3ca-7a3b-4709-8a5d-6b565b993c7b", "node_type": "1", "metadata": {"window": "And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n"}, "hash": "32ce9ea6cd6c39c03f5d39fecd99a2cc12fea2a944b1cc1a8c3bbe164505b9b9", "class_name": "RelatedNodeInfo"}}, "text": "Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products. ", "start_char_idx": 1301, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5aad3ca-7a3b-4709-8a5d-6b565b993c7b": {"__data__": {"id_": "f5aad3ca-7a3b-4709-8a5d-6b565b993c7b", "embedding": null, "metadata": {"window": "And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e61107d1-d8a3-4908-aa57-1604cff2243c", "node_type": "1", "metadata": {"window": "To \ndo so, we  have implemented measures to protect and retain our frontline employees and maintain the \ncontinuity of our  operations.  And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities. ", "original_text": "Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41a95271710bbaae879b4f01e3b87329496124d87e686cb41527aecfec36baf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e206fcab-c20f-41b6-bfcc-694ce27776b1", "node_type": "1", "metadata": {"window": "As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities. "}, "hash": "02efa7e4209985cf8b7d628fdc5a779f18973b531d03e158f85595a4e621112a", "class_name": "RelatedNodeInfo"}}, "text": "Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n", "start_char_idx": 1440, "end_char_idx": 1660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e206fcab-c20f-41b6-bfcc-694ce27776b1": {"__data__": {"id_": "e206fcab-c20f-41b6-bfcc-694ce27776b1", "embedding": null, "metadata": {"window": "As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5aad3ca-7a3b-4709-8a5d-6b565b993c7b", "node_type": "1", "metadata": {"window": "And early on, we proactively and successfully implemented remote work \npolicies for office employees.  \n As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d636212d4fbfdaf2a75c85aaca619ad157a5fae2fbcc2c30c29b0796ca10a43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eecdc177-1450-4ef1-804e-bfdfd4a6496b", "node_type": "1", "metadata": {"window": "Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities. "}, "hash": "176fbb5f006ae230f7cf762941c5b021c26491a4e86105848c216dd22ac20602", "class_name": "RelatedNodeInfo"}}, "text": "For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities. ", "start_char_idx": 1660, "end_char_idx": 1842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eecdc177-1450-4ef1-804e-bfdfd4a6496b": {"__data__": {"id_": "eecdc177-1450-4ef1-804e-bfdfd4a6496b", "embedding": null, "metadata": {"window": "Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e206fcab-c20f-41b6-bfcc-694ce27776b1", "node_type": "1", "metadata": {"window": "As the pandemic unfolds in different ways, and on different timetables around the world, our teams \nacross the  company are adapting to new working environments and responding to industry -wide \nchallenges with tenacity,  speed, and creati vity.  Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edb3f0a821cf92fcdca0ccf811732731ee4fa3c564680b5a306da6edffe99556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7834ebb6-79a3-4bf8-9e7c-3727d40a7619", "node_type": "1", "metadata": {"window": "Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  "}, "hash": "5d1d51f3e799f877848ab8cb727594d6786c7970726264bfbd488d94eb7b999d", "class_name": "RelatedNodeInfo"}}, "text": "We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities. ", "start_char_idx": 1842, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7834ebb6-79a3-4bf8-9e7c-3727d40a7619": {"__data__": {"id_": "7834ebb6-79a3-4bf8-9e7c-3727d40a7619", "embedding": null, "metadata": {"window": "Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab5469dc246bec4f7bd0a1f7540eb25b02838a3bb34e3dd9259eff52fffd5892", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eecdc177-1450-4ef1-804e-bfdfd4a6496b", "node_type": "1", "metadata": {"window": "Our global manufacturing, procurement and logistics \nteams are finding innovative ways to  consistently produce and ship medical products.  Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d846258199f2751f6118444f425f289db3850e56370e1cdc1cf36ff46bdb09d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96293e33-04ef-46d5-9572-fbed3bf95574", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n", "original_text": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days. "}, "hash": "20ad2b8b73bbcfa8ad73e629a44cab6828b1f17ffe70798d9a30252aa7e66008", "class_name": "RelatedNodeInfo"}}, "text": "We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "start_char_idx": 1956, "end_char_idx": 2236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96293e33-04ef-46d5-9572-fbed3bf95574": {"__data__": {"id_": "96293e33-04ef-46d5-9572-fbed3bf95574", "embedding": null, "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n", "original_text": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7834ebb6-79a3-4bf8-9e7c-3727d40a7619", "node_type": "1", "metadata": {"window": "Faced with \nsignificantly increased demand for mask s, gowns, and  other products , our R&D, manufacturing, \nengineeri ng, quality and regulatory teams have been working together to  increase supply in creative \nways.  \n For example, we have invested in, retrofitted and redeployed equipment to manufacture additional \nsurgical mask s, procedure gowns and face shields in our North American facilities.  We have also \nrepurposed production lines to  make items like hand sanitizer and wipes for use in our facilities.  We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "original_text": "We're \ngrateful for the opportunity to serve our  communities and healthcare providers, and we are using the \nfull scale and b readth of our distribution, sourcing  and manufacturing capabilities to provide essential \nmedical suppl ies and pharmaceuticals to customers each day.  ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86e1e17a6e64bc9470e2a379a5d29f8a8915c007e96d19050b562a48e912d784", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81a335f0-8d41-4892-8aef-835c9a9ae8be", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike. ", "original_text": "Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand. "}, "hash": "d62ef8f284a18070a4b212ebca237a8c07aeddf20173bd63f91146ec9c71aac3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days. ", "start_char_idx": 0, "end_char_idx": 145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81a335f0-8d41-4892-8aef-835c9a9ae8be": {"__data__": {"id_": "81a335f0-8d41-4892-8aef-835c9a9ae8be", "embedding": null, "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike. ", "original_text": "Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96293e33-04ef-46d5-9572-fbed3bf95574", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n", "original_text": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "592b2e724df5a6eb16ad529b0dbacacde8ecfa4ad51f04876b372882a3c7541b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33a41ec0-f22e-4122-9fca-eef39a56634c", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers. ", "original_text": "I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n"}, "hash": "85815923ea10f93bffb12cb1bfe72b3321ec366f9d60751afc2fda72e171a298", "class_name": "RelatedNodeInfo"}}, "text": "Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand. ", "start_char_idx": 145, "end_char_idx": 295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33a41ec0-f22e-4122-9fca-eef39a56634c": {"__data__": {"id_": "33a41ec0-f22e-4122-9fca-eef39a56634c", "embedding": null, "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers. ", "original_text": "I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81a335f0-8d41-4892-8aef-835c9a9ae8be", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike. ", "original_text": "Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62c63977f2b5c95b97e53a7677262310a04490e7c8e646906f13fa2ad1d3e7a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fabbe10-7bfa-466d-b864-21f74db00518", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n", "original_text": "Now, I'll turn to Dave to discuss the financials.  \n \n"}, "hash": "36b5d61f85c4a1bddbf429a0e009fc19b9702b47c7ab0219e91c1f56975cdb0b", "class_name": "RelatedNodeInfo"}}, "text": "I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n", "start_char_idx": 295, "end_char_idx": 431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fabbe10-7bfa-466d-b864-21f74db00518": {"__data__": {"id_": "5fabbe10-7bfa-466d-b864-21f74db00518", "embedding": null, "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n", "original_text": "Now, I'll turn to Dave to discuss the financials.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33a41ec0-f22e-4122-9fca-eef39a56634c", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers. ", "original_text": "I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db335f855931c2827824a3417904578f5da8d696d04fd42159b978edb11550e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7ea531b-4f77-44e6-9bf1-3a6c1496ccff", "node_type": "1", "metadata": {"window": "Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance. ", "original_text": "David C. Evans:  \nThanks, Mike. "}, "hash": "a6a2f7166bf992a82d88363d28e7155bb7be66e311b34357b5af9609f4f17378", "class_name": "RelatedNodeInfo"}}, "text": "Now, I'll turn to Dave to discuss the financials.  \n \n", "start_char_idx": 431, "end_char_idx": 485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7ea531b-4f77-44e6-9bf1-3a6c1496ccff": {"__data__": {"id_": "f7ea531b-4f77-44e6-9bf1-3a6c1496ccff", "embedding": null, "metadata": {"window": "Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance. ", "original_text": "David C. Evans:  \nThanks, Mike. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fabbe10-7bfa-466d-b864-21f74db00518", "node_type": "1", "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n", "original_text": "Now, I'll turn to Dave to discuss the financials.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2313c49b9e80b60dbfeecaa7a88849439ca5e998c5d77ec3ff93d6f68dd8bf9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fefc8c4-a858-49dc-890f-2b5293c9a505", "node_type": "1", "metadata": {"window": "I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3. ", "original_text": "I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers. "}, "hash": "db36f7841380991f0bb8b2ce1a0af0c69fac0de2a66f05ba0f0ba74d1281c66b", "class_name": "RelatedNodeInfo"}}, "text": "David C. Evans:  \nThanks, Mike. ", "start_char_idx": 485, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fefc8c4-a858-49dc-890f-2b5293c9a505": {"__data__": {"id_": "8fefc8c4-a858-49dc-890f-2b5293c9a505", "embedding": null, "metadata": {"window": "I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3. ", "original_text": "I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7ea531b-4f77-44e6-9bf1-3a6c1496ccff", "node_type": "1", "metadata": {"window": "Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance. ", "original_text": "David C. Evans:  \nThanks, Mike. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f53ade038896f34b2da248bd0d6d2675ebf6a2c454c05a18f9ec7aa7c1ce982e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc97964e-9abd-47bb-83fe-8d8f25686de0", "node_type": "1", "metadata": {"window": "Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4. ", "original_text": "I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n"}, "hash": "2057e04a7011627b4e35625adcdbab75213391da28b47dbe65d3c40acd9269f3", "class_name": "RelatedNodeInfo"}}, "text": "I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers. ", "start_char_idx": 517, "end_char_idx": 782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc97964e-9abd-47bb-83fe-8d8f25686de0": {"__data__": {"id_": "dc97964e-9abd-47bb-83fe-8d8f25686de0", "embedding": null, "metadata": {"window": "Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4. ", "original_text": "I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fefc8c4-a858-49dc-890f-2b5293c9a505", "node_type": "1", "metadata": {"window": "I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3. ", "original_text": "I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9007083164e447f770a1cca507838c58e121dcc887f8857a2fe25a3a429cfd8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62f46d5f-b627-4300-9f04-b4ecaf3fa6d0", "node_type": "1", "metadata": {"window": "David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n", "original_text": "Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance. "}, "hash": "7c9a94a2921dfb1ec7d19c9cd7fc00abf2de726257e4563e8d563582137701f7", "class_name": "RelatedNodeInfo"}}, "text": "I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n", "start_char_idx": 782, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62f46d5f-b627-4300-9f04-b4ecaf3fa6d0": {"__data__": {"id_": "62f46d5f-b627-4300-9f04-b4ecaf3fa6d0", "embedding": null, "metadata": {"window": "David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n", "original_text": "Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc97964e-9abd-47bb-83fe-8d8f25686de0", "node_type": "1", "metadata": {"window": "Now, I'll turn to Dave to discuss the financials.  \n \n David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4. ", "original_text": "I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fde43490a1fe390a628e43ff16773e11245acdcf16d885bc4262c9e014740b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e2bad4d-a489-4723-b840-cb5100fac882", "node_type": "1", "metadata": {"window": "I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.  ", "original_text": "We saw  a modest net positive impact related to COVID -19 in Q3. "}, "hash": "4d1d4519728c434bc8abfc5ec294f7958b5bfa72187b8d8eeea9e11d87332978", "class_name": "RelatedNodeInfo"}}, "text": "Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance. ", "start_char_idx": 891, "end_char_idx": 1119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e2bad4d-a489-4723-b840-cb5100fac882": {"__data__": {"id_": "0e2bad4d-a489-4723-b840-cb5100fac882", "embedding": null, "metadata": {"window": "I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.  ", "original_text": "We saw  a modest net positive impact related to COVID -19 in Q3. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62f46d5f-b627-4300-9f04-b4ecaf3fa6d0", "node_type": "1", "metadata": {"window": "David C. Evans:  \nThanks, Mike.  I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n", "original_text": "Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd96fca04db90c3d252060c9d43f6ce72c507651a45eb067852dbc00a604df34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b7691ce-1b60-4174-8820-63c9b5573e0d", "node_type": "1", "metadata": {"window": "I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion. ", "original_text": "We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4. "}, "hash": "e42e25139ad838369c7ee2255dbd8fc2f930dfbbd426aea53d0039d1f6bf71ef", "class_name": "RelatedNodeInfo"}}, "text": "We saw  a modest net positive impact related to COVID -19 in Q3. ", "start_char_idx": 1119, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b7691ce-1b60-4174-8820-63c9b5573e0d": {"__data__": {"id_": "7b7691ce-1b60-4174-8820-63c9b5573e0d", "embedding": null, "metadata": {"window": "I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion. ", "original_text": "We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e2bad4d-a489-4723-b840-cb5100fac882", "node_type": "1", "metadata": {"window": "I'd also like to recognize all of our teams for their incredible efforts serving our \ncustomers during  these extraordinary times and I w ant to express appreciation for our suppliers and \npartners who've worked  diligently with us to support healthcare providers.  I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.  ", "original_text": "We saw  a modest net positive impact related to COVID -19 in Q3. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de1d9d3b6e7ae7cbad2f964b47505181a6a4f54654d63ba23ad9cad9158f43ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "361a28e5-5844-4f7c-a889-4a5f0e61b5f5", "node_type": "1", "metadata": {"window": "Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion. ", "original_text": "This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n"}, "hash": "f78ca1bb8325384bd5f0046691daa23e5be2cf507d9b6542c512aa558021001d", "class_name": "RelatedNodeInfo"}}, "text": "We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4. ", "start_char_idx": 1184, "end_char_idx": 1277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "361a28e5-5844-4f7c-a889-4a5f0e61b5f5": {"__data__": {"id_": "361a28e5-5844-4f7c-a889-4a5f0e61b5f5", "embedding": null, "metadata": {"window": "Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion. ", "original_text": "This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b7691ce-1b60-4174-8820-63c9b5573e0d", "node_type": "1", "metadata": {"window": "I've been proud to be \nassociated with Cardinal Health and all its  employees over these past nine months.  \n Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion. ", "original_text": "We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4344eddd546b124c853bcfa7e3b5429067f18be90010b092d7b31a30ffce1fe1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec7eb97e-ba38-4b60-a9c4-b8d11c624883", "node_type": "1", "metadata": {"window": "We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n", "original_text": "Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.  "}, "hash": "e23863d5a23fe00b3f887b167011a1cdad0bfee8a308c063865ad3d031927da5", "class_name": "RelatedNodeInfo"}}, "text": "This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n", "start_char_idx": 1277, "end_char_idx": 1531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec7eb97e-ba38-4b60-a9c4-b8d11c624883": {"__data__": {"id_": "ec7eb97e-ba38-4b60-a9c4-b8d11c624883", "embedding": null, "metadata": {"window": "We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n", "original_text": "Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.  ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "361a28e5-5844-4f7c-a889-4a5f0e61b5f5", "node_type": "1", "metadata": {"window": "Before I dive into specifi c results, I will share the macro level financial impact of COVID -19 as I think \nthis will help  put appropriate context around my subsequent commentary on third quarter results in \nFY 2020 guidance.  We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion. ", "original_text": "This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0bce7b838a5912cd88867b056950c9dc7cd40ffe71bc1265c0b522f0bc0e14e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0190f7f-0553-4324-a3a9-dc99a4f24f7e", "node_type": "1", "metadata": {"window": "We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion. ", "original_text": "Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion. "}, "hash": "a995e76e30e9ea38b8fb4045f65d899638bb1bb1ef9b54bea1e1b7c71100fb41", "class_name": "RelatedNodeInfo"}}, "text": "Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.  ", "start_char_idx": 1531, "end_char_idx": 1644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0190f7f-0553-4324-a3a9-dc99a4f24f7e": {"__data__": {"id_": "b0190f7f-0553-4324-a3a9-dc99a4f24f7e", "embedding": null, "metadata": {"window": "We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion. ", "original_text": "Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec7eb97e-ba38-4b60-a9c4-b8d11c624883", "node_type": "1", "metadata": {"window": "We saw  a modest net positive impact related to COVID -19 in Q3.  We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n", "original_text": "Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.  ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86200b2fad7d0b1880719ac7c9acab82b291e750639677ce5ee983a40ba36c68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1f5f981-f85a-4de7-aa64-20ca449e0333", "node_type": "1", "metadata": {"window": "This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n", "original_text": "SG&A increased 6% to $1.2 billion. "}, "hash": "58599fb9ae79ab9ab8186d57741398f77cfaf6138d21ed54fbb0a70b928fc171", "class_name": "RelatedNodeInfo"}}, "text": "Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion. ", "start_char_idx": 1644, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1f5f981-f85a-4de7-aa64-20ca449e0333": {"__data__": {"id_": "b1f5f981-f85a-4de7-aa64-20ca449e0333", "embedding": null, "metadata": {"window": "This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n", "original_text": "SG&A increased 6% to $1.2 billion. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0190f7f-0553-4324-a3a9-dc99a4f24f7e", "node_type": "1", "metadata": {"window": "We expect a \nmore significant , net negative impact to  both earnings and margin rate in Q4.  This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion. ", "original_text": "Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e58ef5b5d059b4fc49ba319cc836d5f22df02da5dc3577dada7dd54c7cd79ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5760f66b-59a8-4b86-9ad2-08f0898dd9c2", "node_type": "1", "metadata": {"window": "Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n"}, "hash": "7525122458b849c7e33dbd0976e7a9740d37fe5b50713e605b466be969d4b83e", "class_name": "RelatedNodeInfo"}}, "text": "SG&A increased 6% to $1.2 billion. ", "start_char_idx": 1772, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5760f66b-59a8-4b86-9ad2-08f0898dd9c2": {"__data__": {"id_": "5760f66b-59a8-4b86-9ad2-08f0898dd9c2", "embedding": null, "metadata": {"window": "Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1f5f981-f85a-4de7-aa64-20ca449e0333", "node_type": "1", "metadata": {"window": "This fourth quarter \nimpact will be primarily due to a full quarter of reduced  revenues, related to declines in elective \nprocedures in the United States and an exp ected reversal of accelerated  Pharmaceutical sales, which \nI'll discuss in a moment.  \n Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n", "original_text": "SG&A increased 6% to $1.2 billion. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77d9ba153babd17e217d24ce27a383eee87b71a3878bf925a68d210ce5009ded", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98b89f69-cb8b-4b08-a1c6-7c80e9c453e6", "node_type": "1", "metadata": {"window": "Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion. "}, "hash": "bc1de75d5a0ea1b30f3eb1930a2b29db5ed6524682a266b50ed9ddfa11ad5a9d", "class_name": "RelatedNodeInfo"}}, "text": "The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n", "start_char_idx": 1807, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98b89f69-cb8b-4b08-a1c6-7c80e9c453e6": {"__data__": {"id_": "98b89f69-cb8b-4b08-a1c6-7c80e9c453e6", "embedding": null, "metadata": {"window": "Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5760f66b-59a8-4b86-9ad2-08f0898dd9c2", "node_type": "1", "metadata": {"window": "Turning to our results, in Q3 we delivered earnings of $1.62 per share, an increase of 2% from the \nprior year.   Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e634b4a39045b1d941e1862b55070d6d4d9ba4854b3b8d84807f3cced8ad6f9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a213664-a73f-4bfc-8c64-bf2cde3e19d1", "node_type": "1", "metadata": {"window": "SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n"}, "hash": "3e8220705d96ebfdad75775f90e82a283297b88366423fa24705395b70be12fc", "class_name": "RelatedNodeInfo"}}, "text": "Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion. ", "start_char_idx": 1915, "end_char_idx": 2018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a213664-a73f-4bfc-8c64-bf2cde3e19d1": {"__data__": {"id_": "8a213664-a73f-4bfc-8c64-bf2cde3e19d1", "embedding": null, "metadata": {"window": "SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98b89f69-cb8b-4b08-a1c6-7c80e9c453e6", "node_type": "1", "metadata": {"window": "Total company revenue increased 11% versus last year to $39.2  billion, with consolidated \ngross margin up 7% to  $1.9 billion.  SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da1bee18a830b9afc57b903003f97a62a1242b51e60b4fbe856eaa2deb8f2a19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c85234a-e6e6-4866-8009-84a41e0b0b9e", "node_type": "1", "metadata": {"window": "The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  "}, "hash": "4c3b7ff1e48017169d33df961affa2da375b8119275af4bab49c4ebdf1a98447", "class_name": "RelatedNodeInfo"}}, "text": "This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n", "start_char_idx": 2018, "end_char_idx": 2213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c85234a-e6e6-4866-8009-84a41e0b0b9e": {"__data__": {"id_": "3c85234a-e6e6-4866-8009-84a41e0b0b9e", "embedding": null, "metadata": {"window": "The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "203d7831-9a1e-4994-ad7b-38359fb616ae", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0685646895a606c7c99c61b8afbe595bf47f2ebfd118f739d4c38b158819b1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a213664-a73f-4bfc-8c64-bf2cde3e19d1", "node_type": "1", "metadata": {"window": "SG&A increased 6% to $1.2 billion.  The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02706a65422f81ebdfd44c0c62eb01397ce753af0701a88eaf9b0aab1973ff18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30e2e3dd-3dfc-4587-82e6-93c06053dd8a", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n", "original_text": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.  "}, "hash": "c8b3f7535808e25a81277e95b3916154f5ffc4352add844368cf1ddff4085a7f", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "start_char_idx": 2213, "end_char_idx": 2369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30e2e3dd-3dfc-4587-82e6-93c06053dd8a": {"__data__": {"id_": "30e2e3dd-3dfc-4587-82e6-93c06053dd8a", "embedding": null, "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n", "original_text": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.  ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c85234a-e6e6-4866-8009-84a41e0b0b9e", "node_type": "1", "metadata": {"window": "The net result was growth in \nconsolidated operating earnings of  8% from the prior year to $719 million.  \n Moving below operating earnings, interest and other i ncome and expense increased 28% to $79 \nmillion.  This was  primarily driven by the decline in the value of our deferred compensation plan \ninvestments, partially offset by  lower interest expense as we continue to reduce our long -term debt.  \n As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "original_text": "As a reminder, chan ges to deferred compensation reported in other income and expense are fully \noffset in  corporate SG&A and have no bottom line impact.  ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd9cdc804a4522970d0456b2e78e478f83a1fd2cee70d9dd2e27bb546d6d4895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92b489fb-4e54-4944-adf5-8fa74c0fa3b1", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs. ", "original_text": "In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n"}, "hash": "086d8f5c02b44aabca81bb5f6fd581bdf488d038b5d29fd5591c45afd917ea0e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.  ", "start_char_idx": 0, "end_char_idx": 83, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92b489fb-4e54-4944-adf5-8fa74c0fa3b1": {"__data__": {"id_": "92b489fb-4e54-4944-adf5-8fa74c0fa3b1", "embedding": null, "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs. ", "original_text": "In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30e2e3dd-3dfc-4587-82e6-93c06053dd8a", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n", "original_text": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.  ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b513cf08d719958b71394b5a1120f534de56113ff78c9b087660abdc8cc254a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94df387e-fc74-41e8-8ec5-d901d461606c", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows. ", "original_text": "Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items. "}, "hash": "7061e0849562a94cf264d8866c061faa991819e07767b433a4033fb7c1d8c72f", "class_name": "RelatedNodeInfo"}}, "text": "In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n", "start_char_idx": 83, "end_char_idx": 248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94df387e-fc74-41e8-8ec5-d901d461606c": {"__data__": {"id_": "94df387e-fc74-41e8-8ec5-d901d461606c", "embedding": null, "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows. ", "original_text": "Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92b489fb-4e54-4944-adf5-8fa74c0fa3b1", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs. ", "original_text": "In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc2e8a86f2da577892c2a78ae773c98fd04f60207c2843b28c21d21246cb4380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aebccdd-a4c4-4624-8528-8ead929185a3", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n", "original_text": "Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n"}, "hash": "546356000677f5863c9fa2c03ff21f519bbb0ec0564438ebde36b7e7a77b5750", "class_name": "RelatedNodeInfo"}}, "text": "Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items. ", "start_char_idx": 248, "end_char_idx": 417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aebccdd-a4c4-4624-8528-8ead929185a3": {"__data__": {"id_": "9aebccdd-a4c4-4624-8528-8ead929185a3", "embedding": null, "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n", "original_text": "Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94df387e-fc74-41e8-8ec5-d901d461606c", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows. ", "original_text": "Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3df441aec13872551504ba9fcbc03117415369ce92a3bab457b025518c4cc4cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42799e2f-1243-447b-aafe-6b0c1ce1836c", "node_type": "1", "metadata": {"window": "In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma. ", "original_text": "Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs. "}, "hash": "4f4f9e96cf483651b2e9cc88a65ec118943bd263bab61a1c7a542236e6c44799", "class_name": "RelatedNodeInfo"}}, "text": "Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n", "start_char_idx": 417, "end_char_idx": 632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42799e2f-1243-447b-aafe-6b0c1ce1836c": {"__data__": {"id_": "42799e2f-1243-447b-aafe-6b0c1ce1836c", "embedding": null, "metadata": {"window": "In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma. ", "original_text": "Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aebccdd-a4c4-4624-8528-8ead929185a3", "node_type": "1", "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n", "original_text": "Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b505d9fc9fcb9372ae36fd99d8f512dc8aa1fea45e134ec9c09708e3213ab9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "098a5eb5-2e31-404b-ae34-f8c207a202d2", "node_type": "1", "metadata": {"window": "Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n", "original_text": "Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows. "}, "hash": "8ab863e836a3a35dd64a05d9bced202ea4099d15babf95cc9729fd83c4e5cead", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs. ", "start_char_idx": 632, "end_char_idx": 783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "098a5eb5-2e31-404b-ae34-f8c207a202d2": {"__data__": {"id_": "098a5eb5-2e31-404b-ae34-f8c207a202d2", "embedding": null, "metadata": {"window": "Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n", "original_text": "Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42799e2f-1243-447b-aafe-6b0c1ce1836c", "node_type": "1", "metadata": {"window": "In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma. ", "original_text": "Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da8a79ad6d0e30dbc44001ba56a2839aae6b215e2c506986b773a75c89e1f379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e51f8497-c080-4b48-8dec-012ab4a4ad2e", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n", "original_text": "We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n"}, "hash": "35195be2c6fb6c44b460a9d54030f5dae4a5428fd46ee9e4098b77b240c5b8fb", "class_name": "RelatedNodeInfo"}}, "text": "Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows. ", "start_char_idx": 783, "end_char_idx": 991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e51f8497-c080-4b48-8dec-012ab4a4ad2e": {"__data__": {"id_": "e51f8497-c080-4b48-8dec-012ab4a4ad2e", "embedding": null, "metadata": {"window": "Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n", "original_text": "We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "098a5eb5-2e31-404b-ae34-f8c207a202d2", "node_type": "1", "metadata": {"window": "Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n", "original_text": "Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12c35203dd742642bd7722be4876f26660a5105c45f86eab1cc25abe423dbe8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c6c1516-d044-4b9d-9d78-c5866fbb09c1", "node_type": "1", "metadata": {"window": "Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales. ", "original_text": "Moving on to segment results, starting with Pharma. "}, "hash": "fd773f0c209ffbdbb39e6d8ff2d792d0d0f46841d2eca27dc865d600ff80c5bb", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n", "start_char_idx": 991, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c6c1516-d044-4b9d-9d78-c5866fbb09c1": {"__data__": {"id_": "1c6c1516-d044-4b9d-9d78-c5866fbb09c1", "embedding": null, "metadata": {"window": "Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales. ", "original_text": "Moving on to segment results, starting with Pharma. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e51f8497-c080-4b48-8dec-012ab4a4ad2e", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n", "original_text": "We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e74dcaf5a9a4d98a5136674841933021a33cb95c59f623a96be722ab5a801ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa88b5bf-7242-4b40-a623-d31421a2ca77", "node_type": "1", "metadata": {"window": "Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n", "original_text": "Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n"}, "hash": "beff476f80d6f47be0fc8b23df536180084282e4ea1c1645bc82d40853358eb7", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to segment results, starting with Pharma. ", "start_char_idx": 1202, "end_char_idx": 1254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa88b5bf-7242-4b40-a623-d31421a2ca77": {"__data__": {"id_": "aa88b5bf-7242-4b40-a623-d31421a2ca77", "embedding": null, "metadata": {"window": "Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n", "original_text": "Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c6c1516-d044-4b9d-9d78-c5866fbb09c1", "node_type": "1", "metadata": {"window": "Moving on to cash flow, op erating cash flow for the quarter was approximately $1.7 billion as we \nfocused foremost  on addressing our customer needs.  Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales. ", "original_text": "Moving on to segment results, starting with Pharma. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dad2f1df003d5d5fbc3005b4933cd14886d2d43e91243af0600047d8479ff92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28293a30-5966-435a-8444-7181fd190b54", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus. ", "original_text": "Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n"}, "hash": "b51c6a40f0d67efdf221995820f332453aa7e68d8e44f69c4fece2350bad6323", "class_name": "RelatedNodeInfo"}}, "text": "Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n", "start_char_idx": 1254, "end_char_idx": 1425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28293a30-5966-435a-8444-7181fd190b54": {"__data__": {"id_": "28293a30-5966-435a-8444-7181fd190b54", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus. ", "original_text": "Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa88b5bf-7242-4b40-a623-d31421a2ca77", "node_type": "1", "metadata": {"window": "Keep in mind that the timing of inventory \npurchases and the collections on  those sales as well as the day of the week in which the qua rter ends \nall have the potential to impact point -in-time cash flows.  We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n", "original_text": "Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5df8e72a6976525488c722fbfecd316cb4062b2308a002df374f9cbef6f005a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36cbbb52-e410-49fb-b3c9-8342799920e4", "node_type": "1", "metadata": {"window": "Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales. "}, "hash": "f3dd02283176c6ea406cdb04cd198ffc64ec549a243ef8c91f569e11d3ffc50a", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n", "start_char_idx": 1425, "end_char_idx": 1588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36cbbb52-e410-49fb-b3c9-8342799920e4": {"__data__": {"id_": "36cbbb52-e410-49fb-b3c9-8342799920e4", "embedding": null, "metadata": {"window": "Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28293a30-5966-435a-8444-7181fd190b54", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of \n$2.3 billion and we continue to have access to an  additional $3 billion of liquidity in the form of our \ncommercial paper program and AR securit ization facility.  \n Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus. ", "original_text": "Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93298034180573ee1d63a77407f4a0c084737eaa2071722bacec4989ec301e88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a77a687-4ca1-470a-b09d-036fdc30cdf1", "node_type": "1", "metadata": {"window": "Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n"}, "hash": "ee87026ef9be0759bb6ba37b50c37f397addc792b4749113db21277a5a90e14c", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales. ", "start_char_idx": 1588, "end_char_idx": 1675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a77a687-4ca1-470a-b09d-036fdc30cdf1": {"__data__": {"id_": "2a77a687-4ca1-470a-b09d-036fdc30cdf1", "embedding": null, "metadata": {"window": "Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36cbbb52-e410-49fb-b3c9-8342799920e4", "node_type": "1", "metadata": {"window": "Moving on to segment results, starting with Pharma.  Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fde82f6ad3feeb7c8f1afbba0e0f2bf327de4d4aedb932447797a65d7eff1911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b15b3f2-3ebf-4fcd-a7a0-bfa99684ab3f", "node_type": "1", "metadata": {"window": "Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus. "}, "hash": "051db0179301b46605f0e70bf540516577037932ae4470160e0ee24d6a6f7f62", "class_name": "RelatedNodeInfo"}}, "text": "We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n", "start_char_idx": 1675, "end_char_idx": 1842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b15b3f2-3ebf-4fcd-a7a0-bfa99684ab3f": {"__data__": {"id_": "9b15b3f2-3ebf-4fcd-a7a0-bfa99684ab3f", "embedding": null, "metadata": {"window": "Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a77a687-4ca1-470a-b09d-036fdc30cdf1", "node_type": "1", "metadata": {"window": "Segment revenue increased 12% to $35.1 billion \ndue to  sales growth from Pharmaceutical Distribution customers, and to a lesser extent, Specialty \nSolutions customers.  \n Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd627532edabf3b97ff72cd3129ee88d747a7a3d4cf06ba3aef9a24f7f93a5f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "634cdeb9-3570-4b44-94af-f60a3aea64cd", "node_type": "1", "metadata": {"window": "In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  "}, "hash": "5809a0c0861a9d9998184c8ac16651e362571632d8bfd8568bc674fe5a4ec5f8", "class_name": "RelatedNodeInfo"}}, "text": "Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus. ", "start_char_idx": 1842, "end_char_idx": 2057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "634cdeb9-3570-4b44-94af-f60a3aea64cd": {"__data__": {"id_": "634cdeb9-3570-4b44-94af-f60a3aea64cd", "embedding": null, "metadata": {"window": "In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "749249e8-6903-4e13-875f-1cd11e6d2165", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30a645657b19fd178dca165a5f939d16635480b31dc90815bba7a5ddb8a7c081", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b15b3f2-3ebf-4fcd-a7a0-bfa99684ab3f", "node_type": "1", "metadata": {"window": "Segment profit was f lat at $534 million, reflecting both the strong performance of our generics \nprogram and the  adverse impact of customer contract renewals.  \n In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus. ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9e05130de49bf966617ad0f7c07f5a17656c2c804744aa0a0f44a80f50facd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4152882d-6b49-4bc8-aa8d-68622a4004d5", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial. ", "original_text": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics. "}, "hash": "523c07af1bbd3e322073ad4d32914b83aaffac47156e5ffeaf01ce96fe479db9", "class_name": "RelatedNodeInfo"}}, "text": "While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "start_char_idx": 2057, "end_char_idx": 2311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4152882d-6b49-4bc8-aa8d-68622a4004d5": {"__data__": {"id_": "4152882d-6b49-4bc8-aa8d-68622a4004d5", "embedding": null, "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial. ", "original_text": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "634cdeb9-3570-4b44-94af-f60a3aea64cd", "node_type": "1", "metadata": {"window": "In the quarter and more specifically in March, we saw a surge in Pharmaceutical sales.  We believe \nthis was  driven by a ccelerated purchases related to the COVID -19 pandemic and we are \nexperiencing below -average  sales early in the fourth quarter.  \n Though not a material driver in the third quarter, activity in our Nuclear and Specialty businesses \nstarted to slow in  March, as elective procedures and physician office visits began to be impacted by \nthe virus.  While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "original_text": "While we expect  these activities to gradually rebound over the calendar year, the reduced \nactivity will be more impactful to our  fourth quarter, particularly in our Nuclear business which has \nhigher margin products and a more fixed cost  structure.  ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecb943e97237563482cd5f899ee448dcc83ad94d20c044e308eaae04228d7ee5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75efbcfd-48cb-49c7-a0af-aeff075fbf4f", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n", "original_text": "We were encouraged to see another quarter \nof consistent dynamics within the generics market. "}, "hash": "b9c7435e177c670d5574bdac5f660bb3860e0fc1bd57c0279c04bede59bc7b9b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics. ", "start_char_idx": 0, "end_char_idx": 74, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75efbcfd-48cb-49c7-a0af-aeff075fbf4f": {"__data__": {"id_": "75efbcfd-48cb-49c7-a0af-aeff075fbf4f", "embedding": null, "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n", "original_text": "We were encouraged to see another quarter \nof consistent dynamics within the generics market. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4152882d-6b49-4bc8-aa8d-68622a4004d5", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial. ", "original_text": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84c4c87e1d8b9738fd567c51c4d293f08b5033ecff70a0bbdbba3d3e625c51a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af051180-8157-4b17-93b9-0980d2158c13", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions. ", "original_text": "Recall, we first began to see th is in the fourth of \nour fiscal 2019.  "}, "hash": "e855ebab594e6b1824e46c694ee38c971beeec40410b58f53380cb98adf04860", "class_name": "RelatedNodeInfo"}}, "text": "We were encouraged to see another quarter \nof consistent dynamics within the generics market. ", "start_char_idx": 74, "end_char_idx": 168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af051180-8157-4b17-93b9-0980d2158c13": {"__data__": {"id_": "af051180-8157-4b17-93b9-0980d2158c13", "embedding": null, "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions. ", "original_text": "Recall, we first began to see th is in the fourth of \nour fiscal 2019.  ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75efbcfd-48cb-49c7-a0af-aeff075fbf4f", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n", "original_text": "We were encouraged to see another quarter \nof consistent dynamics within the generics market. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa58d6ded217377fe5d9907e9b377d975a588df17a970213681959efd1152a10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae18e658-6f18-4dfb-8bef-d3f062814da6", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n", "original_text": "If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial. "}, "hash": "1feb6afd8110f40656bf4fb6d19452f15b2172241350f3e82ea7111e05a2f907", "class_name": "RelatedNodeInfo"}}, "text": "Recall, we first began to see th is in the fourth of \nour fiscal 2019.  ", "start_char_idx": 168, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae18e658-6f18-4dfb-8bef-d3f062814da6": {"__data__": {"id_": "ae18e658-6f18-4dfb-8bef-d3f062814da6", "embedding": null, "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n", "original_text": "If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af051180-8157-4b17-93b9-0980d2158c13", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions. ", "original_text": "Recall, we first began to see th is in the fourth of \nour fiscal 2019.  ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45e7d274904c8695598607cdb3453e409c0a5b0f6fa0b9d212c4a1c266465d0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa8a91b7-2825-4834-8883-25af351ff4bc", "node_type": "1", "metadata": {"window": "We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways. ", "original_text": "As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n"}, "hash": "d31a317f13c04a0f6bfc5ce3a79de5f7b39e8bab1fc8ba30c8d244f72cd20d78", "class_name": "RelatedNodeInfo"}}, "text": "If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial. ", "start_char_idx": 240, "end_char_idx": 359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa8a91b7-2825-4834-8883-25af351ff4bc": {"__data__": {"id_": "aa8a91b7-2825-4834-8883-25af351ff4bc", "embedding": null, "metadata": {"window": "We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways. ", "original_text": "As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae18e658-6f18-4dfb-8bef-d3f062814da6", "node_type": "1", "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n", "original_text": "If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5678d7926c6cf47bf3fd203012761ba1d8d456989d3a10622c0b2408649a69a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5a30577-7ea7-445d-af1e-7f4c4db88116", "node_type": "1", "metadata": {"window": "Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture. ", "original_text": "Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions. "}, "hash": "4a721a558704818b0d105c48dcf050dc297512a89e59e956eda740bf37535ba1", "class_name": "RelatedNodeInfo"}}, "text": "As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n", "start_char_idx": 359, "end_char_idx": 458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5a30577-7ea7-445d-af1e-7f4c4db88116": {"__data__": {"id_": "b5a30577-7ea7-445d-af1e-7f4c4db88116", "embedding": null, "metadata": {"window": "Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture. ", "original_text": "Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa8a91b7-2825-4834-8883-25af351ff4bc", "node_type": "1", "metadata": {"window": "We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways. ", "original_text": "As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32468116ae05072852605caf2f634b18efa22674e4d26b578492b82da2574a48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bc5d0c3-9f40-4da5-a990-f2cdc4b014dd", "node_type": "1", "metadata": {"window": "If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures. ", "original_text": "Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n"}, "hash": "d4b3fef01b127af6385596ebad9696986246476391cc4a21ff9acef8d9d4c44f", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions. ", "start_char_idx": 458, "end_char_idx": 616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bc5d0c3-9f40-4da5-a990-f2cdc4b014dd": {"__data__": {"id_": "8bc5d0c3-9f40-4da5-a990-f2cdc4b014dd", "embedding": null, "metadata": {"window": "If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures. ", "original_text": "Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5a30577-7ea7-445d-af1e-7f4c4db88116", "node_type": "1", "metadata": {"window": "Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture. ", "original_text": "Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6ffe829ed2d8e05b97e23053bb866317e9b9e5508f2d2163749002e661f3056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22f4960d-f503-4e65-b960-8faf257b5282", "node_type": "1", "metadata": {"window": "As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n", "original_text": "In the quarter, we saw the global pandemic affect the segment in various ways. "}, "hash": "5d66b1cf00420a406a821f5b45ec4c8ab142310fcb8e247402b8f514ce23ed0a", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n", "start_char_idx": 616, "end_char_idx": 791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22f4960d-f503-4e65-b960-8faf257b5282": {"__data__": {"id_": "22f4960d-f503-4e65-b960-8faf257b5282", "embedding": null, "metadata": {"window": "As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n", "original_text": "In the quarter, we saw the global pandemic affect the segment in various ways. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bc5d0c3-9f40-4da5-a990-f2cdc4b014dd", "node_type": "1", "metadata": {"window": "If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial.  As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures. ", "original_text": "Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74f790f09236db99cefc82bf50925f5bd9f0c4101fc29864ef0ebb1139077c06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79c63d20-9bee-4afe-9cad-ddce8c200e24", "node_type": "1", "metadata": {"window": "Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand. ", "original_text": "We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture. "}, "hash": "d1a82d232ce1eae0343c67b51b1eeb99ee4bcf5ba6cae15c782c0972a5256ea4", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, we saw the global pandemic affect the segment in various ways. ", "start_char_idx": 791, "end_char_idx": 870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79c63d20-9bee-4afe-9cad-ddce8c200e24": {"__data__": {"id_": "79c63d20-9bee-4afe-9cad-ddce8c200e24", "embedding": null, "metadata": {"window": "Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand. ", "original_text": "We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22f4960d-f503-4e65-b960-8faf257b5282", "node_type": "1", "metadata": {"window": "As always, factors like mix and new launches could influence quarter -\nto-quarter comparability.  \n Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n", "original_text": "In the quarter, we saw the global pandemic affect the segment in various ways. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fe53877aaf5874f9014b9fbba5e7361e89f7bee9c2458f7bc57917198df7281", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14cdd861-8fbb-47f3-813f-bef194e623f6", "node_type": "1", "metadata": {"window": "Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n", "original_text": "Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures. "}, "hash": "c0342cd7c62d84ca659969c6ef7ad70372bc7f0bf7b2f9bd1d76ab3befc138d7", "class_name": "RelatedNodeInfo"}}, "text": "We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture. ", "start_char_idx": 870, "end_char_idx": 973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14cdd861-8fbb-47f3-813f-bef194e623f6": {"__data__": {"id_": "14cdd861-8fbb-47f3-813f-bef194e623f6", "embedding": null, "metadata": {"window": "Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n", "original_text": "Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79c63d20-9bee-4afe-9cad-ddce8c200e24", "node_type": "1", "metadata": {"window": "Turning now to the Medical segment, revenue increased 5% to $4.1 billion, due to growth in products \nand distribution and Cardinal Health at -Home Solutions.  Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand. ", "original_text": "We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b871f48d22e12b4bdea7b89e5a6595457a5550abe9efd96f8d52036289bcf40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44cb5d2a-f234-494e-991d-148b2e55f4fb", "node_type": "1", "metadata": {"window": "In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n", "original_text": "This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n"}, "hash": "564b4aee57266df412a95ba96a8aac5e8a7204a50db7868092fe28cc0bdd7b0d", "class_name": "RelatedNodeInfo"}}, "text": "Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures. ", "start_char_idx": 973, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44cb5d2a-f234-494e-991d-148b2e55f4fb": {"__data__": {"id_": "44cb5d2a-f234-494e-991d-148b2e55f4fb", "embedding": null, "metadata": {"window": "In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n", "original_text": "This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14cdd861-8fbb-47f3-813f-bef194e623f6", "node_type": "1", "metadata": {"window": "Segment profit increased 15% to $178 \nmillion due to an  increase in products and distribution, including bene fits from global manufacturing \nand cost savings initiatives.  \n In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n", "original_text": "Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba12a08121a6126e702cfc992bd3621f782ae9a531444bbcb598f0603150a1bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71458cf0-b4ad-4a67-8594-9e5d88b8b6b5", "node_type": "1", "metadata": {"window": "We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment. ", "original_text": "Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand. "}, "hash": "ab7a59904a383c2e37c6e2df98eafa186f8b215d0ad51ac0e18191fb8ed9a55d", "class_name": "RelatedNodeInfo"}}, "text": "This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n", "start_char_idx": 1136, "end_char_idx": 1304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71458cf0-b4ad-4a67-8594-9e5d88b8b6b5": {"__data__": {"id_": "71458cf0-b4ad-4a67-8594-9e5d88b8b6b5", "embedding": null, "metadata": {"window": "We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment. ", "original_text": "Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44cb5d2a-f234-494e-991d-148b2e55f4fb", "node_type": "1", "metadata": {"window": "In the quarter, we saw the global pandemic affect the segment in various ways.  We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n", "original_text": "This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "584977290216c1c47986594ee6e5ea3afe3b1675dd795c4e6a3b1fc0efd37ef2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db548959-ce87-4f23-95ea-7cb25513f129", "node_type": "1", "metadata": {"window": "Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n", "original_text": "We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n"}, "hash": "9fbde297d8b7a8ca08a57d9f32172ddff3ac0fc13e5bd7aa1808cc788ec98ae8", "class_name": "RelatedNodeInfo"}}, "text": "Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand. ", "start_char_idx": 1304, "end_char_idx": 1467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db548959-ce87-4f23-95ea-7cb25513f129": {"__data__": {"id_": "db548959-ce87-4f23-95ea-7cb25513f129", "embedding": null, "metadata": {"window": "Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n", "original_text": "We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71458cf0-b4ad-4a67-8594-9e5d88b8b6b5", "node_type": "1", "metadata": {"window": "We've seen an \nunprecedented  increase in demand for PPE products that we both source and manufacture.  Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment. ", "original_text": "Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e6fa29a97d107da5b43051e4cf45231396a414f950c02e07a41f64c1c059af7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db542f41-5869-49d5-8108-88e273f9f670", "node_type": "1", "metadata": {"window": "This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date. ", "original_text": "Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n"}, "hash": "a60f59ef4983f3762a59e825aae217d47e7b2f6324aa67334844e96b868d61db", "class_name": "RelatedNodeInfo"}}, "text": "We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n", "start_char_idx": 1467, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db542f41-5869-49d5-8108-88e273f9f670": {"__data__": {"id_": "db542f41-5869-49d5-8108-88e273f9f670", "embedding": null, "metadata": {"window": "This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date. ", "original_text": "Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db548959-ce87-4f23-95ea-7cb25513f129", "node_type": "1", "metadata": {"window": "Because \nthe sur ge quickly  outstripped inventories on -hand and available market capacity to supply new PPE, \nwe implemented disciplined  allocation procedures.  This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n", "original_text": "We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b00a3e08522961493e858106795c6bafee3d6fa49be14551866c62950fb98f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "860d13e7-24db-48b0-b69b-c81fdbd74e51", "node_type": "1", "metadata": {"window": "Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment. "}, "hash": "e45a2c400123b0fc47bc6f5d90cab06ccf70f620473bab8df15ce4fed90728a3", "class_name": "RelatedNodeInfo"}}, "text": "Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n", "start_char_idx": 1610, "end_char_idx": 1827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "860d13e7-24db-48b0-b69b-c81fdbd74e51": {"__data__": {"id_": "860d13e7-24db-48b0-b69b-c81fdbd74e51", "embedding": null, "metadata": {"window": "Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db542f41-5869-49d5-8108-88e273f9f670", "node_type": "1", "metadata": {"window": "This was done in collaboration with our customers \nto balance demand and available  supply, taking into account geog raphic areas experiencing the \ngreatest impacts.  \n Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date. ", "original_text": "Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31292636b06969bc2fe898da162f2f598d64c9788ab226ad8e5ee15e37f14d4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cbf9a44-c7ab-47c7-9a23-4ecf95b2d421", "node_type": "1", "metadata": {"window": "We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n"}, "hash": "23dbeab343c9add581231ff95ce126ddb1e3e888b83acf0328c801cf7a963c47", "class_name": "RelatedNodeInfo"}}, "text": "As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment. ", "start_char_idx": 1827, "end_char_idx": 1971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cbf9a44-c7ab-47c7-9a23-4ecf95b2d421": {"__data__": {"id_": "5cbf9a44-c7ab-47c7-9a23-4ecf95b2d421", "embedding": null, "metadata": {"window": "We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "860d13e7-24db-48b0-b69b-c81fdbd74e51", "node_type": "1", "metadata": {"window": "Due to ongoing market -wide supply constraints, we do not expect to see a similar increase in PPE -\nrelated sales in  the fourth quarter, despite elevated demand.  We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2768b7691a099451f608f43e09e95fdfb4f85c28c9c414375f922a3c21b1a57e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0be642c0-4f5d-437f-99b5-7d5027184dca", "node_type": "1", "metadata": {"window": "Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date. "}, "hash": "a600b8e33e553983e5e195f3a0a932fc33b786c6aa638f21aa50f6fb43740497", "class_name": "RelatedNodeInfo"}}, "text": "Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n", "start_char_idx": 1971, "end_char_idx": 2065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0be642c0-4f5d-437f-99b5-7d5027184dca": {"__data__": {"id_": "0be642c0-4f5d-437f-99b5-7d5027184dca", "embedding": null, "metadata": {"window": "Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cbf9a44-c7ab-47c7-9a23-4ecf95b2d421", "node_type": "1", "metadata": {"window": "We continue to maximize our internal \nmanufacturin g capacity and  collaborate with our supplier partners to address this dramatic increase.  \n Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e53990c6f8681ef507dbc01d57f238087394595783a6d040cc6d2ada83ab441", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e5a6ec7-d85e-4752-ba53-4fc24e66c4ae", "node_type": "1", "metadata": {"window": "As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  "}, "hash": "f875d0700ff2ee285124f73fe0f3b1b00b9cc84420014fbeea9e361dc5683391", "class_name": "RelatedNodeInfo"}}, "text": "Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date. ", "start_char_idx": 2065, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e5a6ec7-d85e-4752-ba53-4fc24e66c4ae": {"__data__": {"id_": "3e5a6ec7-d85e-4752-ba53-4fc24e66c4ae", "embedding": null, "metadata": {"window": "As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b03e4ed01a9f56a3deb5019b2b4e18fd92ed3c4a495d65654d34541ced35e847", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0be642c0-4f5d-437f-99b5-7d5027184dca", "node_type": "1", "metadata": {"window": "Inversely, given the broader declines in elective procedures, we have seen a decrease in demand for \nmany of our  higher margin offerings, like customer surgical kits, C ordis and legacy Patient Recovery \nproducts.  \n As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f458027a40f91690a2559b8087c68bd924e12ca1ae1f2bd59bafcb33f2e4858a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d636f73e-d9e9-424c-8ec3-fa613ec66a47", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n", "original_text": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n"}, "hash": "beb0ff734e5db99893495f990b74e741c8067a5802f275563230cf159f771484", "class_name": "RelatedNodeInfo"}}, "text": "Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "start_char_idx": 2151, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d636f73e-d9e9-424c-8ec3-fa613ec66a47": {"__data__": {"id_": "d636f73e-d9e9-424c-8ec3-fa613ec66a47", "embedding": null, "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n", "original_text": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e5a6ec7-d85e-4752-ba53-4fc24e66c4ae", "node_type": "1", "metadata": {"window": "As we look to Q4, I will remind you that we'll be lapping the large charge we booked in the fourth \nquarter of fiscal  2019 in the Med segment.  Recall that this related to an exclusive distribution \nagreement with t he Cordis supplier.  \n Turning briefly to fiscal 2020 guidance, we're pleased with our performance to -date.  Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "original_text": "Our underlying \nbusiness  fundamentals have been strong, as have the momentum and progress of strategic initiatives \nacross the company.  ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9a7d238365e5a3099f42c2dfb85c49ab6a026b887aaaa5a2a91bf6a491b8afe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e88910ab-474b-465d-973f-1a2a8c3e48cf", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months. ", "original_text": "We're also reaffirming assumptions provided last quarter for the Medical segment and corporate. "}, "hash": "18749df03861558de1a73c35f4d6cc3f8be0c58c335de2fc76169aa031ddc609", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n", "start_char_idx": 0, "end_char_idx": 189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e88910ab-474b-465d-973f-1a2a8c3e48cf": {"__data__": {"id_": "e88910ab-474b-465d-973f-1a2a8c3e48cf", "embedding": null, "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months. ", "original_text": "We're also reaffirming assumptions provided last quarter for the Medical segment and corporate. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d636f73e-d9e9-424c-8ec3-fa613ec66a47", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n", "original_text": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b412412655db3f2aab784ae2f3e896c1afc6aaa2b99fc3f32866902fa061eb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e085bd20-8625-4761-92b7-dfa6cbc823a7", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are. ", "original_text": "We \nare, however, making one update to our Pharma segment assumptions.  "}, "hash": "6dd336bc4739b6f52f61bee8f1bbc59df9abd42b0cc55a871546e557f5ad8577", "class_name": "RelatedNodeInfo"}}, "text": "We're also reaffirming assumptions provided last quarter for the Medical segment and corporate. ", "start_char_idx": 189, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e085bd20-8625-4761-92b7-dfa6cbc823a7": {"__data__": {"id_": "e085bd20-8625-4761-92b7-dfa6cbc823a7", "embedding": null, "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are. ", "original_text": "We \nare, however, making one update to our Pharma segment assumptions.  ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e88910ab-474b-465d-973f-1a2a8c3e48cf", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months. ", "original_text": "We're also reaffirming assumptions provided last quarter for the Medical segment and corporate. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "feceddfd16cfad9159e6155482a6807d6b98d2956bf01ca84f68617531eceab0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa34f45b-6b4f-42ff-8711-a72c7ae3c763", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n", "original_text": "Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n"}, "hash": "2cc36113e2f9b81379ee8083357ee0cd7627ee4d6a11caa429b8ad98b25c7e6f", "class_name": "RelatedNodeInfo"}}, "text": "We \nare, however, making one update to our Pharma segment assumptions.  ", "start_char_idx": 285, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa34f45b-6b4f-42ff-8711-a72c7ae3c763": {"__data__": {"id_": "fa34f45b-6b4f-42ff-8711-a72c7ae3c763", "embedding": null, "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n", "original_text": "Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e085bd20-8625-4761-92b7-dfa6cbc823a7", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are. ", "original_text": "We \nare, however, making one update to our Pharma segment assumptions.  ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f53bc77fd1d9df030c4d1423b731382012856dc101b664dc4f6fbb4543fcea02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ee6df7d-f160-4a9e-a834-e41289f11c47", "node_type": "1", "metadata": {"window": "We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months. ", "original_text": "Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months. "}, "hash": "befb797eafe41c4a2846d19332523836391ea5f0aeeb77a899069ab1b58ee868", "class_name": "RelatedNodeInfo"}}, "text": "Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n", "start_char_idx": 357, "end_char_idx": 488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ee6df7d-f160-4a9e-a834-e41289f11c47": {"__data__": {"id_": "8ee6df7d-f160-4a9e-a834-e41289f11c47", "embedding": null, "metadata": {"window": "We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months. ", "original_text": "Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa34f45b-6b4f-42ff-8711-a72c7ae3c763", "node_type": "1", "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n", "original_text": "Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8954a29326ea25d1b617909ac07368e43a0aaf9446146183715ab26f7a9e796", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9996967f-a582-4417-816f-48e788724bef", "node_type": "1", "metadata": {"window": "We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n", "original_text": "It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are. "}, "hash": "9d4408093869d04f8778c471bfe6999744e8a03743280c78629ea4efcc8a622d", "class_name": "RelatedNodeInfo"}}, "text": "Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months. ", "start_char_idx": 488, "end_char_idx": 643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9996967f-a582-4417-816f-48e788724bef": {"__data__": {"id_": "9996967f-a582-4417-816f-48e788724bef", "embedding": null, "metadata": {"window": "We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n", "original_text": "It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ee6df7d-f160-4a9e-a834-e41289f11c47", "node_type": "1", "metadata": {"window": "We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months. ", "original_text": "Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "888debff7c8961f91cff9dda15f7396b759ab49276f0b1a1648cb5958cb69c53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2231776a-b253-4843-a8d2-6d70963969d3", "node_type": "1", "metadata": {"window": "Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason. ", "original_text": "This is a special place \nwith an honorable mission  and an  enviable culture.  \n"}, "hash": "ef86c93bbfa9f07c82e7d33dadeb1617b963398c73d6952f76ce8ab14d143124", "class_name": "RelatedNodeInfo"}}, "text": "It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are. ", "start_char_idx": 643, "end_char_idx": 769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2231776a-b253-4843-a8d2-6d70963969d3": {"__data__": {"id_": "2231776a-b253-4843-a8d2-6d70963969d3", "embedding": null, "metadata": {"window": "Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason. ", "original_text": "This is a special place \nwith an honorable mission  and an  enviable culture.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9996967f-a582-4417-816f-48e788724bef", "node_type": "1", "metadata": {"window": "We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n", "original_text": "It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa6656dce9764d5d47c1c2b587a52a62b36e4e52c1a26689c93f3deeb66377e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a4d179c-b36e-449b-bee1-6750b0a4def8", "node_type": "1", "metadata": {"window": "Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.  ", "original_text": "I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months. "}, "hash": "638023c39b2ee625fe33e970c7c08e394f49cbd373970712b4293b11bb38dc68", "class_name": "RelatedNodeInfo"}}, "text": "This is a special place \nwith an honorable mission  and an  enviable culture.  \n", "start_char_idx": 769, "end_char_idx": 849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a4d179c-b36e-449b-bee1-6750b0a4def8": {"__data__": {"id_": "8a4d179c-b36e-449b-bee1-6750b0a4def8", "embedding": null, "metadata": {"window": "Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.  ", "original_text": "I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2231776a-b253-4843-a8d2-6d70963969d3", "node_type": "1", "metadata": {"window": "Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason. ", "original_text": "This is a special place \nwith an honorable mission  and an  enviable culture.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2c745a66b37f2644e7f7607479f946e91e451bc12ec680803adbdf2c39260ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dffa1ad6-375a-481d-8d43-4e15be89a0f3", "node_type": "1", "metadata": {"window": "It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n", "original_text": "I'll treasure the relationships I've forged here for \na long time to  come.  \n"}, "hash": "f1a5cb2e8d9f907b5dfc56246ed3e5c7e74693942a74424c59227e3361533b03", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months. ", "start_char_idx": 849, "end_char_idx": 1011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dffa1ad6-375a-481d-8d43-4e15be89a0f3": {"__data__": {"id_": "dffa1ad6-375a-481d-8d43-4e15be89a0f3", "embedding": null, "metadata": {"window": "It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n", "original_text": "I'll treasure the relationships I've forged here for \na long time to  come.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a4d179c-b36e-449b-bee1-6750b0a4def8", "node_type": "1", "metadata": {"window": "Before handing this back to Mike, I just want to share what a privile ge it's been to be a part of the \nCardinal Health  team over these past nine months.  It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.  ", "original_text": "I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b8533eb8f4ddedcb3c5eb79402373fc5f7ed582d0ebe19ccd612c865290145d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaa97317-79bd-4c18-bbce-2a58362131ca", "node_type": "1", "metadata": {"window": "This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths. ", "original_text": "Finally, and most importantly, I would like to extend a very warm welcome to Jason. "}, "hash": "ce6eef499f9e6ec25f14aef5118c6b578d7eea3754543d89dd45cf317c056425", "class_name": "RelatedNodeInfo"}}, "text": "I'll treasure the relationships I've forged here for \na long time to  come.  \n", "start_char_idx": 1011, "end_char_idx": 1089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaa97317-79bd-4c18-bbce-2a58362131ca": {"__data__": {"id_": "eaa97317-79bd-4c18-bbce-2a58362131ca", "embedding": null, "metadata": {"window": "This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths. ", "original_text": "Finally, and most importantly, I would like to extend a very warm welcome to Jason. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dffa1ad6-375a-481d-8d43-4e15be89a0f3", "node_type": "1", "metadata": {"window": "It's through those experiences I witnessed how \nextraordinary this company is  and how talented and committed the people are.  This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n", "original_text": "I'll treasure the relationships I've forged here for \na long time to  come.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "890263880df6265d6c7d564216d14dab6002cd45ea5f92507b3581bfd5ed8763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f661a2f-38e9-4ec0-8471-20417d966356", "node_type": "1", "metadata": {"window": "I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO. ", "original_text": "It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.  "}, "hash": "d381e73de8a7ca85f160a1d28e3f3db18554c399602dcc0d689de2219653dbb8", "class_name": "RelatedNodeInfo"}}, "text": "Finally, and most importantly, I would like to extend a very warm welcome to Jason. ", "start_char_idx": 1089, "end_char_idx": 1173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f661a2f-38e9-4ec0-8471-20417d966356": {"__data__": {"id_": "1f661a2f-38e9-4ec0-8471-20417d966356", "embedding": null, "metadata": {"window": "I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO. ", "original_text": "It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.  ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaa97317-79bd-4c18-bbce-2a58362131ca", "node_type": "1", "metadata": {"window": "This is a special place \nwith an honorable mission  and an  enviable culture.  \n I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths. ", "original_text": "Finally, and most importantly, I would like to extend a very warm welcome to Jason. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93fd4737b9ed5c53e4ed5964a76125c314c568dbda527d4770896e17f67d1d5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e07078a-677a-4135-b15c-ac1702539d69", "node_type": "1", "metadata": {"window": "I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization. ", "original_text": "With that, let me turn it back over to Mike.  \n  \n"}, "hash": "2ffbd5d17be5af582f823e329c3b090ddfad8aaf4742dd3a8be73edd9487e70e", "class_name": "RelatedNodeInfo"}}, "text": "It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.  ", "start_char_idx": 1173, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e07078a-677a-4135-b15c-ac1702539d69": {"__data__": {"id_": "4e07078a-677a-4135-b15c-ac1702539d69", "embedding": null, "metadata": {"window": "I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization. ", "original_text": "With that, let me turn it back over to Mike.  \n  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f661a2f-38e9-4ec0-8471-20417d966356", "node_type": "1", "metadata": {"window": "I'd like to thank the finance team for their support and patience and the full Cardinal Health family for \ntheir dedication in navigating these past nine months.  I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO. ", "original_text": "It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.  ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b90e40d2ef92985a325d22d304e8faafbde36b120c04ef36719a1cd0641ba564", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45d1c651-ac2c-42f9-9099-69165d1fb620", "node_type": "1", "metadata": {"window": "Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27. ", "original_text": "Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths. "}, "hash": "0fc934b863758a1fe76ee9c171837c18186ddf142f4a401e650caad1c972965e", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it back over to Mike.  \n  \n", "start_char_idx": 1328, "end_char_idx": 1378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45d1c651-ac2c-42f9-9099-69165d1fb620": {"__data__": {"id_": "45d1c651-ac2c-42f9-9099-69165d1fb620", "embedding": null, "metadata": {"window": "Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27. ", "original_text": "Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e07078a-677a-4135-b15c-ac1702539d69", "node_type": "1", "metadata": {"window": "I'll treasure the relationships I've forged here for \na long time to  come.  \n Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization. ", "original_text": "With that, let me turn it back over to Mike.  \n  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59e8b4d4e964d141f381590333973c483f1d58559abe2fcd7004d76b87f86345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c26159d7-6a9f-4e8e-97fa-95d63ff99051", "node_type": "1", "metadata": {"window": "It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions. ", "original_text": "He has  been a trusted advisor and a skilled CFO. "}, "hash": "939e9abca876abc17fba95bf7d0712decc72c17504a6e0867c21f0223ecd91b3", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths. ", "start_char_idx": 1378, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c26159d7-6a9f-4e8e-97fa-95d63ff99051": {"__data__": {"id_": "c26159d7-6a9f-4e8e-97fa-95d63ff99051", "embedding": null, "metadata": {"window": "It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions. ", "original_text": "He has  been a trusted advisor and a skilled CFO. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45d1c651-ac2c-42f9-9099-69165d1fb620", "node_type": "1", "metadata": {"window": "Finally, and most importantly, I would like to extend a very warm welcome to Jason.  It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27. ", "original_text": "Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf084b83d5e600d1435cd6933c2c587e533e5e4aee5bfa4b4839911466af3830", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52ba60ff-f304-4c4a-94c1-dfd324baf341", "node_type": "1", "metadata": {"window": "With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "And his leadership has contributed \nsignificantl y to our executive team  and the finance organization. "}, "hash": "9124d33d6e8fd6695605cb22a93b22c42ff98602ecdc99ba58bc61a00ee7a6d1", "class_name": "RelatedNodeInfo"}}, "text": "He has  been a trusted advisor and a skilled CFO. ", "start_char_idx": 1510, "end_char_idx": 1560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52ba60ff-f304-4c4a-94c1-dfd324baf341": {"__data__": {"id_": "52ba60ff-f304-4c4a-94c1-dfd324baf341", "embedding": null, "metadata": {"window": "With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "And his leadership has contributed \nsignificantl y to our executive team  and the finance organization. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c26159d7-6a9f-4e8e-97fa-95d63ff99051", "node_type": "1", "metadata": {"window": "It's been great to \nhave him on  board and I look forward to working closely with him over the next few weeks to help \nmake  this a seamless  transition.   With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions. ", "original_text": "He has  been a trusted advisor and a skilled CFO. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0ee6aa29c082e82278c64e77e58e5f71f9469b612cc05946dfeb546e544fb82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b320b0eb-c56a-4bc1-bee8-47d26b245d27", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27. "}, "hash": "794843ad5c4f747aa91b25ca474153f718b1e759dea7624c61f82f3481bd9035", "class_name": "RelatedNodeInfo"}}, "text": "And his leadership has contributed \nsignificantl y to our executive team  and the finance organization. ", "start_char_idx": 1560, "end_char_idx": 1664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b320b0eb-c56a-4bc1-bee8-47d26b245d27": {"__data__": {"id_": "b320b0eb-c56a-4bc1-bee8-47d26b245d27", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52ba60ff-f304-4c4a-94c1-dfd324baf341", "node_type": "1", "metadata": {"window": "With that, let me turn it back over to Mike.  \n  \n Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "And his leadership has contributed \nsignificantl y to our executive team  and the finance organization. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "670fd95c0302c6c26d16e7a059bcd9c3eaed9b5f43347d75ed299c99ffd1cdaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07f6a125-6228-4382-8fb8-603b093135f1", "node_type": "1", "metadata": {"window": "He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions. "}, "hash": "ade7f792132a3055c420862484403f45136849d0a21e9ace6567c3d70ab112b2", "class_name": "RelatedNodeInfo"}}, "text": "We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27. ", "start_char_idx": 1664, "end_char_idx": 1775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07f6a125-6228-4382-8fb8-603b093135f1": {"__data__": {"id_": "07f6a125-6228-4382-8fb8-603b093135f1", "embedding": null, "metadata": {"window": "He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b320b0eb-c56a-4bc1-bee8-47d26b245d27", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \n   \nThank you doesn't seem like nearly enough for all that Dave has accomplished over the last nine \nmonths.  He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d83dd2a57a2760faf16607a7f505ae374123855e6467cc84faa9de7710a4d4ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f2ef7b-de1c-458d-bbe1-c48bc20de7ba", "node_type": "1", "metadata": {"window": "And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  "}, "hash": "e1e038069fbc38171fe67ce1eed6d93a72f63e29355d754fbb34a3a2141f8267", "class_name": "RelatedNodeInfo"}}, "text": "Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions. ", "start_char_idx": 1775, "end_char_idx": 1989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f2ef7b-de1c-458d-bbe1-c48bc20de7ba": {"__data__": {"id_": "f4f2ef7b-de1c-458d-bbe1-c48bc20de7ba", "embedding": null, "metadata": {"window": "And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0617acc4ccde83dca5f6921ecfcbdd7a292850e361f9e2507fcb2a6b37435ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07f6a125-6228-4382-8fb8-603b093135f1", "node_type": "1", "metadata": {"window": "He has  been a trusted advisor and a skilled CFO.  And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions. ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9b3606475d3eac0cf9cc135ba84dea57e54d4973a596dff8e25b9e0c74ded30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "582b5cdd-d86f-48b6-ba87-8601003b5935", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team. ", "original_text": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n"}, "hash": "dc84dfe033d5fcd2136aec7303a27d0edb5b8bb4c2532432855732b6b37dc980", "class_name": "RelatedNodeInfo"}}, "text": "With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "start_char_idx": 1989, "end_char_idx": 2181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "582b5cdd-d86f-48b6-ba87-8601003b5935": {"__data__": {"id_": "582b5cdd-d86f-48b6-ba87-8601003b5935", "embedding": null, "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team. ", "original_text": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f2ef7b-de1c-458d-bbe1-c48bc20de7ba", "node_type": "1", "metadata": {"window": "And his leadership has contributed \nsignificantl y to our executive team  and the finance organization.  We appreciate his ongoing work to \nensure a seamless transition with Jason Hollar,  who joined us on April 27.  Dave will remain with us \nuntil May 26, at which time Jason will officially assume the  CFO rol e. Jason has been getting up to \nspeed for the last few weeks and I already appreciate his candor and  contributions.  With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "original_text": "With his strong \nleadership background, deep financial expertise and prior experiences managing  dynamic \nenvironments, he will be a true asset  to our team as we navigate this pivotal time.  ", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89f51b0060102f292dc7efc865aa5fbf7b84bcac2d9ae22fc25914b210b8cb1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db374b57-1515-46d0-91ff-0a1f79bf0fea", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us. ", "original_text": "Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well. "}, "hash": "cede50b368e348369ea051d7839823378b33bfe70d8a1ffe4793162587cfe5fd", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n", "start_char_idx": 0, "end_char_idx": 83, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db374b57-1515-46d0-91ff-0a1f79bf0fea": {"__data__": {"id_": "db374b57-1515-46d0-91ff-0a1f79bf0fea", "embedding": null, "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us. ", "original_text": "Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "582b5cdd-d86f-48b6-ba87-8601003b5935", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team. ", "original_text": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c5b59f0a4998c9720894200d2a2d6d53016643543c4f17ab5d1f37fd8e5811f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ac16330-f3d9-4dca-8906-96fb652b7338", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share. ", "original_text": "I've appreciated the partnership from both of you as I get \nup to speed.  "}, "hash": "46e7cb58e7802487838220f30bdd56df89d1240a50e1f6af5ad4571405692bb8", "class_name": "RelatedNodeInfo"}}, "text": "Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well. ", "start_char_idx": 83, "end_char_idx": 144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ac16330-f3d9-4dca-8906-96fb652b7338": {"__data__": {"id_": "5ac16330-f3d9-4dca-8906-96fb652b7338", "embedding": null, "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share. ", "original_text": "I've appreciated the partnership from both of you as I get \nup to speed.  ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db374b57-1515-46d0-91ff-0a1f79bf0fea", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us. ", "original_text": "Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd2e799dfa29660b9f32332752acbf345ed8bb0d896f9efbce5f746da2e59aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3407171b-87ef-4b76-9d3a-29cd41580a3f", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n", "original_text": "I'm really excit ed to join the team. "}, "hash": "f00782637fb4d8c06eaf6a43e6a916320d2356a276154e1647d77df59e305a69", "class_name": "RelatedNodeInfo"}}, "text": "I've appreciated the partnership from both of you as I get \nup to speed.  ", "start_char_idx": 144, "end_char_idx": 218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3407171b-87ef-4b76-9d3a-29cd41580a3f": {"__data__": {"id_": "3407171b-87ef-4b76-9d3a-29cd41580a3f", "embedding": null, "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n", "original_text": "I'm really excit ed to join the team. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ac16330-f3d9-4dca-8906-96fb652b7338", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share. ", "original_text": "I've appreciated the partnership from both of you as I get \nup to speed.  ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1be870f07e4cc0113f27ca86eed6a7a4b95553b3c426ca029e9cc5d985c11818", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d4d0bbd-b912-44b4-a1db-5a5a892b63bd", "node_type": "1", "metadata": {"window": "Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason. ", "original_text": "While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us. "}, "hash": "cbbf270b55627b9f63cecc47fe7db12310d117adea8c4e13bd8e54bbd540799b", "class_name": "RelatedNodeInfo"}}, "text": "I'm really excit ed to join the team. ", "start_char_idx": 218, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d4d0bbd-b912-44b4-a1db-5a5a892b63bd": {"__data__": {"id_": "9d4d0bbd-b912-44b4-a1db-5a5a892b63bd", "embedding": null, "metadata": {"window": "Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason. ", "original_text": "While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3407171b-87ef-4b76-9d3a-29cd41580a3f", "node_type": "1", "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n", "original_text": "I'm really excit ed to join the team. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edbb842b9116817523355f500ec061622dfa94b7b3b0d6357b512898bf0f32e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0db27ef7-e234-4451-b45e-fe7e630bf68e", "node_type": "1", "metadata": {"window": "I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic. ", "original_text": "What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share. "}, "hash": "4195b895dac236bfad6f11e4e199994b48d1d26c0c9fdd26824149caa1a9a8cf", "class_name": "RelatedNodeInfo"}}, "text": "While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us. ", "start_char_idx": 256, "end_char_idx": 392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0db27ef7-e234-4451-b45e-fe7e630bf68e": {"__data__": {"id_": "0db27ef7-e234-4451-b45e-fe7e630bf68e", "embedding": null, "metadata": {"window": "I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic. ", "original_text": "What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d4d0bbd-b912-44b4-a1db-5a5a892b63bd", "node_type": "1", "metadata": {"window": "Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason. ", "original_text": "While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d88928fbfc0571a006f41d437c09f7c6d451babcecfae7ed31ba3c9919524765", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e7351b6-7c80-4455-bddd-f624606f7984", "node_type": "1", "metadata": {"window": "I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty. ", "original_text": "I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n"}, "hash": "1b54eaa0a118bd31bfbf12308c0d819a7542c542a3abd811b5cfce24ade69c76", "class_name": "RelatedNodeInfo"}}, "text": "What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share. ", "start_char_idx": 392, "end_char_idx": 554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e7351b6-7c80-4455-bddd-f624606f7984": {"__data__": {"id_": "2e7351b6-7c80-4455-bddd-f624606f7984", "embedding": null, "metadata": {"window": "I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty. ", "original_text": "I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0db27ef7-e234-4451-b45e-fe7e630bf68e", "node_type": "1", "metadata": {"window": "I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic. ", "original_text": "What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cec93184b1f4ba71f19e8f544ec84e491d7665d9db762dde3e7ca20841616e23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f03a22d6-7d2a-4a10-869c-e4e3adb7ec56", "node_type": "1", "metadata": {"window": "While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business. ", "original_text": "Michael C. Kaufmann:  \nThanks, Jason. "}, "hash": "77d4e23636f66da4f065ce5dc5f1326b5fb6d4a84ca59b997c26a7d556c44306", "class_name": "RelatedNodeInfo"}}, "text": "I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n", "start_char_idx": 554, "end_char_idx": 643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f03a22d6-7d2a-4a10-869c-e4e3adb7ec56": {"__data__": {"id_": "f03a22d6-7d2a-4a10-869c-e4e3adb7ec56", "embedding": null, "metadata": {"window": "While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business. ", "original_text": "Michael C. Kaufmann:  \nThanks, Jason. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e7351b6-7c80-4455-bddd-f624606f7984", "node_type": "1", "metadata": {"window": "I'm really excit ed to join the team.  While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty. ", "original_text": "I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87a9aabb3e4218c87a0670a63f8182ff109e2707b344ece9f876049f64981130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddbc55aa-8b21-48d7-8f47-ead88f7ee0e2", "node_type": "1", "metadata": {"window": "What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.  ", "original_text": "In my opening comments, I discussed our immediate response to the global \npandem ic. "}, "hash": "7afdffd3af6e556946f1c2ab78bd37fd6ce1027d9c6b0cef7b5b3626acf4b6b4", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nThanks, Jason. ", "start_char_idx": 643, "end_char_idx": 681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddbc55aa-8b21-48d7-8f47-ead88f7ee0e2": {"__data__": {"id_": "ddbc55aa-8b21-48d7-8f47-ead88f7ee0e2", "embedding": null, "metadata": {"window": "What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.  ", "original_text": "In my opening comments, I discussed our immediate response to the global \npandem ic. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f03a22d6-7d2a-4a10-869c-e4e3adb7ec56", "node_type": "1", "metadata": {"window": "While Cardinal is and has been an industry leader that \nis essential to care,  there are still tremendous opportunities in front of us.  What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business. ", "original_text": "Michael C. Kaufmann:  \nThanks, Jason. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d25bd6a43fd89585940452b5c8f5af8ec07493b3bb1065aac6998727f6b1fb8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9828afcb-3180-4346-ab32-c964ccdb8061", "node_type": "1", "metadata": {"window": "I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it. ", "original_text": "It's clear  that the current environment presents uncertainty. "}, "hash": "8b7cb4c7063c328c69eb645a42e92ba068ad66f554d719c16c27a135fcbf2f92", "class_name": "RelatedNodeInfo"}}, "text": "In my opening comments, I discussed our immediate response to the global \npandem ic. ", "start_char_idx": 681, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9828afcb-3180-4346-ab32-c964ccdb8061": {"__data__": {"id_": "9828afcb-3180-4346-ab32-c964ccdb8061", "embedding": null, "metadata": {"window": "I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it. ", "original_text": "It's clear  that the current environment presents uncertainty. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddbc55aa-8b21-48d7-8f47-ead88f7ee0e2", "node_type": "1", "metadata": {"window": "What really drew me to \nCardinal Health was both the  strength of the current team as well as the posit ive culture and values of \nthe organization that I share.  I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.  ", "original_text": "In my opening comments, I discussed our immediate response to the global \npandem ic. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22031c992c682603522044c9cf90a8932a2aaf58dd72c84b9e12209ea8e3a5bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a51ed7b-8e98-4aa3-a996-8b8b252f4801", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n", "original_text": "And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business. "}, "hash": "4909bdcfa1a8cb2bc063f4179af91a5a42fc8c3cbaad2d6f5419dbdbff7268e0", "class_name": "RelatedNodeInfo"}}, "text": "It's clear  that the current environment presents uncertainty. ", "start_char_idx": 766, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a51ed7b-8e98-4aa3-a996-8b8b252f4801": {"__data__": {"id_": "4a51ed7b-8e98-4aa3-a996-8b8b252f4801", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n", "original_text": "And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9828afcb-3180-4346-ab32-c964ccdb8061", "node_type": "1", "metadata": {"window": "I look  forward to meeting and interacting with many of you over the \ncoming months.  \n \n Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it. ", "original_text": "It's clear  that the current environment presents uncertainty. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ceae3ccbef07f0a7bd1322abfd85e598e2aba0028399035e329a1a28085aaa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afc2e198-e2e8-41c2-bc01-632f70681657", "node_type": "1", "metadata": {"window": "In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem. ", "original_text": "I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.  "}, "hash": "07140cb60e78aa8f4b93eb0a8b963fc65d7536f024224fb4fbe85545677a91a8", "class_name": "RelatedNodeInfo"}}, "text": "And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business. ", "start_char_idx": 829, "end_char_idx": 1004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afc2e198-e2e8-41c2-bc01-632f70681657": {"__data__": {"id_": "afc2e198-e2e8-41c2-bc01-632f70681657", "embedding": null, "metadata": {"window": "In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem. ", "original_text": "I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.  ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a51ed7b-8e98-4aa3-a996-8b8b252f4801", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nThanks, Jason.  In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n", "original_text": "And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00b8e90d1ca3aef9df0a21de8fdf6cd8b7501ad749235b4807e9601931d3dfc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd87ec13-ae44-4ec2-872e-8ab5bb42b3b0", "node_type": "1", "metadata": {"window": "It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures. ", "original_text": "It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it. "}, "hash": "baa4714328e0ee1b0592bd8292c8f255317f4dd8052ce7352df818ac6af9cd41", "class_name": "RelatedNodeInfo"}}, "text": "I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.  ", "start_char_idx": 1004, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd87ec13-ae44-4ec2-872e-8ab5bb42b3b0": {"__data__": {"id_": "bd87ec13-ae44-4ec2-872e-8ab5bb42b3b0", "embedding": null, "metadata": {"window": "It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures. ", "original_text": "It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afc2e198-e2e8-41c2-bc01-632f70681657", "node_type": "1", "metadata": {"window": "In my opening comments, I discussed our immediate response to the global \npandem ic.  It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem. ", "original_text": "I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.  ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f0f5c1c21120fa3840f0bf24a1b8593d9e2a971c7ba0556df616960e7ce7341", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17c38b86-b821-4105-963b-3eaa3ad53a15", "node_type": "1", "metadata": {"window": "And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business. ", "original_text": "This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n"}, "hash": "d3a4e8e701f6f90bb803af81f81699487f5b3d3290e8853b062d850c249395ad", "class_name": "RelatedNodeInfo"}}, "text": "It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it. ", "start_char_idx": 1109, "end_char_idx": 1353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17c38b86-b821-4105-963b-3eaa3ad53a15": {"__data__": {"id_": "17c38b86-b821-4105-963b-3eaa3ad53a15", "embedding": null, "metadata": {"window": "And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business. ", "original_text": "This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd87ec13-ae44-4ec2-872e-8ab5bb42b3b0", "node_type": "1", "metadata": {"window": "It's clear  that the current environment presents uncertainty.  And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures. ", "original_text": "It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b476991a094565e71243c886c62793b1edf1841500b7985623f06e4dc0ce028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85b38c9d-8354-4bd8-b912-e41aeb3729fb", "node_type": "1", "metadata": {"window": "I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio. ", "original_text": "With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem. "}, "hash": "22a5db685a60f658d0f21dd004a5d13a0d43089cc04308afe6b6792899e29ab8", "class_name": "RelatedNodeInfo"}}, "text": "This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n", "start_char_idx": 1353, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85b38c9d-8354-4bd8-b912-e41aeb3729fb": {"__data__": {"id_": "85b38c9d-8354-4bd8-b912-e41aeb3729fb", "embedding": null, "metadata": {"window": "I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio. ", "original_text": "With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17c38b86-b821-4105-963b-3eaa3ad53a15", "node_type": "1", "metadata": {"window": "And although there are many \nvariables to consider as we look  ahead, I'd like to highlight three areas to watch that we believe could \nmost meaningfully affect our business.  I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business. ", "original_text": "This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8a8174d719b7ea2e7e89bff6c85c7dcad3ea4a82ef271b49d4260a54a3f52c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2580da52-0a87-4c41-9169-ae65f47e3849", "node_type": "1", "metadata": {"window": "It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.  ", "original_text": "First, elective procedures. "}, "hash": "5a230ab1015d5f0d2d76ef65a1c51e47a1f9e16dbff1bac20a8af07edb714add", "class_name": "RelatedNodeInfo"}}, "text": "With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem. ", "start_char_idx": 1459, "end_char_idx": 1607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2580da52-0a87-4c41-9169-ae65f47e3849": {"__data__": {"id_": "2580da52-0a87-4c41-9169-ae65f47e3849", "embedding": null, "metadata": {"window": "It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.  ", "original_text": "First, elective procedures. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85b38c9d-8354-4bd8-b912-e41aeb3729fb", "node_type": "1", "metadata": {"window": "I'll  then share so me strategic actions we're taking to best \nposition Cardinal Health for the future.   It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio. ", "original_text": "With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fedc688a467c30886a7a0b919b7692e613aae755f4e47fdc087ee4955e7de28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d995c8f-b301-4432-bb9d-251746f6cdb0", "node_type": "1", "metadata": {"window": "This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels. ", "original_text": "When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business. "}, "hash": "d9748f38f5228944c8363b3b871faa9011dcbbc65f4c228931690395e61f4366", "class_name": "RelatedNodeInfo"}}, "text": "First, elective procedures. ", "start_char_idx": 1607, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d995c8f-b301-4432-bb9d-251746f6cdb0": {"__data__": {"id_": "3d995c8f-b301-4432-bb9d-251746f6cdb0", "embedding": null, "metadata": {"window": "This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels. ", "original_text": "When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2580da52-0a87-4c41-9169-ae65f47e3849", "node_type": "1", "metadata": {"window": "It is important to note that each of these three areas will be \naffected by the trajectory of the virus itself, including  its potential resurgence and manageability and \nthe timeline for developing and distributing ways to test and treat  it.  This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.  ", "original_text": "First, elective procedures. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0492775456a91f49f5157ab4fdfa92b40eab4f152e490d6433792c0687461a24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d22990ed-d09d-4e4b-ab01-2193a3cd9740", "node_type": "1", "metadata": {"window": "With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio. "}, "hash": "da5f029be385c3d3868c15ac2598e1692631da4fd0055152805f9e7936a99c89", "class_name": "RelatedNodeInfo"}}, "text": "When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business. ", "start_char_idx": 1635, "end_char_idx": 1824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d22990ed-d09d-4e4b-ab01-2193a3cd9740": {"__data__": {"id_": "d22990ed-d09d-4e4b-ab01-2193a3cd9740", "embedding": null, "metadata": {"window": "With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d995c8f-b301-4432-bb9d-251746f6cdb0", "node_type": "1", "metadata": {"window": "This, in turn, affects when and to \nwhat extent the global environment returns to some relative normal.  \n With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels. ", "original_text": "When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef3c5fd8fe92f71508527749e274000832132d6a1db5a3fd64ae5e55615597de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c336615-c783-4ccd-b2c0-174a6d29bbe9", "node_type": "1", "metadata": {"window": "First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.  "}, "hash": "53e4c9671ee4e3904244d7648381ea023708cbb33f770297a6a867b8c54006c1", "class_name": "RelatedNodeInfo"}}, "text": "In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio. ", "start_char_idx": 1824, "end_char_idx": 1965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c336615-c783-4ccd-b2c0-174a6d29bbe9": {"__data__": {"id_": "3c336615-c783-4ccd-b2c0-174a6d29bbe9", "embedding": null, "metadata": {"window": "First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.  ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d22990ed-d09d-4e4b-ab01-2193a3cd9740", "node_type": "1", "metadata": {"window": "With that backdrop, I'd like to highlight elective procedures, generics availability a nd pricing and the \npotential for  changes in our ecosystem.  First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f4ee6ba843fce1f1fb34a02224f7e6e421298ef4d9831aaa4dc6dff96373484", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f203f410-cd4c-4139-ace2-99a4d2d6c82a", "node_type": "1", "metadata": {"window": "When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels. "}, "hash": "56a704816717cb4a1983791846b02867f0f4d357ee779c102873761999178d74", "class_name": "RelatedNodeInfo"}}, "text": "And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.  ", "start_char_idx": 1965, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f203f410-cd4c-4139-ace2-99a4d2d6c82a": {"__data__": {"id_": "f203f410-cd4c-4139-ace2-99a4d2d6c82a", "embedding": null, "metadata": {"window": "When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c336615-c783-4ccd-b2c0-174a6d29bbe9", "node_type": "1", "metadata": {"window": "First, elective procedures.  When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.  ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd614f94de00a4b7b170f4127a7a52691bcefb3bfb413bc09a6df056d270f9a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff85b395-e1e2-4afc-a6ae-3b3e9c1b8530", "node_type": "1", "metadata": {"window": "In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "It's also possible that we might see a "}, "hash": "a1f69b9cf69955a6e637b9f63b9a08e919994e5ebf57d44cbd767525ca7cf7c9", "class_name": "RelatedNodeInfo"}}, "text": "Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels. ", "start_char_idx": 2112, "end_char_idx": 2237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff85b395-e1e2-4afc-a6ae-3b3e9c1b8530": {"__data__": {"id_": "ff85b395-e1e2-4afc-a6ae-3b3e9c1b8530", "embedding": null, "metadata": {"window": "In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "It's also possible that we might see a ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43fee25992176271a90d57dc20ad25070e15768d41bf4f9a0b2fd3b016440e2f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f203f410-cd4c-4139-ace2-99a4d2d6c82a", "node_type": "1", "metadata": {"window": "When and how patients re -enter \nnon-emergency areas of  the healthcare system, including elective medical procedures and physician \noffice visits, affects multiple areas of  our business.  In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels. ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1547086295ef22242f697ea29b607e9063a01fe9fc650cdb632713c5a73f718", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3007680-b3b7-44ec-bbcc-5205e5586f3d", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge. ", "original_text": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand. "}, "hash": "9edaf9605c66ed9f76d51e3c109fb5cc0e76c8ad6eeeeb608b1b8bfb42c77650", "class_name": "RelatedNodeInfo"}}, "text": "It's also possible that we might see a ", "start_char_idx": 2237, "end_char_idx": 2276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3007680-b3b7-44ec-bbcc-5205e5586f3d": {"__data__": {"id_": "d3007680-b3b7-44ec-bbcc-5205e5586f3d", "embedding": null, "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge. ", "original_text": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff85b395-e1e2-4afc-a6ae-3b3e9c1b8530", "node_type": "1", "metadata": {"window": "In Med, the decline in elective procedures is \ncausing significantly lower demand for some of the  higher margin offerings in our portfolio.  And in \nPharma, we are seeing challenges in our Nuclear business and, to  a lesser extent, the physician  \noffice area of our Specialty business.   Although we expect near -term headwinds in these areas, we do \nbelieve demand will eventually rebound to  historical levels.  It's also possible that we might see a ", "original_text": "It's also possible that we might see a ", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "646354ba7af54b712e8276f9750e1afed035179132f71bc17dbad37f5aebf987", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4af601d1-be99-483e-b139-56a28239ef1c", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n", "original_text": "We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n"}, "hash": "3f72810ec46419dffdf5802064249b7f46dfd195b9995fe95a9e29d3072c9799", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand. ", "start_char_idx": 0, "end_char_idx": 66, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4af601d1-be99-483e-b139-56a28239ef1c": {"__data__": {"id_": "4af601d1-be99-483e-b139-56a28239ef1c", "embedding": null, "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n", "original_text": "We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3007680-b3b7-44ec-bbcc-5205e5586f3d", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge. ", "original_text": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f9dbaf74ad80f10258b313f8b6365915f1d8d98509623fac1eac616297a8278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73f4f911-ca1d-4a5f-ae5c-7a6629da8c4a", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions. ", "original_text": "Second, generics availability and pricing. "}, "hash": "a43d3ef3558bf4225bc1b701c741aa3f3b78861909ee57ec13435d5c7444c47c", "class_name": "RelatedNodeInfo"}}, "text": "We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n", "start_char_idx": 66, "end_char_idx": 212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73f4f911-ca1d-4a5f-ae5c-7a6629da8c4a": {"__data__": {"id_": "73f4f911-ca1d-4a5f-ae5c-7a6629da8c4a", "embedding": null, "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions. ", "original_text": "Second, generics availability and pricing. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4af601d1-be99-483e-b139-56a28239ef1c", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n", "original_text": "We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2251f5dfcc9b0ece5d1b987c5e949aa44c24254c3307f732e56735b09b1e2aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab7a0fb1-d89e-454f-bafe-ac95aab90574", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n", "original_text": "Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge. "}, "hash": "1f62493c26e6c078e03af728a32bcfa667c659e786ed8f16f310d87c3b1bfdb2", "class_name": "RelatedNodeInfo"}}, "text": "Second, generics availability and pricing. ", "start_char_idx": 212, "end_char_idx": 255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab7a0fb1-d89e-454f-bafe-ac95aab90574": {"__data__": {"id_": "ab7a0fb1-d89e-454f-bafe-ac95aab90574", "embedding": null, "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n", "original_text": "Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73f4f911-ca1d-4a5f-ae5c-7a6629da8c4a", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions. ", "original_text": "Second, generics availability and pricing. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "281b8197574be11c1c3d88c9c77ccf6b728279160ca099d504a8ef3e368a6cdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6cd5125-1b30-4d45-8c78-6f86e91ec3a8", "node_type": "1", "metadata": {"window": "We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem. ", "original_text": "Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n"}, "hash": "e6f2468ca38c3155eae186192edc0422c8dd8ea7e1e764ef8aaebb7abc50417a", "class_name": "RelatedNodeInfo"}}, "text": "Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge. ", "start_char_idx": 255, "end_char_idx": 434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6cd5125-1b30-4d45-8c78-6f86e91ec3a8": {"__data__": {"id_": "e6cd5125-1b30-4d45-8c78-6f86e91ec3a8", "embedding": null, "metadata": {"window": "We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem. ", "original_text": "Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab7a0fb1-d89e-454f-bafe-ac95aab90574", "node_type": "1", "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n", "original_text": "Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73a6821c7aa29b817bcf9ae66bb3a6bc2d081b6158bcee4236979e840be56a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97ac17e6-c08d-49df-ac67-fab9b0c7b1f7", "node_type": "1", "metadata": {"window": "Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future. ", "original_text": "Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions. "}, "hash": "c57da1ef36ad11ee97e7665d973a1bb039c396a08ea8e7e8706db2dd205cbf63", "class_name": "RelatedNodeInfo"}}, "text": "Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n", "start_char_idx": 434, "end_char_idx": 621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97ac17e6-c08d-49df-ac67-fab9b0c7b1f7": {"__data__": {"id_": "97ac17e6-c08d-49df-ac67-fab9b0c7b1f7", "embedding": null, "metadata": {"window": "Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future. ", "original_text": "Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6cd5125-1b30-4d45-8c78-6f86e91ec3a8", "node_type": "1", "metadata": {"window": "We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem. ", "original_text": "Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17f4d926c18ef772be2fd1f118647c454ddc77dc6b7b020cfae76895daa620d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "563930c4-7de4-4f8c-9d6c-aeff4e013c49", "node_type": "1", "metadata": {"window": "Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve. ", "original_text": "Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n"}, "hash": "92531a5baafe4ca73badc964d92bfd0503fdb906c4579d75570ed0d04c814ae3", "class_name": "RelatedNodeInfo"}}, "text": "Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions. ", "start_char_idx": 621, "end_char_idx": 795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "563930c4-7de4-4f8c-9d6c-aeff4e013c49": {"__data__": {"id_": "563930c4-7de4-4f8c-9d6c-aeff4e013c49", "embedding": null, "metadata": {"window": "Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve. ", "original_text": "Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97ac17e6-c08d-49df-ac67-fab9b0c7b1f7", "node_type": "1", "metadata": {"window": "Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future. ", "original_text": "Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ff74ff8da850102b75a3a7db5322c1eb1eb352ec074b1c190f5ce4cbbe2aa9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ad20631-e557-4e2e-87d3-48a7456c9c48", "node_type": "1", "metadata": {"window": "Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment. ", "original_text": "Third, potential changes in our ecosystem. "}, "hash": "ab34258c59981ea1d12972cc61e24088b415ca69b3102a9bb2508516012163d1", "class_name": "RelatedNodeInfo"}}, "text": "Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n", "start_char_idx": 795, "end_char_idx": 983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ad20631-e557-4e2e-87d3-48a7456c9c48": {"__data__": {"id_": "5ad20631-e557-4e2e-87d3-48a7456c9c48", "embedding": null, "metadata": {"window": "Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment. ", "original_text": "Third, potential changes in our ecosystem. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "563930c4-7de4-4f8c-9d6c-aeff4e013c49", "node_type": "1", "metadata": {"window": "Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge.  Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve. ", "original_text": "Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "793d99bd244c83c354816f43fa8f7e5421c91ac522e3416c3363336a58d120b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5a02dd9-a1bb-4882-b9fd-dcff6ea25947", "node_type": "1", "metadata": {"window": "Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n", "original_text": "Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future. "}, "hash": "760a1f5d61ae5c83964ad426f49dc8f6dc0ddd991fe1b438d0e53343e5a8da22", "class_name": "RelatedNodeInfo"}}, "text": "Third, potential changes in our ecosystem. ", "start_char_idx": 983, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5a02dd9-a1bb-4882-b9fd-dcff6ea25947": {"__data__": {"id_": "c5a02dd9-a1bb-4882-b9fd-dcff6ea25947", "embedding": null, "metadata": {"window": "Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n", "original_text": "Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ad20631-e557-4e2e-87d3-48a7456c9c48", "node_type": "1", "metadata": {"window": "Things  like potential export restrictions or the impact of the virus on \nmanufacturing capabilities in key countries may affect  the availability of finished goods  or raw \nmaterials.  \n Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment. ", "original_text": "Third, potential changes in our ecosystem. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1327562e64fb841ad833a8451896cf413f8e36a60df3c188e1eb475abbd32f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09b7b9ff-6b1c-445b-a556-13e66650174d", "node_type": "1", "metadata": {"window": "Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest. ", "original_text": "We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve. "}, "hash": "e83a46ee257062e65e006cb37197537a5dbebfea103522219315e3831efb7f84", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future. ", "start_char_idx": 1026, "end_char_idx": 1151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09b7b9ff-6b1c-445b-a556-13e66650174d": {"__data__": {"id_": "09b7b9ff-6b1c-445b-a556-13e66650174d", "embedding": null, "metadata": {"window": "Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest. ", "original_text": "We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5a02dd9-a1bb-4882-b9fd-dcff6ea25947", "node_type": "1", "metadata": {"window": "Although we've seen some temporary spikes in demand for certain products, the team has partnered \nwell with  both customers and suppliers to help mitigate these disruptions.  Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n", "original_text": "Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebf9bb65544bda7b2379fbe8b470449f689f08ebeb6f9ee588057ff458e035a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "add8066b-de6d-4c13-8384-2a4c06de1854", "node_type": "1", "metadata": {"window": "Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n", "original_text": "I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment. "}, "hash": "7e32533d67f77455346cfc691aed275d1b83cc8c34aa93462ebd9dbb3bb0ba9a", "class_name": "RelatedNodeInfo"}}, "text": "We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve. ", "start_char_idx": 1151, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "add8066b-de6d-4c13-8384-2a4c06de1854": {"__data__": {"id_": "add8066b-de6d-4c13-8384-2a4c06de1854", "embedding": null, "metadata": {"window": "Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n", "original_text": "I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09b7b9ff-6b1c-445b-a556-13e66650174d", "node_type": "1", "metadata": {"window": "Red Oak's strengths in data \nand analytics as well  as its visibili ty in understanding of the supply chain are key capabilities that we \nwill utilize during this time of rapid  change.  \n Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest. ", "original_text": "We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6fe4dcd79d7b415a9963b61df3c09bf499c672c0c8b17327cef7561e71ccfe4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5de87ed0-742c-4de1-9ebd-3cc25b949c94", "node_type": "1", "metadata": {"window": "Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible. ", "original_text": "These are just three of the many areas we are  monitoring.  \n"}, "hash": "0540af23aaecb73223556edd191c6f3f0fff6e0f32ce7719af761b3846291dd1", "class_name": "RelatedNodeInfo"}}, "text": "I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment. ", "start_char_idx": 1381, "end_char_idx": 1514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5de87ed0-742c-4de1-9ebd-3cc25b949c94": {"__data__": {"id_": "5de87ed0-742c-4de1-9ebd-3cc25b949c94", "embedding": null, "metadata": {"window": "Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible. ", "original_text": "These are just three of the many areas we are  monitoring.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "add8066b-de6d-4c13-8384-2a4c06de1854", "node_type": "1", "metadata": {"window": "Third, potential changes in our ecosystem.  Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n", "original_text": "I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e75b7e4e2bef6764a278b1429f1ee4f6ee09a7fd00ec9cd47ca289634005f62b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2673e92f-d667-4498-95c8-6e0d64b6668d", "node_type": "1", "metadata": {"window": "We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply. ", "original_text": "In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest. "}, "hash": "2d8c7dacd3308cd9789f1d5d7b1a2b41192b3e668d4807a49326487d83397c93", "class_name": "RelatedNodeInfo"}}, "text": "These are just three of the many areas we are  monitoring.  \n", "start_char_idx": 1514, "end_char_idx": 1575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2673e92f-d667-4498-95c8-6e0d64b6668d": {"__data__": {"id_": "2673e92f-d667-4498-95c8-6e0d64b6668d", "embedding": null, "metadata": {"window": "We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply. ", "original_text": "In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5de87ed0-742c-4de1-9ebd-3cc25b949c94", "node_type": "1", "metadata": {"window": "Clearly, the coronavirus has changed the way we and all \ncompanies  are currently operating and wil l operate in the future.  We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible. ", "original_text": "These are just three of the many areas we are  monitoring.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a88bf9438ec5dc809a1df565e601ed2966297b46e4d3bb9006093c67139773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bd3e19f-ee49-4b69-8dcb-d9d0675beecf", "node_type": "1", "metadata": {"window": "I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts. ", "original_text": "Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n"}, "hash": "6bc7a246864a74159177aaf7b9482912690e779bf481d9ad4293b94d80d12a88", "class_name": "RelatedNodeInfo"}}, "text": "In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest. ", "start_char_idx": 1575, "end_char_idx": 1698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bd3e19f-ee49-4b69-8dcb-d9d0675beecf": {"__data__": {"id_": "2bd3e19f-ee49-4b69-8dcb-d9d0675beecf", "embedding": null, "metadata": {"window": "I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts. ", "original_text": "Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2673e92f-d667-4498-95c8-6e0d64b6668d", "node_type": "1", "metadata": {"window": "We are monitoring the economic \nconditions, changes, shifts  and various timetables for recovery for the participants in the healthcare \necosystem, including, but not limited to,  suppliers, customers and the patients they serve.  I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply. ", "original_text": "In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad9111946c98a8e1b64cb92edff9f6c6800627f5d936b1d334331fa161c014e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d75a3ed8-5561-43e5-9fe6-dae4863dfd05", "node_type": "1", "metadata": {"window": "These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld. ", "original_text": "First, we're partnering to address unpreced ented demand as  much as possible. "}, "hash": "2ccfa94ad9d50fdffa2d541d7ead5410d0f3ecf8378733aef04f013375a7e51c", "class_name": "RelatedNodeInfo"}}, "text": "Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n", "start_char_idx": 1698, "end_char_idx": 1858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d75a3ed8-5561-43e5-9fe6-dae4863dfd05": {"__data__": {"id_": "d75a3ed8-5561-43e5-9fe6-dae4863dfd05", "embedding": null, "metadata": {"window": "These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld. ", "original_text": "First, we're partnering to address unpreced ented demand as  much as possible. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bd3e19f-ee49-4b69-8dcb-d9d0675beecf", "node_type": "1", "metadata": {"window": "I'll discuss \nhow we are adjusting our strategies to best position  ourselves in light of these potential changes in \njust a moment.  These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts. ", "original_text": "Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba728935a85b581da579fc20ee5bd7aef1723ae189c0f9a8bf3a9264f7ac41db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b962b2dc-d2ac-4c45-a1a6-58d0f774553d", "node_type": "1", "metadata": {"window": "In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution. ", "original_text": "Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply. "}, "hash": "5b21b7edf048e6109e89853eba32d87b3a8913a1df5058dc9eb727fa9049dff5", "class_name": "RelatedNodeInfo"}}, "text": "First, we're partnering to address unpreced ented demand as  much as possible. ", "start_char_idx": 1858, "end_char_idx": 1937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b962b2dc-d2ac-4c45-a1a6-58d0f774553d": {"__data__": {"id_": "b962b2dc-d2ac-4c45-a1a6-58d0f774553d", "embedding": null, "metadata": {"window": "In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution. ", "original_text": "Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d75a3ed8-5561-43e5-9fe6-dae4863dfd05", "node_type": "1", "metadata": {"window": "These are just three of the many areas we are  monitoring.  \n In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld. ", "original_text": "First, we're partnering to address unpreced ented demand as  much as possible. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dc689b5e66e0088506d771e230a50fc41e06a4f45f8f74f56c0b10cae747675", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71d31f4d-2002-4849-94b1-c2f23a7df5c4", "node_type": "1", "metadata": {"window": "Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts. "}, "hash": "82aed1781f2b7660d7cf7a79ec81e53152d6e26b9180c0464fafa39a8ff7da2d", "class_name": "RelatedNodeInfo"}}, "text": "Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply. ", "start_char_idx": 1937, "end_char_idx": 2119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71d31f4d-2002-4849-94b1-c2f23a7df5c4": {"__data__": {"id_": "71d31f4d-2002-4849-94b1-c2f23a7df5c4", "embedding": null, "metadata": {"window": "Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b962b2dc-d2ac-4c45-a1a6-58d0f774553d", "node_type": "1", "metadata": {"window": "In response to these shifting dynamics, we have taken strategic actions across the company to \npartner, adapt and  invest.  Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution. ", "original_text": "Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f81fdc54287855dafe8665021338f80e9a47484dd96ad05a0bad03474b62f074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42cc6cb9-465a-4970-abfe-2e41ce42b3fe", "node_type": "1", "metadata": {"window": "First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld. "}, "hash": "be57cd687489d547ba898fa142db4e69f1a63ceb9e36a6ec2fd55f4b1631d779", "class_name": "RelatedNodeInfo"}}, "text": "We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts. ", "start_char_idx": 2119, "end_char_idx": 2271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42cc6cb9-465a-4970-abfe-2e41ce42b3fe": {"__data__": {"id_": "42cc6cb9-465a-4970-abfe-2e41ce42b3fe", "embedding": null, "metadata": {"window": "First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71d31f4d-2002-4849-94b1-c2f23a7df5c4", "node_type": "1", "metadata": {"window": "Let me briefly touch on each of these and share how we are leveraging our \nscale and heritage to better  serve the healthcare system now and into the future.  \n First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bde2a2fd6b7fc0612418a8e7952bb32027f485293d4862b45d905453f5c4520", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "278d3c37-7560-4e58-9eb6-ffb5b5bcc51d", "node_type": "1", "metadata": {"window": "Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution. "}, "hash": "2c84db4f772e132d20a7558c89d207ee8d3461baa466c55a270583bd55e88715", "class_name": "RelatedNodeInfo"}}, "text": "We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld. ", "start_char_idx": 2271, "end_char_idx": 2432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "278d3c37-7560-4e58-9eb6-ffb5b5bcc51d": {"__data__": {"id_": "278d3c37-7560-4e58-9eb6-ffb5b5bcc51d", "embedding": null, "metadata": {"window": "Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42cc6cb9-465a-4970-abfe-2e41ce42b3fe", "node_type": "1", "metadata": {"window": "First, we're partnering to address unpreced ented demand as  much as possible.  Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efa246481f4a0f7b1b914ee796e4c02313277512c56f03bf5b981b800d724224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcf5ad57-eef0-4e4b-85c5-cdeb4c45b123", "node_type": "1", "metadata": {"window": "We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We will continue "}, "hash": "82337e8036a52d84e8ffea4bf526b713bb23110f7e52966305f97d3dc4c51ff3", "class_name": "RelatedNodeInfo"}}, "text": "Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution. ", "start_char_idx": 2432, "end_char_idx": 2642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcf5ad57-eef0-4e4b-85c5-cdeb4c45b123": {"__data__": {"id_": "bcf5ad57-eef0-4e4b-85c5-cdeb4c45b123", "embedding": null, "metadata": {"window": "We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We will continue ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f760b89b02149e15456f56e1561faeb92c6b1c6fc81a4453f766a01fc6e415", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "278d3c37-7560-4e58-9eb6-ffb5b5bcc51d", "node_type": "1", "metadata": {"window": "Surges in demand \nhave challenged the underlying supply in the marketplace and we have  worked with partners across \nthe supply chain to help identify alternative sources of supply.  We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a7441b2ae36a71143190cbaeea3e4aadf84df3d81212df076e2c226c273b504", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d271b624-ccd9-4633-b8f5-909defc99c9f", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward. ", "original_text": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n"}, "hash": "4ae141b7c35cf2b09067571e6e402f622e6666aa205a7cae95bac8b3fc367632", "class_name": "RelatedNodeInfo"}}, "text": "We will continue ", "start_char_idx": 2642, "end_char_idx": 2659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d271b624-ccd9-4633-b8f5-909defc99c9f": {"__data__": {"id_": "d271b624-ccd9-4633-b8f5-909defc99c9f", "embedding": null, "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward. ", "original_text": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcf5ad57-eef0-4e4b-85c5-cdeb4c45b123", "node_type": "1", "metadata": {"window": "We are even  partnering with non -\ntraditional  healthcare companies to develop creative, safe solutions to increase production of  critical \nproducts.  We're also collaborating with innovative companies like Battelle , one of the largest private, \nnonprofit  research and development organizations in the wor ld.  Their teams received FDA \nauthorization  for collecting, decontaminating, and returning N95 respirator masks to healthcare \npersonnel in the  US and we are working with them to provide an end -to-end solution.  We will continue ", "original_text": "We will continue ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a1f89de2f08cb87f8904d9d24cf58a475e41a854021bc1f90e65f200f786c29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "710069eb-ffa5-4728-a7b3-498ba5a860dc", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n", "original_text": "Second, we're remaining and flexible and adaptable. "}, "hash": "f7c8d9bf064322c667f1b290d1b92c503c537a3411eebd2d2f29c9ad599fe5d6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n", "start_char_idx": 0, "end_char_idx": 152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "710069eb-ffa5-4728-a7b3-498ba5a860dc": {"__data__": {"id_": "710069eb-ffa5-4728-a7b3-498ba5a860dc", "embedding": null, "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n", "original_text": "Second, we're remaining and flexible and adaptable. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d271b624-ccd9-4633-b8f5-909defc99c9f", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward. ", "original_text": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "257eb9c2d63babf5108c23f27b6542c2fc80db3cbdd376d0a8bf3b0008e98cf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e085cbf5-9c24-4e47-86c8-20196f656065", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities. ", "original_text": "COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly. "}, "hash": "cc2c3d38e8610f573dfe0bd44ebe087fc554d19fe9552697d2bfcfaca002a0e1", "class_name": "RelatedNodeInfo"}}, "text": "Second, we're remaining and flexible and adaptable. ", "start_char_idx": 152, "end_char_idx": 204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e085cbf5-9c24-4e47-86c8-20196f656065": {"__data__": {"id_": "e085cbf5-9c24-4e47-86c8-20196f656065", "embedding": null, "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities. ", "original_text": "COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "710069eb-ffa5-4728-a7b3-498ba5a860dc", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n", "original_text": "Second, we're remaining and flexible and adaptable. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d9348a15bfab90c1c83db3d46edf7faf511cb1045800e4c673de6c9fdb929c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "892bebc3-1d24-4cd7-9908-9dc2cd8f5874", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n", "original_text": "For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward. "}, "hash": "71bfd1a9d47c58119627b84ab7b535ff612f7509e1952cc0d68d3dd21ac7972e", "class_name": "RelatedNodeInfo"}}, "text": "COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly. ", "start_char_idx": 204, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "892bebc3-1d24-4cd7-9908-9dc2cd8f5874": {"__data__": {"id_": "892bebc3-1d24-4cd7-9908-9dc2cd8f5874", "embedding": null, "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n", "original_text": "For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e085cbf5-9c24-4e47-86c8-20196f656065", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities. ", "original_text": "COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ba8ed04297183e6be35af703b5385021ce124ad8e88bf625f6b1695d46cc020", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a3c95c-487f-47cd-a461-4f0bb4269423", "node_type": "1", "metadata": {"window": "Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term. ", "original_text": "For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n"}, "hash": "b29ca7a4e4e4bbcbdd5d496b6dd2c2784cfba0fe6711571801756c3c30526792", "class_name": "RelatedNodeInfo"}}, "text": "For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward. ", "start_char_idx": 342, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a3c95c-487f-47cd-a461-4f0bb4269423": {"__data__": {"id_": "52a3c95c-487f-47cd-a461-4f0bb4269423", "embedding": null, "metadata": {"window": "Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term. ", "original_text": "For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "892bebc3-1d24-4cd7-9908-9dc2cd8f5874", "node_type": "1", "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n", "original_text": "For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4b578b21b1d0959abb827f1bbaedaf9ef8c0a2065d13502132e62b92021eabe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6088d735-1f1e-4546-8f1c-883d17cb1517", "node_type": "1", "metadata": {"window": "COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n", "original_text": "In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities. "}, "hash": "45d52973b8319925ecc1cdf613266c0bb63d00c84bd6de65a8709fbea5d514ca", "class_name": "RelatedNodeInfo"}}, "text": "For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n", "start_char_idx": 545, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6088d735-1f1e-4546-8f1c-883d17cb1517": {"__data__": {"id_": "6088d735-1f1e-4546-8f1c-883d17cb1517", "embedding": null, "metadata": {"window": "COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n", "original_text": "In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a3c95c-487f-47cd-a461-4f0bb4269423", "node_type": "1", "metadata": {"window": "Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term. ", "original_text": "For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e71771ca6eecf66bc1db1d538456ab185e8d641c024bd85da4ef0e058ce4d42d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0a2b6da-96a4-4fd0-ba91-c417c890f5b6", "node_type": "1", "metadata": {"window": "For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts. ", "original_text": "In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n"}, "hash": "d4b55f4e1971ac0caf417bd557d583107fdafb2f46742fc6408f10579c5c7d73", "class_name": "RelatedNodeInfo"}}, "text": "In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities. ", "start_char_idx": 672, "end_char_idx": 817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0a2b6da-96a4-4fd0-ba91-c417c890f5b6": {"__data__": {"id_": "d0a2b6da-96a4-4fd0-ba91-c417c890f5b6", "embedding": null, "metadata": {"window": "For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts. ", "original_text": "In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6088d735-1f1e-4546-8f1c-883d17cb1517", "node_type": "1", "metadata": {"window": "COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n", "original_text": "In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce86394f59ed8fd3a9f2b7bcfdf96f69c29acd3232568b3dc6061d5834a2bf0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0bc9290-f02d-4b48-897a-79db89a3b67c", "node_type": "1", "metadata": {"window": "For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n", "original_text": "Finally, we're continuing to invest in our  business for the long -term. "}, "hash": "69fe5435185629c7d3340863e502512715438efa914848878774b6fc3d2fb672", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n", "start_char_idx": 817, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0bc9290-f02d-4b48-897a-79db89a3b67c": {"__data__": {"id_": "f0bc9290-f02d-4b48-897a-79db89a3b67c", "embedding": null, "metadata": {"window": "For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n", "original_text": "Finally, we're continuing to invest in our  business for the long -term. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0a2b6da-96a4-4fd0-ba91-c417c890f5b6", "node_type": "1", "metadata": {"window": "For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward.  For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts. ", "original_text": "In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3d08ae2fb8d6ac7613f4709cadae861834e528d2a03b4c4b753f53dbae5ea7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6629fb00-3ea5-4b60-bede-255e8642e393", "node_type": "1", "metadata": {"window": "In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation. ", "original_text": "These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n"}, "hash": "f31b8260176be74c1e97d92cec479ff848ad6925d5e01d200ba832366fba8a7d", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we're continuing to invest in our  business for the long -term. ", "start_char_idx": 1010, "end_char_idx": 1083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6629fb00-3ea5-4b60-bede-255e8642e393": {"__data__": {"id_": "6629fb00-3ea5-4b60-bede-255e8642e393", "embedding": null, "metadata": {"window": "In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation. ", "original_text": "These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0bc9290-f02d-4b48-897a-79db89a3b67c", "node_type": "1", "metadata": {"window": "For \nthat reason, across the co mpany, we are evaluating  how to use our capabilities, talent and \ntechnologies in new ways.  \n In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n", "original_text": "Finally, we're continuing to invest in our  business for the long -term. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b91e1ed278ecb091db2fe754607a5b138ee339584f2d99aa13eef1e9338c3399", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73afc2e0-14fc-4349-bc62-1e461145a4e3", "node_type": "1", "metadata": {"window": "In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n", "original_text": "For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts. "}, "hash": "57a35fcb40e56c2c9943234f180ecc49db370e608b3e5f100bea5a347247ca1a", "class_name": "RelatedNodeInfo"}}, "text": "These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n", "start_char_idx": 1083, "end_char_idx": 1283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73afc2e0-14fc-4349-bc62-1e461145a4e3": {"__data__": {"id_": "73afc2e0-14fc-4349-bc62-1e461145a4e3", "embedding": null, "metadata": {"window": "In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n", "original_text": "For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6629fb00-3ea5-4b60-bede-255e8642e393", "node_type": "1", "metadata": {"window": "In Med, we will focus on furthering our  commercial initiatives, optimizing our supply chain and \nidentifying product development opportunities.  In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation. ", "original_text": "These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3393c3b981e9f7e313f252c6974a1a24111610646813a2b8c0b2f9c1e0b5651c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdb5dc83-2bc1-44c1-a707-725a01ab1154", "node_type": "1", "metadata": {"window": "Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years. ", "original_text": "We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n"}, "hash": "69e08cb0c462a2a7435dfbd0a43e53657e40946bc6ed44d26d52287e696f1195", "class_name": "RelatedNodeInfo"}}, "text": "For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts. ", "start_char_idx": 1283, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdb5dc83-2bc1-44c1-a707-725a01ab1154": {"__data__": {"id_": "fdb5dc83-2bc1-44c1-a707-725a01ab1154", "embedding": null, "metadata": {"window": "Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years. ", "original_text": "We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73afc2e0-14fc-4349-bc62-1e461145a4e3", "node_type": "1", "metadata": {"window": "In Pharma,  we are comm itted to enhancing our \ncustomer engagement experience as well as supporting our customers with  new offerings and \nhelping them innovate through this time of change.  \n Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n", "original_text": "For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82930cd45ad184694da188566af0c4f065f2bef21aca7977e27f2f88acc0ba60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c96c0cda-e0a3-43c1-85c4-6f55331e24c7", "node_type": "1", "metadata": {"window": "These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.  ", "original_text": "Now, let me shift gears and discuss capital allocation. "}, "hash": "8ec6d130e6a2e5bde5e99e16da14ffc13dc1c276457c2294cd65bf529472473c", "class_name": "RelatedNodeInfo"}}, "text": "We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n", "start_char_idx": 1440, "end_char_idx": 1523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c96c0cda-e0a3-43c1-85c4-6f55331e24c7": {"__data__": {"id_": "c96c0cda-e0a3-43c1-85c4-6f55331e24c7", "embedding": null, "metadata": {"window": "These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.  ", "original_text": "Now, let me shift gears and discuss capital allocation. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdb5dc83-2bc1-44c1-a707-725a01ab1154", "node_type": "1", "metadata": {"window": "Finally, we're continuing to invest in our  business for the long -term.  These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years. ", "original_text": "We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3892983642784415a98b886ba7b9e45ce09fc7f46109af96b4ad6cbe0e1aa3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24bbf2d6-9761-4bd0-b972-69351fb0fcb3", "node_type": "1", "metadata": {"window": "For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020. ", "original_text": "We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n"}, "hash": "5895d926bf753d7ac4c7c6a99b1c74defd0f1716025345277fb5ba0c352b7336", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me shift gears and discuss capital allocation. ", "start_char_idx": 1523, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24bbf2d6-9761-4bd0-b972-69351fb0fcb3": {"__data__": {"id_": "24bbf2d6-9761-4bd0-b972-69351fb0fcb3", "embedding": null, "metadata": {"window": "For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020. ", "original_text": "We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c96c0cda-e0a3-43c1-85c4-6f55331e24c7", "node_type": "1", "metadata": {"window": "These significant inv estments will \nbe focused on our IT infrastructure, including our  customer ordering platforms, key businesses such \nas at -Home and Specialty and our employees to name a few.  \n For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.  ", "original_text": "Now, let me shift gears and discuss capital allocation. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5dd4f4f7ffe24352fa71e89ef5c81d966933a0ae4c377716fde8d1fb9b79ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b321fb9-94c2-4524-aa6a-e1bfa727591d", "node_type": "1", "metadata": {"window": "We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years. "}, "hash": "364bf6aaafe25b108f7ec1366696edfe79d480cee394aaa55cb382b735ea71c6", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n", "start_char_idx": 1579, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b321fb9-94c2-4524-aa6a-e1bfa727591d": {"__data__": {"id_": "6b321fb9-94c2-4524-aa6a-e1bfa727591d", "embedding": null, "metadata": {"window": "We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24bbf2d6-9761-4bd0-b972-69351fb0fcb3", "node_type": "1", "metadata": {"window": "For these and other investments throughout the company, we are utilizing portions of  the savings \ngenerated  through our ongoing cost optimization efforts.  We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020. ", "original_text": "We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f024c838e65b6404d369d9d31805393b4ce0599db2197384fe27321d2f001b6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00f02eaa-813e-4971-903c-07d8791a08c3", "node_type": "1", "metadata": {"window": "Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "Further, we remain committed to improving our balance sheet through \nfurther deleveraging.  "}, "hash": "1401f7fddf782a3a1c8f47743c15720063a1f2e25b868511f83b32e259572ab6", "class_name": "RelatedNodeInfo"}}, "text": "Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years. ", "start_char_idx": 1807, "end_char_idx": 1942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00f02eaa-813e-4971-903c-07d8791a08c3": {"__data__": {"id_": "00f02eaa-813e-4971-903c-07d8791a08c3", "embedding": null, "metadata": {"window": "Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "Further, we remain committed to improving our balance sheet through \nfurther deleveraging.  ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b321fb9-94c2-4524-aa6a-e1bfa727591d", "node_type": "1", "metadata": {"window": "We remain on track to deliver on our savings \ngoals for fiscal 2020  and beyond.  \n Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59eed11aebd5777b4bc0a96d064e1a4857f8fd11f94650e9d4a6bf66037cc3ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc577726-2b7f-468b-82b9-4536bfc7ecd7", "node_type": "1", "metadata": {"window": "We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020. "}, "hash": "f5b4a58f266dbdb366ccb6f9bf8992ce8c7b1baf47355c54065c1f6fbe1cdb3e", "class_name": "RelatedNodeInfo"}}, "text": "Further, we remain committed to improving our balance sheet through \nfurther deleveraging.  ", "start_char_idx": 1942, "end_char_idx": 2034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc577726-2b7f-468b-82b9-4536bfc7ecd7": {"__data__": {"id_": "bc577726-2b7f-468b-82b9-4536bfc7ecd7", "embedding": null, "metadata": {"window": "We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00f02eaa-813e-4971-903c-07d8791a08c3", "node_type": "1", "metadata": {"window": "Now, let me shift gears and discuss capital allocation.  We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "Further, we remain committed to improving our balance sheet through \nfurther deleveraging.  ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75f30713b2febfc5786f74b3392c6c41c4652c8b7148ab6563209f73572563f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c265e83f-5927-4651-ae83-b6feba8c4a9f", "node_type": "1", "metadata": {"window": "Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  "}, "hash": "7495cf7f8ec6a97747e94f3c0c530714aa9f521f9821fafdcbab4d0959f1908a", "class_name": "RelatedNodeInfo"}}, "text": "As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020. ", "start_char_idx": 2034, "end_char_idx": 2146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c265e83f-5927-4651-ae83-b6feba8c4a9f": {"__data__": {"id_": "c265e83f-5927-4651-ae83-b6feba8c4a9f", "embedding": null, "metadata": {"window": "Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f47569da70b8bf1475ddd0d5816ced6c6bb4dfe374a2db55eebeadedc11259da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc577726-2b7f-468b-82b9-4536bfc7ecd7", "node_type": "1", "metadata": {"window": "We remain committed to a disciplined and \nbalanced c apital  allocation approach that prioritizes reinvesting in the business, maintaining a strong \nbalance sheet and returning  cash to shareholders in the form of a dividend.  \n Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020. ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49849bae5720935b628dda44aac8b78c21c55e3cd0ff4dc3363831d704030999", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89de6a7c-2c3b-42d3-b50a-b5b099498361", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n", "original_text": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases. "}, "hash": "ecbfa6d0c76b581c6fe95e69852b834ae6689b54c56ced1d1ac81897e3d1fac4", "class_name": "RelatedNodeInfo"}}, "text": "With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "start_char_idx": 2146, "end_char_idx": 2236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89de6a7c-2c3b-42d3-b50a-b5b099498361": {"__data__": {"id_": "89de6a7c-2c3b-42d3-b50a-b5b099498361", "embedding": null, "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n", "original_text": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c265e83f-5927-4651-ae83-b6feba8c4a9f", "node_type": "1", "metadata": {"window": "Capital expenditures remain a critical priority going forward, so we expect to annuall y spend at least \nwhat we  have in prior years.  Further, we remain committed to improving our balance sheet through \nfurther deleveraging.   As Dave mentioned, we're on track to reduce outstanding long -term debt by at \nleast $1 billion in fiscal 2020.  With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "original_text": "With  respe ct to the dividend, our board of directors recently approved a \n1% increase.  ", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0aba88b6704536589f8ee6efca5058214851ad27f5d8210b05a6eaa2b944559", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c63123f1-7f39-4ddc-a297-812b84e5496b", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n", "original_text": "But in the near -term, \nour other  capital allocation priorities take precedence.  \n"}, "hash": "8bfde77605807b72f0ed242838ae77973c029b5bc82ccf96374641c7b236c6bb", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases. ", "start_char_idx": 0, "end_char_idx": 99, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c63123f1-7f39-4ddc-a297-812b84e5496b": {"__data__": {"id_": "c63123f1-7f39-4ddc-a297-812b84e5496b", "embedding": null, "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n", "original_text": "But in the near -term, \nour other  capital allocation priorities take precedence.  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89de6a7c-2c3b-42d3-b50a-b5b099498361", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n", "original_text": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64dcfd43aa206465c058484f780fd141746a8db8bb7b32e202b1e542dee37fe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "822a17fc-a4d5-4509-b5fe-4f3e837ab5b6", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry. ", "original_text": "To close, we are focused on supporting the healthcare system now and into the future. "}, "hash": "c6cd769ae4b5901e0a2308bec1748bec4c965d906434a394a2013faa9e061cbb", "class_name": "RelatedNodeInfo"}}, "text": "But in the near -term, \nour other  capital allocation priorities take precedence.  \n", "start_char_idx": 99, "end_char_idx": 183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "822a17fc-a4d5-4509-b5fe-4f3e837ab5b6": {"__data__": {"id_": "822a17fc-a4d5-4509-b5fe-4f3e837ab5b6", "embedding": null, "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry. ", "original_text": "To close, we are focused on supporting the healthcare system now and into the future. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c63123f1-7f39-4ddc-a297-812b84e5496b", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n", "original_text": "But in the near -term, \nour other  capital allocation priorities take precedence.  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ab8bbd350181bf0783f2e709dab74ec979f218d9ebb60faa6c683febb6db35d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "930fc1e2-44b4-4e1d-b093-0ddc2ff5db2b", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n", "original_text": "We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n"}, "hash": "10219afdfb5b863696ff8729b035609213971f3fdf1b7a25f796f5a7caf8132d", "class_name": "RelatedNodeInfo"}}, "text": "To close, we are focused on supporting the healthcare system now and into the future. ", "start_char_idx": 183, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "930fc1e2-44b4-4e1d-b093-0ddc2ff5db2b": {"__data__": {"id_": "930fc1e2-44b4-4e1d-b093-0ddc2ff5db2b", "embedding": null, "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n", "original_text": "We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "822a17fc-a4d5-4509-b5fe-4f3e837ab5b6", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry. ", "original_text": "To close, we are focused on supporting the healthcare system now and into the future. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0e1d260091c178ea5f0239a39e984bbe52279b83273982cacd189899bca67bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63100f90-1753-449d-958a-1677ea6eb6ac", "node_type": "1", "metadata": {"window": "But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n", "original_text": "Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n"}, "hash": "2365788ea5839bb4868cae3368a6390fae411ad5e4bda3a332f14535f06171f4", "class_name": "RelatedNodeInfo"}}, "text": "We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n", "start_char_idx": 269, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63100f90-1753-449d-958a-1677ea6eb6ac": {"__data__": {"id_": "63100f90-1753-449d-958a-1677ea6eb6ac", "embedding": null, "metadata": {"window": "But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n", "original_text": "Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "930fc1e2-44b4-4e1d-b093-0ddc2ff5db2b", "node_type": "1", "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n", "original_text": "We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48b5265211abd1df662b4b830944828386c975eb7c752f803500d39d59292556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "657f7e60-0917-4307-a889-13c344593a9b", "node_type": "1", "metadata": {"window": "To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far. ", "original_text": "Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry. "}, "hash": "0fc1459f86c5f4e9012bbbaad168bc1bf6818f29f1bfae987ce6b73ea88b22c3", "class_name": "RelatedNodeInfo"}}, "text": "Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n", "start_char_idx": 381, "end_char_idx": 479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "657f7e60-0917-4307-a889-13c344593a9b": {"__data__": {"id_": "657f7e60-0917-4307-a889-13c344593a9b", "embedding": null, "metadata": {"window": "To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far. ", "original_text": "Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63100f90-1753-449d-958a-1677ea6eb6ac", "node_type": "1", "metadata": {"window": "But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n", "original_text": "Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5dcc5a633e165b62543db2aada442ecc30967cb763866434b4b503c24f2af4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3804f37c-73be-4382-9d97-a121e17477b7", "node_type": "1", "metadata": {"window": "We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.  ", "original_text": "It is a privilege, now more than ever, to be essential to care.  \n"}, "hash": "6053be23b65ba82eae09dfca69c87e09f1bf5cf1745639c8e07b0717ad5ff205", "class_name": "RelatedNodeInfo"}}, "text": "Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry. ", "start_char_idx": 479, "end_char_idx": 606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3804f37c-73be-4382-9d97-a121e17477b7": {"__data__": {"id_": "3804f37c-73be-4382-9d97-a121e17477b7", "embedding": null, "metadata": {"window": "We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.  ", "original_text": "It is a privilege, now more than ever, to be essential to care.  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "657f7e60-0917-4307-a889-13c344593a9b", "node_type": "1", "metadata": {"window": "To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far. ", "original_text": "Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9deb2f0dec469453e99d911723757a0a3d0357b1188e1757f7f900e4360e090", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "333a88c0-fa9e-4c12-959b-6ef93f9a48d4", "node_type": "1", "metadata": {"window": "Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter. ", "original_text": "With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n"}, "hash": "fd87943ccf489403423e1b9d2b5e418a7eea5a93b8a24bb367860d0a13cc6755", "class_name": "RelatedNodeInfo"}}, "text": "It is a privilege, now more than ever, to be essential to care.  \n", "start_char_idx": 606, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "333a88c0-fa9e-4c12-959b-6ef93f9a48d4": {"__data__": {"id_": "333a88c0-fa9e-4c12-959b-6ef93f9a48d4", "embedding": null, "metadata": {"window": "Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter. ", "original_text": "With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3804f37c-73be-4382-9d97-a121e17477b7", "node_type": "1", "metadata": {"window": "We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.  ", "original_text": "It is a privilege, now more than ever, to be essential to care.  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "926ee1b085b3c5f747c0c2f068625f5169e2f0c4017aca2603a5aed02687029b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af596633-cc2c-4019-b9db-c660dc332cc8", "node_type": "1", "metadata": {"window": "Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n", "original_text": "Michael Cherny:  \nGood morning and thanks for all the color so far. "}, "hash": "7a07e5c99ad5dcfb99285441ba4e6f3b71692861266b7cce1a3532606bbcb4d2", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n", "start_char_idx": 672, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af596633-cc2c-4019-b9db-c660dc332cc8": {"__data__": {"id_": "af596633-cc2c-4019-b9db-c660dc332cc8", "embedding": null, "metadata": {"window": "Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n", "original_text": "Michael Cherny:  \nGood morning and thanks for all the color so far. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "333a88c0-fa9e-4c12-959b-6ef93f9a48d4", "node_type": "1", "metadata": {"window": "Simultaneously, we are  maintaining a strategic focus on positioning ourselves f or the future.  \n Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter. ", "original_text": "With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fed4b2f717f22e1ecff8816cf5c4e0d5f2ef9578fb566abefe0666417e3c0b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cf21122-2b83-46a3-9030-e3a08763a5d6", "node_type": "1", "metadata": {"window": "It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range. ", "original_text": "I just want to dive a little bit more into some of the \n4Q dynamics.  "}, "hash": "b65430eff8058813c8a762f307ad1b3a7341c85fca9732d70ffa9789a51976ab", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny:  \nGood morning and thanks for all the color so far. ", "start_char_idx": 876, "end_char_idx": 944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cf21122-2b83-46a3-9030-e3a08763a5d6": {"__data__": {"id_": "9cf21122-2b83-46a3-9030-e3a08763a5d6", "embedding": null, "metadata": {"window": "It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range. ", "original_text": "I just want to dive a little bit more into some of the \n4Q dynamics.  ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af596633-cc2c-4019-b9db-c660dc332cc8", "node_type": "1", "metadata": {"window": "Finally, I'd like to reiterate my gratitude for our employees as well as for our customers and partners \nacross the  industry.  It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n", "original_text": "Michael Cherny:  \nGood morning and thanks for all the color so far. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9df326d0f4cd2758f7069df81db7329759d67468d55e50e33d88fbfc872cbc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c1a310-03d5-4b3b-94cb-7518d4dd506e", "node_type": "1", "metadata": {"window": "With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n", "original_text": "Mike, in particular, the reduction in the Pharma outlook for the next quarter. "}, "hash": "da8808235cf48947ff509d546ae2b32697bda3bb5ccd86a80267928580a0ac11", "class_name": "RelatedNodeInfo"}}, "text": "I just want to dive a little bit more into some of the \n4Q dynamics.  ", "start_char_idx": 944, "end_char_idx": 1014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2c1a310-03d5-4b3b-94cb-7518d4dd506e": {"__data__": {"id_": "a2c1a310-03d5-4b3b-94cb-7518d4dd506e", "embedding": null, "metadata": {"window": "With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n", "original_text": "Mike, in particular, the reduction in the Pharma outlook for the next quarter. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cf21122-2b83-46a3-9030-e3a08763a5d6", "node_type": "1", "metadata": {"window": "It is a privilege, now more than ever, to be essential to care.  \n With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range. ", "original_text": "I just want to dive a little bit more into some of the \n4Q dynamics.  ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8f6e06585c06874c1f4a254033c73fd133e263f61fe1bb4311287415476264e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c8e4e2e-cf4e-47a4-9315-964de1feb705", "node_type": "1", "metadata": {"window": "Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n"}, "hash": "304b02b731ed0ba304dad0d8406d5e94f73bed2a273d9f0a0024aca00fb97f46", "class_name": "RelatedNodeInfo"}}, "text": "Mike, in particular, the reduction in the Pharma outlook for the next quarter. ", "start_char_idx": 1014, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c8e4e2e-cf4e-47a4-9315-964de1feb705": {"__data__": {"id_": "1c8e4e2e-cf4e-47a4-9315-964de1feb705", "embedding": null, "metadata": {"window": "Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c1a310-03d5-4b3b-94cb-7518d4dd506e", "node_type": "1", "metadata": {"window": "With that, I'll now pause to open it up for question s. \n \nQUESTION AND ANSWER SECTION  \nOperator : [Operator Instructions] We will take our first question from Michael Cherny with Bank of \nAmerica.  \n  \n Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n", "original_text": "Mike, in particular, the reduction in the Pharma outlook for the next quarter. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a0edb998c9362e176635e500e0069ab6453f158853267c6de2d9e5c5937482d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cce6acd8-68aa-45ae-bfbc-ec77c3ecf3de", "node_type": "1", "metadata": {"window": "I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "And then as  you think about 4Q, mid single -digits can be a wide range. "}, "hash": "8fd145676885a81dfe3a02161b268561fa5a7e9c8105a4899cd6bc8150d24091", "class_name": "RelatedNodeInfo"}}, "text": "Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n", "start_char_idx": 1093, "end_char_idx": 1235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cce6acd8-68aa-45ae-bfbc-ec77c3ecf3de": {"__data__": {"id_": "cce6acd8-68aa-45ae-bfbc-ec77c3ecf3de", "embedding": null, "metadata": {"window": "I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "And then as  you think about 4Q, mid single -digits can be a wide range. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c8e4e2e-cf4e-47a4-9315-964de1feb705", "node_type": "1", "metadata": {"window": "Michael Cherny:  \nGood morning and thanks for all the color so far.  I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad09f050df9e6fac1ed58d92bad24ac1ad327249a962784fc4ae4e31251a63d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "006d845d-fb74-47ad-b2d3-cfd002ddad66", "node_type": "1", "metadata": {"window": "Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n"}, "hash": "de5610c2b7c0470c719bbc2549634cde3e06bdeef7749688bd441a6fade5ab8b", "class_name": "RelatedNodeInfo"}}, "text": "And then as  you think about 4Q, mid single -digits can be a wide range. ", "start_char_idx": 1235, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "006d845d-fb74-47ad-b2d3-cfd002ddad66": {"__data__": {"id_": "006d845d-fb74-47ad-b2d3-cfd002ddad66", "embedding": null, "metadata": {"window": "Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cce6acd8-68aa-45ae-bfbc-ec77c3ecf3de", "node_type": "1", "metadata": {"window": "I just want to dive a little bit more into some of the \n4Q dynamics.   Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "And then as  you think about 4Q, mid single -digits can be a wide range. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e619033267d8416134e541390b08e3b5b44074bbd5c013d76c23255c7a679901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00ab13ba-d369-4303-96de-c2c21e2a0ff6", "node_type": "1", "metadata": {"window": "Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "David C. Evans:  "}, "hash": "7061210b7d2e9ebec818d07846c048af869e00149c5cbb6dcc7e6d25d79df1d8", "class_name": "RelatedNodeInfo"}}, "text": "Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n", "start_char_idx": 1308, "end_char_idx": 1526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00ab13ba-d369-4303-96de-c2c21e2a0ff6": {"__data__": {"id_": "00ab13ba-d369-4303-96de-c2c21e2a0ff6", "embedding": null, "metadata": {"window": "Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "David C. Evans:  ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fa0c02d-c316-411c-b922-52f8188b521d", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d08d1d1725b80f8d66ec71aa9c523241a383fc33c6ba6681cf8dc10d7cf8437", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "006d845d-fb74-47ad-b2d3-cfd002ddad66", "node_type": "1", "metadata": {"window": "Mike, in particular, the reduction in the Pharma outlook for the next quarter.  Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3196a7fa4e3e5e755df8e944206d31e96869e9216ee946418b634e2e019aa663", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b28b522-08ea-48eb-813a-1b8dceadf5b2", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n", "original_text": " \nPage 11 of 31 \n \nSo Michael, this is Dave. "}, "hash": "f8297a9b22f913e7d021e2a52acf105864109223a668cccba3d21546271f582d", "class_name": "RelatedNodeInfo"}}, "text": "David C. Evans:  ", "start_char_idx": 1526, "end_char_idx": 1543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b28b522-08ea-48eb-813a-1b8dceadf5b2": {"__data__": {"id_": "0b28b522-08ea-48eb-813a-1b8dceadf5b2", "embedding": null, "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n", "original_text": " \nPage 11 of 31 \n \nSo Michael, this is Dave. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00ab13ba-d369-4303-96de-c2c21e2a0ff6", "node_type": "1", "metadata": {"window": "Is there \nany way to characterize or  frame how much of this is tied to expectations or what you saw relative to \npull-through perspective?  \n And then as  you think about 4Q, mid single -digits can be a wide range.  Within mid single -digits, how \ndo you think about what  has to happen in the business qualitatively to get to the varying different \ndegrees of where you fall out for mid  single -digit performance for the  year?  \n \n David C. Evans:  ", "original_text": "David C. Evans:  ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81638253ab43415b1e71d48ad87f798724c67d9fc60f89f7220a600815a5f8e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06995ff8-e152-4920-bd38-f7549104a8b0", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well. ", "original_text": "Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n"}, "hash": "2dae93ed82c742b3ca971e7c5b3a767af950a8ff14353bbaba9990c8b4823153", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 31 \n \nSo Michael, this is Dave. ", "start_char_idx": 0, "end_char_idx": 45, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06995ff8-e152-4920-bd38-f7549104a8b0": {"__data__": {"id_": "06995ff8-e152-4920-bd38-f7549104a8b0", "embedding": null, "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well. ", "original_text": "Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b28b522-08ea-48eb-813a-1b8dceadf5b2", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n", "original_text": " \nPage 11 of 31 \n \nSo Michael, this is Dave. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7712f36107de6b590827033fe0bca76c20a34f1b309889149eb21245d1e19d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da607590-e0d9-48dc-b388-0735c301dc23", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year. ", "original_text": "With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs. "}, "hash": "30a416e29ddc52eaeae0b269897bf512bf276d0d8f0d8d7f2369cc2e57d25e21", "class_name": "RelatedNodeInfo"}}, "text": "Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n", "start_char_idx": 45, "end_char_idx": 149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da607590-e0d9-48dc-b388-0735c301dc23": {"__data__": {"id_": "da607590-e0d9-48dc-b388-0735c301dc23", "embedding": null, "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year. ", "original_text": "With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06995ff8-e152-4920-bd38-f7549104a8b0", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well. ", "original_text": "Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7dc46eaf1a02a4b5abaa0c5e433340e911bd23ac8362f6b9f2a6d831c2974229", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7736ba52-bab6-4141-9941-a927692c579a", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number. ", "original_text": "So the \nNuclear business itself is the biggest  impact year -over-year.  \n"}, "hash": "a034fb07eacb414627cef1c60baed6e9a13dab0a6bc241062edb881c2db04ff1", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs. ", "start_char_idx": 149, "end_char_idx": 446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7736ba52-bab6-4141-9941-a927692c579a": {"__data__": {"id_": "7736ba52-bab6-4141-9941-a927692c579a", "embedding": null, "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number. ", "original_text": "So the \nNuclear business itself is the biggest  impact year -over-year.  \n", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da607590-e0d9-48dc-b388-0735c301dc23", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year. ", "original_text": "With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad24a0dd051e93ebebfeb63aea752804b41e6ba0adaa3000413ab5e9d45ddf2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "649c388a-3d4c-4b08-a2d8-60f144fca0fc", "node_type": "1", "metadata": {"window": "Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind. ", "original_text": "Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well. "}, "hash": "eb0dac7e4095d7a849a928388348a12fc338ca0b2bb4a4674b40c1b76737dfa9", "class_name": "RelatedNodeInfo"}}, "text": "So the \nNuclear business itself is the biggest  impact year -over-year.  \n", "start_char_idx": 446, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "649c388a-3d4c-4b08-a2d8-60f144fca0fc": {"__data__": {"id_": "649c388a-3d4c-4b08-a2d8-60f144fca0fc", "embedding": null, "metadata": {"window": "Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind. ", "original_text": "Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7736ba52-bab6-4141-9941-a927692c579a", "node_type": "1", "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number. ", "original_text": "So the \nNuclear business itself is the biggest  impact year -over-year.  \n", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64d36fe600272ea45b1227425ef1c078d0522d6f1d7739a375ad1fbaa52d4d59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77e4c049-5b2f-4c11-92e2-20f9cdfff8a8", "node_type": "1", "metadata": {"window": "With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic. ", "original_text": "So \nthose are a  couple of the biggest drivers that you find year -over-year. "}, "hash": "b8f66241fa8b693c62fd5b5537b2f23765bf32b0847e21b113b92f4b507a58b0", "class_name": "RelatedNodeInfo"}}, "text": "Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well. ", "start_char_idx": 520, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77e4c049-5b2f-4c11-92e2-20f9cdfff8a8": {"__data__": {"id_": "77e4c049-5b2f-4c11-92e2-20f9cdfff8a8", "embedding": null, "metadata": {"window": "With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic. ", "original_text": "So \nthose are a  couple of the biggest drivers that you find year -over-year. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "649c388a-3d4c-4b08-a2d8-60f144fca0fc", "node_type": "1", "metadata": {"window": "Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind. ", "original_text": "Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bf2a4cd729595c7a5883bdb9bbbb932abaff6a26894857cd00fdcad132c2961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0ddb713-1f49-4773-ac88-c7112cd8dc87", "node_type": "1", "metadata": {"window": "So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n", "original_text": "Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number. "}, "hash": "3ac65f539238899e05384578de533ef8cf4001896b51e42f8203c14d1e26372f", "class_name": "RelatedNodeInfo"}}, "text": "So \nthose are a  couple of the biggest drivers that you find year -over-year. ", "start_char_idx": 618, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0ddb713-1f49-4773-ac88-c7112cd8dc87": {"__data__": {"id_": "c0ddb713-1f49-4773-ac88-c7112cd8dc87", "embedding": null, "metadata": {"window": "So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n", "original_text": "Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77e4c049-5b2f-4c11-92e2-20f9cdfff8a8", "node_type": "1", "metadata": {"window": "With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic. ", "original_text": "So \nthose are a  couple of the biggest drivers that you find year -over-year. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e801d4df50e5aefd74b4f427a0d62eebd925ff7734874e76371072968cf457", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a211a202-0e29-4747-9b4c-948fc940f742", "node_type": "1", "metadata": {"window": "Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah. ", "original_text": "But, yeah, I would \nsay that's probably the biggest  tailwind. "}, "hash": "493c1fae61628064ab8fef1535a4d48471aa99da10f8c4b09df8df2692c5e3a9", "class_name": "RelatedNodeInfo"}}, "text": "Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number. ", "start_char_idx": 696, "end_char_idx": 809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a211a202-0e29-4747-9b4c-948fc940f742": {"__data__": {"id_": "a211a202-0e29-4747-9b4c-948fc940f742", "embedding": null, "metadata": {"window": "Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah. ", "original_text": "But, yeah, I would \nsay that's probably the biggest  tailwind. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0ddb713-1f49-4773-ac88-c7112cd8dc87", "node_type": "1", "metadata": {"window": "So the \nNuclear business itself is the biggest  impact year -over-year.  \n Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n", "original_text": "Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca9039cf3b9c6d2ddad2582dbeab8dc5cc090b5cc2c1b9a812137891a047ba61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a46f34e-3e2b-4009-920e-37c084d4abf8", "node_type": "1", "metadata": {"window": "So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term. ", "original_text": "So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic. "}, "hash": "2ffd94a0ef59e9fb342406bdf9896f22843fb13afb3015153ac889fff24eaeb1", "class_name": "RelatedNodeInfo"}}, "text": "But, yeah, I would \nsay that's probably the biggest  tailwind. ", "start_char_idx": 809, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a46f34e-3e2b-4009-920e-37c084d4abf8": {"__data__": {"id_": "3a46f34e-3e2b-4009-920e-37c084d4abf8", "embedding": null, "metadata": {"window": "So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term. ", "original_text": "So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a211a202-0e29-4747-9b4c-948fc940f742", "node_type": "1", "metadata": {"window": "Recall on a year -over-year basis, we have the ongoing headwind of the contract renewals as well.  So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah. ", "original_text": "But, yeah, I would \nsay that's probably the biggest  tailwind. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "514a3fbbdcf1442c5c091a3510397ed9be98481cebaa9206f14f7ab107a27220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91e3c0ca-4ebc-442a-a766-a88ec32f7128", "node_type": "1", "metadata": {"window": "Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot. ", "original_text": "So, Mike, do you want to provide more \ncolor on th at then?  \n  \n"}, "hash": "35639a33b2789e1e821f7489e1c0640ef1424efb0880506de586fefbf604844a", "class_name": "RelatedNodeInfo"}}, "text": "So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic. ", "start_char_idx": 872, "end_char_idx": 996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91e3c0ca-4ebc-442a-a766-a88ec32f7128": {"__data__": {"id_": "91e3c0ca-4ebc-442a-a766-a88ec32f7128", "embedding": null, "metadata": {"window": "Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot. ", "original_text": "So, Mike, do you want to provide more \ncolor on th at then?  \n  \n", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a46f34e-3e2b-4009-920e-37c084d4abf8", "node_type": "1", "metadata": {"window": "So \nthose are a  couple of the biggest drivers that you find year -over-year.  Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term. ", "original_text": "So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a550f73af0d63b352b7ef08e32ec9195a71fdd669ae03d1f9d15651311c3d1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02164be0-07a3-45ae-ae5e-42f3d3bbab3d", "node_type": "1", "metadata": {"window": "But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace. ", "original_text": "Michael C. Kaufmann:  \n  \nYeah. "}, "hash": "fac1d8dd42489129ddb279aaf51fc2e8e200577bb1b801c355e9b06d18e9bb87", "class_name": "RelatedNodeInfo"}}, "text": "So, Mike, do you want to provide more \ncolor on th at then?  \n  \n", "start_char_idx": 996, "end_char_idx": 1061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02164be0-07a3-45ae-ae5e-42f3d3bbab3d": {"__data__": {"id_": "02164be0-07a3-45ae-ae5e-42f3d3bbab3d", "embedding": null, "metadata": {"window": "But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace. ", "original_text": "Michael C. Kaufmann:  \n  \nYeah. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91e3c0ca-4ebc-442a-a766-a88ec32f7128", "node_type": "1", "metadata": {"window": "Now, offsetting that is the \ncontinued stability in the  generics market dynamic, thoug h a much smaller number.  But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot. ", "original_text": "So, Mike, do you want to provide more \ncolor on th at then?  \n  \n", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2505797d020dfa2fe93253f38dacc313d48529b028ee3d7c8a48b16a903552d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ee92a5e-4001-4f79-93ac-97e5b9cc91b9", "node_type": "1", "metadata": {"window": "So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there. ", "original_text": "I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term. "}, "hash": "dfc20d72f08f7f34f280a26f2b3abcbcf94c99c1df610f377f6c869fe4565675", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \n  \nYeah. ", "start_char_idx": 1061, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ee92a5e-4001-4f79-93ac-97e5b9cc91b9": {"__data__": {"id_": "2ee92a5e-4001-4f79-93ac-97e5b9cc91b9", "embedding": null, "metadata": {"window": "So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there. ", "original_text": "I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02164be0-07a3-45ae-ae5e-42f3d3bbab3d", "node_type": "1", "metadata": {"window": "But, yeah, I would \nsay that's probably the biggest  tailwind.  So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace. ", "original_text": "Michael C. Kaufmann:  \n  \nYeah. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c3205689dba0cd8c6cc957c82fc1efbe59cf2d22b6a469f809969d58803f2f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3a8fa65-591a-4aab-be98-e88c47a3ae25", "node_type": "1", "metadata": {"window": "So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can. ", "original_text": "It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot. "}, "hash": "f61cd1fda925cb0fa080894313576d1e9d1b9473f75e35bab7ab5f057562390f", "class_name": "RelatedNodeInfo"}}, "text": "I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term. ", "start_char_idx": 1093, "end_char_idx": 1223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3a8fa65-591a-4aab-be98-e88c47a3ae25": {"__data__": {"id_": "a3a8fa65-591a-4aab-be98-e88c47a3ae25", "embedding": null, "metadata": {"window": "So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can. ", "original_text": "It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ee92a5e-4001-4f79-93ac-97e5b9cc91b9", "node_type": "1", "metadata": {"window": "So, year -over-year, it's elective procedures, the contract \nrenewals, marginally offset by the generic  program's dynamic.  So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there. ", "original_text": "I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b0f685e3b966c0a8b8be4185ecdaf9346044e62219dde2c6f4a378eed81c6dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adb60a02-0f07-43fb-a60c-4d71d1844471", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go. ", "original_text": "It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace. "}, "hash": "87eb553483a8f0a66bdc67e7ca97d6c901d9a0a26e78bfebcf7829e65a344e7a", "class_name": "RelatedNodeInfo"}}, "text": "It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot. ", "start_char_idx": 1223, "end_char_idx": 1385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adb60a02-0f07-43fb-a60c-4d71d1844471": {"__data__": {"id_": "adb60a02-0f07-43fb-a60c-4d71d1844471", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go. ", "original_text": "It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3a8fa65-591a-4aab-be98-e88c47a3ae25", "node_type": "1", "metadata": {"window": "So, Mike, do you want to provide more \ncolor on th at then?  \n  \n Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can. ", "original_text": "It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4746c6839b23b990b2555df464635fd6573f4c0900ca6563bd1cd8f57844be6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a15b0ed-39b9-4db4-9ccd-13d8a8556d18", "node_type": "1", "metadata": {"window": "I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n", "original_text": "So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there. "}, "hash": "d7b49436e8dd1a48aedb07a64a63a5b03ec4c3acad09367d5bff35a3bc333999", "class_name": "RelatedNodeInfo"}}, "text": "It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace. ", "start_char_idx": 1385, "end_char_idx": 1515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a15b0ed-39b9-4db4-9ccd-13d8a8556d18": {"__data__": {"id_": "2a15b0ed-39b9-4db4-9ccd-13d8a8556d18", "embedding": null, "metadata": {"window": "I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n", "original_text": "So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adb60a02-0f07-43fb-a60c-4d71d1844471", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \n  \nYeah.  I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go. ", "original_text": "It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aa6b7ac98fe27d63ff1f692d1825835733aab42397d001eb2ff282d1715c96f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc101d1a-7bc5-4b2d-a5b0-4b9209a54039", "node_type": "1", "metadata": {"window": "It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can. "}, "hash": "fb67c976aaecc53c06c5a1fbd9a8ecbb078b82fd026ece6acab8b5f963c6c963", "class_name": "RelatedNodeInfo"}}, "text": "So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there. ", "start_char_idx": 1515, "end_char_idx": 1646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc101d1a-7bc5-4b2d-a5b0-4b9209a54039": {"__data__": {"id_": "dc101d1a-7bc5-4b2d-a5b0-4b9209a54039", "embedding": null, "metadata": {"window": "It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a15b0ed-39b9-4db4-9ccd-13d8a8556d18", "node_type": "1", "metadata": {"window": "I think the only thing I would add, Michael, is that our Nuclear business, we feel really good \nabout over the  mid-to-long-term.  It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n", "original_text": "So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b25f32b034e5c17d4c7452addea9b3fa293ccbfd1b0b39eed30343dbb67e8edd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "047fd61d-ce6a-4c47-b42d-b1f85a963dbe", "node_type": "1", "metadata": {"window": "It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go. "}, "hash": "26c21386b99368b666f77e4d75fa3bf18d1a7e9f379c2ac0da6c0334d7734f91", "class_name": "RelatedNodeInfo"}}, "text": "And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can. ", "start_char_idx": 1646, "end_char_idx": 1755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "047fd61d-ce6a-4c47-b42d-b1f85a963dbe": {"__data__": {"id_": "047fd61d-ce6a-4c47-b42d-b1f85a963dbe", "embedding": null, "metadata": {"window": "It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc101d1a-7bc5-4b2d-a5b0-4b9209a54039", "node_type": "1", "metadata": {"window": "It's a business that we remain committed to and I know that probably \nis a surprise to a lot of  folks that it's a headwind because we don't talk about it a lot.  It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92b6460372a9a17897fdad480e62f12c8c59b9347c8603cc5e2dea5665939d52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "446d4d8b-b072-4f64-8a31-ab3d307ea1ca", "node_type": "1", "metadata": {"window": "So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "And so that's why we have decided to invest in that business, take some short -term pain. \n"}, "hash": "6437f8ba017da71dc106a1d5676bf2f55860f8ef1ba079e471c06e16899843e9", "class_name": "RelatedNodeInfo"}}, "text": "But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go. ", "start_char_idx": 1755, "end_char_idx": 1929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "446d4d8b-b072-4f64-8a31-ab3d307ea1ca": {"__data__": {"id_": "446d4d8b-b072-4f64-8a31-ab3d307ea1ca", "embedding": null, "metadata": {"window": "So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "And so that's why we have decided to invest in that business, take some short -term pain. \n", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "047fd61d-ce6a-4c47-b42d-b1f85a963dbe", "node_type": "1", "metadata": {"window": "It's been a \nbusiness that's been growing, but it has  seen a significant reduction in it's \u2013 the procedures in its \nmarketplace.  So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a7ed48731b873aba95b6cf868449249de6e88af86da84dbc1504ef00c19f208", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b4d3123-c02a-4c3b-8bac-55631259eee8", "node_type": "1", "metadata": {"window": "And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  "}, "hash": "9e61b948b85d0914557f7df1ddfb9a0aee629733ff68fa3a5f5aad8779a2844d", "class_name": "RelatedNodeInfo"}}, "text": "And so that's why we have decided to invest in that business, take some short -term pain. \n", "start_char_idx": 1929, "end_char_idx": 2020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b4d3123-c02a-4c3b-8bac-55631259eee8": {"__data__": {"id_": "8b4d3123-c02a-4c3b-8bac-55631259eee8", "embedding": null, "metadata": {"window": "And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174dd8923f9aa8de62c1059dec4c79fb257485f561ef47c61d24a6c6b5e08711", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "446d4d8b-b072-4f64-8a31-ab3d307ea1ca", "node_type": "1", "metadata": {"window": "So it's seen a significant reduction and we  thought long and hard about it, but we feel \nreally good about our positioning there.  And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "And so that's why we have decided to invest in that business, take some short -term pain. \n", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a8e554e49ffa5da8adecd319d846e2edc2669cfb2a25aab3042ae6dfcbb81b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a516d43-ffe9-4025-86e3-9479991119ca", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question. ", "original_text": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n"}, "hash": "4212b6f2820be6eaf0bb9d71e79625ee5b89dc38dc6886fb1ae87be2bd07abdd", "class_name": "RelatedNodeInfo"}}, "text": "As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "start_char_idx": 2020, "end_char_idx": 2236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a516d43-ffe9-4025-86e3-9479991119ca": {"__data__": {"id_": "1a516d43-ffe9-4025-86e3-9479991119ca", "embedding": null, "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question. ", "original_text": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b4d3123-c02a-4c3b-8bac-55631259eee8", "node_type": "1", "metadata": {"window": "And so we're doing everything  we can to maintain the cost or \nto manage the costs as effectively as we can.  But these tend to be more technical  jobs that are hard \nto replace and we don' t want to put ourselves in a position that when it bounces back that we're  not \nready to go.  And so that's why we have decided to invest in that business, take some short -term pain. \n As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "original_text": "As Dave said, we expect actually Nuclear to be the biggest negative driver in Q4, even bigger than \ncustomer contract  renewals but we want to be prepared for that business to rebound, which we \nbelieve it will be.  ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f57064fb67476d2c00b1f9ccd3169b587294e8d88081ab1c5a0a98e72e04d37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "352f4fd6-d6aa-4ab6-850f-ca9664748831", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about. ", "original_text": "Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n"}, "hash": "739f9317816f23c1d4abff8dc7978f752520f02215c573fc2df85209a840d1a0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n", "start_char_idx": 0, "end_char_idx": 64, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "352f4fd6-d6aa-4ab6-850f-ca9664748831": {"__data__": {"id_": "352f4fd6-d6aa-4ab6-850f-ca9664748831", "embedding": null, "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about. ", "original_text": "Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a516d43-ffe9-4025-86e3-9479991119ca", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question. ", "original_text": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "461a1549eb300cce475ea842d291be74ebb4eefc9e2700babdcfe6ad8a74bbd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "264e33bb-5543-461c-a7ea-571d621234b5", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends. ", "original_text": "Glen Santa ngelo:  \nOh, yeah. "}, "hash": "defaa2d1bec8e88ca6e7fb2ce36804097b04953d3ab9e05b27614e64197ad741", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n", "start_char_idx": 64, "end_char_idx": 138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "264e33bb-5543-461c-a7ea-571d621234b5": {"__data__": {"id_": "264e33bb-5543-461c-a7ea-571d621234b5", "embedding": null, "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends. ", "original_text": "Glen Santa ngelo:  \nOh, yeah. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "352f4fd6-d6aa-4ab6-850f-ca9664748831", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about. ", "original_text": "Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf7e1d53f36a6b3f69f97a3bacdd44e33e1e50db659c5ce84cf983622fd6465f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1a818e8-dc95-4de2-b248-0dacab932c49", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable. ", "original_text": "Thanks for taking the question. "}, "hash": "8530bf44f58ac0e5a46602104ea136cead9447edf5f2783d5a4fb69baf223c93", "class_name": "RelatedNodeInfo"}}, "text": "Glen Santa ngelo:  \nOh, yeah. ", "start_char_idx": 138, "end_char_idx": 168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1a818e8-dc95-4de2-b248-0dacab932c49": {"__data__": {"id_": "a1a818e8-dc95-4de2-b248-0dacab932c49", "embedding": null, "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable. ", "original_text": "Thanks for taking the question. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "264e33bb-5543-461c-a7ea-571d621234b5", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends. ", "original_text": "Glen Santa ngelo:  \nOh, yeah. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40ec138b7e72c849dfca91387cc6cce55617bff3fbc7667acffe7ec8e43dcc66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15e3f369-f085-4640-be41-a100a2e2d5c5", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas? ", "original_text": "Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about. "}, "hash": "c6c1403856d33428dee63d2fd3618fdc533c7458d1d53fd48db67b2f1dc4e825", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 168, "end_char_idx": 200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15e3f369-f085-4640-be41-a100a2e2d5c5": {"__data__": {"id_": "15e3f369-f085-4640-be41-a100a2e2d5c5", "embedding": null, "metadata": {"window": "Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas? ", "original_text": "Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1a818e8-dc95-4de2-b248-0dacab932c49", "node_type": "1", "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable. ", "original_text": "Thanks for taking the question. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8abbefcdfb64492052e75289c5d0fc9dadfa11eff3e35bcd8c9ab043c24c805a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c8ab6c7-7569-4d34-a53c-b2890dfe8aee", "node_type": "1", "metadata": {"window": "Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n", "original_text": "The first  was on the generic pricing trends. "}, "hash": "b694247ebfdb4671d7e0dafe03e9ae54a3bbb6a1b013a0439ce9eda5877688fa", "class_name": "RelatedNodeInfo"}}, "text": "Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about. ", "start_char_idx": 200, "end_char_idx": 403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c8ab6c7-7569-4d34-a53c-b2890dfe8aee": {"__data__": {"id_": "9c8ab6c7-7569-4d34-a53c-b2890dfe8aee", "embedding": null, "metadata": {"window": "Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n", "original_text": "The first  was on the generic pricing trends. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15e3f369-f085-4640-be41-a100a2e2d5c5", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas? ", "original_text": "Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8aca2cc6533555096284085c9d12ae7d89dbf3b553b627ca1ec80d07a4299640", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72b8aedc-2336-4656-b687-a0f1fff8f838", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure. ", "original_text": "And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable. "}, "hash": "e5b03929ef5d0d1df64d45a43aead64548651fbe4947ebb946a204ec83a204b2", "class_name": "RelatedNodeInfo"}}, "text": "The first  was on the generic pricing trends. ", "start_char_idx": 403, "end_char_idx": 449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72b8aedc-2336-4656-b687-a0f1fff8f838": {"__data__": {"id_": "72b8aedc-2336-4656-b687-a0f1fff8f838", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure. ", "original_text": "And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c8ab6c7-7569-4d34-a53c-b2890dfe8aee", "node_type": "1", "metadata": {"window": "Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n", "original_text": "The first  was on the generic pricing trends. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de78c8f075017121802ad857d70580a1c3151be24050974f4d7143bdb6262bb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3d12beb-a0d3-46f8-8279-b6e461e61f2f", "node_type": "1", "metadata": {"window": "Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question. ", "original_text": "So I was just curious if you  can comment on those two areas? "}, "hash": "0670b9de1ec80f6e21d80601c081b43009accd3f2bed471cac27c042e6e9ed8c", "class_name": "RelatedNodeInfo"}}, "text": "And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable. ", "start_char_idx": 449, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3d12beb-a0d3-46f8-8279-b6e461e61f2f": {"__data__": {"id_": "c3d12beb-a0d3-46f8-8279-b6e461e61f2f", "embedding": null, "metadata": {"window": "Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question. ", "original_text": "So I was just curious if you  can comment on those two areas? ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72b8aedc-2336-4656-b687-a0f1fff8f838", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure. ", "original_text": "And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "140a2514f44cc6964ca59d4498cfc86e44ac35ba1f831e13b3f7767e0bd03835", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "877c0743-d9ea-46ba-a9ec-9a73232e5a54", "node_type": "1", "metadata": {"window": "The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge. ", "original_text": "Thanks very much.  \n  \n"}, "hash": "5d09996adaa4d307bd67a7fb888e53fe1b7bc2f54ddbe9a0fec99c0398047e71", "class_name": "RelatedNodeInfo"}}, "text": "So I was just curious if you  can comment on those two areas? ", "start_char_idx": 594, "end_char_idx": 656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "877c0743-d9ea-46ba-a9ec-9a73232e5a54": {"__data__": {"id_": "877c0743-d9ea-46ba-a9ec-9a73232e5a54", "embedding": null, "metadata": {"window": "The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge. ", "original_text": "Thanks very much.  \n  \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3d12beb-a0d3-46f8-8279-b6e461e61f2f", "node_type": "1", "metadata": {"window": "Hey, Mike, in your prepared remarks, you sort of called \nthree areas that  you were monitoring closely and I was just kind of curious to maybe follow -up on two \nother things that you all  talked about.  The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question. ", "original_text": "So I was just curious if you  can comment on those two areas? ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9f6eab09d9d70196b9d6ac75e7688e9d9bc96f9458b5404ecfcb65a05c8e2b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4359e524-5d0f-4215-a0e5-58140ef628a5", "node_type": "1", "metadata": {"window": "And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell. ", "original_text": "Michael C. Kaufmann:  \nSure. "}, "hash": "f7d28b375d50d5f46b641f981b540708fe615d1c48bba986351d1ffab148fbc2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much.  \n  \n", "start_char_idx": 656, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4359e524-5d0f-4215-a0e5-58140ef628a5": {"__data__": {"id_": "4359e524-5d0f-4215-a0e5-58140ef628a5", "embedding": null, "metadata": {"window": "And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell. ", "original_text": "Michael C. Kaufmann:  \nSure. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "877c0743-d9ea-46ba-a9ec-9a73232e5a54", "node_type": "1", "metadata": {"window": "The first  was on the generic pricing trends.  And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge. ", "original_text": "Thanks very much.  \n  \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "852640d9def27078b02f21b66b0277d7da3718894ea84108258856065a4d681c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d1bab7b-22c0-42f9-a214-8f08638701ea", "node_type": "1", "metadata": {"window": "So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n", "original_text": "Thanks for the question. "}, "hash": "f3e20ec759e74b430cef61422b43fe7ff0e005307bb5cbabff30c9cc4989b619", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nSure. ", "start_char_idx": 679, "end_char_idx": 708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d1bab7b-22c0-42f9-a214-8f08638701ea": {"__data__": {"id_": "3d1bab7b-22c0-42f9-a214-8f08638701ea", "embedding": null, "metadata": {"window": "So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n", "original_text": "Thanks for the question. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4359e524-5d0f-4215-a0e5-58140ef628a5", "node_type": "1", "metadata": {"window": "And secondly, I think \non the Medical side, you said that  there's an expectation that the recent above -average demand may \nnot be sustainable.  So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell. ", "original_text": "Michael C. Kaufmann:  \nSure. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "770c59744f802614282af27bc31c4993c73c9aa37c00d467f5bff3f2cafc13f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86b89665-ca8a-4ec4-be41-34ee0bbe380d", "node_type": "1", "metadata": {"window": "Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge. "}, "hash": "a662811cb003645b995d9e92565a073e0b2d7aaf4064ccad75b3bd7e43ce6187", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 708, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86b89665-ca8a-4ec4-be41-34ee0bbe380d": {"__data__": {"id_": "86b89665-ca8a-4ec4-be41-34ee0bbe380d", "embedding": null, "metadata": {"window": "Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d1bab7b-22c0-42f9-a214-8f08638701ea", "node_type": "1", "metadata": {"window": "So I was just curious if you  can comment on those two areas?  Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n", "original_text": "Thanks for the question. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "012c2aba71afb9ceff581225188885fccbafc49b549e41d3ff16761c79f13d5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9855f5e0-47f5-414b-b1db-55bfb84fe3ef", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "And we actually managed it really \nwell. "}, "hash": "d7a6d17f0a246a403fab22170c2c172379540b3906573782bd5d4b78eaa998f3", "class_name": "RelatedNodeInfo"}}, "text": "Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge. ", "start_char_idx": 733, "end_char_idx": 1072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9855f5e0-47f5-414b-b1db-55bfb84fe3ef": {"__data__": {"id_": "9855f5e0-47f5-414b-b1db-55bfb84fe3ef", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "And we actually managed it really \nwell. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86b89665-ca8a-4ec4-be41-34ee0bbe380d", "node_type": "1", "metadata": {"window": "Thanks very much.  \n  \n Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "326ceb07a74b36f4989936b988fdb6dea63f31580823154a756500a2b8548db4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "744cb3ad-6258-4d1a-b1f5-416261b51c7f", "node_type": "1", "metadata": {"window": "Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n"}, "hash": "486c9a23b22a9d9b9992b066bca8c134c5f54242473251d45f1bc2e94dcc9aee", "class_name": "RelatedNodeInfo"}}, "text": "And we actually managed it really \nwell. ", "start_char_idx": 1072, "end_char_idx": 1113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "744cb3ad-6258-4d1a-b1f5-416261b51c7f": {"__data__": {"id_": "744cb3ad-6258-4d1a-b1f5-416261b51c7f", "embedding": null, "metadata": {"window": "Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9855f5e0-47f5-414b-b1db-55bfb84fe3ef", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nSure.  Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "And we actually managed it really \nwell. ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd64310f73dab21fa630df454e7f2131be0a80da5e4fa843eb67027258743335", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47af2890-d7fa-444a-9ab9-3e516e81bfab", "node_type": "1", "metadata": {"window": "Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with "}, "hash": "6c433d846d410b375a0252ac47369d94e1f40152b0634ba5c77648a4eb5e498e", "class_name": "RelatedNodeInfo"}}, "text": "And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n", "start_char_idx": 1113, "end_char_idx": 1523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47af2890-d7fa-444a-9ab9-3e516e81bfab": {"__data__": {"id_": "47af2890-d7fa-444a-9ab9-3e516e81bfab", "embedding": null, "metadata": {"window": "Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c0c90ca6cd55d370e12a284e316ce5781fa7ba64715e330d2e4e5b9db2b32e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "744cb3ad-6258-4d1a-b1f5-416261b51c7f", "node_type": "1", "metadata": {"window": "Thanks for the question.  Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c64780221fdd0771497c1cc37b19f3c985bc5f1f25b0fc17cd6d80ad7c80e58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ea0c74b-db93-4a59-ad8b-b1cb3449ddd4", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock. ", "original_text": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1. "}, "hash": "127e1580d99d5376aeda6372cc9ac3fe383057bd86c0aa14c7f02309e3341fc5", "class_name": "RelatedNodeInfo"}}, "text": "So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "start_char_idx": 1523, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ea0c74b-db93-4a59-ad8b-b1cb3449ddd4": {"__data__": {"id_": "5ea0c74b-db93-4a59-ad8b-b1cb3449ddd4", "embedding": null, "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock. ", "original_text": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47af2890-d7fa-444a-9ab9-3e516e81bfab", "node_type": "1", "metadata": {"window": "Yeah, in the generics area of availability and pricing, we look at \u2013 Q3, \nthere were  some early challenges but our team at Red Oak did a fantastic job on the generics side, \nmaking sure , understanding where we thought those supply disruptions might be, adding some new \nvendors to the program,  buying some inventory ahead of the surge.  And we actually managed it really \nwell.  And so far we're seeing that in  Q4, but it's always hard to know rig ht now with this COVID, \nwhere it might be re -surge, where we might see some  export restrictions in certain countries, where \ncertain manufacturing or raw materials might have challenges that  could create either availability \nissues that might cause price inc reases or raw material increases that might create  some price \nincreases.  \n So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "original_text": "So at this point in time, I'm not saying that we're calling out anything different than what we've seen \ngenerally, but  it's something we want to keep an eye on because there's just th is added situation with ", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "301acd8dcf4fb1a5ed6bf9d466bde1e0316a0ac51ce6a5e79305e8ce2c0ef15c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b49b04b0-bcd1-4b39-8917-4573cdf148b3", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock. ", "original_text": "So we're \njust going to keep our eye on it and  we'll be ready to react accordingly. "}, "hash": "2935ca89ff0da9dd44c381c07dc90bff8b75ddfb76f4476694f09a8c4d1a86e9", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1. ", "start_char_idx": 0, "end_char_idx": 111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b49b04b0-bcd1-4b39-8917-4573cdf148b3": {"__data__": {"id_": "b49b04b0-bcd1-4b39-8917-4573cdf148b3", "embedding": null, "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock. ", "original_text": "So we're \njust going to keep our eye on it and  we'll be ready to react accordingly. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ea0c74b-db93-4a59-ad8b-b1cb3449ddd4", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock. ", "original_text": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d55147edb9cab505881de4080f7fb10c2bdea8d09824ed5745e247b7d826296", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c3a57e9-bc09-42b1-85d8-b9e18239fbf5", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment. ", "original_text": "And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n"}, "hash": "eb1fe6d3ba486dd3288a89ede9e92c23c3b9253e7b859f5e9dd0f853a231899d", "class_name": "RelatedNodeInfo"}}, "text": "So we're \njust going to keep our eye on it and  we'll be ready to react accordingly. ", "start_char_idx": 111, "end_char_idx": 196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c3a57e9-bc09-42b1-85d8-b9e18239fbf5": {"__data__": {"id_": "9c3a57e9-bc09-42b1-85d8-b9e18239fbf5", "embedding": null, "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment. ", "original_text": "And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b49b04b0-bcd1-4b39-8917-4573cdf148b3", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock. ", "original_text": "So we're \njust going to keep our eye on it and  we'll be ready to react accordingly. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed0902e84ef6ba5e5f75af255031754a48b3944687f0d8412b1e09438cb19e95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad38d5a5-95e4-4a7b-9a2c-40f752b54497", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n", "original_text": "On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock. "}, "hash": "27672aa94e3ac80e50c399e2b0d27ce18c22fdd6a3fbc1574488c0b3e3c844db", "class_name": "RelatedNodeInfo"}}, "text": "And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n", "start_char_idx": 196, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad38d5a5-95e4-4a7b-9a2c-40f752b54497": {"__data__": {"id_": "ad38d5a5-95e4-4a7b-9a2c-40f752b54497", "embedding": null, "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n", "original_text": "On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c3a57e9-bc09-42b1-85d8-b9e18239fbf5", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment. ", "original_text": "And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "290add3ca572639df16d67f4b2510d8b86c6888e910f84188bc5b574018526cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cf6391a-661d-4903-adde-a2803dbbe887", "node_type": "1", "metadata": {"window": "So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you. ", "original_text": "That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock. "}, "hash": "9f3589e666e62a5b243beb4a0985a2d819db92b2a64dbafe2c3e7ebc1b66b4f3", "class_name": "RelatedNodeInfo"}}, "text": "On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock. ", "start_char_idx": 327, "end_char_idx": 458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cf6391a-661d-4903-adde-a2803dbbe887": {"__data__": {"id_": "0cf6391a-661d-4903-adde-a2803dbbe887", "embedding": null, "metadata": {"window": "So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you. ", "original_text": "That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad38d5a5-95e4-4a7b-9a2c-40f752b54497", "node_type": "1", "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n", "original_text": "On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "412d418d1744a95307097b3a02258444619673906bc09de548eb06939af13b60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43e2d246-f70d-414d-b127-b9ebc4fe4260", "node_type": "1", "metadata": {"window": "And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n", "original_text": "By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment. "}, "hash": "d8836b8044470faae6bba481e75ea67b884c5b1831c851a88f694441f7780300", "class_name": "RelatedNodeInfo"}}, "text": "That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock. ", "start_char_idx": 458, "end_char_idx": 654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43e2d246-f70d-414d-b127-b9ebc4fe4260": {"__data__": {"id_": "43e2d246-f70d-414d-b127-b9ebc4fe4260", "embedding": null, "metadata": {"window": "And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n", "original_text": "By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cf6391a-661d-4903-adde-a2803dbbe887", "node_type": "1", "metadata": {"window": "So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you. ", "original_text": "That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89191545914cad8586cbf278ce631b7561591519b1fa84e6f3437a8fdaa099e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12e5eefc-7b8e-4fd3-b76d-5a63b6f91ae0", "node_type": "1", "metadata": {"window": "On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n", "original_text": "And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n"}, "hash": "0b49cc1001a42351ebd7679bc77d81fe54412f66ba1bdbe9da4f88c6ff45d6b3", "class_name": "RelatedNodeInfo"}}, "text": "By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment. ", "start_char_idx": 654, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12e5eefc-7b8e-4fd3-b76d-5a63b6f91ae0": {"__data__": {"id_": "12e5eefc-7b8e-4fd3-b76d-5a63b6f91ae0", "embedding": null, "metadata": {"window": "On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n", "original_text": "And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43e2d246-f70d-414d-b127-b9ebc4fe4260", "node_type": "1", "metadata": {"window": "And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n", "original_text": "By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb1e186bc5b3e9c095c89470703894598b2650ef87e361ed95e9cfa73ea6a41e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e93a299a-7b92-44b3-8fac-c6f7cc75160a", "node_type": "1", "metadata": {"window": "That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah. ", "original_text": "Kevin Moran:  \nThank you. "}, "hash": "d8b4fd43c0c16f7c2659a51a36cd6e1f36cf40f5ea7ffbd5097bdf943e4d9e59", "class_name": "RelatedNodeInfo"}}, "text": "And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n", "start_char_idx": 802, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e93a299a-7b92-44b3-8fac-c6f7cc75160a": {"__data__": {"id_": "e93a299a-7b92-44b3-8fac-c6f7cc75160a", "embedding": null, "metadata": {"window": "That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah. ", "original_text": "Kevin Moran:  \nThank you. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12e5eefc-7b8e-4fd3-b76d-5a63b6f91ae0", "node_type": "1", "metadata": {"window": "On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock.  That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n", "original_text": "And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88d068418a3b3d23c14bf6e5b89a82aecc42b0386d8fd5e3dfdb76315ea01601", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ecc8617-5719-41e3-962b-dd958ceb613b", "node_type": "1", "metadata": {"window": "By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions. ", "original_text": "Next question, please.  \n  \n"}, "hash": "9ba1fcb60c90a19f5fa9ad14d35aba4eea3f84f624a88a688cb6fb9868352bc1", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nThank you. ", "start_char_idx": 995, "end_char_idx": 1021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ecc8617-5719-41e3-962b-dd958ceb613b": {"__data__": {"id_": "1ecc8617-5719-41e3-962b-dd958ceb613b", "embedding": null, "metadata": {"window": "By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions. ", "original_text": "Next question, please.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e93a299a-7b92-44b3-8fac-c6f7cc75160a", "node_type": "1", "metadata": {"window": "That's probably the one thing that people to probably conne ct is that in Q3 \nwe saw significant surge,  but we were able to essentially meet the demand of the surge because we \nhad safety stock.  By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah. ", "original_text": "Kevin Moran:  \nThank you. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da8737e5be8f01c8d0a58cf69d9008c14e4d08e5bca2157b349750ccf2ce6878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "873af012-f235-4246-afe6-44635ee0686d", "node_type": "1", "metadata": {"window": "And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch. ", "original_text": "Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n"}, "hash": "e0986a5e06c9f008cca397eedcc48acbc7bf3d3d32ded9d7660c91c8a909ffff", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please.  \n  \n", "start_char_idx": 1021, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "873af012-f235-4246-afe6-44635ee0686d": {"__data__": {"id_": "873af012-f235-4246-afe6-44635ee0686d", "embedding": null, "metadata": {"window": "And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch. ", "original_text": "Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ecc8617-5719-41e3-962b-dd958ceb613b", "node_type": "1", "metadata": {"window": "By early in our Q4,  we had blown through that safety stock, and so now we're really \nonly able to supply what we're able to get in  replenishment.  And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions. ", "original_text": "Next question, please.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4566f31350bb84c7884d63d41b52f9141b50f54d69a29ec8ea5593c99d386728", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4751fc01-3853-409f-b486-2c138f075294", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business. ", "original_text": "George Hill:  \nYeah. "}, "hash": "05ac9af5c4dfcd36db5af33e80dff64d4f52abf4e97be4652e5f36b9fed8526a", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n", "start_char_idx": 1049, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4751fc01-3853-409f-b486-2c138f075294": {"__data__": {"id_": "4751fc01-3853-409f-b486-2c138f075294", "embedding": null, "metadata": {"window": "Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business. ", "original_text": "George Hill:  \nYeah. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "873af012-f235-4246-afe6-44635ee0686d", "node_type": "1", "metadata": {"window": "And that's why we're seeing that our PPE \nsales, we do not expect to see them to be the same as  we saw in the surge in Q3, that, again, we had \na safety stock to work oursel ves through.  \n  \n Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch. ", "original_text": "Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3869700a383cc85d7e408a41e1996812f116c689e2732dbb3ad7e584a2e5d2ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a49cf7d-d0cc-4a34-9b38-7a399ba010bc", "node_type": "1", "metadata": {"window": "Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown? ", "original_text": "Good morning, guys, and thanks for taking the questions. "}, "hash": "e69572468f02d5bd08c58f8658a3049f71c70ecdabf2f8bb1912885609c7cfb8", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  \nYeah. ", "start_char_idx": 1122, "end_char_idx": 1143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a49cf7d-d0cc-4a34-9b38-7a399ba010bc": {"__data__": {"id_": "9a49cf7d-d0cc-4a34-9b38-7a399ba010bc", "embedding": null, "metadata": {"window": "Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown? ", "original_text": "Good morning, guys, and thanks for taking the questions. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4751fc01-3853-409f-b486-2c138f075294", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nThank you.  Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business. ", "original_text": "George Hill:  \nYeah. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f01d7cd70ae60bccffea5f0e6c1b4cb2506a521a48da20363e4140b8d9f3e38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f311b8c4-4d3a-41ff-8081-165f4b004fcc", "node_type": "1", "metadata": {"window": "Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n", "original_text": "I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch. "}, "hash": "7d426e8ff043bfd49dd37b3f3adb516e0e566291c396140095d4a5c1663e7b33", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, guys, and thanks for taking the questions. ", "start_char_idx": 1143, "end_char_idx": 1200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f311b8c4-4d3a-41ff-8081-165f4b004fcc": {"__data__": {"id_": "f311b8c4-4d3a-41ff-8081-165f4b004fcc", "embedding": null, "metadata": {"window": "Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n", "original_text": "I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a49cf7d-d0cc-4a34-9b38-7a399ba010bc", "node_type": "1", "metadata": {"window": "Next question, please.  \n  \n Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown? ", "original_text": "Good morning, guys, and thanks for taking the questions. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f69dbb16cc9a3ab4b3f43c3dbb8fd497c1cf35eca803ff81ca88e325c72f45d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c532b3e3-db96-4b75-9eeb-a4f1e4f80e1e", "node_type": "1", "metadata": {"window": "George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business. "}, "hash": "f353d278751743ecc2889cfea440197806fc00e2ff95f7e34a1504f5475bc64b", "class_name": "RelatedNodeInfo"}}, "text": "I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch. ", "start_char_idx": 1200, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c532b3e3-db96-4b75-9eeb-a4f1e4f80e1e": {"__data__": {"id_": "c532b3e3-db96-4b75-9eeb-a4f1e4f80e1e", "embedding": null, "metadata": {"window": "George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f311b8c4-4d3a-41ff-8081-165f4b004fcc", "node_type": "1", "metadata": {"window": "Operator : Next question comes from George Hill with Deutsche Bank.  \n  \n George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n", "original_text": "I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcad8bcab52a04161658ebfb7ccab8ecdc6c71889a7bae5bdf51daf415b69386", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd2b6a05-9b97-484a-b68c-20d57123a569", "node_type": "1", "metadata": {"window": "Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown? "}, "hash": "2e2c1d9996e995d07030f32e433616ec67f9dd706d9eb36a5461c08a55b2bcae", "class_name": "RelatedNodeInfo"}}, "text": "I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business. ", "start_char_idx": 1347, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd2b6a05-9b97-484a-b68c-20d57123a569": {"__data__": {"id_": "bd2b6a05-9b97-484a-b68c-20d57123a569", "embedding": null, "metadata": {"window": "Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown? ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c532b3e3-db96-4b75-9eeb-a4f1e4f80e1e", "node_type": "1", "metadata": {"window": "George Hill:  \nYeah.  Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99cbdb05d82b709896059640ca45fb19bf48bb14d2f07fc5e16d220bda506657", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4372b2dc-c7dc-4ce2-8be4-a502e4913aa6", "node_type": "1", "metadata": {"window": "I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "I kind of expected a significant  guidance change to Q4.  \n  \n"}, "hash": "0d1bb64a1973f94fa1f178b48231b88fc52bca59392f299c241d4afc23b860f3", "class_name": "RelatedNodeInfo"}}, "text": "And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown? ", "start_char_idx": 1509, "end_char_idx": 1652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4372b2dc-c7dc-4ce2-8be4-a502e4913aa6": {"__data__": {"id_": "4372b2dc-c7dc-4ce2-8be4-a502e4913aa6", "embedding": null, "metadata": {"window": "I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "I kind of expected a significant  guidance change to Q4.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd2b6a05-9b97-484a-b68c-20d57123a569", "node_type": "1", "metadata": {"window": "Good morning, guys, and thanks for taking the questions.  I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown? ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d69f871f882926bab8960938453ac31d96db243d5d5874d802bbd0d4f4abaad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab54e2b8-6192-4865-9f38-9b3994d9d260", "node_type": "1", "metadata": {"window": "I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "Michael C. Kaufmann:  "}, "hash": "1cdb7b28d9627c67108e43ddad8032ce6a1d5969eca2c706f388e1fe88a093cf", "class_name": "RelatedNodeInfo"}}, "text": "I kind of expected a significant  guidance change to Q4.  \n  \n", "start_char_idx": 1652, "end_char_idx": 1714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab54e2b8-6192-4865-9f38-9b3994d9d260": {"__data__": {"id_": "ab54e2b8-6192-4865-9f38-9b3994d9d260", "embedding": null, "metadata": {"window": "I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "Michael C. Kaufmann:  ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681625e378c6591b3a1ee62d65386bbe9b561778b54b1ad37441b8808affdf7f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4372b2dc-c7dc-4ce2-8be4-a502e4913aa6", "node_type": "1", "metadata": {"window": "I guess, Mike, given all the color that \nyou've  provided about the Med -Surg business, I'm surprised the guidanc e there isn't changing as \nmuch.  I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "I kind of expected a significant  guidance change to Q4.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d669b93af41179d1d063195fe3dc9f892953aeb2931ba1a2d107a38e1f0f5519", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb573523-e553-4dd9-ba46-17aa28396c71", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year. ", "original_text": " \nPage 14 of 31 \n \nYeah. "}, "hash": "3c01dd703ead564d5afe0776be8498cd84d47e4e74d0fc159d9a64da6dccc527", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  ", "start_char_idx": 1714, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb573523-e553-4dd9-ba46-17aa28396c71": {"__data__": {"id_": "fb573523-e553-4dd9-ba46-17aa28396c71", "embedding": null, "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year. ", "original_text": " \nPage 14 of 31 \n \nYeah. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab54e2b8-6192-4865-9f38-9b3994d9d260", "node_type": "1", "metadata": {"window": "I guess could  you talk about the puts and takes when I think I guess about like the regular way \nmedical supplies business  versus like the AssuraMed  business.  And I guess, can you talk about I \nguess more what's going on  inside the segment and kind of how it relates to the guidance not coming \ndown?  I kind of expected a significant  guidance change to Q4.  \n  \n Michael C. Kaufmann:  ", "original_text": "Michael C. Kaufmann:  ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e350cc16b7191804107b5e0694060d123dc98c6fdd8cb59b3d0c109581c058c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d30a0feb-15a6-43aa-a179-dba6c28ca67c", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n", "original_text": "Thanks for the question. "}, "hash": "c64445a2075f75447e5f401348861b7885aa7e551340710863456b4c78b92402", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 31 \n \nYeah. ", "start_char_idx": 0, "end_char_idx": 25, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d30a0feb-15a6-43aa-a179-dba6c28ca67c": {"__data__": {"id_": "d30a0feb-15a6-43aa-a179-dba6c28ca67c", "embedding": null, "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n", "original_text": "Thanks for the question. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb573523-e553-4dd9-ba46-17aa28396c71", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year. ", "original_text": " \nPage 14 of 31 \n \nYeah. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2aca70f6ca7cc8031cc6e8449b6e6e1155f2b0980f50812cdfa42537043dfc55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2468c24-5034-49fa-aac5-5acaa56b6d3d", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives . ", "original_text": "A couple of things. "}, "hash": "e68a4e8a2d7becc708de45bd34006c43dc9bc6b09aa9988c5bd1e3b9262bb865", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 25, "end_char_idx": 50, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2468c24-5034-49fa-aac5-5acaa56b6d3d": {"__data__": {"id_": "c2468c24-5034-49fa-aac5-5acaa56b6d3d", "embedding": null, "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives . ", "original_text": "A couple of things. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d30a0feb-15a6-43aa-a179-dba6c28ca67c", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n", "original_text": "Thanks for the question. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75111be4125356c34f800d51bd7e398d45e3bf724456801bee729760b8fce54c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f83d19a-1926-4c4f-948a-181504c1add4", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment. ", "original_text": "Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year. "}, "hash": "197da0b5e42fe71a7c73f4b7a8eee087c25b4663358c0e1e921a5ab782bf27e3", "class_name": "RelatedNodeInfo"}}, "text": "A couple of things. ", "start_char_idx": 50, "end_char_idx": 70, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f83d19a-1926-4c4f-948a-181504c1add4": {"__data__": {"id_": "7f83d19a-1926-4c4f-948a-181504c1add4", "embedding": null, "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment. ", "original_text": "Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2468c24-5034-49fa-aac5-5acaa56b6d3d", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives . ", "original_text": "A couple of things. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a45b2c55359b9d7deaef62f0fc734e1b5f056e988eb1571b3c1410390713729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df993d7f-7fc1-43b1-8573-efbf0d3447ca", "node_type": "1", "metadata": {"window": "Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers. ", "original_text": "So that would be number one.  \n"}, "hash": "c675c03610a86112af96ad612ef8995a18cff91b5e426ad0661878c7d6ad26b7", "class_name": "RelatedNodeInfo"}}, "text": "Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year. ", "start_char_idx": 70, "end_char_idx": 297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df993d7f-7fc1-43b1-8573-efbf0d3447ca": {"__data__": {"id_": "df993d7f-7fc1-43b1-8573-efbf0d3447ca", "embedding": null, "metadata": {"window": "Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers. ", "original_text": "So that would be number one.  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f83d19a-1926-4c4f-948a-181504c1add4", "node_type": "1", "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment. ", "original_text": "Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53794076d0adbcbc3694a64756768e0ae7f94b582b8d87d9cb6e330184dc99c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4724f829-484b-418d-91ae-dc9f93098701", "node_type": "1", "metadata": {"window": "A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business. ", "original_text": "And then, number two is going to be our cost initiatives . "}, "hash": "8e14a47e544b774541daa267902ccd39e63e8084c274c430c4de2aaad29f24bb", "class_name": "RelatedNodeInfo"}}, "text": "So that would be number one.  \n", "start_char_idx": 297, "end_char_idx": 328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4724f829-484b-418d-91ae-dc9f93098701": {"__data__": {"id_": "4724f829-484b-418d-91ae-dc9f93098701", "embedding": null, "metadata": {"window": "A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business. ", "original_text": "And then, number two is going to be our cost initiatives . ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df993d7f-7fc1-43b1-8573-efbf0d3447ca", "node_type": "1", "metadata": {"window": "Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers. ", "original_text": "So that would be number one.  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "321d899d822cb68cc0d71e3c851dc3dd73e9ac23af2e497b8fb99fb0aa0129d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64e1848b-da30-42c1-aa8c-de09de026e6a", "node_type": "1", "metadata": {"window": "Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n", "original_text": "We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment. "}, "hash": "db9e85085aa2c5622c0acd7e3777c3f95a7cbc08e255b7834ccf8145a399e7ed", "class_name": "RelatedNodeInfo"}}, "text": "And then, number two is going to be our cost initiatives . ", "start_char_idx": 328, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64e1848b-da30-42c1-aa8c-de09de026e6a": {"__data__": {"id_": "64e1848b-da30-42c1-aa8c-de09de026e6a", "embedding": null, "metadata": {"window": "Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n", "original_text": "We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4724f829-484b-418d-91ae-dc9f93098701", "node_type": "1", "metadata": {"window": "A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business. ", "original_text": "And then, number two is going to be our cost initiatives . ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "691dcc4092bba16e057bd207e546615d4946c6067ce4d28de603b09025ad3fe8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0496584-5380-4a64-9f1d-5abf282465bc", "node_type": "1", "metadata": {"window": "So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses. ", "original_text": "So \nthose two are going to  be the two really big positive drivers. "}, "hash": "08203e46b212dacd913884a5dac0184f3043f56ac046ef7854eceee307be5dc4", "class_name": "RelatedNodeInfo"}}, "text": "We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment. ", "start_char_idx": 387, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0496584-5380-4a64-9f1d-5abf282465bc": {"__data__": {"id_": "b0496584-5380-4a64-9f1d-5abf282465bc", "embedding": null, "metadata": {"window": "So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses. ", "original_text": "So \nthose two are going to  be the two really big positive drivers. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64e1848b-da30-42c1-aa8c-de09de026e6a", "node_type": "1", "metadata": {"window": "Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year.  So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n", "original_text": "We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de37dff12a6bbe2289a7cad160c4459ff7dd71efb5f2b1fb22049158afbb52c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f57243a-a037-4699-a869-702a50ac906d", "node_type": "1", "metadata": {"window": "And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures. ", "original_text": "We're also going to see strong \nperforma nce in our at -Home business, our  Services business. "}, "hash": "e39067d7aa0167cd9dfa893ec281fbe432f5ab60ca2e64380cb1a51f5291374a", "class_name": "RelatedNodeInfo"}}, "text": "So \nthose two are going to  be the two really big positive drivers. ", "start_char_idx": 538, "end_char_idx": 606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f57243a-a037-4699-a869-702a50ac906d": {"__data__": {"id_": "0f57243a-a037-4699-a869-702a50ac906d", "embedding": null, "metadata": {"window": "And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures. ", "original_text": "We're also going to see strong \nperforma nce in our at -Home business, our  Services business. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0496584-5380-4a64-9f1d-5abf282465bc", "node_type": "1", "metadata": {"window": "So that would be number one.  \n And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses. ", "original_text": "So \nthose two are going to  be the two really big positive drivers. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a17d4294e99190910f133d159dec4a8e7e7c1f25ab71c862747cb3b8f6ff7da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f415084f-90bb-45bc-b11c-7e14f1f06f6b", "node_type": "1", "metadata": {"window": "We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver. ", "original_text": "And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n"}, "hash": "d51abfeca413c9fecf794d5aca889385a723318429297dca39af6ab7e36b8725", "class_name": "RelatedNodeInfo"}}, "text": "We're also going to see strong \nperforma nce in our at -Home business, our  Services business. ", "start_char_idx": 606, "end_char_idx": 701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f415084f-90bb-45bc-b11c-7e14f1f06f6b": {"__data__": {"id_": "f415084f-90bb-45bc-b11c-7e14f1f06f6b", "embedding": null, "metadata": {"window": "We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver. ", "original_text": "And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f57243a-a037-4699-a869-702a50ac906d", "node_type": "1", "metadata": {"window": "And then, number two is going to be our cost initiatives .  We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures. ", "original_text": "We're also going to see strong \nperforma nce in our at -Home business, our  Services business. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5fdc5849870ab4291391c12f4ed3daaa1080bbbff716e875e949a3733f43857", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f12125b4-14f4-4fee-a71a-9cc8f81c0d63", "node_type": "1", "metadata": {"window": "So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n", "original_text": "And so we're seeing strong performances from the businesses. "}, "hash": "7da7277c26e67e773922ac3bc0256cc53bac4b3cd79ef0ae13fe36e031c178d6", "class_name": "RelatedNodeInfo"}}, "text": "And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n", "start_char_idx": 701, "end_char_idx": 836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f12125b4-14f4-4fee-a71a-9cc8f81c0d63": {"__data__": {"id_": "f12125b4-14f4-4fee-a71a-9cc8f81c0d63", "embedding": null, "metadata": {"window": "So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n", "original_text": "And so we're seeing strong performances from the businesses. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f415084f-90bb-45bc-b11c-7e14f1f06f6b", "node_type": "1", "metadata": {"window": "We've been really, really getting after it when \nit comes to  looking at both our manufacturing, distribution and overall cost in the Medical segment.  So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver. ", "original_text": "And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df9111b1fbc889f59fe5e9a990755482b492570426338fa5cdeb21bc84299b4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18119403-7a62-40f4-b1cb-663a38b34b9a", "node_type": "1", "metadata": {"window": "We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "Clearly, the  negative is we're getting \nhit very hard  on elective procedures. "}, "hash": "78ed391baf4ec44413805f3179064c4f672f59c4fba1f1b0d36778e443c2e337", "class_name": "RelatedNodeInfo"}}, "text": "And so we're seeing strong performances from the businesses. ", "start_char_idx": 836, "end_char_idx": 897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18119403-7a62-40f4-b1cb-663a38b34b9a": {"__data__": {"id_": "18119403-7a62-40f4-b1cb-663a38b34b9a", "embedding": null, "metadata": {"window": "We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "Clearly, the  negative is we're getting \nhit very hard  on elective procedures. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f12125b4-14f4-4fee-a71a-9cc8f81c0d63", "node_type": "1", "metadata": {"window": "So \nthose two are going to  be the two really big positive drivers.  We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n", "original_text": "And so we're seeing strong performances from the businesses. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a9b323ce3748e1cf5739d09ba1dd0f451ec0a02d4635f8a16621f308b7e4150", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bf5233a-3754-42ec-b624-52bc36407ebf", "node_type": "1", "metadata": {"window": "And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n", "original_text": "And so our higher margin product businesses are the biggest \nnegative driver. "}, "hash": "57e4937182035a2904778ce870b599b03fa3648f8254f62d419b7d2cd27dbe2d", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, the  negative is we're getting \nhit very hard  on elective procedures. ", "start_char_idx": 897, "end_char_idx": 977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bf5233a-3754-42ec-b624-52bc36407ebf": {"__data__": {"id_": "2bf5233a-3754-42ec-b624-52bc36407ebf", "embedding": null, "metadata": {"window": "And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n", "original_text": "And so our higher margin product businesses are the biggest \nnegative driver. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18119403-7a62-40f4-b1cb-663a38b34b9a", "node_type": "1", "metadata": {"window": "We're also going to see strong \nperforma nce in our at -Home business, our  Services business.  And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "Clearly, the  negative is we're getting \nhit very hard  on elective procedures. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f410227588dcf7f0006d4b0dc38ed3b2ab5a5682dacdfe5823d4257b4540396d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f86b732a-bc6f-4701-bd75-d31ca09e9bb6", "node_type": "1", "metadata": {"window": "And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat. ", "original_text": "But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n"}, "hash": "700fffa0248746e3d000c316c3bbe59bf92dd2b8e1d8d1a52b0676a553cef7c0", "class_name": "RelatedNodeInfo"}}, "text": "And so our higher margin product businesses are the biggest \nnegative driver. ", "start_char_idx": 977, "end_char_idx": 1055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f86b732a-bc6f-4701-bd75-d31ca09e9bb6": {"__data__": {"id_": "f86b732a-bc6f-4701-bd75-d31ca09e9bb6", "embedding": null, "metadata": {"window": "And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat. ", "original_text": "But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bf5233a-3754-42ec-b624-52bc36407ebf", "node_type": "1", "metadata": {"window": "And, as you can imagine, our Lab \nDistribution business, which we don't talk about a lot  generally, has had increased volumes, too.  \n And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n", "original_text": "And so our higher margin product businesses are the biggest \nnegative driver. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33df30c29704e8d91cbfd39180ab3f0e23177b1d43a62d2020c68aa416066b2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8314f892-6b71-4a09-b2b6-c10c270f84f4", "node_type": "1", "metadata": {"window": "Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n"}, "hash": "d3e2dfe384bddd634e5aa391a590cc4bf62d46e85835819d7fe16d512b5cc7bd", "class_name": "RelatedNodeInfo"}}, "text": "But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n", "start_char_idx": 1055, "end_char_idx": 1265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8314f892-6b71-4a09-b2b6-c10c270f84f4": {"__data__": {"id_": "8314f892-6b71-4a09-b2b6-c10c270f84f4", "embedding": null, "metadata": {"window": "Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f86b732a-bc6f-4701-bd75-d31ca09e9bb6", "node_type": "1", "metadata": {"window": "And so we're seeing strong performances from the businesses.  Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat. ", "original_text": "But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d5829d17926583e3587f8526cea24a12829d921336152be047c7f27cec9d126", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb281b36-5c5d-4add-b1d8-033fbec81fab", "node_type": "1", "metadata": {"window": "And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better. ", "original_text": "Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n"}, "hash": "d259d1b32b98b7a115cd6fb98d4fa5b588a1caefd93e607c773515772ad7a23b", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext question, please.  \n  \n", "start_char_idx": 1265, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb281b36-5c5d-4add-b1d8-033fbec81fab": {"__data__": {"id_": "fb281b36-5c5d-4add-b1d8-033fbec81fab", "embedding": null, "metadata": {"window": "And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better. ", "original_text": "Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8314f892-6b71-4a09-b2b6-c10c270f84f4", "node_type": "1", "metadata": {"window": "Clearly, the  negative is we're getting \nhit very hard  on elective procedures.  And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc2392a37f1d863e5ca5d56e57e2f337412d6852ec55a5766f31b62e10684f9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aacc820-955a-4257-a784-1d523c18369b", "node_type": "1", "metadata": {"window": "But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter. ", "original_text": "Robert P. Jones:  \nGreat. "}, "hash": "18791ee34c7f22c266c181554e23f4f2b56d45ed9644956576b5b2057baac4bf", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n", "start_char_idx": 1308, "end_char_idx": 1382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aacc820-955a-4257-a784-1d523c18369b": {"__data__": {"id_": "1aacc820-955a-4257-a784-1d523c18369b", "embedding": null, "metadata": {"window": "But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter. ", "original_text": "Robert P. Jones:  \nGreat. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb281b36-5c5d-4add-b1d8-033fbec81fab", "node_type": "1", "metadata": {"window": "And so our higher margin product businesses are the biggest \nnegative driver.  But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better. ", "original_text": "Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee637aa4a502f04cc557c3aff3e603942c3a5d1a52042925802d89bf9e86b824", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac22d7c4-eef1-4bf8-8d39-08779184b92c", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "Thanks for the question. "}, "hash": "d9e01efef8428fe5c767721006dffde894b6c918db80da99b9fd626803c40a6c", "class_name": "RelatedNodeInfo"}}, "text": "Robert P. Jones:  \nGreat. ", "start_char_idx": 1382, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac22d7c4-eef1-4bf8-8d39-08779184b92c": {"__data__": {"id_": "ac22d7c4-eef1-4bf8-8d39-08779184b92c", "embedding": null, "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "Thanks for the question. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aacc820-955a-4257-a784-1d523c18369b", "node_type": "1", "metadata": {"window": "But I think  the piece that is the key here is the excellent work that we're doing on the \ncost side and the perform ance of some  of what might be considered our smaller business in the \nMedical segment.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter. ", "original_text": "Robert P. Jones:  \nGreat. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "837893328bc55e079cce736e0cebc817c1bb030bfca6ed2b2741a01606aa3037", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8abadbf-12e9-4bf1-a6ef-9c30d0fa94be", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better. "}, "hash": "7995ba9e85666c1724c03a806e92d6569611bce96289345c8abc21de6ba73392", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 25, "end_char_idx": 50, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8abadbf-12e9-4bf1-a6ef-9c30d0fa94be": {"__data__": {"id_": "a8abadbf-12e9-4bf1-a6ef-9c30d0fa94be", "embedding": null, "metadata": {"window": "Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac22d7c4-eef1-4bf8-8d39-08779184b92c", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "Thanks for the question. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4fe3044b771bf87338ee6129ead95771a3f3ade16c513e86fa75b42249ab3c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cef8176-765c-4e04-a9d1-debacb7b2a99", "node_type": "1", "metadata": {"window": "Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter. "}, "hash": "8142008d55f5c269f110492110d5b7851e5bb67a6e957c1618c96b2daacb2ae6", "class_name": "RelatedNodeInfo"}}, "text": "I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better. ", "start_char_idx": 1433, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cef8176-765c-4e04-a9d1-debacb7b2a99": {"__data__": {"id_": "5cef8176-765c-4e04-a9d1-debacb7b2a99", "embedding": null, "metadata": {"window": "Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8abadbf-12e9-4bf1-a6ef-9c30d0fa94be", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Robert Jones with Goldman Sachs.  \n  \n Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24c2ae1da4914d9a4131ba79429ae8af2338af5cf8a3a3e71701f8362281eb61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed3b5309-5b3a-4f86-bd53-2af31cb2291a", "node_type": "1", "metadata": {"window": "Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  "}, "hash": "1ba5187ebf1001ad68ffe864e2d803e80c46e93735a935f962ee9b8cb0e24bb7", "class_name": "RelatedNodeInfo"}}, "text": "I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter. ", "start_char_idx": 1556, "end_char_idx": 1745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed3b5309-5b3a-4f86-bd53-2af31cb2291a": {"__data__": {"id_": "ed3b5309-5b3a-4f86-bd53-2af31cb2291a", "embedding": null, "metadata": {"window": "Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "359153e041b53876d87754593aa4cad36f3e2800c9a21157c21857c0ed981b31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cef8176-765c-4e04-a9d1-debacb7b2a99", "node_type": "1", "metadata": {"window": "Robert P. Jones:  \nGreat.  Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98494ab0865da5e19971a4197efba3f17f16ded779397b4836f0057ca00b783e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42245d64-a55d-4b90-bf2d-a3b4cc4060f2", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3. ", "original_text": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business? "}, "hash": "d49e7c5ce9a254e9326a103ad9f5379b3a851d21f28eee5b2416061fec1fdae4", "class_name": "RelatedNodeInfo"}}, "text": "So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "start_char_idx": 1745, "end_char_idx": 1937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42245d64-a55d-4b90-bf2d-a3b4cc4060f2": {"__data__": {"id_": "42245d64-a55d-4b90-bf2d-a3b4cc4060f2", "embedding": null, "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3. ", "original_text": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business? ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed3b5309-5b3a-4f86-bd53-2af31cb2291a", "node_type": "1", "metadata": {"window": "Thanks for the question.  I guess just, Mike, going back to the Pharma segment, I wanted to \njust understand the guidance there a little bit better.  I know it's probably been several years since \nyou've quantified  the Nuclear business, but sounds like that's kind of a standout as far a s the \ndowndraft you expect to see next  quarter.  So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "original_text": "So I was wondering if you could give any context around \nthe size of that business today versus probably  several years ago when we probably had a clearer \nsign of the size of that business.  ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9df7ad0098c29afe270093da2c8eeb27527cc79f277a4c0f3bc8af5feda6a199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efd5d409-2dfe-4233-b199-e52a776a84c0", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there. ", "original_text": "Thanks.  \n  \n"}, "hash": "8441f6d99ab03e26e44deb93fb4e02ed09000d018a60a9d2f35404b450fa64b4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business? ", "start_char_idx": 0, "end_char_idx": 391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efd5d409-2dfe-4233-b199-e52a776a84c0": {"__data__": {"id_": "efd5d409-2dfe-4233-b199-e52a776a84c0", "embedding": null, "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there. ", "original_text": "Thanks.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42245d64-a55d-4b90-bf2d-a3b4cc4060f2", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3. ", "original_text": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business? ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd49fab7ca891a7a031c082269eaaa7b7bfd67115ba1498cf503a653322bbee2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49bd4eb6-a94f-4427-90ea-32f470786c3d", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3. ", "original_text": "Michael C. Kaufmann:  \nYes. "}, "hash": "212349015e9adda98185c90948188ffc0a629ae3fd8f076ef9f05d689a637fc4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n  \n", "start_char_idx": 391, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49bd4eb6-a94f-4427-90ea-32f470786c3d": {"__data__": {"id_": "49bd4eb6-a94f-4427-90ea-32f470786c3d", "embedding": null, "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3. ", "original_text": "Michael C. Kaufmann:  \nYes. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efd5d409-2dfe-4233-b199-e52a776a84c0", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there. ", "original_text": "Thanks.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51756e3686cbd20085e649d8b044bebcca362ec02e7de140ec36fcdbd806cb74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2953fe2-adf2-43b0-844f-6476a7b70bad", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril. ", "original_text": "So from a core business standpoint, what we saw was a surge in our Q3. "}, "hash": "241ed8181a955061a005417725fbabeb0a27d075755591e9a2e65c5b3ab59e00", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nYes. ", "start_char_idx": 404, "end_char_idx": 432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2953fe2-adf2-43b0-844f-6476a7b70bad": {"__data__": {"id_": "b2953fe2-adf2-43b0-844f-6476a7b70bad", "embedding": null, "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril. ", "original_text": "So from a core business standpoint, what we saw was a surge in our Q3. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49bd4eb6-a94f-4427-90ea-32f470786c3d", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3. ", "original_text": "Michael C. Kaufmann:  \nYes. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d2c914c9ce89474e3d8d2473d92f677bff1821d179d63907802cf2acda6d22f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9b38bbf-853b-400d-966e-a1d44d3acda0", "node_type": "1", "metadata": {"window": "Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.  ", "original_text": "I think you can see \nthat through a  lot of the data out there. "}, "hash": "856b77e2eabc36f883a80597c2fc116a0d4a42ce3c364f1b979b8be716ce090b", "class_name": "RelatedNodeInfo"}}, "text": "So from a core business standpoint, what we saw was a surge in our Q3. ", "start_char_idx": 432, "end_char_idx": 503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9b38bbf-853b-400d-966e-a1d44d3acda0": {"__data__": {"id_": "e9b38bbf-853b-400d-966e-a1d44d3acda0", "embedding": null, "metadata": {"window": "Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.  ", "original_text": "I think you can see \nthat through a  lot of the data out there. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2953fe2-adf2-43b0-844f-6476a7b70bad", "node_type": "1", "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril. ", "original_text": "So from a core business standpoint, what we saw was a surge in our Q3. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dddbf40c09d008a369b48d1da535fee991ac81f5c0354130d683ffbdc9f90c5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e89674c9-3bca-486e-bb46-995d44cfae3a", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma. ", "original_text": "As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3. "}, "hash": "a7d62b2df9b63d64b150fe68726b20373ed592922358d5210e3a1857497aebdb", "class_name": "RelatedNodeInfo"}}, "text": "I think you can see \nthat through a  lot of the data out there. ", "start_char_idx": 503, "end_char_idx": 567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e89674c9-3bca-486e-bb46-995d44cfae3a": {"__data__": {"id_": "e89674c9-3bca-486e-bb46-995d44cfae3a", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma. ", "original_text": "As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9b38bbf-853b-400d-966e-a1d44d3acda0", "node_type": "1", "metadata": {"window": "Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.  ", "original_text": "I think you can see \nthat through a  lot of the data out there. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca8b83290fc278fa01528035f0b11452e1f9b863940551ec8ecc1f0f889eeb55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48d1ee29-1c8c-4305-9322-6cf80f2416a1", "node_type": "1", "metadata": {"window": "So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down. ", "original_text": "And we've seen the reversal of that already through \nApril. "}, "hash": "31370e7a16d207021ef9ee8189ea5f3b6df60344c4c33d91b7390a8fbccbeb71", "class_name": "RelatedNodeInfo"}}, "text": "As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3. ", "start_char_idx": 567, "end_char_idx": 673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48d1ee29-1c8c-4305-9322-6cf80f2416a1": {"__data__": {"id_": "48d1ee29-1c8c-4305-9322-6cf80f2416a1", "embedding": null, "metadata": {"window": "So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down. ", "original_text": "And we've seen the reversal of that already through \nApril. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e89674c9-3bca-486e-bb46-995d44cfae3a", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma. ", "original_text": "As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2107b40b92cd88051d9d47fd5d9e5a147b4376a07c323f2a883e6e76de18570c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cd73546-7cd9-4a9c-8b52-633cf9b0e823", "node_type": "1", "metadata": {"window": "I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong. ", "original_text": "So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.  "}, "hash": "b85c89768f40e5e903834dbae4134e0e20784c0140860c3fecf273c6d05bac59", "class_name": "RelatedNodeInfo"}}, "text": "And we've seen the reversal of that already through \nApril. ", "start_char_idx": 673, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cd73546-7cd9-4a9c-8b52-633cf9b0e823": {"__data__": {"id_": "8cd73546-7cd9-4a9c-8b52-633cf9b0e823", "embedding": null, "metadata": {"window": "I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong. ", "original_text": "So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.  ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48d1ee29-1c8c-4305-9322-6cf80f2416a1", "node_type": "1", "metadata": {"window": "So from a core business standpoint, what we saw was a surge in our Q3.  I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down. ", "original_text": "And we've seen the reversal of that already through \nApril. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bbbcee3ea014d379e29ef63e35e38f207f6289080168994b0801fbd695ae63a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "497ce74c-3b9a-481c-aa5a-76a96f0f812d", "node_type": "1", "metadata": {"window": "As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n", "original_text": "So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma. "}, "hash": "96f4889798b113b184980ab2a8f83505ca7d8edd9b530f88297920675ead329d", "class_name": "RelatedNodeInfo"}}, "text": "So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.  ", "start_char_idx": 733, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "497ce74c-3b9a-481c-aa5a-76a96f0f812d": {"__data__": {"id_": "497ce74c-3b9a-481c-aa5a-76a96f0f812d", "embedding": null, "metadata": {"window": "As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n", "original_text": "So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cd73546-7cd9-4a9c-8b52-633cf9b0e823", "node_type": "1", "metadata": {"window": "I think you can see \nthat through a  lot of the data out there.  As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong. ", "original_text": "So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.  ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3b5274649bf6add9762b3d7d262275cb15c29699f3f63edc51aa740de8c8ef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0a97a85-6525-423f-8728-a8ea560db9d3", "node_type": "1", "metadata": {"window": "And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars. ", "original_text": "We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down. "}, "hash": "05cbbc214467d306567fa1dab1173adae3d07e437a771fd72a69664f863ecc24", "class_name": "RelatedNodeInfo"}}, "text": "So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma. ", "start_char_idx": 1051, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0a97a85-6525-423f-8728-a8ea560db9d3": {"__data__": {"id_": "f0a97a85-6525-423f-8728-a8ea560db9d3", "embedding": null, "metadata": {"window": "And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars. ", "original_text": "We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "497ce74c-3b9a-481c-aa5a-76a96f0f812d", "node_type": "1", "metadata": {"window": "As Dave mentioned in his script, we saw a surge in Q3 which \nled to upside in our Pharma  business in Q3.  And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n", "original_text": "So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ebe96f30169d73e347031d996cf22a3be5b143735a73c4fc077fc823b321649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2482b5f5-c155-46cb-83df-fbe7c177e78d", "node_type": "1", "metadata": {"window": "So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n", "original_text": "And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong. "}, "hash": "9ccb3c2bb75125fe89aaf46887257f70e7aee6712d2c432eecbe642547360e7c", "class_name": "RelatedNodeInfo"}}, "text": "We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down. ", "start_char_idx": 1146, "end_char_idx": 1263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2482b5f5-c155-46cb-83df-fbe7c177e78d": {"__data__": {"id_": "2482b5f5-c155-46cb-83df-fbe7c177e78d", "embedding": null, "metadata": {"window": "So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n", "original_text": "And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0a97a85-6525-423f-8728-a8ea560db9d3", "node_type": "1", "metadata": {"window": "And we've seen the reversal of that already through \nApril.  So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars. ", "original_text": "We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6197cf1c0f17e6713e765968ba252c80486b2f4c5390c21033eac7cb7283eb03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27fc0892-a5ec-4715-b091-684c47640808", "node_type": "1", "metadata": {"window": "So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business. ", "original_text": "So we expect to see a little bit of that.  \n"}, "hash": "af73287ce49286ab994cb436fe7dfc47d622ba7f53cf0e381a09066524d48cd1", "class_name": "RelatedNodeInfo"}}, "text": "And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong. ", "start_char_idx": 1263, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27fc0892-a5ec-4715-b091-684c47640808": {"__data__": {"id_": "27fc0892-a5ec-4715-b091-684c47640808", "embedding": null, "metadata": {"window": "So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business. ", "original_text": "So we expect to see a little bit of that.  \n", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2482b5f5-c155-46cb-83df-fbe7c177e78d", "node_type": "1", "metadata": {"window": "So if you probably add the two quarters  together, our assumption is that Pharma would be \nrelatively consistent from an overall sales growth standpoint,  again, unless we see some types of \nsurges again in this quarter that we're not necessarily anticipating, but the  surge in Q3 we see \nreversing in Q4 on Pharma.   So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n", "original_text": "And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22000df43fccf425c7fed0bdcce808c9c6326dfaeca0d1e7354c68c00ba53cfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c260a7d7-2292-4879-8a50-95a7b2752637", "node_type": "1", "metadata": {"window": "We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n", "original_text": "Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars. "}, "hash": "8f0ed332289e4fc1f23c9ff8a51b95fc5e554385edbb19777420212feab0512c", "class_name": "RelatedNodeInfo"}}, "text": "So we expect to see a little bit of that.  \n", "start_char_idx": 1431, "end_char_idx": 1475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c260a7d7-2292-4879-8a50-95a7b2752637": {"__data__": {"id_": "c260a7d7-2292-4879-8a50-95a7b2752637", "embedding": null, "metadata": {"window": "We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n", "original_text": "Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27fc0892-a5ec-4715-b091-684c47640808", "node_type": "1", "metadata": {"window": "So that's the big \u2013 really bigg est driver between Q3 and Q4 when it \ncomes to overall Pharma.  We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business. ", "original_text": "So we expect to see a little bit of that.  \n", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82f10fa101789b8ecb3a9c2335ffa9f53e6200e0c43c21e35f97485ae39d7468", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30786cf3-9dec-4dd8-b651-39dc7f9352f7", "node_type": "1", "metadata": {"window": "And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals. ", "original_text": "Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n"}, "hash": "70692d981ea7179e3fe283d28ca970f2b8b95b0d7adee0ce00da4aea764fd4a7", "class_name": "RelatedNodeInfo"}}, "text": "Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars. ", "start_char_idx": 1475, "end_char_idx": 1613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30786cf3-9dec-4dd8-b651-39dc7f9352f7": {"__data__": {"id_": "30786cf3-9dec-4dd8-b651-39dc7f9352f7", "embedding": null, "metadata": {"window": "And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals. ", "original_text": "Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c260a7d7-2292-4879-8a50-95a7b2752637", "node_type": "1", "metadata": {"window": "We did see some,  and expect to see some, decline in Q4 on our Specialty \nbusiness because doctors' visits are down.  And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n", "original_text": "Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55714a59c3a6be4c31effae797a87ad1f47f1a0e2c72ed4b4c37726134210ca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "882d2d84-eea5-4338-901b-906f5411791c", "node_type": "1", "metadata": {"window": "So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time. ", "original_text": "And so what we're seeing, as Dave  mentioned, this is a high fixed cost business. "}, "hash": "ed0f7d4dc72f7c0f827462990b504f5d6ac974976d375d36139e91eeecb77928", "class_name": "RelatedNodeInfo"}}, "text": "Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n", "start_char_idx": 1613, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "882d2d84-eea5-4338-901b-906f5411791c": {"__data__": {"id_": "882d2d84-eea5-4338-901b-906f5411791c", "embedding": null, "metadata": {"window": "So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time. ", "original_text": "And so what we're seeing, as Dave  mentioned, this is a high fixed cost business. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30786cf3-9dec-4dd8-b651-39dc7f9352f7", "node_type": "1", "metadata": {"window": "And when you  look at both oncology, and rheumatology, \nnephrology, you are seein g more office visit decreases in some of the  non-oncology areas where \nwe're strong.  So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals. ", "original_text": "Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "320ef80b03fab84c7f4c3f8a07f6faee71aca038484830b775b239c6e8db05ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5baaa71a-ac23-4756-a430-470b69ddb90f", "node_type": "1", "metadata": {"window": "Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n"}, "hash": "fedbdfa12f58f5a4f071d27ba0dd2a128b2d0b7eb32718ccbbf5c07d47ff8863", "class_name": "RelatedNodeInfo"}}, "text": "And so what we're seeing, as Dave  mentioned, this is a high fixed cost business. ", "start_char_idx": 1776, "end_char_idx": 1858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5baaa71a-ac23-4756-a430-470b69ddb90f": {"__data__": {"id_": "5baaa71a-ac23-4756-a430-470b69ddb90f", "embedding": null, "metadata": {"window": "Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "882d2d84-eea5-4338-901b-906f5411791c", "node_type": "1", "metadata": {"window": "So we expect to see a little bit of that.  \n Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time. ", "original_text": "And so what we're seeing, as Dave  mentioned, this is a high fixed cost business. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbd8ebe66354d03238c4d8f26fa5da491aa681a1589e60f02aca894213d2a686", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04af0390-afce-4f47-ae80-44143f2d00ed", "node_type": "1", "metadata": {"window": "Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals. "}, "hash": "32d1e2094bdac6c8594779c9deb6ad54905c044060c077f51b1573390666109b", "class_name": "RelatedNodeInfo"}}, "text": "And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n", "start_char_idx": 1858, "end_char_idx": 2043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04af0390-afce-4f47-ae80-44143f2d00ed": {"__data__": {"id_": "04af0390-afce-4f47-ae80-44143f2d00ed", "embedding": null, "metadata": {"window": "Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5baaa71a-ac23-4756-a430-470b69ddb90f", "node_type": "1", "metadata": {"window": "Specifically, as it relates to Nuclear, it's about a $900 million top line business that's been growing \neach of the last  couple ye ars.  Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64933d039a5edec9469c11258180656fd80c7d6fb82f7d57d87e2ff3e89003ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c29078f-0b9c-42aa-b8b1-9763b18afa0e", "node_type": "1", "metadata": {"window": "And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "Now, again, that's an estimate at this point in time. "}, "hash": "e3170efbe045b636a1677a988962bbad181090b7062b3984487594d6f01d515a", "class_name": "RelatedNodeInfo"}}, "text": "And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals. ", "start_char_idx": 2043, "end_char_idx": 2284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c29078f-0b9c-42aa-b8b1-9763b18afa0e": {"__data__": {"id_": "7c29078f-0b9c-42aa-b8b1-9763b18afa0e", "embedding": null, "metadata": {"window": "And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "Now, again, that's an estimate at this point in time. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04af0390-afce-4f47-ae80-44143f2d00ed", "node_type": "1", "metadata": {"window": "Ever since we had the couple of year period where there was a \nsignificant reduction in the  procedures done in that business, we've seen some consistent growth. \n And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d98de787941f993fb08fe31410afd8a7bc2cdb75da0c149d7486c9d6e5ba8be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47913828-89e8-4816-9f74-d9add8b27729", "node_type": "1", "metadata": {"window": "And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it "}, "hash": "2d4e20825c7e4f9b9f0dcaf6ca1ab0eab4836fed63429510ab0d3e75cbaa739a", "class_name": "RelatedNodeInfo"}}, "text": "Now, again, that's an estimate at this point in time. ", "start_char_idx": 2284, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47913828-89e8-4816-9f74-d9add8b27729": {"__data__": {"id_": "47913828-89e8-4816-9f74-d9add8b27729", "embedding": null, "metadata": {"window": "And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bf766eb37e9b80dd7f7e366f89f1617b842b7c6cb11280d71dfd8ed2de2d31a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c29078f-0b9c-42aa-b8b1-9763b18afa0e", "node_type": "1", "metadata": {"window": "And so what we're seeing, as Dave  mentioned, this is a high fixed cost business.  And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "Now, again, that's an estimate at this point in time. ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a22a1580fb27d9ae6bba12abc74dc75fd8be19d78a93e1e965b7dad86cbcc288", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21455c87-6eff-4b11-b87d-ca0f653af770", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n", "original_text": " \nPage 16 of 31 \n \nfor the mid to long -term. "}, "hash": "7bf6de55f8b1c1452b2cc83246aa7e191b3d2f36e71e8423d41d35097d2c492d", "class_name": "RelatedNodeInfo"}}, "text": "But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "start_char_idx": 2338, "end_char_idx": 2466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21455c87-6eff-4b11-b87d-ca0f653af770": {"__data__": {"id_": "21455c87-6eff-4b11-b87d-ca0f653af770", "embedding": null, "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n", "original_text": " \nPage 16 of 31 \n \nfor the mid to long -term. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47913828-89e8-4816-9f74-d9add8b27729", "node_type": "1", "metadata": {"window": "And so whe n you \nsee the procedures decline as dramatically as we  did and you have a high fixed cost, we're seeing a \nsignificant impact to the bottom line of the Nuclear business.  \n And to try to give it some size \u2013 because we're not going to get into specific details on it, but to give it \nsome size,  we expected in Q4 to be the number one negative year -over-year driver, even larger than \ncustomer contract  renewals.  Now, again, that's an estimate at this point in time.  But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "original_text": "But right now we are \nexpecting that business to  have a larger negative year -over-year impact, but, again, feel good about it ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bdee1908ff9adad8a24e501309df644f3f4ba6b29607cf95080ba35d3e7d884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd4ff66e-54c0-46a5-b819-554c56007aa4", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n", "original_text": "So we remain  committed to it. "}, "hash": "9c178cb1cffea05f0be602d7031f7bda5ec3c10f9ac7cbcb81941b9003bc17c5", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 31 \n \nfor the mid to long -term. ", "start_char_idx": 0, "end_char_idx": 46, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd4ff66e-54c0-46a5-b819-554c56007aa4": {"__data__": {"id_": "bd4ff66e-54c0-46a5-b819-554c56007aa4", "embedding": null, "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n", "original_text": "So we remain  committed to it. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21455c87-6eff-4b11-b87d-ca0f653af770", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n", "original_text": " \nPage 16 of 31 \n \nfor the mid to long -term. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "185af9b25da021c0aef7a74c2c34881b099ffd81b297c7cf0e372b41725e287e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f25be417-2a78-4e8b-8626-bf41669292f6", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi. ", "original_text": "And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n"}, "hash": "75bed3cb55ae3bb33ffa26de1251bdc59b1b1e0120e799a35381880175e3c4c6", "class_name": "RelatedNodeInfo"}}, "text": "So we remain  committed to it. ", "start_char_idx": 46, "end_char_idx": 77, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f25be417-2a78-4e8b-8626-bf41669292f6": {"__data__": {"id_": "f25be417-2a78-4e8b-8626-bf41669292f6", "embedding": null, "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi. ", "original_text": "And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd4ff66e-54c0-46a5-b819-554c56007aa4", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n", "original_text": "So we remain  committed to it. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2143db9a7039db5c195edf80ae7b876617d1ef304c5c4bf7c594532e8c79b5a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3db26af-84f0-4b1b-b924-53c60ade9477", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call. ", "original_text": "Kevin Moran:  \nNext question,  please.  \n  \n"}, "hash": "fc30eb224d63491ce24b6251ac0da2fe37d49001c6a9bf425905aecedaecd6da", "class_name": "RelatedNodeInfo"}}, "text": "And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n", "start_char_idx": 77, "end_char_idx": 182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3db26af-84f0-4b1b-b924-53c60ade9477": {"__data__": {"id_": "b3db26af-84f0-4b1b-b924-53c60ade9477", "embedding": null, "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call. ", "original_text": "Kevin Moran:  \nNext question,  please.  \n  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f25be417-2a78-4e8b-8626-bf41669292f6", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi. ", "original_text": "And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f643f549835246e605cef148b42df251fd8de4ef8d634806bd294a2e0ce79525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0ec53c9-d436-4072-b46b-84a06ad9202a", "node_type": "1", "metadata": {"window": "So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit. ", "original_text": "Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n"}, "hash": "356dd26160a444fba370039ff0069d38dc233acf4e7b9667c74cf2f643cc78b6", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext question,  please.  \n  \n", "start_char_idx": 182, "end_char_idx": 226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0ec53c9-d436-4072-b46b-84a06ad9202a": {"__data__": {"id_": "a0ec53c9-d436-4072-b46b-84a06ad9202a", "embedding": null, "metadata": {"window": "So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit. ", "original_text": "Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3db26af-84f0-4b1b-b924-53c60ade9477", "node_type": "1", "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call. ", "original_text": "Kevin Moran:  \nNext question,  please.  \n  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2602cb7f11481cdaca71f3d33f7b2de3b4ee3fa5b664ce2d03abbddbf2542eb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bca1875c-5182-4e40-9725-0ef8af8ccc15", "node_type": "1", "metadata": {"window": "And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder. ", "original_text": "Kevin Caliendo:  \nHi. "}, "hash": "24240fa14a4d7a70cb0314034cd93b35b49c460d16f22d2e88c8904404db14f6", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n", "start_char_idx": 226, "end_char_idx": 292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bca1875c-5182-4e40-9725-0ef8af8ccc15": {"__data__": {"id_": "bca1875c-5182-4e40-9725-0ef8af8ccc15", "embedding": null, "metadata": {"window": "And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder. ", "original_text": "Kevin Caliendo:  \nHi. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0ec53c9-d436-4072-b46b-84a06ad9202a", "node_type": "1", "metadata": {"window": "So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit. ", "original_text": "Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1667df5b5a0b23c64ab739a406b482b5c4aacf1b16d382360243291eeeb227b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9e8bdb0-c25c-4fd0-a992-36103013afe0", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace? ", "original_text": "Thanks for taking my call. "}, "hash": "17c5a83f6ed846788aa6433c93f69c09686b7d50fcb48b59c97bd2f515d9dfb8", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:  \nHi. ", "start_char_idx": 292, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9e8bdb0-c25c-4fd0-a992-36103013afe0": {"__data__": {"id_": "e9e8bdb0-c25c-4fd0-a992-36103013afe0", "embedding": null, "metadata": {"window": "Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace? ", "original_text": "Thanks for taking my call. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bca1875c-5182-4e40-9725-0ef8af8ccc15", "node_type": "1", "metadata": {"window": "And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder. ", "original_text": "Kevin Caliendo:  \nHi. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c441444bbdf3e943d9bdc79f38175cd3f356a9e1d6527873454b4ead3c7ba27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69ed922f-4896-4f4a-bd21-0f9ccf1fb1a8", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating? ", "original_text": "I want to ask about generics a little bit. "}, "hash": "64de1619399c763b5eaefe48b94934d157a1e537b5f514285946dec4a530245e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my call. ", "start_char_idx": 314, "end_char_idx": 341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69ed922f-4896-4f4a-bd21-0f9ccf1fb1a8": {"__data__": {"id_": "69ed922f-4896-4f4a-bd21-0f9ccf1fb1a8", "embedding": null, "metadata": {"window": "Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating? ", "original_text": "I want to ask about generics a little bit. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9e8bdb0-c25c-4fd0-a992-36103013afe0", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question,  please.  \n  \n Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace? ", "original_text": "Thanks for taking my call. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a54a7de26705c52506802a5dc9455a369d340efbcebc275244ef854cb6c3f08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "454dd7f4-6244-41d2-834c-4177a59def4b", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit? ", "original_text": "I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder. "}, "hash": "ee1aa5aa6de6edede56fc7b55ad5048c5e0391ae06b8a0810642141f6a2e07ee", "class_name": "RelatedNodeInfo"}}, "text": "I want to ask about generics a little bit. ", "start_char_idx": 341, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "454dd7f4-6244-41d2-834c-4177a59def4b": {"__data__": {"id_": "454dd7f4-6244-41d2-834c-4177a59def4b", "embedding": null, "metadata": {"window": "Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit? ", "original_text": "I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69ed922f-4896-4f4a-bd21-0f9ccf1fb1a8", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Kevin Caliendo with UBS.  \n  \n Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating? ", "original_text": "I want to ask about generics a little bit. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6659e801c7a212905476775723386195684ba39ffe8106de3fa95532be6cd0c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b18e9ca4-2c32-4d3d-b7ef-437025187992", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n", "original_text": "Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace? "}, "hash": "2bc932702743ac83ea51b99613da2263284fd826da6a4adeaccedf44878d2711", "class_name": "RelatedNodeInfo"}}, "text": "I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder. ", "start_char_idx": 384, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b18e9ca4-2c32-4d3d-b7ef-437025187992": {"__data__": {"id_": "b18e9ca4-2c32-4d3d-b7ef-437025187992", "embedding": null, "metadata": {"window": "Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n", "original_text": "Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace? ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "454dd7f4-6244-41d2-834c-4177a59def4b", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  \nHi.  Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit? ", "original_text": "I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89d08a5edfbd55bc5e3a2888cfbd9d9da53ab259b5a461731f4db3c9c6ac4ea8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b54f6165-4740-404d-bbc2-63f4742181a8", "node_type": "1", "metadata": {"window": "I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "Is it that the \ndeflation is moderating? "}, "hash": "59e437414fdab4b1b85d4cb956dac8e78b77c90235905ee9ce50090415cd6a9d", "class_name": "RelatedNodeInfo"}}, "text": "Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace? ", "start_char_idx": 514, "end_char_idx": 609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b54f6165-4740-404d-bbc2-63f4742181a8": {"__data__": {"id_": "b54f6165-4740-404d-bbc2-63f4742181a8", "embedding": null, "metadata": {"window": "I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "Is it that the \ndeflation is moderating? ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b18e9ca4-2c32-4d3d-b7ef-437025187992", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n", "original_text": "Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace? ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59165aa59f3e7f3a97161c54f084e825891ac3099d437c5bbe28f752ce31e766", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "237391d0-7f76-4026-8577-62b18ed8f8f3", "node_type": "1", "metadata": {"window": "I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected. ", "original_text": "Are the spreads  tightening a little bit? "}, "hash": "6f24b5adfaf1e4d09aec2cc0cd2c48ee66d60306be226fb17207edf70e3a2085", "class_name": "RelatedNodeInfo"}}, "text": "Is it that the \ndeflation is moderating? ", "start_char_idx": 609, "end_char_idx": 650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "237391d0-7f76-4026-8577-62b18ed8f8f3": {"__data__": {"id_": "237391d0-7f76-4026-8577-62b18ed8f8f3", "embedding": null, "metadata": {"window": "I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected. ", "original_text": "Are the spreads  tightening a little bit? ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b54f6165-4740-404d-bbc2-63f4742181a8", "node_type": "1", "metadata": {"window": "I want to ask about generics a little bit.  I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "Is it that the \ndeflation is moderating? ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "578afb1ca14cb0e53bd6b19916caadd4075c505b089a1f71ef2c068eafe466ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0413ad28-e5d4-4f44-9437-d850e05b30ef", "node_type": "1", "metadata": {"window": "Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n", "original_text": "What do you expect going forward with \nregards to the generics business?  \n  \n"}, "hash": "c6fd61fb7428ed93cb948fcc6b1215efc55c08499339a6142f9227d3fc5708ef", "class_name": "RelatedNodeInfo"}}, "text": "Are the spreads  tightening a little bit? ", "start_char_idx": 650, "end_char_idx": 692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0413ad28-e5d4-4f44-9437-d850e05b30ef": {"__data__": {"id_": "0413ad28-e5d4-4f44-9437-d850e05b30ef", "embedding": null, "metadata": {"window": "Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n", "original_text": "What do you expect going forward with \nregards to the generics business?  \n  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "237391d0-7f76-4026-8577-62b18ed8f8f3", "node_type": "1", "metadata": {"window": "I think you said that the generics \nhave been  improving since Q4 of last year and thus the com ps will get incrementally harder.  Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected. ", "original_text": "Are the spreads  tightening a little bit? ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e726fcd64556b83810d844b2cb4be652b2392ceb0f6050826a4e98a71511a12e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "074aad28-3129-4127-a7de-0233f141e54f", "node_type": "1", "metadata": {"window": "Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "Michael C. Kaufmann:  \nYeah. "}, "hash": "99f59db5b5153970fd79713d8425b3c3fa4faa972d1178f7fbd52c26e5ced066", "class_name": "RelatedNodeInfo"}}, "text": "What do you expect going forward with \nregards to the generics business?  \n  \n", "start_char_idx": 692, "end_char_idx": 770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "074aad28-3129-4127-a7de-0233f141e54f": {"__data__": {"id_": "074aad28-3129-4127-a7de-0233f141e54f", "embedding": null, "metadata": {"window": "Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0413ad28-e5d4-4f44-9437-d850e05b30ef", "node_type": "1", "metadata": {"window": "Can you \ntalk \u2013 can you give us  a little more detail on what's happening in that marketplace?  Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n", "original_text": "What do you expect going forward with \nregards to the generics business?  \n  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f797af27e5aa6fc3f70a5aa93231230dcafb86c946902b4c5e1b851bbd2723c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4f83654-18cc-4b27-90b4-45efaa9c5129", "node_type": "1", "metadata": {"window": "Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected. "}, "hash": "21884f61d1a69a95b4ee1394bd8f4fb5f7ac81afd72a256f6492173811a484a3", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nYeah. ", "start_char_idx": 770, "end_char_idx": 799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4f83654-18cc-4b27-90b4-45efaa9c5129": {"__data__": {"id_": "e4f83654-18cc-4b27-90b4-45efaa9c5129", "embedding": null, "metadata": {"window": "Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "074aad28-3129-4127-a7de-0233f141e54f", "node_type": "1", "metadata": {"window": "Is it that the \ndeflation is moderating?  Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91fe3c0669f3238fa14841865b2f30c33503a7d19da9397780492138c3de7cd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab21c85f-6222-4725-bea0-adf87782eb88", "node_type": "1", "metadata": {"window": "What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n"}, "hash": "a8fdfe21e4acbacb17e247bcfc7b747f610691a215822c55b49a7dc3e4c613a2", "class_name": "RelatedNodeInfo"}}, "text": "Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected. ", "start_char_idx": 799, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab21c85f-6222-4725-bea0-adf87782eb88": {"__data__": {"id_": "ab21c85f-6222-4725-bea0-adf87782eb88", "embedding": null, "metadata": {"window": "What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4f83654-18cc-4b27-90b4-45efaa9c5129", "node_type": "1", "metadata": {"window": "Are the spreads  tightening a little bit?  What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4dbba60832aa09789e76bb9a730949bc0210a3d68c60311136c0424ec7a93d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1725c2bc-7fe0-4eb2-abd4-7ba8e18271bc", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  "}, "hash": "6964d8dc87834cb04cbe49ed56cc05557946d08e40edb12abf3ddb03fbc3dee0", "class_name": "RelatedNodeInfo"}}, "text": "So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n", "start_char_idx": 1057, "end_char_idx": 1132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1725c2bc-7fe0-4eb2-abd4-7ba8e18271bc": {"__data__": {"id_": "1725c2bc-7fe0-4eb2-abd4-7ba8e18271bc", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2dfb3a05-26da-4478-a3a7-94617c67271c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf36fd0b1c1a232eeae9cf90ba315d3a9744bd01866e6ece23f51969712557de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab21c85f-6222-4725-bea0-adf87782eb88", "node_type": "1", "metadata": {"window": "What do you expect going forward with \nregards to the generics business?  \n  \n Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "128e1211a6b0fbacd40659d7f948420b8aee5c6d2d38890bbdaab397cf808a76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43b284d8-6b27-4d0b-9f61-739fd80d9a25", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year. ", "original_text": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years. "}, "hash": "27fb63588723a4ec1600b6c912c0b4f1fbe53773f662af86b9b2268d9bc45082", "class_name": "RelatedNodeInfo"}}, "text": "But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "start_char_idx": 1132, "end_char_idx": 1633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43b284d8-6b27-4d0b-9f61-739fd80d9a25": {"__data__": {"id_": "43b284d8-6b27-4d0b-9f61-739fd80d9a25", "embedding": null, "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year. ", "original_text": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1725c2bc-7fe0-4eb2-abd4-7ba8e18271bc", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  Generics, as I said, is one of the three key areas we're keeping our eyes on because it's an \narea that, with  COVID -19, could see impacts related to raw material changes in cost, export \nrestrict ions, manufacturing facilities  may or may not be affected.  So there's a lot of potential dynamics \nthat we have to keep our eye on.  \n But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "original_text": "But as you  know, our generics program really has four components, which is: the cost side, which is \ngenerally managed by  Red Oak and we continue to see very strong performance by that team; the \nsell price side that we talk about and,  again, we've invested a lot of capabilities into our pricing and \nanalytics team, because our overall goal is to  maintain that margin per unit, whic h is really the key, \nwhich, as we said before, is why we went away from talking  about individual components.  ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "501c8c190fa85b98ce55e02512b0d5295bb3fb453bb5324847b4dbbbf8c97276", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdc41274-c4a9-4beb-9cf7-f279da071d87", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n", "original_text": "That's generally running about \nas expected. "}, "hash": "f151d734a7f54aa10de8b46010b6fe80f004aa317b3b0cbfc43df017b4c007dd", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years. ", "start_char_idx": 0, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdc41274-c4a9-4beb-9cf7-f279da071d87": {"__data__": {"id_": "cdc41274-c4a9-4beb-9cf7-f279da071d87", "embedding": null, "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n", "original_text": "That's generally running about \nas expected. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43b284d8-6b27-4d0b-9f61-739fd80d9a25", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year. ", "original_text": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9733bcb9ceb7417f1ee91350d4fcc05fee670e1584bb943ab858ee7a59d6d460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7439a986-f98d-4304-9209-54997c0db3a0", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n", "original_text": "And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year. "}, "hash": "fc9e19ef308ec902fb3cfbb36a87c1225bb07719c986db0caa0a153116205a50", "class_name": "RelatedNodeInfo"}}, "text": "That's generally running about \nas expected. ", "start_char_idx": 285, "end_char_idx": 330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7439a986-f98d-4304-9209-54997c0db3a0": {"__data__": {"id_": "7439a986-f98d-4304-9209-54997c0db3a0", "embedding": null, "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n", "original_text": "And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdc41274-c4a9-4beb-9cf7-f279da071d87", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n", "original_text": "That's generally running about \nas expected. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3cf4170a9907001b8ecc14dd4db04bcd68bad0ec78c685eeff01f6af0bbb0cde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3774e732-5fdf-481a-905a-977452468483", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n", "original_text": "We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year. "}, "hash": "a55de714ab6a04a136dd8726f9ebf22fb24b416e259a2129d15c17a937eca91c", "class_name": "RelatedNodeInfo"}}, "text": "And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year. ", "start_char_idx": 330, "end_char_idx": 515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3774e732-5fdf-481a-905a-977452468483": {"__data__": {"id_": "3774e732-5fdf-481a-905a-977452468483", "embedding": null, "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n", "original_text": "We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7439a986-f98d-4304-9209-54997c0db3a0", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n", "original_text": "And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75a405c7b88267869b6e315038b9cc9f9255702a1d12bc5afbcab3fb6c3ef957", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69489ca9-f47f-4b69-a373-9ce0d9c38a48", "node_type": "1", "metadata": {"window": "That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah. ", "original_text": "Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n"}, "hash": "b4dc498edfcd5a45d13864a0caa974c8938b7e9cdebc7eae8c19c41a01019605", "class_name": "RelatedNodeInfo"}}, "text": "We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year. ", "start_char_idx": 515, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69489ca9-f47f-4b69-a373-9ce0d9c38a48": {"__data__": {"id_": "69489ca9-f47f-4b69-a373-9ce0d9c38a48", "embedding": null, "metadata": {"window": "That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah. ", "original_text": "Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3774e732-5fdf-481a-905a-977452468483", "node_type": "1", "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n", "original_text": "We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d083c0521dcf3d0bf5dc696b13806c7ed3bf978525e9c057f7abd469a73ded12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a4b8114-a257-42b7-bdae-89836d41b0b3", "node_type": "1", "metadata": {"window": "And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question. ", "original_text": "Kevin Moran:  \nNext question, please.  \n \n"}, "hash": "f4d1578066c11969ba7864d7bed52dc88bee4e8d572b4363622aa87a8b812ddc", "class_name": "RelatedNodeInfo"}}, "text": "Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n", "start_char_idx": 613, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a4b8114-a257-42b7-bdae-89836d41b0b3": {"__data__": {"id_": "2a4b8114-a257-42b7-bdae-89836d41b0b3", "embedding": null, "metadata": {"window": "And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question. ", "original_text": "Kevin Moran:  \nNext question, please.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69489ca9-f47f-4b69-a373-9ce0d9c38a48", "node_type": "1", "metadata": {"window": "That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah. ", "original_text": "Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297b134152ca0a7c3dd2010c098559b126c3373bb969ecd841ae5f3739df168e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2106419f-e98f-417b-aab0-46ed02f273b3", "node_type": "1", "metadata": {"window": "We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed. ", "original_text": "Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n"}, "hash": "21e4d5608e101c0f2ba292e2eeac283b791626dea47d7ae4cf8387738c78c096", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext question, please.  \n \n", "start_char_idx": 739, "end_char_idx": 781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2106419f-e98f-417b-aab0-46ed02f273b3": {"__data__": {"id_": "2106419f-e98f-417b-aab0-46ed02f273b3", "embedding": null, "metadata": {"window": "We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed. ", "original_text": "Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a4b8114-a257-42b7-bdae-89836d41b0b3", "node_type": "1", "metadata": {"window": "And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question. ", "original_text": "Kevin Moran:  \nNext question, please.  \n \n", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2fe50309292e4e29ae4ea39f4a7ce5c046d20c09769f654f0e4f62d119b65a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae1bd7f-08ec-4b29-933b-9a2ab013a7fd", "node_type": "1", "metadata": {"window": "Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear? ", "original_text": "Charles Rhyee:  \nYeah. "}, "hash": "a9a7e2b2d68d31e5f394e60ad47cb624cb5073038ea1fa5ae6e7de594b7a70b8", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n", "start_char_idx": 781, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ae1bd7f-08ec-4b29-933b-9a2ab013a7fd": {"__data__": {"id_": "0ae1bd7f-08ec-4b29-933b-9a2ab013a7fd", "embedding": null, "metadata": {"window": "Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear? ", "original_text": "Charles Rhyee:  \nYeah. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2106419f-e98f-417b-aab0-46ed02f273b3", "node_type": "1", "metadata": {"window": "We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year.  Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed. ", "original_text": "Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3baad82b97b455d837d2bbc5915808289761cbfc23bc8e20611490559d7f779d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69656d43-f6f1-4d2d-b462-ade11e3b1ff0", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter. ", "original_text": "Thanks for taking the question. "}, "hash": "4eee1890c4e81e402c2acd4e43411e21d7b8646613050f055f65e3a21e418f84", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  \nYeah. ", "start_char_idx": 848, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69656d43-f6f1-4d2d-b462-ade11e3b1ff0": {"__data__": {"id_": "69656d43-f6f1-4d2d-b462-ade11e3b1ff0", "embedding": null, "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter. ", "original_text": "Thanks for taking the question. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ae1bd7f-08ec-4b29-933b-9a2ab013a7fd", "node_type": "1", "metadata": {"window": "Not quite as big \npotentially with some of the COVID impact, but we still exp ect it to be a  net positive for the year.  \n  \n Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear? ", "original_text": "Charles Rhyee:  \nYeah. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "017e20faf8d188f04ad9707b9c45219503bd1f6465f9398a0558eb3316fc88ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "461ba17c-e075-4b2c-a12e-ce2485bc7d3f", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n", "original_text": "Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed. "}, "hash": "4f14c7c7416c7ea037f8c3684a4dcacabd1600f44cffebc67400b699c5e31b5b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 871, "end_char_idx": 903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "461ba17c-e075-4b2c-a12e-ce2485bc7d3f": {"__data__": {"id_": "461ba17c-e075-4b2c-a12e-ce2485bc7d3f", "embedding": null, "metadata": {"window": "Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n", "original_text": "Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69656d43-f6f1-4d2d-b462-ade11e3b1ff0", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter. ", "original_text": "Thanks for taking the question. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e30bc870df5cb3bfb4a9c1edb35bac8a0315e4ab930009da521140e1ba61a6a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22619191-4ca7-4e8b-b273-a331eab41384", "node_type": "1", "metadata": {"window": "Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home. ", "original_text": "Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear? "}, "hash": "3ca18f2dc0c6b902dd3c095c81e1e1462028bcf108f9dc7a3f7262d64a8cb337", "class_name": "RelatedNodeInfo"}}, "text": "Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed. ", "start_char_idx": 903, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22619191-4ca7-4e8b-b273-a331eab41384": {"__data__": {"id_": "22619191-4ca7-4e8b-b273-a331eab41384", "embedding": null, "metadata": {"window": "Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home. ", "original_text": "Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear? ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "461ba17c-e075-4b2c-a12e-ce2485bc7d3f", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Charles Rhyee with Cowen.  \n  \n Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n", "original_text": "Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5169308a73703b9eb83b1487a0690b241ec4efa5d8a908b59578de55a3325588", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a3e22b6-534e-4cda-8f02-d56b3a4135fd", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now. ", "original_text": "Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter. "}, "hash": "aba9841ad019cd3f3693e2b6b8456bac1cbaf57405d235c22b01c03488aeb63e", "class_name": "RelatedNodeInfo"}}, "text": "Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear? ", "start_char_idx": 1107, "end_char_idx": 1231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a3e22b6-534e-4cda-8f02-d56b3a4135fd": {"__data__": {"id_": "0a3e22b6-534e-4cda-8f02-d56b3a4135fd", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now. ", "original_text": "Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22619191-4ca7-4e8b-b273-a331eab41384", "node_type": "1", "metadata": {"window": "Charles Rhyee:  \nYeah.  Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home. ", "original_text": "Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear? ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5abb7555b20b1cc819773436496e611c65ea9fc33cc0006bb9d69ed677ee5df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a126231-57d1-4db7-b51a-06fe46249ecc", "node_type": "1", "metadata": {"window": "Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business? ", "original_text": "Is thi s something that you are expecting as well as you project  internally?  \n"}, "hash": "c0b594519a5119a3ddbf526fa5dc1e81afd24e1f7683ba72e30046d7c69e9464", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter. ", "start_char_idx": 1231, "end_char_idx": 1481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a126231-57d1-4db7-b51a-06fe46249ecc": {"__data__": {"id_": "3a126231-57d1-4db7-b51a-06fe46249ecc", "embedding": null, "metadata": {"window": "Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business? ", "original_text": "Is thi s something that you are expecting as well as you project  internally?  \n", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a3e22b6-534e-4cda-8f02-d56b3a4135fd", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now. ", "original_text": "Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c2c01620eb64594392a2b084dc65c19e9e456a19c0eaac5f9cdbe42e10c2e10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c743fa55-3b22-4245-a82e-d77f1cfda0b4", "node_type": "1", "metadata": {"window": "Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home. "}, "hash": "fef2285126a90f4d9b7ffd6d153a57edc9e2a1fb33d84ff5b8a38f9a25173bed", "class_name": "RelatedNodeInfo"}}, "text": "Is thi s something that you are expecting as well as you project  internally?  \n", "start_char_idx": 1481, "end_char_idx": 1561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c743fa55-3b22-4245-a82e-d77f1cfda0b4": {"__data__": {"id_": "c743fa55-3b22-4245-a82e-d77f1cfda0b4", "embedding": null, "metadata": {"window": "Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a126231-57d1-4db7-b51a-06fe46249ecc", "node_type": "1", "metadata": {"window": "Mike, maybe building on that can you give us a sense on how  \nyou're  thinking about \u2013 if 4Q is sort of a net negative and obviously we have Nuclear and a few other \nof the headwinds  that you discussed.  Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business? ", "original_text": "Is thi s something that you are expecting as well as you project  internally?  \n", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2866ee48779ee061c1c01d13688e35c9b74115b775fc646b39ce7adaad178611", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "514f28bb-0dc1-4ef0-84f8-b74abbd09376", "node_type": "1", "metadata": {"window": "Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "A lot of stuff \nis doing virtual now. "}, "hash": "ffd8339dd59cd0ae4d9d11d76cee66368b99de1e16422403a18550f1363ea6b8", "class_name": "RelatedNodeInfo"}}, "text": "And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home. ", "start_char_idx": 1561, "end_char_idx": 1652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "514f28bb-0dc1-4ef0-84f8-b74abbd09376": {"__data__": {"id_": "514f28bb-0dc1-4ef0-84f8-b74abbd09376", "embedding": null, "metadata": {"window": "Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "A lot of stuff \nis doing virtual now. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c743fa55-3b22-4245-a82e-d77f1cfda0b4", "node_type": "1", "metadata": {"window": "Your thoughts on how you expect things to recover in terms of \nvolumes as we get into the  back half of the calendar y ear?  Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b1e90b31fb0992d4a9c55a5df53f063d181e67d6976b20dc05e861f08a50ed6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41827d0f-b5c3-43ce-aa06-051f18381a80", "node_type": "1", "metadata": {"window": "Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business? "}, "hash": "b3b6631b7290df0545d8223145a6c91aff5786d9ff5017fc43130d30aafce88a", "class_name": "RelatedNodeInfo"}}, "text": "A lot of stuff \nis doing virtual now. ", "start_char_idx": 1652, "end_char_idx": 1690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41827d0f-b5c3-43ce-aa06-051f18381a80": {"__data__": {"id_": "41827d0f-b5c3-43ce-aa06-051f18381a80", "embedding": null, "metadata": {"window": "Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business? ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "514f28bb-0dc1-4ef0-84f8-b74abbd09376", "node_type": "1", "metadata": {"window": "Obviously, we had a number of companies \nthat have reported kind of giving their  estimates on sort of a recovery path and in particular, some \nhave discussed seeing more than 100% of volumes  kind of in the, let's say, the fourth calendar \nquarter.  Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "A lot of stuff \nis doing virtual now. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ce5fd3c0cbff5536d5b95c1e0becaad6f65969c4e7ce4a0387b6ad99bbed715", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81c28042-17bb-40ec-9e35-87a3eb53d0ca", "node_type": "1", "metadata": {"window": "And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "Thanks.  \n  "}, "hash": "14a4ae0060436b6cfbc9f7004a79f0e5a9639339fb6403166849a8bec5b45657", "class_name": "RelatedNodeInfo"}}, "text": "Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business? ", "start_char_idx": 1690, "end_char_idx": 1852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81c28042-17bb-40ec-9e35-87a3eb53d0ca": {"__data__": {"id_": "81c28042-17bb-40ec-9e35-87a3eb53d0ca", "embedding": null, "metadata": {"window": "And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "Thanks.  \n  ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fdbe04a6a94ea2de71e37870c65e0c7c24c17fa1c411e2419b756a651ebd169", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41827d0f-b5c3-43ce-aa06-051f18381a80", "node_type": "1", "metadata": {"window": "Is thi s something that you are expecting as well as you project  internally?  \n And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business? ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb4834e448a0afd389726d4e0ab2f774b475410a7f6c01eb72674d54d9a22b13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3ead348-569b-4155-ba93-d492960a9f0b", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout. ", "original_text": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah. "}, "hash": "59ae15153c052ccfbfa92237a53c2ab30aa1ff33177b4641ec01a2c82b0c8772", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n  ", "start_char_idx": 1852, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3ead348-569b-4155-ba93-d492960a9f0b": {"__data__": {"id_": "f3ead348-569b-4155-ba93-d492960a9f0b", "embedding": null, "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout. ", "original_text": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81c28042-17bb-40ec-9e35-87a3eb53d0ca", "node_type": "1", "metadata": {"window": "And just to clarify \u2013 and just one other thing was you talked about the Cardinal at -Home.  A lot of stuff \nis doing virtual now.  Do you expect a change in overall patterns of how people se e their providers in \nthe future and  does that create a great opportunity for the at -Home business?  Thanks.  \n  ", "original_text": "Thanks.  \n  ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bce253164c90494a945861079a3827c9618bae718d31a0c7d652eb2592b4b2ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b4137ab-abc8-4718-8c2a-cc08895b735a", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business. ", "original_text": "I'll start with that then I'll go back to the other. "}, "hash": "a588bc2a5240cf5acbfb607c5f6e6ad991f463cfd1933c9ac8d022dc5bba96fb", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b4137ab-abc8-4718-8c2a-cc08895b735a": {"__data__": {"id_": "7b4137ab-abc8-4718-8c2a-cc08895b735a", "embedding": null, "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business. ", "original_text": "I'll start with that then I'll go back to the other. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3ead348-569b-4155-ba93-d492960a9f0b", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout. ", "original_text": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65eace8ae6a74726833058af38247b56d30d6184e6bb30c728d314f866f4e90e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3b8d24e-4da7-4f9c-b571-6618fb935d75", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently. ", "original_text": "We do feel really good about how our at -Home \nbusiness is  positioned . "}, "hash": "630b64bcb3c0b2b78fe4ef3d356046ae7824aa735192a1d8c8c0fee1b50a0644", "class_name": "RelatedNodeInfo"}}, "text": "I'll start with that then I'll go back to the other. ", "start_char_idx": 48, "end_char_idx": 101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3b8d24e-4da7-4f9c-b571-6618fb935d75": {"__data__": {"id_": "c3b8d24e-4da7-4f9c-b571-6618fb935d75", "embedding": null, "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently. ", "original_text": "We do feel really good about how our at -Home \nbusiness is  positioned . ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b4137ab-abc8-4718-8c2a-cc08895b735a", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business. ", "original_text": "I'll start with that then I'll go back to the other. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af982efae855c8fed1307f66846aebbda75fd0083ad9c0770ac3f6c40475a859", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d1a79c3-932c-44ba-9212-d3744d3403cd", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n", "original_text": "This has been a trend we've been seeing for a while now, we've been calling \nout. "}, "hash": "7579e07a9f732473ac8230489b65cb3cf3c883d3d0ee7828140f4d381f5200b4", "class_name": "RelatedNodeInfo"}}, "text": "We do feel really good about how our at -Home \nbusiness is  positioned . ", "start_char_idx": 101, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d1a79c3-932c-44ba-9212-d3744d3403cd": {"__data__": {"id_": "4d1a79c3-932c-44ba-9212-d3744d3403cd", "embedding": null, "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n", "original_text": "This has been a trend we've been seeing for a while now, we've been calling \nout. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3b8d24e-4da7-4f9c-b571-6618fb935d75", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently. ", "original_text": "We do feel really good about how our at -Home \nbusiness is  positioned . ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c91a2669738ba9e3081536a53498a04cc54a5a6e4e23732d3176a826d193d10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a68887e-86a2-4c42-895e-c44a52b4b266", "node_type": "1", "metadata": {"window": "I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August. ", "original_text": "We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business. "}, "hash": "0376ff366c669790cf8eaaeb133a95b8bdaf753f543ff7c3d692eb62a198f070", "class_name": "RelatedNodeInfo"}}, "text": "This has been a trend we've been seeing for a while now, we've been calling \nout. ", "start_char_idx": 174, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a68887e-86a2-4c42-895e-c44a52b4b266": {"__data__": {"id_": "2a68887e-86a2-4c42-895e-c44a52b4b266", "embedding": null, "metadata": {"window": "I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August. ", "original_text": "We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d1a79c3-932c-44ba-9212-d3744d3403cd", "node_type": "1", "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n", "original_text": "This has been a trend we've been seeing for a while now, we've been calling \nout. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0176ae0bc40d3eaa5d12a21a5aabc507487aa43b1d20236f070181d538c06c89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "540b244d-5bd5-4d50-bac9-ded7692de678", "node_type": "1", "metadata": {"window": "We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor. ", "original_text": "It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently. "}, "hash": "e23a1f01e9a69091f14f5cd5b5e16990305fd345b93aae11e7ea3d426f7018d2", "class_name": "RelatedNodeInfo"}}, "text": "We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business. ", "start_char_idx": 256, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "540b244d-5bd5-4d50-bac9-ded7692de678": {"__data__": {"id_": "540b244d-5bd5-4d50-bac9-ded7692de678", "embedding": null, "metadata": {"window": "We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor. ", "original_text": "It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a68887e-86a2-4c42-895e-c44a52b4b266", "node_type": "1", "metadata": {"window": "I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August. ", "original_text": "We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9b9f19fe6834694803db1aa2a58f5289d11ab02f95d397b799ef77e21e6662c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58775dc0-40fe-4c10-8f53-64bd99c33939", "node_type": "1", "metadata": {"window": "This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end. ", "original_text": "So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n"}, "hash": "135f4df112b3c99a7029f58569f5c47587964874009ec448878151ec5604ced3", "class_name": "RelatedNodeInfo"}}, "text": "It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently. ", "start_char_idx": 381, "end_char_idx": 522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58775dc0-40fe-4c10-8f53-64bd99c33939": {"__data__": {"id_": "58775dc0-40fe-4c10-8f53-64bd99c33939", "embedding": null, "metadata": {"window": "This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end. ", "original_text": "So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "540b244d-5bd5-4d50-bac9-ded7692de678", "node_type": "1", "metadata": {"window": "We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor. ", "original_text": "It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bd5fca675d4a8c9370e6d40217dccd1d04210d4de01a15645a6b3d424e3cbbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "660389fc-1a3d-4a74-8546-d2fb473fa5a2", "node_type": "1", "metadata": {"window": "We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with. ", "original_text": "As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August. "}, "hash": "25c01c3a7949a5cbef8a4d4ea4ae7c2e9a8aa65060603977b0dbae38d1347a81", "class_name": "RelatedNodeInfo"}}, "text": "So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n", "start_char_idx": 522, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "660389fc-1a3d-4a74-8546-d2fb473fa5a2": {"__data__": {"id_": "660389fc-1a3d-4a74-8546-d2fb473fa5a2", "embedding": null, "metadata": {"window": "We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with. ", "original_text": "As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58775dc0-40fe-4c10-8f53-64bd99c33939", "node_type": "1", "metadata": {"window": "This has been a trend we've been seeing for a while now, we've been calling \nout.  We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end. ", "original_text": "So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5da534ab6083ca0215c3891cc5a919e7873246e7de75d0f7c9cb98d6c00d4c9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a612802e-5ee3-46ad-becc-b16089dd7c7b", "node_type": "1", "metadata": {"window": "It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n", "original_text": "But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor. "}, "hash": "57db8ea9b3a9a1dc1b73f5df765f24efc31740833e800b20ab80682a96144936", "class_name": "RelatedNodeInfo"}}, "text": "As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August. ", "start_char_idx": 711, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a612802e-5ee3-46ad-becc-b16089dd7c7b": {"__data__": {"id_": "a612802e-5ee3-46ad-becc-b16089dd7c7b", "embedding": null, "metadata": {"window": "It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n", "original_text": "But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "660389fc-1a3d-4a74-8546-d2fb473fa5a2", "node_type": "1", "metadata": {"window": "We think that this  COVID -19 will just accelerate that trend and we really like the way we're \npositioned in that business.  It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with. ", "original_text": "As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a658600ea5c93bc41a563ef0fd06e74b52117e70e1b4db0502578ce241672fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc27d7ce-74cb-44da-b797-4d4c69d65c7d", "node_type": "1", "metadata": {"window": "So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March. ", "original_text": "We're lucky \nin the sense that we have the benefit of being a June 30  year-end. "}, "hash": "35f1ea6ee88bafe67082811cc8b14787e8f02901ccaa13bc4ea0a79b39aba216", "class_name": "RelatedNodeInfo"}}, "text": "But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor. ", "start_char_idx": 963, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc27d7ce-74cb-44da-b797-4d4c69d65c7d": {"__data__": {"id_": "dc27d7ce-74cb-44da-b797-4d4c69d65c7d", "embedding": null, "metadata": {"window": "So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March. ", "original_text": "We're lucky \nin the sense that we have the benefit of being a June 30  year-end. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a612802e-5ee3-46ad-becc-b16089dd7c7b", "node_type": "1", "metadata": {"window": "It's a  business we have been investing in significa ntly on our interactions \nwith the patient, how to run that business  more efficiently.  So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n", "original_text": "But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c740aa1778a67a666eccf0bf6c31c30914485e8e37b5bf951c89419e11690f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "561623fa-9a36-4a3c-98b1-cec0c61222c8", "node_type": "1", "metadata": {"window": "As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures. ", "original_text": "We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with. "}, "hash": "c7d6f1f29aaa8bf4d216ea6c1da6c02c9801b340c131de2943d7602605ad5433", "class_name": "RelatedNodeInfo"}}, "text": "We're lucky \nin the sense that we have the benefit of being a June 30  year-end. ", "start_char_idx": 1107, "end_char_idx": 1188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "561623fa-9a36-4a3c-98b1-cec0c61222c8": {"__data__": {"id_": "561623fa-9a36-4a3c-98b1-cec0c61222c8", "embedding": null, "metadata": {"window": "As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures. ", "original_text": "We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc27d7ce-74cb-44da-b797-4d4c69d65c7d", "node_type": "1", "metadata": {"window": "So we have and are expecting to have \nsignificant internal investments into that business going  forward because we do believe it's going to \nbe a significant growth area go ing forward.  \n As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March. ", "original_text": "We're lucky \nin the sense that we have the benefit of being a June 30  year-end. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0fcf086078e829400dd57bf94a43545aec58b3fdc569e8a9af79bd7afff4078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "857b438a-71bb-475e-90b6-454b7e4c42e6", "node_type": "1", "metadata": {"window": "But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n", "original_text": "We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n"}, "hash": "7c6d4d9abfd901b76627e6596e9000fee46e33efa993dfb86329f07980d477d5", "class_name": "RelatedNodeInfo"}}, "text": "We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with. ", "start_char_idx": 1188, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "857b438a-71bb-475e-90b6-454b7e4c42e6": {"__data__": {"id_": "857b438a-71bb-475e-90b6-454b7e4c42e6", "embedding": null, "metadata": {"window": "But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n", "original_text": "We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "561623fa-9a36-4a3c-98b1-cec0c61222c8", "node_type": "1", "metadata": {"window": "As far as the forecast goes, as you know it's our kind of way we work because we don't talk a lot \nabout the  following year until we get there and so we'll give you the color and obviously all the \nappropriate thoughts on fiscal  year 2021 in August.  But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures. ", "original_text": "We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4c9b83a6217d8ccac96f16bf5de9a8bcb5632064e1c7688191e8564d0312209", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b65e98f9-55e3-4403-82af-38022bc7cc7d", "node_type": "1", "metadata": {"window": "We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done. ", "original_text": "But in the terms of elective procedures, obviously we started to see a fall -off in March. "}, "hash": "3865004a20c900fb6be8dd59050ba64315b4cb19580b27a648f4622c37b4f002", "class_name": "RelatedNodeInfo"}}, "text": "We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n", "start_char_idx": 1461, "end_char_idx": 1602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b65e98f9-55e3-4403-82af-38022bc7cc7d": {"__data__": {"id_": "b65e98f9-55e3-4403-82af-38022bc7cc7d", "embedding": null, "metadata": {"window": "We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done. ", "original_text": "But in the terms of elective procedures, obviously we started to see a fall -off in March. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "857b438a-71bb-475e-90b6-454b7e4c42e6", "node_type": "1", "metadata": {"window": "But I will try to give you at least color in this \nelective procedures area; and on the rest of the  stuff, we're going to continue to monitor.  We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n", "original_text": "We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "457170fc10c50b5e28e33821dd833e64ff4e2ef79b15614479670beead31f850", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ab1f55b-1b55-45d3-9779-146542b4260f", "node_type": "1", "metadata": {"window": "We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021. ", "original_text": "We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures. "}, "hash": "b8b15d643a588da9dc2abef1e36c8c871491ae773d679c67d0a173e61f1aa503", "class_name": "RelatedNodeInfo"}}, "text": "But in the terms of elective procedures, obviously we started to see a fall -off in March. ", "start_char_idx": 1602, "end_char_idx": 1693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ab1f55b-1b55-45d3-9779-146542b4260f": {"__data__": {"id_": "7ab1f55b-1b55-45d3-9779-146542b4260f", "embedding": null, "metadata": {"window": "We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021. ", "original_text": "We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b65e98f9-55e3-4403-82af-38022bc7cc7d", "node_type": "1", "metadata": {"window": "We're lucky \nin the sense that we have the benefit of being a June 30  year-end.  We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done. ", "original_text": "But in the terms of elective procedures, obviously we started to see a fall -off in March. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b472267fed44171c61a1c25297c733b45ace5a7d0271e15b82835161c7f3e13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a627f41a-17df-4f8f-b11a-0335b71f9fe5", "node_type": "1", "metadata": {"window": "We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent. ", "original_text": "We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n"}, "hash": "cf0c9bd392093cda2951da11198fe87701671d18f0356b96a7c8db014d86a1bf", "class_name": "RelatedNodeInfo"}}, "text": "We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures. ", "start_char_idx": 1693, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a627f41a-17df-4f8f-b11a-0335b71f9fe5": {"__data__": {"id_": "a627f41a-17df-4f8f-b11a-0335b71f9fe5", "embedding": null, "metadata": {"window": "We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent. ", "original_text": "We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ab1f55b-1b55-45d3-9779-146542b4260f", "node_type": "1", "metadata": {"window": "We can take this next quart er, \nreally evaluate the trends in generics, the economic health of the  ecosystem with all of our customers \nand how are they doing and how will they hold up in the ongoing  environment, and we feel really \ngood about who we're partnered with.  We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021. ", "original_text": "We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01694a9672e842e2eb917e7618bca591b1b35fe9fb50e417382eddbbdf77fa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1cea348-2749-46e7-8296-423ba887349e", "node_type": "1", "metadata": {"window": "But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there. ", "original_text": "Our point of view is that there's still a lot of work to be done. "}, "hash": "77341af67988a0aa3dfde0a70d6bff8549beab8eaad4680e0d78aa268aae4a3e", "class_name": "RelatedNodeInfo"}}, "text": "We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n", "start_char_idx": 1810, "end_char_idx": 2011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1cea348-2749-46e7-8296-423ba887349e": {"__data__": {"id_": "f1cea348-2749-46e7-8296-423ba887349e", "embedding": null, "metadata": {"window": "But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there. ", "original_text": "Our point of view is that there's still a lot of work to be done. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a627f41a-17df-4f8f-b11a-0335b71f9fe5", "node_type": "1", "metadata": {"window": "We tend to be pa rtnered with the folks that  are more likely to be \nconsolidators than consolidatees, and we feel really good about that.  \n But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent. ", "original_text": "We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "714fec90b121f8c5300ccea94e8172ecedf5c4201c2968e8e9132132479cc559", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7bcb8ff-d23b-4442-a661-8ab5716ac7e1", "node_type": "1", "metadata": {"window": "We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward. ", "original_text": "We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021. "}, "hash": "b8b6559d6361affa4105c4697aa2124176bc2cb8712500ad3a9b8246ab31dec5", "class_name": "RelatedNodeInfo"}}, "text": "Our point of view is that there's still a lot of work to be done. ", "start_char_idx": 2011, "end_char_idx": 2077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7bcb8ff-d23b-4442-a661-8ab5716ac7e1": {"__data__": {"id_": "b7bcb8ff-d23b-4442-a661-8ab5716ac7e1", "embedding": null, "metadata": {"window": "We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward. ", "original_text": "We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1cea348-2749-46e7-8296-423ba887349e", "node_type": "1", "metadata": {"window": "But in the terms of elective procedures, obviously we started to see a fall -off in March.  We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there. ", "original_text": "Our point of view is that there's still a lot of work to be done. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8685ae0908aba7cdcd580383b7c49cbabc0dd451f5bf6d252b426ed0b53f9993", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f89fd6f-0369-465f-bef6-0d2b0095978b", "node_type": "1", "metadata": {"window": "We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent. "}, "hash": "f69f1ec9074e6363030672b0f7e752e6489bd4f22776d0a8b6af460bca4b78ae", "class_name": "RelatedNodeInfo"}}, "text": "We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021. ", "start_char_idx": 2077, "end_char_idx": 2339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f89fd6f-0369-465f-bef6-0d2b0095978b": {"__data__": {"id_": "4f89fd6f-0369-465f-bef6-0d2b0095978b", "embedding": null, "metadata": {"window": "We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7bcb8ff-d23b-4442-a661-8ab5716ac7e1", "node_type": "1", "metadata": {"window": "We expect our \nQ4 to be  significantly down, bot h sequentially and year -over-year in terms of elective procedures.  We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward. ", "original_text": "We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe7bc6465b31141322976a366f0c0b1548a65520c07918a826b1d6a002fa170a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d164f2ed-1b10-4c1e-821e-f49ffeba1c74", "node_type": "1", "metadata": {"window": "Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We \nhope it will be there. "}, "hash": "f187cab2739aed574d22849fc24a2b5a0d14f8bc3a8982a6d4cf3e32e3c785e4", "class_name": "RelatedNodeInfo"}}, "text": "We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent. ", "start_char_idx": 2339, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d164f2ed-1b10-4c1e-821e-f49ffeba1c74": {"__data__": {"id_": "d164f2ed-1b10-4c1e-821e-f49ffeba1c74", "embedding": null, "metadata": {"window": "Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We \nhope it will be there. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f89fd6f-0369-465f-bef6-0d2b0095978b", "node_type": "1", "metadata": {"window": "We \ndo expect to see it  get a little bit better as the quarter progresses but we do not expect an exit rate of \nour Q4 that would put us back  with elective procedures in \u2013 back to where they were.  \n Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7732af9d51b67349cb4c49a424277303e891229c9958afa433d98a28cd73296", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b7ab8ce-5781-4798-89bb-e552417836f3", "node_type": "1", "metadata": {"window": "We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward. "}, "hash": "20dceddc4c236be0fcac9d0ba2e43f6d23966fe0adee1df05487a7c49dd14b5b", "class_name": "RelatedNodeInfo"}}, "text": "We \nhope it will be there. ", "start_char_idx": 2534, "end_char_idx": 2561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b7ab8ce-5781-4798-89bb-e552417836f3": {"__data__": {"id_": "3b7ab8ce-5781-4798-89bb-e552417836f3", "embedding": null, "metadata": {"window": "We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d164f2ed-1b10-4c1e-821e-f49ffeba1c74", "node_type": "1", "metadata": {"window": "Our point of view is that there's still a lot of work to be done.  We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We \nhope it will be there. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7330df3f83fecf0c669d35df2000bb98ce1ccdd79e79cefb6897887ef875ff28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afba3be8-d9cc-48fd-af98-96bc2c050cff", "node_type": "1", "metadata": {"window": "We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  "}, "hash": "e1f5261c6ddd0c7292ecaefd29fb38f96cba1de639c01dd2e581bcd354cf849f", "class_name": "RelatedNodeInfo"}}, "text": "We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward. ", "start_char_idx": 2561, "end_char_idx": 2671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afba3be8-d9cc-48fd-af98-96bc2c050cff": {"__data__": {"id_": "afba3be8-d9cc-48fd-af98-96bc2c050cff", "embedding": null, "metadata": {"window": "We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e9c9524d2e6f8fc02b45da7866460f8b3d7145174e7ef7400ba4fc8650e051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b7ab8ce-5781-4798-89bb-e552417836f3", "node_type": "1", "metadata": {"window": "We think it's going to be definitely choppy \nand our  current thoughts \u2013 but we're going to refine these as we go forward and get a chance to look \nat it as though we  would not expect ele ctive procedures to fully recover in the first half of our fiscal \n2021.  We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec02b96e81c11ba6e7ee0ff276d5b87c5dce0eb660f37a1d9d1720ee5c7ce6d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb500f35-3c0e-4b92-9f4f-9417aedad024", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful. ", "original_text": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n"}, "hash": "2a0e83cbabe9e6ce6746bec4174df78fc5d7e6f3f1798151860c1d1e9ff5420f", "class_name": "RelatedNodeInfo"}}, "text": "So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "start_char_idx": 2671, "end_char_idx": 2821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb500f35-3c0e-4b92-9f4f-9417aedad024": {"__data__": {"id_": "eb500f35-3c0e-4b92-9f4f-9417aedad024", "embedding": null, "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful. ", "original_text": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afba3be8-d9cc-48fd-af98-96bc2c050cff", "node_type": "1", "metadata": {"window": "We would think that they  would have more likely to fully recover in our second half but we'll give \nmore color later on and we are going to  continue to look at that pent -up demand compo nent.  We \nhope it will be there.  We think it could be there but  there's a lot of things that we need to look at to \nunderstand going forward.  So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "original_text": "So I would tell you the biggest color is  we do not expect to see a full \nrecovery until the second half of our fiscal  2021 on elective procedures.  ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6db517f65f75e8fe4267536f8f280e8f3de8b099b0fc200bf1af260fe536d516", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85ad8cab-bc38-4275-8f73-8e8e07a3f921", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements. ", "original_text": "Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n"}, "hash": "a0523538d76452ba6789e61af1eb108a4cfb7ccb44f15c245f1524441569edb0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n", "start_char_idx": 0, "end_char_idx": 64, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85ad8cab-bc38-4275-8f73-8e8e07a3f921": {"__data__": {"id_": "85ad8cab-bc38-4275-8f73-8e8e07a3f921", "embedding": null, "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements. ", "original_text": "Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb500f35-3c0e-4b92-9f4f-9417aedad024", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful. ", "original_text": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3d07c6621b7693c4a6bb61fb9ac051a41caac9e2b72233b1687a25e20ed52d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6b65184-8e52-41d5-a27d-56fc3d442c16", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past. ", "original_text": "Eric Percher:  \nThank you and thanks for the efforts alongside the commentary. "}, "hash": "143eef69270d3b73950d95706a5c34c3d1ea503afbc1ccf3d9b266a777498174", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n", "start_char_idx": 64, "end_char_idx": 141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6b65184-8e52-41d5-a27d-56fc3d442c16": {"__data__": {"id_": "a6b65184-8e52-41d5-a27d-56fc3d442c16", "embedding": null, "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past. ", "original_text": "Eric Percher:  \nThank you and thanks for the efforts alongside the commentary. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85ad8cab-bc38-4275-8f73-8e8e07a3f921", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements. ", "original_text": "Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "508adb65744ffcb2e2a82d3956c9b417cd436a19a475ea8920d743508f60c89e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73fe196b-b0d7-4fba-86ae-3e01aae760a6", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business? ", "original_text": "A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful. "}, "hash": "6a43c1ed519b841fd8658b543438ce047d010522fcbd6a547be40c367edbca83", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  \nThank you and thanks for the efforts alongside the commentary. ", "start_char_idx": 141, "end_char_idx": 220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73fe196b-b0d7-4fba-86ae-3e01aae760a6": {"__data__": {"id_": "73fe196b-b0d7-4fba-86ae-3e01aae760a6", "embedding": null, "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business? ", "original_text": "A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6b65184-8e52-41d5-a27d-56fc3d442c16", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past. ", "original_text": "Eric Percher:  \nThank you and thanks for the efforts alongside the commentary. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74f611342eec65147199db51ad631390a0babbe9cfbc9e81cb1dd3ea908e39eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f63b88e6-b643-48dd-807a-e240e50fa93b", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n", "original_text": "You mentioned some of the better \nperforming elements. "}, "hash": "812f27fd0d06ecdc034bca77a4d034c3763becff65c6c3527793659632367e60", "class_name": "RelatedNodeInfo"}}, "text": "A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful. ", "start_char_idx": 220, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f63b88e6-b643-48dd-807a-e240e50fa93b": {"__data__": {"id_": "f63b88e6-b643-48dd-807a-e240e50fa93b", "embedding": null, "metadata": {"window": "Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n", "original_text": "You mentioned some of the better \nperforming elements. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73fe196b-b0d7-4fba-86ae-3e01aae760a6", "node_type": "1", "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business? ", "original_text": "A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7708af525df42c0945659e0bddd9e5a0a02d4f388e8775c219f058ca4f0ec292", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "223f5381-6e99-4c6d-8c48-7b8a35cf00fe", "node_type": "1", "metadata": {"window": "Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "I know you've  sized at -Home at around $2 billion in the past. "}, "hash": "637a64f42000e59b97cd1f085fc74716285a028fd98cb041754a1fa5751419c1", "class_name": "RelatedNodeInfo"}}, "text": "You mentioned some of the better \nperforming elements. ", "start_char_idx": 309, "end_char_idx": 364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "223f5381-6e99-4c6d-8c48-7b8a35cf00fe": {"__data__": {"id_": "223f5381-6e99-4c6d-8c48-7b8a35cf00fe", "embedding": null, "metadata": {"window": "Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "I know you've  sized at -Home at around $2 billion in the past. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f63b88e6-b643-48dd-807a-e240e50fa93b", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n", "original_text": "You mentioned some of the better \nperforming elements. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83ce35cc0cef38edfe896f4226f05c90a0665b11675ad29abc1dc095b8e3354d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d905754d-a061-412d-9eb4-59f136ffcd9a", "node_type": "1", "metadata": {"window": "A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at. ", "original_text": "You mentioned \nServices and Lab but can you help us with the  remainder of the business? "}, "hash": "b6eee89e47bb119309ca7f08b38308a7ed81e02416716b1c5ba8e63ea1721672", "class_name": "RelatedNodeInfo"}}, "text": "I know you've  sized at -Home at around $2 billion in the past. ", "start_char_idx": 364, "end_char_idx": 428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d905754d-a061-412d-9eb4-59f136ffcd9a": {"__data__": {"id_": "d905754d-a061-412d-9eb4-59f136ffcd9a", "embedding": null, "metadata": {"window": "A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at. ", "original_text": "You mentioned \nServices and Lab but can you help us with the  remainder of the business? ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "223f5381-6e99-4c6d-8c48-7b8a35cf00fe", "node_type": "1", "metadata": {"window": "Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "I know you've  sized at -Home at around $2 billion in the past. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6169fafdaa94ba92eaf310c46daecb576094ebfdeff883c25beefab0e52238e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d3e173e-eff0-4cd2-bc6b-47ecafafd94e", "node_type": "1", "metadata": {"window": "You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.  ", "original_text": "And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n"}, "hash": "f1928039352066b7fca69659cb8a9bd725abcf500f1935ee3152b26a7ccaf50c", "class_name": "RelatedNodeInfo"}}, "text": "You mentioned \nServices and Lab but can you help us with the  remainder of the business? ", "start_char_idx": 428, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d3e173e-eff0-4cd2-bc6b-47ecafafd94e": {"__data__": {"id_": "0d3e173e-eff0-4cd2-bc6b-47ecafafd94e", "embedding": null, "metadata": {"window": "You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.  ", "original_text": "And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d905754d-a061-412d-9eb4-59f136ffcd9a", "node_type": "1", "metadata": {"window": "A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful.  You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at. ", "original_text": "You mentioned \nServices and Lab but can you help us with the  remainder of the business? ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d50967949a662e90f01a5fd3aee95e9434ee0f7bdd74ac7c21720149f24f7a4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "241255c5-98ce-4207-a1c7-b7f8f19c55d1", "node_type": "1", "metadata": {"window": "I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain. ", "original_text": "Michael C. Kaufmann:  \nYeah. "}, "hash": "d7b5c5a2492d4dbe7f71064bef695c3acdabae2a1efb3d3310e59f5cde518a69", "class_name": "RelatedNodeInfo"}}, "text": "And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n", "start_char_idx": 517, "end_char_idx": 786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "241255c5-98ce-4207-a1c7-b7f8f19c55d1": {"__data__": {"id_": "241255c5-98ce-4207-a1c7-b7f8f19c55d1", "embedding": null, "metadata": {"window": "I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain. ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d3e173e-eff0-4cd2-bc6b-47ecafafd94e", "node_type": "1", "metadata": {"window": "You mentioned some of the better \nperforming elements.  I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.  ", "original_text": "And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "015c0169e6645fc2174d06555541b90d20561a5b1957c6f82523fe94abc27901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1d786f1-fb6f-469d-8a88-c0bf4c93c0e9", "node_type": "1", "metadata": {"window": "You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n", "original_text": "This is again something we're going to continue to look at. "}, "hash": "e7e30079224a4566a73c0b3f5dd9916787f962cf66ffdc4c4dbbfeaa688e303f", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nYeah. ", "start_char_idx": 786, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1d786f1-fb6f-469d-8a88-c0bf4c93c0e9": {"__data__": {"id_": "b1d786f1-fb6f-469d-8a88-c0bf4c93c0e9", "embedding": null, "metadata": {"window": "You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n", "original_text": "This is again something we're going to continue to look at. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "241255c5-98ce-4207-a1c7-b7f8f19c55d1", "node_type": "1", "metadata": {"window": "I know you've  sized at -Home at around $2 billion in the past.  You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain. ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6da14e9956ae055883cd984bcf03417b3ba68b06061e1b0f3a3e44810719fdf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bf05e53-ed2a-4656-a6d6-cbd8cb20dc63", "node_type": "1", "metadata": {"window": "And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work. ", "original_text": "But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.  "}, "hash": "9f7be02377a93fb1c123ff181ae69d839cf9ca96a761af8eca7a546ea50baf75", "class_name": "RelatedNodeInfo"}}, "text": "This is again something we're going to continue to look at. ", "start_char_idx": 815, "end_char_idx": 875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bf05e53-ed2a-4656-a6d6-cbd8cb20dc63": {"__data__": {"id_": "7bf05e53-ed2a-4656-a6d6-cbd8cb20dc63", "embedding": null, "metadata": {"window": "And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work. ", "original_text": "But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.  ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1d786f1-fb6f-469d-8a88-c0bf4c93c0e9", "node_type": "1", "metadata": {"window": "You mentioned \nServices and Lab but can you help us with the  remainder of the business?  And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n", "original_text": "This is again something we're going to continue to look at. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e691710922b50c60a00b438bed1c81e5994177a2d74c37268846d334a4e7435", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a15bb20-3c94-4df6-a186-5dc8f58846e2", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain. "}, "hash": "b8f6611f7db7b6b629a5ccbc9c49570295ad4a8b1d44ab61e7579a1dc1a9cd84", "class_name": "RelatedNodeInfo"}}, "text": "But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.  ", "start_char_idx": 875, "end_char_idx": 1123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a15bb20-3c94-4df6-a186-5dc8f58846e2": {"__data__": {"id_": "8a15bb20-3c94-4df6-a186-5dc8f58846e2", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bf05e53-ed2a-4656-a6d6-cbd8cb20dc63", "node_type": "1", "metadata": {"window": "And I know that Cordis \nand Patient Recovery are portions that are international, maybe  walk us through any commentary you \ncan give in terms of sizing some of the other businesses and how they've  been impacted or expected \nto be impacted in the coming quarter?  \n  \n Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work. ", "original_text": "But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.  ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a423735c47900f18607e25f16cac198c905b412b4bfd18ffb7213fb89d636c68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4981fd4-ce4c-4168-9512-46f9580a470e", "node_type": "1", "metadata": {"window": "This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n"}, "hash": "0a80e6331342d99bbe7c416dde035d8f60dfb26dfd98961359aec4183e75ffab", "class_name": "RelatedNodeInfo"}}, "text": "And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain. ", "start_char_idx": 1123, "end_char_idx": 1272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4981fd4-ce4c-4168-9512-46f9580a470e": {"__data__": {"id_": "e4981fd4-ce4c-4168-9512-46f9580a470e", "embedding": null, "metadata": {"window": "This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a15bb20-3c94-4df6-a186-5dc8f58846e2", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91d772d920a568c129e2cf835b8beeffdecfddf13c86b0c49ce838afaec0da2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f260dc1-2265-4436-890f-39f453509aa0", "node_type": "1", "metadata": {"window": "But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work. "}, "hash": "452bea53315da2e44b26aa553a449c806fc06df4cfb4b22a19fbb67e2a7eb36a", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n", "start_char_idx": 1272, "end_char_idx": 1424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f260dc1-2265-4436-890f-39f453509aa0": {"__data__": {"id_": "5f260dc1-2265-4436-890f-39f453509aa0", "embedding": null, "metadata": {"window": "But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4981fd4-ce4c-4168-9512-46f9580a470e", "node_type": "1", "metadata": {"window": "This is again something we're going to continue to look at.  But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7891038813841807982ac142e699cb7e8213b6fdb2eab8ec5f69d86437fc57bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f27cdd8c-96ab-4276-ac18-fbb48cd884fe", "node_type": "1", "metadata": {"window": "And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "So the two biggest "}, "hash": "f1c6c36a356864a581f7cf63b1a1202180a1b8ba0c4c85d0cf4c663d56135b7a", "class_name": "RelatedNodeInfo"}}, "text": "Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work. ", "start_char_idx": 1424, "end_char_idx": 1602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f27cdd8c-96ab-4276-ac18-fbb48cd884fe": {"__data__": {"id_": "f27cdd8c-96ab-4276-ac18-fbb48cd884fe", "embedding": null, "metadata": {"window": "And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "So the two biggest ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e41f80cb7eeffd954d2dac581d7c08432d9ee604206ecbdb86b0d0fd6e06d829", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f260dc1-2265-4436-890f-39f453509aa0", "node_type": "1", "metadata": {"window": "But as you summarized well, we \nwould think that  our Services business, our at -Home business and our \u2013 well, those two businesses \nwould perform the best going  forward an d the Lab business would perform well in Q4 based on what \nwe saw in Q3.   And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work. ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "757a5ae1292cbc07aac8d60d065369d46fa4916041cd9898f6e020ffac2517bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0de7f71-b31f-490d-b438-3f34db9ee514", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year. ", "original_text": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver. "}, "hash": "a2b48ccfcb515d4e0c960234619e3f207b5fe9748791798ffe28081fd618d165", "class_name": "RelatedNodeInfo"}}, "text": "So the two biggest ", "start_char_idx": 1602, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0de7f71-b31f-490d-b438-3f34db9ee514": {"__data__": {"id_": "f0de7f71-b31f-490d-b438-3f34db9ee514", "embedding": null, "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year. ", "original_text": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f27cdd8c-96ab-4276-ac18-fbb48cd884fe", "node_type": "1", "metadata": {"window": "And the other biggest driver though for us in Q4 is though we're going to continue to \nget after our overall global  manufacturing and supply chain.  We're seeing outstanding work by the \nteam there at making our manufacturing  facilities more efficient, our distribution facilities more \nefficient.  \n Now, of course, we're seeing a lot of added costs related to COVID here and there, expediting \nproduct and things  like that but those guys are doin g a lot of really good work.  So the two biggest ", "original_text": "So the two biggest ", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4b16e38d4e0e77d6aab66f67cd1e7f0eaa171b781c2baa3c1d2631953d3e437", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9dc1854-6934-4ce8-9a2c-44175342c586", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year. ", "original_text": "And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n"}, "hash": "0b13edfa613ebcbf493aae43d2ec3cb5ff911ed8f63dd5d582988844c952bbdd", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver. ", "start_char_idx": 0, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9dc1854-6934-4ce8-9a2c-44175342c586": {"__data__": {"id_": "d9dc1854-6934-4ce8-9a2c-44175342c586", "embedding": null, "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year. ", "original_text": "And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0de7f71-b31f-490d-b438-3f34db9ee514", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year. ", "original_text": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46bc8a97206bd93a9b19eb2a86e244367bb6bbddf261f20eb0612f43dd20c9a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "360774ff-6388-4974-b4fa-7a879845851d", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives. ", "original_text": "David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4. "}, "hash": "c1b58b8eb8e3f4a92129436b6aa5328a3190095cc4b754015a31020b0282c2d0", "class_name": "RelatedNodeInfo"}}, "text": "And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n", "start_char_idx": 317, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "360774ff-6388-4974-b4fa-7a879845851d": {"__data__": {"id_": "360774ff-6388-4974-b4fa-7a879845851d", "embedding": null, "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives. ", "original_text": "David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9dc1854-6934-4ce8-9a2c-44175342c586", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year. ", "original_text": "And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1be9fe8b238ecf2ab51996f3dd56bf511bd73c023370b0321f5e0576288d658", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7d5c0dd-3a97-46c1-b546-8dd0d1904c70", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n", "original_text": "The way I'd distill it down is you have this \ncharge from  last year. "}, "hash": "4e567075fe317d308de56a849210ab753ae085709790cf34c230bf9b0aa84413", "class_name": "RelatedNodeInfo"}}, "text": "David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4. ", "start_char_idx": 696, "end_char_idx": 777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7d5c0dd-3a97-46c1-b546-8dd0d1904c70": {"__data__": {"id_": "f7d5c0dd-3a97-46c1-b546-8dd0d1904c70", "embedding": null, "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n", "original_text": "The way I'd distill it down is you have this \ncharge from  last year. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "360774ff-6388-4974-b4fa-7a879845851d", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives. ", "original_text": "David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2af3ea16d014794d563db74599ae36d9b1ae4ce86c043d921bf76963afa3fc72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ce4f9d3-06df-45ab-8ae0-3be5242c5323", "node_type": "1", "metadata": {"window": "And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "That's nearly equally offset by the loss in elective surgeries this year. "}, "hash": "5f88584741390d4ed90d72228aa9b56eeb6101fecb60b12792027ed3d4fcf11f", "class_name": "RelatedNodeInfo"}}, "text": "The way I'd distill it down is you have this \ncharge from  last year. ", "start_char_idx": 777, "end_char_idx": 847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ce4f9d3-06df-45ab-8ae0-3be5242c5323": {"__data__": {"id_": "2ce4f9d3-06df-45ab-8ae0-3be5242c5323", "embedding": null, "metadata": {"window": "And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "That's nearly equally offset by the loss in elective surgeries this year. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7d5c0dd-3a97-46c1-b546-8dd0d1904c70", "node_type": "1", "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n", "original_text": "The way I'd distill it down is you have this \ncharge from  last year. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f30455cff571d52489c6aea1a55d128c0d430b4fd22e4184706ebad870ea7f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "129ea801-ddd4-4360-9645-dfdc65758741", "node_type": "1", "metadata": {"window": "David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins. ", "original_text": "Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives. "}, "hash": "0457575d208fa63ad8e53864d884c2e0075253e092fbb40f486980e3ed654526", "class_name": "RelatedNodeInfo"}}, "text": "That's nearly equally offset by the loss in elective surgeries this year. ", "start_char_idx": 847, "end_char_idx": 921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "129ea801-ddd4-4360-9645-dfdc65758741": {"__data__": {"id_": "129ea801-ddd4-4360-9645-dfdc65758741", "embedding": null, "metadata": {"window": "David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins. ", "original_text": "Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ce4f9d3-06df-45ab-8ae0-3be5242c5323", "node_type": "1", "metadata": {"window": "And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "That's nearly equally offset by the loss in elective surgeries this year. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba01bc663d891e99afa22001579ab50848b8e2168bd43109a2c8beb41c9fd007", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c8f8758-7f3d-4434-91e2-6bc32c429dc2", "node_type": "1", "metadata": {"window": "The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that. ", "original_text": "Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n"}, "hash": "a3aab9d1e90bff1347d1f6d1e345c2ad447eadb5cc9eed4fd88b360b11e9063e", "class_name": "RelatedNodeInfo"}}, "text": "Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives. ", "start_char_idx": 921, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c8f8758-7f3d-4434-91e2-6bc32c429dc2": {"__data__": {"id_": "3c8f8758-7f3d-4434-91e2-6bc32c429dc2", "embedding": null, "metadata": {"window": "The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that. ", "original_text": "Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "129ea801-ddd4-4360-9645-dfdc65758741", "node_type": "1", "metadata": {"window": "David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins. ", "original_text": "Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e5b9efdda7a3f6e9817b73318203b7cb40010099a724a89724d570535797794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7915ebc7-fae5-46e6-8ac6-ecfd38e29f31", "node_type": "1", "metadata": {"window": "That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n", "original_text": "Michael C. Kaufmann:  \nYeah. "}, "hash": "f4b1a9a7a6d172656eb4cf0f50a461d2495e40733f86754d916988595057bcc2", "class_name": "RelatedNodeInfo"}}, "text": "Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n", "start_char_idx": 1026, "end_char_idx": 1197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7915ebc7-fae5-46e6-8ac6-ecfd38e29f31": {"__data__": {"id_": "7915ebc7-fae5-46e6-8ac6-ecfd38e29f31", "embedding": null, "metadata": {"window": "That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c8f8758-7f3d-4434-91e2-6bc32c429dc2", "node_type": "1", "metadata": {"window": "The way I'd distill it down is you have this \ncharge from  last year.  That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that. ", "original_text": "Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6a297998a63d60a765b90814f9d093242eb5e78335a5ec0f8886320e1bf9cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8636d026-5c95-4caf-89d4-f263cea8b114", "node_type": "1", "metadata": {"window": "Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins. "}, "hash": "16a4bd4fbbb4309bba14ecb748f1fb8c90f19a5f505cb3f207a1ad5dacd34155", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nYeah. ", "start_char_idx": 1197, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8636d026-5c95-4caf-89d4-f263cea8b114": {"__data__": {"id_": "8636d026-5c95-4caf-89d4-f263cea8b114", "embedding": null, "metadata": {"window": "Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7915ebc7-fae5-46e6-8ac6-ecfd38e29f31", "node_type": "1", "metadata": {"window": "That's nearly equally offset by the loss in elective surgeries this year.  Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "523f0d7a896306a63626dba4e1d599eb7361b452bcc312af082db758f7e11489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b347cda-fb3a-4d55-98f7-0018509822a6", "node_type": "1", "metadata": {"window": "Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that. "}, "hash": "d5ea25cac227b9e6b778e131bce42fbe413fdea64e764cbef49b396a44888b52", "class_name": "RelatedNodeInfo"}}, "text": "I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins. ", "start_char_idx": 1226, "end_char_idx": 1365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b347cda-fb3a-4d55-98f7-0018509822a6": {"__data__": {"id_": "5b347cda-fb3a-4d55-98f7-0018509822a6", "embedding": null, "metadata": {"window": "Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8636d026-5c95-4caf-89d4-f263cea8b114", "node_type": "1", "metadata": {"window": "Then we \nhave ongoing cost  benefits driven by global manufacturing supply chain and other ini tiatives.  Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "847a4c3828b58fe22ea8fac7408d3dc81efd80330234c346e6a9a0a2c751c17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32da04e4-b779-4d0d-8da4-fb99086dacd5", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "So know that it's really what \nDave and I tal k about.  \n \n"}, "hash": "0642dd95ef527118faaee8a1228ff8eb1f421010f2be5e105ac4381b6d6dbb78", "class_name": "RelatedNodeInfo"}}, "text": "So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that. ", "start_char_idx": 1365, "end_char_idx": 1498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32da04e4-b779-4d0d-8da4-fb99086dacd5": {"__data__": {"id_": "32da04e4-b779-4d0d-8da4-fb99086dacd5", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "So know that it's really what \nDave and I tal k about.  \n \n", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b347cda-fb3a-4d55-98f7-0018509822a6", "node_type": "1", "metadata": {"window": "Those \nare being more or less offset in  the fourth quarter by incremental cost of supply chain and cost to our \nlabor force; the premiums to our frontline  workers.  \n  \n Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21e41bd398f34dce3b78ff625987a21206b3ea693667836f527dbaec1657c80a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c13633e-7ccb-4314-a25f-f0a0d04f9af2", "node_type": "1", "metadata": {"window": "I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n"}, "hash": "728698d89fd47f042825536b22166ee556cdbdd51398f2fbddaf31a579638d89", "class_name": "RelatedNodeInfo"}}, "text": "So know that it's really what \nDave and I tal k about.  \n \n", "start_char_idx": 1498, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c13633e-7ccb-4314-a25f-f0a0d04f9af2": {"__data__": {"id_": "9c13633e-7ccb-4314-a25f-f0a0d04f9af2", "embedding": null, "metadata": {"window": "I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32da04e4-b779-4d0d-8da4-fb99086dacd5", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "So know that it's really what \nDave and I tal k about.  \n \n", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef551af27e2232e09993d1acb3ad3ab32c8f017ab50742a68045d2004c1a8bf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02fd0e88-481b-47d4-8941-7605ce06583b", "node_type": "1", "metadata": {"window": "So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "Operator : Our next question comes from Jailendra Singh with Credit Suisse.  "}, "hash": "d85ede308176ba4295c30b60ede2a67886b57381737ce0e0dfb2fdb42b6174d6", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext question, please.  \n  \n", "start_char_idx": 1557, "end_char_idx": 1600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02fd0e88-481b-47d4-8941-7605ce06583b": {"__data__": {"id_": "02fd0e88-481b-47d4-8941-7605ce06583b", "embedding": null, "metadata": {"window": "So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa77dba6bb778d8e8cc0a085836ea033f2384c02b62fede69e3d15f451106841", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c13633e-7ccb-4314-a25f-f0a0d04f9af2", "node_type": "1", "metadata": {"window": "I will emphasize one thing: We have not used this pande mic and demand for products as an \nopportunity  expand to Medical product margins.  So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7833e2407f736a8fad14885e3036e880a071a3085ad8279682f5c8d8062d33a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f419adfd-3ba5-45c9-b60e-f8f23247ce2d", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n", "original_text": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi. "}, "hash": "3e406fda8e858056690e95b4bb4e4cf33ad882b86692d9cc4f57caa36fe56efd", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "start_char_idx": 1600, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f419adfd-3ba5-45c9-b60e-f8f23247ce2d": {"__data__": {"id_": "f419adfd-3ba5-45c9-b60e-f8f23247ce2d", "embedding": null, "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n", "original_text": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02fd0e88-481b-47d4-8941-7605ce06583b", "node_type": "1", "metadata": {"window": "So it's important to know that, that increase is not \ndue to expansion, of taking  opportunity to raise price or anything like that.  So know that it's really what \nDave and I tal k about.  \n \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "original_text": "Operator : Our next question comes from Jailendra Singh with Credit Suisse.  ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2a37256d3a7e7e7566f85eb6a2d51ea612853381c686676039920baa6f48834", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "134cf7bc-7833-483f-9b2f-abb4f764cb8e", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah. ", "original_text": "Good morning. "}, "hash": "840274c5c9e52d2640b40434dd16f51a66fe82e59adea9dc7143dd9a363eed00", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi. ", "start_char_idx": 0, "end_char_idx": 45, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "134cf7bc-7833-483f-9b2f-abb4f764cb8e": {"__data__": {"id_": "134cf7bc-7833-483f-9b2f-abb4f764cb8e", "embedding": null, "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah. ", "original_text": "Good morning. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f419adfd-3ba5-45c9-b60e-f8f23247ce2d", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n", "original_text": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ff09d33ad00dbae4581429768ff2de91fcccafea2a247f405d8a45f50d4f100", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66e31c2d-7343-4aa9-a2b2-ec37fabf6c91", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question. ", "original_text": "Thanks everyone. "}, "hash": "74e7ad97fcedb59e849eadc01a913b312d32c250cb7cb3190eff07669a1bfca4", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 45, "end_char_idx": 59, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66e31c2d-7343-4aa9-a2b2-ec37fabf6c91": {"__data__": {"id_": "66e31c2d-7343-4aa9-a2b2-ec37fabf6c91", "embedding": null, "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question. ", "original_text": "Thanks everyone. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "134cf7bc-7833-483f-9b2f-abb4f764cb8e", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah. ", "original_text": "Good morning. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "643d168d191230ca8829ef52eb5fc4e6a7011c648189f37f8880eb1a32c6aca1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "458a603f-3872-4068-9fc3-8dc4b7453fd8", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels. ", "original_text": "I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n"}, "hash": "95b9baffaee5ff80d1e3f4c531a550289b3b90c7ccb6dfadb6ee6a4ad874deec", "class_name": "RelatedNodeInfo"}}, "text": "Thanks everyone. ", "start_char_idx": 59, "end_char_idx": 76, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "458a603f-3872-4068-9fc3-8dc4b7453fd8": {"__data__": {"id_": "458a603f-3872-4068-9fc3-8dc4b7453fd8", "embedding": null, "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels. ", "original_text": "I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66e31c2d-7343-4aa9-a2b2-ec37fabf6c91", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question. ", "original_text": "Thanks everyone. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c84b755fbc2e3c9564d3508380e867bd0960e3f7cfefb7c0c425f0250c85db8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "502b1bbc-9259-44a8-b24a-fc4f77bc0729", "node_type": "1", "metadata": {"window": "Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order. ", "original_text": "Michael C. Kaufmann:  \nYeah. "}, "hash": "905dcd53547be56a41d22f1cc052cb97258aeb10d9f282b4616fdafdaa51613e", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n", "start_char_idx": 76, "end_char_idx": 460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "502b1bbc-9259-44a8-b24a-fc4f77bc0729": {"__data__": {"id_": "502b1bbc-9259-44a8-b24a-fc4f77bc0729", "embedding": null, "metadata": {"window": "Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order. ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "458a603f-3872-4068-9fc3-8dc4b7453fd8", "node_type": "1", "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels. ", "original_text": "I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5596150b3aca4d1a87f809002cf1eec037a8d8af4cac64461774fd648ec75a6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db445ba8-52f2-49d3-a3c2-39f5f3c026f4", "node_type": "1", "metadata": {"window": "Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant. ", "original_text": "It's a really interesting question. "}, "hash": "0b767c12c80d11b303d6116e93c71f363d4772bbcb1e90f8f9d5c7a9860b5ec2", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nYeah. ", "start_char_idx": 460, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db445ba8-52f2-49d3-a3c2-39f5f3c026f4": {"__data__": {"id_": "db445ba8-52f2-49d3-a3c2-39f5f3c026f4", "embedding": null, "metadata": {"window": "Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant. ", "original_text": "It's a really interesting question. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "502b1bbc-9259-44a8-b24a-fc4f77bc0729", "node_type": "1", "metadata": {"window": "Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order. ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76640937b86e77e0e4058f32590071a57b6c4aef4792e8b5554f3e03f82ebab5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a293bee-6635-4a99-9920-f7234a3a1268", "node_type": "1", "metadata": {"window": "I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating. ", "original_text": "It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels. "}, "hash": "e38f916264a5fa383800bcfd077a02ab59b59044cc273c1c1a2c411230f8f2cc", "class_name": "RelatedNodeInfo"}}, "text": "It's a really interesting question. ", "start_char_idx": 489, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a293bee-6635-4a99-9920-f7234a3a1268": {"__data__": {"id_": "9a293bee-6635-4a99-9920-f7234a3a1268", "embedding": null, "metadata": {"window": "I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating. ", "original_text": "It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db445ba8-52f2-49d3-a3c2-39f5f3c026f4", "node_type": "1", "metadata": {"window": "Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant. ", "original_text": "It's a really interesting question. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07643cea2f9fcd12fe5589601b9daf15f55a2900262b71e72deff3db5a37b543", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c3e0308-c183-48de-9288-f906ecb0211e", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively. ", "original_text": "There was a little bit of a shift to mail order. "}, "hash": "4d41f37c2e90d775f7fde0c1623a3ca45ea84faf3836ee77c98e6243ee72a332", "class_name": "RelatedNodeInfo"}}, "text": "It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels. ", "start_char_idx": 525, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c3e0308-c183-48de-9288-f906ecb0211e": {"__data__": {"id_": "0c3e0308-c183-48de-9288-f906ecb0211e", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively. ", "original_text": "There was a little bit of a shift to mail order. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a293bee-6635-4a99-9920-f7234a3a1268", "node_type": "1", "metadata": {"window": "I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating. ", "original_text": "It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c1ad7a422ae40fcb388acfda4b0ea07f10edbd617f27944b1aac18eefc611b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3d731c2-9047-40a1-b9fe-163097b9e735", "node_type": "1", "metadata": {"window": "It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well. ", "original_text": "I wouldn't call it  that we've seen \nanything significant. "}, "hash": "f5972a60caa06a2c34e39ccb07f5fb6dab543f15f1a8df6fe26b09ec57b35e44", "class_name": "RelatedNodeInfo"}}, "text": "There was a little bit of a shift to mail order. ", "start_char_idx": 613, "end_char_idx": 662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3d731c2-9047-40a1-b9fe-163097b9e735": {"__data__": {"id_": "a3d731c2-9047-40a1-b9fe-163097b9e735", "embedding": null, "metadata": {"window": "It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well. ", "original_text": "I wouldn't call it  that we've seen \nanything significant. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c3e0308-c183-48de-9288-f906ecb0211e", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively. ", "original_text": "There was a little bit of a shift to mail order. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1296a5a34f6516d296716f16eb7ac6ce04e691a7db93c98cb822b75f97c4dfef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64d52d44-cfa9-4bc9-9a47-362eca8f2485", "node_type": "1", "metadata": {"window": "It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too. ", "original_text": "I still  feel really good about how our retail independents are operating. "}, "hash": "9df3634e3c22ab8faf4da941c01c07b8e8e89ac07340def475eb013589239fd3", "class_name": "RelatedNodeInfo"}}, "text": "I wouldn't call it  that we've seen \nanything significant. ", "start_char_idx": 662, "end_char_idx": 721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64d52d44-cfa9-4bc9-9a47-362eca8f2485": {"__data__": {"id_": "64d52d44-cfa9-4bc9-9a47-362eca8f2485", "embedding": null, "metadata": {"window": "It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too. ", "original_text": "I still  feel really good about how our retail independents are operating. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3d731c2-9047-40a1-b9fe-163097b9e735", "node_type": "1", "metadata": {"window": "It's a really interesting question.  It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well. ", "original_text": "I wouldn't call it  that we've seen \nanything significant. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a69bc11a142338587fc85fa30745201f478a97051a0bae51eb2b52daae0b4799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "066b5237-6b40-47c5-af49-62354a1b877f", "node_type": "1", "metadata": {"window": "There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now. ", "original_text": "They're \ncompeting very effectively. "}, "hash": "eae8b093e0db525f5da60437001946b08e7fdc5a87859b20bfc84a27fbf1fc74", "class_name": "RelatedNodeInfo"}}, "text": "I still  feel really good about how our retail independents are operating. ", "start_char_idx": 721, "end_char_idx": 796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "066b5237-6b40-47c5-af49-62354a1b877f": {"__data__": {"id_": "066b5237-6b40-47c5-af49-62354a1b877f", "embedding": null, "metadata": {"window": "There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now. ", "original_text": "They're \ncompeting very effectively. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64d52d44-cfa9-4bc9-9a47-362eca8f2485", "node_type": "1", "metadata": {"window": "It's hard to decipher because we saw a lot of just pull -forward \nacross all  channels.  There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too. ", "original_text": "I still  feel really good about how our retail independents are operating. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68a350968ac897bc04faa28c56fd0f1e43f295fe156527db566af99df11b92e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2aa5a554-22cd-42cc-8041-483b311c6ac3", "node_type": "1", "metadata": {"window": "I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n", "original_text": "They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well. "}, "hash": "9db8e325dd9055caae36f0961ea5f731aa9cb054bc1204c80df87a9f8e05720d", "class_name": "RelatedNodeInfo"}}, "text": "They're \ncompeting very effectively. ", "start_char_idx": 796, "end_char_idx": 833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2aa5a554-22cd-42cc-8041-483b311c6ac3": {"__data__": {"id_": "2aa5a554-22cd-42cc-8041-483b311c6ac3", "embedding": null, "metadata": {"window": "I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n", "original_text": "They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "066b5237-6b40-47c5-af49-62354a1b877f", "node_type": "1", "metadata": {"window": "There was a little bit of a shift to mail order.  I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now. ", "original_text": "They're \ncompeting very effectively. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4b9f9e64a4b7416fbccf97db666d5fef9fba71d3a331020e81e857035ef9550", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f537312-c6a6-4e96-aba3-f69d39b7ab23", "node_type": "1", "metadata": {"window": "I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us. ", "original_text": "So \u2013 and we did see some 90 -day at retail shift too. "}, "hash": "969c6d5d97be540ed1e4165c14ba4095bfc80e55144b967dfd1ba0045db5a324", "class_name": "RelatedNodeInfo"}}, "text": "They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well. ", "start_char_idx": 833, "end_char_idx": 1030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f537312-c6a6-4e96-aba3-f69d39b7ab23": {"__data__": {"id_": "9f537312-c6a6-4e96-aba3-f69d39b7ab23", "embedding": null, "metadata": {"window": "I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us. ", "original_text": "So \u2013 and we did see some 90 -day at retail shift too. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2aa5a554-22cd-42cc-8041-483b311c6ac3", "node_type": "1", "metadata": {"window": "I wouldn't call it  that we've seen \nanything significant.  I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n", "original_text": "They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31f44d4cb8a84e0c4e41cfbb425467afbbbcb0450214021d616ddf4e3a6b1bbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ce9e252-b553-46c2-9381-433d8244c48f", "node_type": "1", "metadata": {"window": "They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n", "original_text": "So  it's hard to know \nexactly right now. "}, "hash": "ff37ee0220d056abe10ee013770456dedb2f5dd0cc0d14f1b9ec303458f46715", "class_name": "RelatedNodeInfo"}}, "text": "So \u2013 and we did see some 90 -day at retail shift too. ", "start_char_idx": 1030, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ce9e252-b553-46c2-9381-433d8244c48f": {"__data__": {"id_": "2ce9e252-b553-46c2-9381-433d8244c48f", "embedding": null, "metadata": {"window": "They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n", "original_text": "So  it's hard to know \nexactly right now. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f537312-c6a6-4e96-aba3-f69d39b7ab23", "node_type": "1", "metadata": {"window": "I still  feel really good about how our retail independents are operating.  They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us. ", "original_text": "So \u2013 and we did see some 90 -day at retail shift too. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49876dba7257da1db02dc89f0a9a699fe93f0efa948ec6b6deb69d0a449e5809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa1e6c17-8194-4668-9d0b-77dd1dbddbda", "node_type": "1", "metadata": {"window": "They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n", "original_text": "I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n"}, "hash": "fb6cf3d983a67add7587d76c4c0273456dd7942af744216e0d83d29d9a01cbab", "class_name": "RelatedNodeInfo"}}, "text": "So  it's hard to know \nexactly right now. ", "start_char_idx": 1084, "end_char_idx": 1126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa1e6c17-8194-4668-9d0b-77dd1dbddbda": {"__data__": {"id_": "fa1e6c17-8194-4668-9d0b-77dd1dbddbda", "embedding": null, "metadata": {"window": "They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n", "original_text": "I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ce9e252-b553-46c2-9381-433d8244c48f", "node_type": "1", "metadata": {"window": "They're \ncompeting very effectively.  They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n", "original_text": "So  it's hard to know \nexactly right now. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e1889b11c5d5c5cdd9fadbfbd402af394f796086fd635fde4ea1a99282cdf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1b18211-8e50-4abc-8822-55dfc5ab5aef", "node_type": "1", "metadata": {"window": "So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "As we've said in the past, mail order is a lower margin business for us. "}, "hash": "560fcef49e6270fcb72da47d97708c495fc498014a450127f582433c98175b29", "class_name": "RelatedNodeInfo"}}, "text": "I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n", "start_char_idx": 1126, "end_char_idx": 1228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1b18211-8e50-4abc-8822-55dfc5ab5aef": {"__data__": {"id_": "a1b18211-8e50-4abc-8822-55dfc5ab5aef", "embedding": null, "metadata": {"window": "So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "As we've said in the past, mail order is a lower margin business for us. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa1e6c17-8194-4668-9d0b-77dd1dbddbda", "node_type": "1", "metadata": {"window": "They've added  more deliveries those that weren't \u2013 are delivering , those \nthat are working to compete and do  effective things there,  they're continuing to serve their \ncommunities really well.  So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n", "original_text": "I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f90599bd4807c6d9ef7707212806bc0a6d04c60431bb967563d4305e0bb5022f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31ce54a6-5319-4edd-ac16-74f55bb4db23", "node_type": "1", "metadata": {"window": "So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n"}, "hash": "5272cd9023a0b7084865d3e2d8ff325155b559876fa784da2640ee1694c3846d", "class_name": "RelatedNodeInfo"}}, "text": "As we've said in the past, mail order is a lower margin business for us. ", "start_char_idx": 1228, "end_char_idx": 1301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31ce54a6-5319-4edd-ac16-74f55bb4db23": {"__data__": {"id_": "31ce54a6-5319-4edd-ac16-74f55bb4db23", "embedding": null, "metadata": {"window": "So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1b18211-8e50-4abc-8822-55dfc5ab5aef", "node_type": "1", "metadata": {"window": "So \u2013 and we did see some 90 -day at retail shift too.  So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "As we've said in the past, mail order is a lower margin business for us. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae54bfb067ad458c1d15c9fc2ecb2bb71c8f68705cd784c1c9e9b50c85d1913a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8826e3f6-3b19-45df-9694-f991745d989a", "node_type": "1", "metadata": {"window": "I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n"}, "hash": "3622dfa714576c0942416fa28aa7253f447a044887a15e9dda0724bdacef88df", "class_name": "RelatedNodeInfo"}}, "text": "So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n", "start_char_idx": 1301, "end_char_idx": 1540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8826e3f6-3b19-45df-9694-f991745d989a": {"__data__": {"id_": "8826e3f6-3b19-45df-9694-f991745d989a", "embedding": null, "metadata": {"window": "I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31ce54a6-5319-4edd-ac16-74f55bb4db23", "node_type": "1", "metadata": {"window": "So  it's hard to know \nexactly right now.  I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0c7a8f90b610cfb06ee73454c74c9a7e0d247c27c71b0195ae488949c2468fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cd13924-535d-44da-9e1e-5a49bf960d36", "node_type": "1", "metadata": {"window": "As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "Kevin Moran:  \nNext questions, please.  \n  "}, "hash": "acf31498c64eb92af03768c5fe22c33d76d716481bd2e26c0dfaacbd1fd592fc", "class_name": "RelatedNodeInfo"}}, "text": "And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n", "start_char_idx": 1540, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cd13924-535d-44da-9e1e-5a49bf960d36": {"__data__": {"id_": "9cd13924-535d-44da-9e1e-5a49bf960d36", "embedding": null, "metadata": {"window": "As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "Kevin Moran:  \nNext questions, please.  \n  ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "66268ab9-4892-43da-9f34-91db9bd2d796", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98c1c06af6eb4cd5fc716694810b6d41706106e4ad118c6941f0762cfba394d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8826e3f6-3b19-45df-9694-f991745d989a", "node_type": "1", "metadata": {"window": "I think its going to take another couple of quarters to understand how that mix  will \nbe impacted.  \n As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "908f8ac33cbda7d82927ffdfcbe9d5ea335df5f2fcf7686c310d2311757e091a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "704e3bc9-e426-4f23-808d-1c5b8820881c", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question. ", "original_text": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n"}, "hash": "c3da77a1acca0e4da1156d4a3c39e4963eaa24f00bf9e49e223854d52d5df1f3", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext questions, please.  \n  ", "start_char_idx": 1716, "end_char_idx": 1759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "704e3bc9-e426-4f23-808d-1c5b8820881c": {"__data__": {"id_": "704e3bc9-e426-4f23-808d-1c5b8820881c", "embedding": null, "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question. ", "original_text": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cd13924-535d-44da-9e1e-5a49bf960d36", "node_type": "1", "metadata": {"window": "As we've said in the past, mail order is a lower margin business for us.  So if we do see a shift to  there \nand we are obviously working with one of the largest mail order companies, we will see some margin  \nerosion but we still feel reall y good about where our retail independents and chains are positioned. \n And at this  point in time, we don't expect that to be a huge material driver for us in Q4 but we'll have \nto reevaluate that for  next year after we get some more intel.  \n  \n Kevin Moran:  \nNext questions, please.  \n  ", "original_text": "Kevin Moran:  \nNext questions, please.  \n  ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f9d465ba9ef30c01d654d4f38a0336ef57cf114cebe9c062393f11206ffa3b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbc15012-3ac8-49be-9f8d-6ccf4f8ef00a", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession? ", "original_text": "Elizabeth Anderson:  \nHi. "}, "hash": "63feb255370ae344a93339d6b7386f81125cbee4325dc98aa1e61c39ff5f8138", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n", "start_char_idx": 0, "end_char_idx": 98, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbc15012-3ac8-49be-9f8d-6ccf4f8ef00a": {"__data__": {"id_": "fbc15012-3ac8-49be-9f8d-6ccf4f8ef00a", "embedding": null, "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession? ", "original_text": "Elizabeth Anderson:  \nHi. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "704e3bc9-e426-4f23-808d-1c5b8820881c", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question. ", "original_text": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d84db9bdf99dc0eea10356afa8569858c1fbb9b4efe7cc910cb1a1a0da53c7f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccab591d-4dd1-49e6-aac5-cb94e78f95e0", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n", "original_text": "Good morning, guys. "}, "hash": "d3b186e0dbb03d27150abb19dbb93789237aaece48e317a22d560b59785b675f", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:  \nHi. ", "start_char_idx": 98, "end_char_idx": 124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccab591d-4dd1-49e6-aac5-cb94e78f95e0": {"__data__": {"id_": "ccab591d-4dd1-49e6-aac5-cb94e78f95e0", "embedding": null, "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n", "original_text": "Good morning, guys. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbc15012-3ac8-49be-9f8d-6ccf4f8ef00a", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession? ", "original_text": "Elizabeth Anderson:  \nHi. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4809067c911d87e55302f2e3229b7163906ccda1f13a08f5e74fad2e1d5ebb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1646407b-5691-4f92-a576-cc7361435313", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah. ", "original_text": "Thanks for the question. "}, "hash": "c13e58e4e13ca25d7dcf32235ef1f45da8143271cb60860b3d157db00bace1d9", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, guys. ", "start_char_idx": 124, "end_char_idx": 144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1646407b-5691-4f92-a576-cc7361435313": {"__data__": {"id_": "1646407b-5691-4f92-a576-cc7361435313", "embedding": null, "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah. ", "original_text": "Thanks for the question. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccab591d-4dd1-49e6-aac5-cb94e78f95e0", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n", "original_text": "Good morning, guys. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b059f0360759f5ea7f3c3da0e37ca6a217f67c599c556c70cf09a33bb6405e62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d2026d9-9e8d-463b-ab71-684cc8a51d7e", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else. ", "original_text": "I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession? "}, "hash": "bd934333cdb414b61659b0df163ee5b3118bba1113adcf279b760bba53445c79", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 144, "end_char_idx": 169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d2026d9-9e8d-463b-ab71-684cc8a51d7e": {"__data__": {"id_": "6d2026d9-9e8d-463b-ab71-684cc8a51d7e", "embedding": null, "metadata": {"window": "Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else. ", "original_text": "I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession? ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1646407b-5691-4f92-a576-cc7361435313", "node_type": "1", "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah. ", "original_text": "Thanks for the question. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "207f115b1075b99fbf4b9f3978c2f39dc4304a908e2a422807d22aae0af89ac6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "934020f6-5de0-412b-927e-14cf6c3f0248", "node_type": "1", "metadata": {"window": "Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this. ", "original_text": "Thanks.  \n  \n"}, "hash": "08f44a2d22fa390d05fb8a2e0afa958984bd217d1c3b0a462fd0e9f4692720f8", "class_name": "RelatedNodeInfo"}}, "text": "I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession? ", "start_char_idx": 169, "end_char_idx": 492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "934020f6-5de0-412b-927e-14cf6c3f0248": {"__data__": {"id_": "934020f6-5de0-412b-927e-14cf6c3f0248", "embedding": null, "metadata": {"window": "Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this. ", "original_text": "Thanks.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d2026d9-9e8d-463b-ab71-684cc8a51d7e", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else. ", "original_text": "I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession? ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a9cd3e1fcfffcdd3459d81682aaf449aada199f38d9d22aee2dcebf7e7975a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68b994fd-9e7b-489c-b050-61f0b2b498bc", "node_type": "1", "metadata": {"window": "Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n", "original_text": "Michael C. Kauf mann:  \nYeah. "}, "hash": "4cc47aabf9d4c960f603d34b4170ca6f0140a89befc7c59a9fba0d1d290256bd", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n  \n", "start_char_idx": 492, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68b994fd-9e7b-489c-b050-61f0b2b498bc": {"__data__": {"id_": "68b994fd-9e7b-489c-b050-61f0b2b498bc", "embedding": null, "metadata": {"window": "Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n", "original_text": "Michael C. Kauf mann:  \nYeah. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "934020f6-5de0-412b-927e-14cf6c3f0248", "node_type": "1", "metadata": {"window": "Good morning, guys.  Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this. ", "original_text": "Thanks.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "874b2a0a5236003dd8e1c9666e3435dddacecfd0cfc9f96be3a0cde57bed7780", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5a8132c-0fc0-46d8-be8e-10635881664a", "node_type": "1", "metadata": {"window": "I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles. ", "original_text": "It's hard to compare this to anything else. "}, "hash": "9daa5beb047b4dfcaa195910b55295726a94a808c0c3adf0396824d7a664a028", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kauf mann:  \nYeah. ", "start_char_idx": 505, "end_char_idx": 535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5a8132c-0fc0-46d8-be8e-10635881664a": {"__data__": {"id_": "e5a8132c-0fc0-46d8-be8e-10635881664a", "embedding": null, "metadata": {"window": "I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles. ", "original_text": "It's hard to compare this to anything else. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68b994fd-9e7b-489c-b050-61f0b2b498bc", "node_type": "1", "metadata": {"window": "Thanks for the question.  I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n", "original_text": "Michael C. Kauf mann:  \nYeah. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9ccf6726a4b3952b23087fe908372e1e98da227cd908baffe4d91fc16d9b939", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c4ffc91-fa3f-4dee-8aad-2217d9c09eb7", "node_type": "1", "metadata": {"window": "Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.  ", "original_text": "There's really been nothing else like this. "}, "hash": "d9334b117c52d27c9636d59407409e5aeea7840f010142ce91b432073a30384c", "class_name": "RelatedNodeInfo"}}, "text": "It's hard to compare this to anything else. ", "start_char_idx": 535, "end_char_idx": 579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c4ffc91-fa3f-4dee-8aad-2217d9c09eb7": {"__data__": {"id_": "7c4ffc91-fa3f-4dee-8aad-2217d9c09eb7", "embedding": null, "metadata": {"window": "Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.  ", "original_text": "There's really been nothing else like this. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5a8132c-0fc0-46d8-be8e-10635881664a", "node_type": "1", "metadata": {"window": "I noticed this obviously this is complicated by the \nCOVID  impact, but my question was around can you talk about a little \u2013 about how you've seen the \nbusiness performance  in the early parts of prior economic downturns and how maybe qualitatively if \nyou can talk about it over sort of the  longer period of a recession?  Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles. ", "original_text": "It's hard to compare this to anything else. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17618604a42a933c34c3cf0bb09eccf7488a681fffd558081116b1892181ea82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98bbcb90-bbd3-4cd5-a1c3-692a2b21b7cc", "node_type": "1", "metadata": {"window": "Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures. ", "original_text": "But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n"}, "hash": "3c8da4184cc26bb0774c022fa01d09151c5a4a14c4956a2bfa7d62aba28fd015", "class_name": "RelatedNodeInfo"}}, "text": "There's really been nothing else like this. ", "start_char_idx": 579, "end_char_idx": 623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98bbcb90-bbd3-4cd5-a1c3-692a2b21b7cc": {"__data__": {"id_": "98bbcb90-bbd3-4cd5-a1c3-692a2b21b7cc", "embedding": null, "metadata": {"window": "Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures. ", "original_text": "But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c4ffc91-fa3f-4dee-8aad-2217d9c09eb7", "node_type": "1", "metadata": {"window": "Thanks.  \n  \n Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.  ", "original_text": "There's really been nothing else like this. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "332bb7b1f4d01cce683899c3bf94c51491064d75834f88c2029b37453c2fb4ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c54d93d5-b2a0-42fa-9f47-b4b56543eac7", "node_type": "1", "metadata": {"window": "It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n", "original_text": "They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles. "}, "hash": "ac27b5596edae2d92ed869c9fd407c55572e2a8b9b290049c4eb3d4c8aad4816", "class_name": "RelatedNodeInfo"}}, "text": "But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n", "start_char_idx": 623, "end_char_idx": 839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c54d93d5-b2a0-42fa-9f47-b4b56543eac7": {"__data__": {"id_": "c54d93d5-b2a0-42fa-9f47-b4b56543eac7", "embedding": null, "metadata": {"window": "It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n", "original_text": "They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98bbcb90-bbd3-4cd5-a1c3-692a2b21b7cc", "node_type": "1", "metadata": {"window": "Michael C. Kauf mann:  \nYeah.  It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures. ", "original_text": "But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e446ff343e48bb0753a946c32e5abd6c4cbbd8e79c9c55277f0d0428daf205bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "086340db-14ee-41e5-8912-a5bd30feae6a", "node_type": "1", "metadata": {"window": "There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "And so we still feel that will be the case here.  "}, "hash": "29de0ffeb4095665b1527b0ccea4724a28e2baedbc03283a799dec05dc33034d", "class_name": "RelatedNodeInfo"}}, "text": "They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles. ", "start_char_idx": 839, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "086340db-14ee-41e5-8912-a5bd30feae6a": {"__data__": {"id_": "086340db-14ee-41e5-8912-a5bd30feae6a", "embedding": null, "metadata": {"window": "There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "And so we still feel that will be the case here.  ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c54d93d5-b2a0-42fa-9f47-b4b56543eac7", "node_type": "1", "metadata": {"window": "It's hard to compare this to anything else.  There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n", "original_text": "They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89aeaa7454faa379b7dffc389508efa1087acb9f13ad7ea60a5247a9a9d9e1a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cead0a4-b126-4da8-883c-e82a8ae6a170", "node_type": "1", "metadata": {"window": "But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "I think  this one is a little different in the \nsense of how much it has disrupted elective procedures. "}, "hash": "ed9105ca558ca7889a90730d6236516a292205db5de60d2ff4c5f21e0f5860cc", "class_name": "RelatedNodeInfo"}}, "text": "And so we still feel that will be the case here.  ", "start_char_idx": 1057, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cead0a4-b126-4da8-883c-e82a8ae6a170": {"__data__": {"id_": "8cead0a4-b126-4da8-883c-e82a8ae6a170", "embedding": null, "metadata": {"window": "But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "I think  this one is a little different in the \nsense of how much it has disrupted elective procedures. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "086340db-14ee-41e5-8912-a5bd30feae6a", "node_type": "1", "metadata": {"window": "There's really been nothing else like this.  But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "And so we still feel that will be the case here.  ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4be0e7bb4846a4a5536af0a8030f1648cac0fa41d9ac6eb16d68b516c02d0346", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0241a46-9312-4459-a096-4386280cbb92", "node_type": "1", "metadata": {"window": "They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n"}, "hash": "8b1f1f956cf7adc3e9941f81bd1a5938e196f692fe0f5f686654f658cc7f593b", "class_name": "RelatedNodeInfo"}}, "text": "I think  this one is a little different in the \nsense of how much it has disrupted elective procedures. ", "start_char_idx": 1107, "end_char_idx": 1211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0241a46-9312-4459-a096-4386280cbb92": {"__data__": {"id_": "e0241a46-9312-4459-a096-4386280cbb92", "embedding": null, "metadata": {"window": "They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cead0a4-b126-4da8-883c-e82a8ae6a170", "node_type": "1", "metadata": {"window": "But you can \ngo back to  events like 9/11, you can go back to events like the 2008 and 2009, and you can even go \nback to regional events,  and generally what w e see on both of our businesses is they rebound well. \n They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "I think  this one is a little different in the \nsense of how much it has disrupted elective procedures. ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1697c24476dcbe3b1ccde0960e47581ada7de001970a00e44e0c6049a0e54bd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5aa66390-7154-468e-bf6c-555268d33b17", "node_type": "1", "metadata": {"window": "And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n"}, "hash": "21d36cc525883f28dccc320e02830772d905036730a2bf15cc7552ecdad0b10c", "class_name": "RelatedNodeInfo"}}, "text": "But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n", "start_char_idx": 1211, "end_char_idx": 1443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5aa66390-7154-468e-bf6c-555268d33b17": {"__data__": {"id_": "5aa66390-7154-468e-bf6c-555268d33b17", "embedding": null, "metadata": {"window": "And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0241a46-9312-4459-a096-4386280cbb92", "node_type": "1", "metadata": {"window": "They tend to weather challenges like  that incredibly well over the mid - to long -term, so you may see \nsome temporary disruptions or changes, but  generally these businesses tend to perform really well \nover cycles.  And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed3366263539fd4fffb00caa12a960eb01d1c6e456c9d73b449c192586cc074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff4d1feb-5381-4bd1-baff-69ecc403a68d", "node_type": "1", "metadata": {"window": "I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  "}, "hash": "3663c914e18e23a8c411074a9df07850b296bcf246192a0825d363ee6d8a0753", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext question, please.  \n  \n", "start_char_idx": 1443, "end_char_idx": 1486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff4d1feb-5381-4bd1-baff-69ecc403a68d": {"__data__": {"id_": "ff4d1feb-5381-4bd1-baff-69ecc403a68d", "embedding": null, "metadata": {"window": "I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb0983fdad2bf2153baafac0a17acba18b45c2263cee35e84639af76f0841b24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aa66390-7154-468e-bf6c-555268d33b17", "node_type": "1", "metadata": {"window": "And so we still feel that will be the case here.   I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da2ee6abf7a610bc201cd49504099a3d911be1070b16983fbc46df93f3ece88b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9823a5ea-960a-40cd-87d2-12de295413c5", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear. ", "original_text": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah. "}, "hash": "a651ef25f858c98027b99e61be5cd1b74542e9d589c4a02f76e422fb3f3d849c", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "start_char_idx": 1486, "end_char_idx": 1564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9823a5ea-960a-40cd-87d2-12de295413c5": {"__data__": {"id_": "9823a5ea-960a-40cd-87d2-12de295413c5", "embedding": null, "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear. ", "original_text": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff4d1feb-5381-4bd1-baff-69ecc403a68d", "node_type": "1", "metadata": {"window": "I think  this one is a little different in the \nsense of how much it has disrupted elective procedures.  But again we do feel  that those will recover \nand we still are evaluating whether or not we migh t see some surges related to pent -up demand, but \nwe do feel good about the resilience of these businesses over the long -term.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "original_text": "Operator : Next question comes from Ricky Goldwasser with Morgan Stanley.  \n  ", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82bc9db2a28b2e30dcaafd9606755804e3553e642e95f07bcfb43b64d666443b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9606c4c-2543-4396-8625-a44e2edb2073", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year. ", "original_text": "Hi, good morning. "}, "hash": "cbb8020683fb0b0cd0828c954d1262d2b3feaa3924c23fc8cc4135fcaf517ee4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah. ", "start_char_idx": 0, "end_char_idx": 49, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9606c4c-2543-4396-8625-a44e2edb2073": {"__data__": {"id_": "c9606c4c-2543-4396-8625-a44e2edb2073", "embedding": null, "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year. ", "original_text": "Hi, good morning. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9823a5ea-960a-40cd-87d2-12de295413c5", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear. ", "original_text": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c65541bc724740a0f24778dac414ef6d1873665661d06e0c647eed7372667b19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b759f92f-ee34-4db0-8008-d4b2a8c50a56", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million. ", "original_text": "I have one follow -up on Nuclear and then my question. "}, "hash": "f2b0a517e8cb5195e76ff89bea289bdb28dc9287017a263867017aa2bd191c71", "class_name": "RelatedNodeInfo"}}, "text": "Hi, good morning. ", "start_char_idx": 49, "end_char_idx": 67, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b759f92f-ee34-4db0-8008-d4b2a8c50a56": {"__data__": {"id_": "b759f92f-ee34-4db0-8008-d4b2a8c50a56", "embedding": null, "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million. ", "original_text": "I have one follow -up on Nuclear and then my question. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9606c4c-2543-4396-8625-a44e2edb2073", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year. ", "original_text": "Hi, good morning. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52046009614c831cce8a60a84d93093e4fde477f18b09b5be0ad73bfc2caf80d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb59bcb-92bc-4ad5-99a3-f692bc93ea1e", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance? ", "original_text": "So, just that we \nunderstand on  Nuclear. "}, "hash": "5626b769b870ba3b9d8dd17b4280e4ba24b02ca51749ea30aace6a05565e6cab", "class_name": "RelatedNodeInfo"}}, "text": "I have one follow -up on Nuclear and then my question. ", "start_char_idx": 67, "end_char_idx": 122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb59bcb-92bc-4ad5-99a3-f692bc93ea1e": {"__data__": {"id_": "dcb59bcb-92bc-4ad5-99a3-f692bc93ea1e", "embedding": null, "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance? ", "original_text": "So, just that we \nunderstand on  Nuclear. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b759f92f-ee34-4db0-8008-d4b2a8c50a56", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million. ", "original_text": "I have one follow -up on Nuclear and then my question. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02d42658171a2af4815c90e5567d6fe9b8ae97bc28b5074061a17c38415bac4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b4a5066-b73d-45c3-ae21-ce9286163943", "node_type": "1", "metadata": {"window": "Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n", "original_text": "If we think about it, this was I think a $222 million business in the fourth \nquarter of last year. "}, "hash": "ab57102f2fdceca85d336a96d9c56a3debdaf50fb88e182e8acb99a94fb42af1", "class_name": "RelatedNodeInfo"}}, "text": "So, just that we \nunderstand on  Nuclear. ", "start_char_idx": 122, "end_char_idx": 164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b4a5066-b73d-45c3-ae21-ce9286163943": {"__data__": {"id_": "9b4a5066-b73d-45c3-ae21-ce9286163943", "embedding": null, "metadata": {"window": "Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n", "original_text": "If we think about it, this was I think a $222 million business in the fourth \nquarter of last year. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb59bcb-92bc-4ad5-99a3-f692bc93ea1e", "node_type": "1", "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance? ", "original_text": "So, just that we \nunderstand on  Nuclear. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cea7190ddaf07533022e2c775135fa5cbab4c95420a605e5c6640e8b2a5ddba0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74cc3092-f13a-4894-8823-a266ef554235", "node_type": "1", "metadata": {"window": "I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side. ", "original_text": "And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million. "}, "hash": "ccc3432dc70cd6b4dbde8632ad896c59a0696b979c02a608b01b1646785b654d", "class_name": "RelatedNodeInfo"}}, "text": "If we think about it, this was I think a $222 million business in the fourth \nquarter of last year. ", "start_char_idx": 164, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74cc3092-f13a-4894-8823-a266ef554235": {"__data__": {"id_": "74cc3092-f13a-4894-8823-a266ef554235", "embedding": null, "metadata": {"window": "I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side. ", "original_text": "And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b4a5066-b73d-45c3-ae21-ce9286163943", "node_type": "1", "metadata": {"window": "Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n", "original_text": "If we think about it, this was I think a $222 million business in the fourth \nquarter of last year. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e83c9e7a69a8f313a5822a5f5725db8c1fd95a3ff57092f621d29cdf95802b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3314f7b9-3704-46a6-9581-5601b8e4c345", "node_type": "1", "metadata": {"window": "So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic? ", "original_text": "I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance? "}, "hash": "c0fe470f77bc2a87f6440a7666a064813eb7f657296e376746877578f6bc8806", "class_name": "RelatedNodeInfo"}}, "text": "And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million. ", "start_char_idx": 264, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3314f7b9-3704-46a6-9581-5601b8e4c345": {"__data__": {"id_": "3314f7b9-3704-46a6-9581-5601b8e4c345", "embedding": null, "metadata": {"window": "So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic? ", "original_text": "I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance? ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74cc3092-f13a-4894-8823-a266ef554235", "node_type": "1", "metadata": {"window": "I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side. ", "original_text": "And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9dd83fe0ef288f93872e6fd26f717e929b2391c7a86573778689339d9570813e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbffaf0c-230d-4a4d-ae0f-7502a25e69bc", "node_type": "1", "metadata": {"window": "If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost? ", "original_text": "So that's kind  of like the follow -up \nquestion.  \n"}, "hash": "6e07c1b810e72e25c7a1f35a475291a79b4c9424d762b47adf9083a5b9c629a4", "class_name": "RelatedNodeInfo"}}, "text": "I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance? ", "start_char_idx": 393, "end_char_idx": 596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbffaf0c-230d-4a4d-ae0f-7502a25e69bc": {"__data__": {"id_": "dbffaf0c-230d-4a4d-ae0f-7502a25e69bc", "embedding": null, "metadata": {"window": "If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost? ", "original_text": "So that's kind  of like the follow -up \nquestion.  \n", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3314f7b9-3704-46a6-9581-5601b8e4c345", "node_type": "1", "metadata": {"window": "So, just that we \nunderstand on  Nuclear.  If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic? ", "original_text": "I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance? ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62de1c0e2757da715f1e522da7f778e3f0892b1fb7f288d36313295a0f7f12e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efdb9dc0-6108-48f5-9706-c06bd683271c", "node_type": "1", "metadata": {"window": "And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume? ", "original_text": "And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side. "}, "hash": "0b078b79a953b1bbdd2a8c96e0034fc4c823d904fd5d904bbc9c5924f4427c2d", "class_name": "RelatedNodeInfo"}}, "text": "So that's kind  of like the follow -up \nquestion.  \n", "start_char_idx": 596, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efdb9dc0-6108-48f5-9706-c06bd683271c": {"__data__": {"id_": "efdb9dc0-6108-48f5-9706-c06bd683271c", "embedding": null, "metadata": {"window": "And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume? ", "original_text": "And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbffaf0c-230d-4a4d-ae0f-7502a25e69bc", "node_type": "1", "metadata": {"window": "If we think about it, this was I think a $222 million business in the fourth \nquarter of last year.  And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost? ", "original_text": "So that's kind  of like the follow -up \nquestion.  \n", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3b14b312824e819cbb763203583a82cf914c37c02ab8691e130e724435c6c6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4706add1-4082-46d2-838b-f0cd016e92fb", "node_type": "1", "metadata": {"window": "I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n", "original_text": "So just curious as to your \nthoughts on  that dynamic? "}, "hash": "517bf631f5e3c0391f11f574b81efd513b1f52d03399773bcbc7f62ee1e5d6f5", "class_name": "RelatedNodeInfo"}}, "text": "And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side. ", "start_char_idx": 648, "end_char_idx": 1023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4706add1-4082-46d2-838b-f0cd016e92fb": {"__data__": {"id_": "4706add1-4082-46d2-838b-f0cd016e92fb", "embedding": null, "metadata": {"window": "I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n", "original_text": "So just curious as to your \nthoughts on  that dynamic? ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efdb9dc0-6108-48f5-9706-c06bd683271c", "node_type": "1", "metadata": {"window": "And in the  guidance, in EBIT guid ance for the Pharma segment, you lowered \nEBIT guidance by about $18 million to $73  million.  I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume? ", "original_text": "And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00d1e607d1853f0a818fd16ce4d7f22b41863e0bddeca6c1859c61bf6669dae9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddec4dd9-7362-4e27-9738-a619c7c5cd73", "node_type": "1", "metadata": {"window": "So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "And if tha t were  to happen, who would carry that additional cost? "}, "hash": "ead02a71833b9cc5d754a8e1376bbcbfa08b4dafd1d311bddc6c085144569dac", "class_name": "RelatedNodeInfo"}}, "text": "So just curious as to your \nthoughts on  that dynamic? ", "start_char_idx": 1023, "end_char_idx": 1078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddec4dd9-7362-4e27-9738-a619c7c5cd73": {"__data__": {"id_": "ddec4dd9-7362-4e27-9738-a619c7c5cd73", "embedding": null, "metadata": {"window": "So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "And if tha t were  to happen, who would carry that additional cost? ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4706add1-4082-46d2-838b-f0cd016e92fb", "node_type": "1", "metadata": {"window": "I think we knew already about the contracts \nbefore, so should we assume that at $18 million to $73  million change is all Nuclear or is there \nanything else new that was not included in prior guidance?  So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n", "original_text": "So just curious as to your \nthoughts on  that dynamic? ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eec12ddcf4fa59b6328042f77d8880708de2f2c6ecbfa17906a192a71aed46d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b4fca0b-2f2a-4914-974e-97da58b7de65", "node_type": "1", "metadata": {"window": "And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah. ", "original_text": "Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume? "}, "hash": "2478c5a50e19da280e89820f15700b5fdbe757197087145700a1bc4da45bb811", "class_name": "RelatedNodeInfo"}}, "text": "And if tha t were  to happen, who would carry that additional cost? ", "start_char_idx": 1078, "end_char_idx": 1146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b4fca0b-2f2a-4914-974e-97da58b7de65": {"__data__": {"id_": "5b4fca0b-2f2a-4914-974e-97da58b7de65", "embedding": null, "metadata": {"window": "And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah. ", "original_text": "Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume? ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddec4dd9-7362-4e27-9738-a619c7c5cd73", "node_type": "1", "metadata": {"window": "So that's kind  of like the follow -up \nquestion.  \n And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "And if tha t were  to happen, who would carry that additional cost? ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "249e53e63ec845fc0077fc553cc9b8331e2ae8a29244e7f0f924ebc12168aa6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2ae76ac-1461-4015-b43b-db153311bfcc", "node_type": "1", "metadata": {"window": "So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question. ", "original_text": "Thank you.  \n  \n"}, "hash": "eca9da43e4b64160d3845d8f429f899f80c1c5d12ab5a8414c775dfef729384f", "class_name": "RelatedNodeInfo"}}, "text": "Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume? ", "start_char_idx": 1146, "end_char_idx": 1261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2ae76ac-1461-4015-b43b-db153311bfcc": {"__data__": {"id_": "b2ae76ac-1461-4015-b43b-db153311bfcc", "embedding": null, "metadata": {"window": "So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question. ", "original_text": "Thank you.  \n  \n", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b4fca0b-2f2a-4914-974e-97da58b7de65", "node_type": "1", "metadata": {"window": "And my other question is really around just kind of like thinking about long -term fundamentals; Mike \nyou talked  about changes in the ecosystem, some other companies across t he healthcare ecosystem \nare talking about  potential changes to supply chain dynamics and bringing some manufacturing back \nto the US, whether it \u2019s on the  Pharma side or on the Med segment side.  So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah. ", "original_text": "Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume? ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5d8ace9e0e4faa5d5434e9591a6021b071d4fb074c6574295f70e114c1c9c08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12c5c56d-3f0d-4838-b122-fec3a1e16946", "node_type": "1", "metadata": {"window": "And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations. ", "original_text": "Michael C. Kaufmann:  \nYeah. "}, "hash": "3f633fc84f3779dc8609a8ee3892d1bfc223e6c46fe2d8d3f20b2fb969d67b70", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n  \n", "start_char_idx": 1261, "end_char_idx": 1277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12c5c56d-3f0d-4838-b122-fec3a1e16946": {"__data__": {"id_": "12c5c56d-3f0d-4838-b122-fec3a1e16946", "embedding": null, "metadata": {"window": "And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations. ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2ae76ac-1461-4015-b43b-db153311bfcc", "node_type": "1", "metadata": {"window": "So just curious as to your \nthoughts on  that dynamic?  And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question. ", "original_text": "Thank you.  \n  \n", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa99194e074184f5ebc2e5bfd84e9643fa4d0344d44966755b371c5de37ff545", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b343946-72f1-4986-8a70-5bbec30c61e8", "node_type": "1", "metadata": {"window": "Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19. ", "original_text": "I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah. "}, "hash": "2addd558c3fa5c3eeab752828217f53eaa0f0ed3012d07f2d62caff6cc37f827", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nYeah. ", "start_char_idx": 1277, "end_char_idx": 1306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b343946-72f1-4986-8a70-5bbec30c61e8": {"__data__": {"id_": "0b343946-72f1-4986-8a70-5bbec30c61e8", "embedding": null, "metadata": {"window": "Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19. ", "original_text": "I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12c5c56d-3f0d-4838-b122-fec3a1e16946", "node_type": "1", "metadata": {"window": "And if tha t were  to happen, who would carry that additional cost?  Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations. ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d6902d51fd76144c51056051872eebbc428694be108fcb2a93e3abc3579e237", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a21ec32-ce14-471f-8985-fdcdce685ebd", "node_type": "1", "metadata": {"window": "Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty. ", "original_text": "So let me just do a little housekeeping on the first question. "}, "hash": "7d78f053bbb6825e5a80ba7556beb5bfdcfa932d79e80e8cde0404c1b494a733", "class_name": "RelatedNodeInfo"}}, "text": "I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah. ", "start_char_idx": 1306, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a21ec32-ce14-471f-8985-fdcdce685ebd": {"__data__": {"id_": "0a21ec32-ce14-471f-8985-fdcdce685ebd", "embedding": null, "metadata": {"window": "Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty. ", "original_text": "So let me just do a little housekeeping on the first question. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b343946-72f1-4986-8a70-5bbec30c61e8", "node_type": "1", "metadata": {"window": "Is it \ngoing to be the wholesale distributor or is this going to be a  cost that the channel will have to \nassume?  Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19. ", "original_text": "I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a61a4bd1735c32423c1c860f9b923e08d9a2169d6d3eac6d2bdb34edce42d918", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82c1ece9-f24a-4377-b3d4-f9bd496cf318", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date. ", "original_text": "So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations. "}, "hash": "831d8a5bc30bd0a2b396fecd9b38771a18060227958c3b34bcbeb17f01f28ed3", "class_name": "RelatedNodeInfo"}}, "text": "So let me just do a little housekeeping on the first question. ", "start_char_idx": 1446, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82c1ece9-f24a-4377-b3d4-f9bd496cf318": {"__data__": {"id_": "82c1ece9-f24a-4377-b3d4-f9bd496cf318", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date. ", "original_text": "So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a21ec32-ce14-471f-8985-fdcdce685ebd", "node_type": "1", "metadata": {"window": "Thank you.  \n  \n Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty. ", "original_text": "So let me just do a little housekeeping on the first question. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9f5a3b65ac2850cf30608d8ff0aa7dda4de483df9f2b0487a5ebce75c631e69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1ef331a-ebd2-4174-9e2c-73824652a44c", "node_type": "1", "metadata": {"window": "I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "There are other impacts though resulting from COVID -19. "}, "hash": "649de14d25cc20a5ebca839c460a3e8d80187d453cd9311c1719bc6eb2c3a5ff", "class_name": "RelatedNodeInfo"}}, "text": "So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations. ", "start_char_idx": 1509, "end_char_idx": 1678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1ef331a-ebd2-4174-9e2c-73824652a44c": {"__data__": {"id_": "d1ef331a-ebd2-4174-9e2c-73824652a44c", "embedding": null, "metadata": {"window": "I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "There are other impacts though resulting from COVID -19. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82c1ece9-f24a-4377-b3d4-f9bd496cf318", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date. ", "original_text": "So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd0aa9bc8d5f77b394b5bc747e8c47afd384f789e43b46bf27a59f70ad202c7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18666948-8150-42e1-a699-cc72d821aa80", "node_type": "1", "metadata": {"window": "So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty. "}, "hash": "5d58e9ebe967ceae8875ddacea0e19df703bbd6c0fc41ee0199df5698087e449", "class_name": "RelatedNodeInfo"}}, "text": "There are other impacts though resulting from COVID -19. ", "start_char_idx": 1678, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18666948-8150-42e1-a699-cc72d821aa80": {"__data__": {"id_": "18666948-8150-42e1-a699-cc72d821aa80", "embedding": null, "metadata": {"window": "So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1ef331a-ebd2-4174-9e2c-73824652a44c", "node_type": "1", "metadata": {"window": "I'll let Dave start on the nuclear piece and the n I'll come back and talk about the long -term \nfundamentals \u2026 \n  \nDavid C. Evans:  \nYeah.  So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "There are other impacts though resulting from COVID -19. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db2f30d3e970a631c51281a2b7b028242defae7fb9523c1e185adc72ce6e9291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40087d2c-0acc-4d04-85e3-a8a1ad0d6292", "node_type": "1", "metadata": {"window": "So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "So Specialty was a growing  business year -to-date. "}, "hash": "4c3c3ce69c3a0f333b66d2a948d35c1aa25a8a35140be71a105aa63f36776f36", "class_name": "RelatedNodeInfo"}}, "text": "As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty. ", "start_char_idx": 1735, "end_char_idx": 1976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40087d2c-0acc-4d04-85e3-a8a1ad0d6292": {"__data__": {"id_": "40087d2c-0acc-4d04-85e3-a8a1ad0d6292", "embedding": null, "metadata": {"window": "So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "So Specialty was a growing  business year -to-date. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18666948-8150-42e1-a699-cc72d821aa80", "node_type": "1", "metadata": {"window": "So let me just do a little housekeeping on the first question.  So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "daafb587120f3b05eb6a777f194950c332642eca9aba58fedb02f0fed4b4df1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4ff466a-736d-400d-8aba-7c65c526a7be", "node_type": "1", "metadata": {"window": "There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "It was growing in a "}, "hash": "87c01c53eb3b473426bbcda1db026d6912453a08d042e2e5d7c6c05bf0427674", "class_name": "RelatedNodeInfo"}}, "text": "So Specialty was a growing  business year -to-date. ", "start_char_idx": 1976, "end_char_idx": 2028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4ff466a-736d-400d-8aba-7c65c526a7be": {"__data__": {"id_": "c4ff466a-736d-400d-8aba-7c65c526a7be", "embedding": null, "metadata": {"window": "There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "It was growing in a ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01a32722-91b0-499f-aeac-be881aa19ee6", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8de4955f14c03dabc9fbd91d925cac64286489224a311a72416222c221e5ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40087d2c-0acc-4d04-85e3-a8a1ad0d6292", "node_type": "1", "metadata": {"window": "So with respect to the Pharma \nfourth quarter  segment, yeah, I think you kind of characterized Nuclear in broad terms that would be \nconsistent with our  expectations.  There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "So Specialty was a growing  business year -to-date. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e12b1c4d3247f859d43fc256441c9a87a3f99917c00c033cec325bdd3e95072", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "288c1ba1-9618-48b1-8045-cc9b2d18faab", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah. ", "original_text": " \nPage 24 of 31 \n \nhealthy way. "}, "hash": "05e477d1551445e1de7da89ce4ef16edb558aab0e312d9f8cd10d0c2515eeba2", "class_name": "RelatedNodeInfo"}}, "text": "It was growing in a ", "start_char_idx": 2028, "end_char_idx": 2048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "288c1ba1-9618-48b1-8045-cc9b2d18faab": {"__data__": {"id_": "288c1ba1-9618-48b1-8045-cc9b2d18faab", "embedding": null, "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah. ", "original_text": " \nPage 24 of 31 \n \nhealthy way. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4ff466a-736d-400d-8aba-7c65c526a7be", "node_type": "1", "metadata": {"window": "There are other impacts though resulting from COVID -19.  As we \nmentioned in the script, in the  fourth quarter we do expect to see the reversal of the acceleration in \nthe PD volume into Q3, so that will happen  in Q4 and we also expect there to be a modest negative \nimpact related to Specialty.  So Specialty was a growing  business year -to-date.  It was growing in a ", "original_text": "It was growing in a ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06d8005861e4a276ca57eb6e35e1d56d51113c3c1108f062f10c709444768eb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa250749-ade5-4767-b16f-38232adbb12f", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain. ", "original_text": "This slowdown of elective procedures is really going to  negate some of t hat growth. "}, "hash": "1c92b9ee5f414cf09c3af095365bf92caf94b1b7278d57584fe63edb073679fe", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 24 of 31 \n \nhealthy way. ", "start_char_idx": 0, "end_char_idx": 32, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa250749-ade5-4767-b16f-38232adbb12f": {"__data__": {"id_": "aa250749-ade5-4767-b16f-38232adbb12f", "embedding": null, "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain. ", "original_text": "This slowdown of elective procedures is really going to  negate some of t hat growth. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "288c1ba1-9618-48b1-8045-cc9b2d18faab", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah. ", "original_text": " \nPage 24 of 31 \n \nhealthy way. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f71b6cb3180f84ee851dc235cdc48464a77ad3fd31d4e410a4a061276588cc92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3390fa2d-16f2-44b1-86b9-a48fbd8790f3", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens. ", "original_text": "So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n"}, "hash": "737789fe21f636423e596c9569cabfd27afb191e55f4d9736da1fdcf675aaec6", "class_name": "RelatedNodeInfo"}}, "text": "This slowdown of elective procedures is really going to  negate some of t hat growth. ", "start_char_idx": 32, "end_char_idx": 118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3390fa2d-16f2-44b1-86b9-a48fbd8790f3": {"__data__": {"id_": "3390fa2d-16f2-44b1-86b9-a48fbd8790f3", "embedding": null, "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens. ", "original_text": "So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa250749-ade5-4767-b16f-38232adbb12f", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain. ", "original_text": "This slowdown of elective procedures is really going to  negate some of t hat growth. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3348f0828ec99b65874452271090712b25d0c9d7a62a32f7996b1edfdab17873", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25a8b9fd-f101-4677-b28d-ba42f66996bb", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n", "original_text": "Michael C. Kaufmann : \nYeah. "}, "hash": "d6bb62eb858916deec2852058e28f3f739f43b2ee6756a02b8fec1be0e42707b", "class_name": "RelatedNodeInfo"}}, "text": "So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n", "start_char_idx": 118, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25a8b9fd-f101-4677-b28d-ba42f66996bb": {"__data__": {"id_": "25a8b9fd-f101-4677-b28d-ba42f66996bb", "embedding": null, "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n", "original_text": "Michael C. Kaufmann : \nYeah. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3390fa2d-16f2-44b1-86b9-a48fbd8790f3", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens. ", "original_text": "So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94700379e941491d41e0cdbd01038fe2a99851a10d6d89dd2cd7fbabe179f780", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "619bf745-c673-45d9-a329-36e4919764f5", "node_type": "1", "metadata": {"window": "This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses. ", "original_text": "So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain. "}, "hash": "09c3f2c82a3676f7646dadcb31a19cab18ff986907616c0dc26b9de6e20842aa", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann : \nYeah. ", "start_char_idx": 214, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "619bf745-c673-45d9-a329-36e4919764f5": {"__data__": {"id_": "619bf745-c673-45d9-a329-36e4919764f5", "embedding": null, "metadata": {"window": "This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses. ", "original_text": "So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25a8b9fd-f101-4677-b28d-ba42f66996bb", "node_type": "1", "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n", "original_text": "Michael C. Kaufmann : \nYeah. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "652bd3f2fc14f3d275c1703422942ae8415043bc762e783c94cb90567d1d4a96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3be44112-77f8-4691-8603-ddaafcfd6838", "node_type": "1", "metadata": {"window": "So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it. ", "original_text": "We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens. "}, "hash": "b78819933139b0e38eaa9658655f0ff9fc302535ccbe4d6cc19c12755dada222", "class_name": "RelatedNodeInfo"}}, "text": "So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain. ", "start_char_idx": 243, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3be44112-77f8-4691-8603-ddaafcfd6838": {"__data__": {"id_": "3be44112-77f8-4691-8603-ddaafcfd6838", "embedding": null, "metadata": {"window": "So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it. ", "original_text": "We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "619bf745-c673-45d9-a329-36e4919764f5", "node_type": "1", "metadata": {"window": "This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses. ", "original_text": "So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c41027f99fe253ad2a7a1acafdb8b179e81fae5b841604e839f9730d01ff5320", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ddd95c8-a18e-4484-a2ca-e58f3c0d370f", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally. ", "original_text": "We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n"}, "hash": "33088610adf7bea7b15d214d31dccb475e5dffd43c60de92cb1cceb50bb530f3", "class_name": "RelatedNodeInfo"}}, "text": "We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens. ", "start_char_idx": 360, "end_char_idx": 485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ddd95c8-a18e-4484-a2ca-e58f3c0d370f": {"__data__": {"id_": "2ddd95c8-a18e-4484-a2ca-e58f3c0d370f", "embedding": null, "metadata": {"window": "Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally. ", "original_text": "We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3be44112-77f8-4691-8603-ddaafcfd6838", "node_type": "1", "metadata": {"window": "So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it. ", "original_text": "We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b26d20bb69e9afe698e57ff35656ea17b5c87b318c4108cdd0fe8963f465e426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf4fcfe8-ca0a-4200-b77a-01e73e31e000", "node_type": "1", "metadata": {"window": "So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.  ", "original_text": "We'll continue to look at that and we've not se en any supply disruptions in those businesses. "}, "hash": "025ed9a2bee3157733c58231e9e3569efe096e8276097eb3cd7a7fca5f152e7b", "class_name": "RelatedNodeInfo"}}, "text": "We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n", "start_char_idx": 485, "end_char_idx": 586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf4fcfe8-ca0a-4200-b77a-01e73e31e000": {"__data__": {"id_": "cf4fcfe8-ca0a-4200-b77a-01e73e31e000", "embedding": null, "metadata": {"window": "So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.  ", "original_text": "We'll continue to look at that and we've not se en any supply disruptions in those businesses. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ddd95c8-a18e-4484-a2ca-e58f3c0d370f", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann : \nYeah.  So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally. ", "original_text": "We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b222e5926e3cf9644d61056e9993f3b9a4acbcd116bf33c29a54a5114deb4590", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4259711b-620c-403d-93db-8de01cccaf42", "node_type": "1", "metadata": {"window": "We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there. ", "original_text": "But it  \nwasn't all of it. "}, "hash": "058524ad15ab32b87d3626c611c18e93f2264294e74ffcd6c3800004e810d9b5", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to look at that and we've not se en any supply disruptions in those businesses. ", "start_char_idx": 586, "end_char_idx": 681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4259711b-620c-403d-93db-8de01cccaf42": {"__data__": {"id_": "4259711b-620c-403d-93db-8de01cccaf42", "embedding": null, "metadata": {"window": "We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there. ", "original_text": "But it  \nwasn't all of it. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf4fcfe8-ca0a-4200-b77a-01e73e31e000", "node_type": "1", "metadata": {"window": "So as far as the supply chain goes, as you can imagine with COVID -19, we are evaluating our \noverall  supply chain.  We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.  ", "original_text": "We'll continue to look at that and we've not se en any supply disruptions in those businesses. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3fbcb498cb8e99aee7a1bebc1787b7b924876d962e34c323cb24178b245fb74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9024357f-6ec6-4f97-8f0e-4d1601536b14", "node_type": "1", "metadata": {"window": "We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there . ", "original_text": "So we were sourcing globally. "}, "hash": "2988da98f36159b07f1d6968e2ca6efdf2ce108b894ceb580042bb96866a12fb", "class_name": "RelatedNodeInfo"}}, "text": "But it  \nwasn't all of it. ", "start_char_idx": 681, "end_char_idx": 708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9024357f-6ec6-4f97-8f0e-4d1601536b14": {"__data__": {"id_": "9024357f-6ec6-4f97-8f0e-4d1601536b14", "embedding": null, "metadata": {"window": "We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there . ", "original_text": "So we were sourcing globally. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4259711b-620c-403d-93db-8de01cccaf42", "node_type": "1", "metadata": {"window": "We were, as you know, working through that, but with these changes we are \nlooking at our global  footprint with a new lens.  We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there. ", "original_text": "But it  \nwasn't all of it. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddea8e2c02874d1fd7693839bd09fd906cbb76615817a6bd9c520c98ef434420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d181847-42d3-43a2-bd54-3883c44a68ff", "node_type": "1", "metadata": {"window": "We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time. ", "original_text": "I'm sure we will continue to be a global sourcer.  "}, "hash": "5555063cc293003dfb917f846d34c75edd5924e37ce3f98864ac0fa194b91028", "class_name": "RelatedNodeInfo"}}, "text": "So we were sourcing globally. ", "start_char_idx": 708, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d181847-42d3-43a2-bd54-3883c44a68ff": {"__data__": {"id_": "9d181847-42d3-43a2-bd54-3883c44a68ff", "embedding": null, "metadata": {"window": "We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time. ", "original_text": "I'm sure we will continue to be a global sourcer.  ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9024357f-6ec6-4f97-8f0e-4d1601536b14", "node_type": "1", "metadata": {"window": "We do some of our manufacturing right now for masks \nand certain other products in  North America.  \n We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there . ", "original_text": "So we were sourcing globally. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16ecaf9892328e3c7f6c0a9c93ff727a4e6424ac3addfc6a5f620463a09349b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1a4ed92-0a0b-4917-adf7-96649524f076", "node_type": "1", "metadata": {"window": "But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n", "original_text": "We will \nabsolutely take a look at China and how it plays in there. "}, "hash": "db5c2cd3e32fe9a3df9883b0eaf5aa10c38293af659bc36df0e4c3ea0e673c41", "class_name": "RelatedNodeInfo"}}, "text": "I'm sure we will continue to be a global sourcer.  ", "start_char_idx": 738, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1a4ed92-0a0b-4917-adf7-96649524f076": {"__data__": {"id_": "c1a4ed92-0a0b-4917-adf7-96649524f076", "embedding": null, "metadata": {"window": "But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n", "original_text": "We will \nabsolutely take a look at China and how it plays in there. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d181847-42d3-43a2-bd54-3883c44a68ff", "node_type": "1", "metadata": {"window": "We'll continue to look at that and we've not se en any supply disruptions in those businesses.  But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time. ", "original_text": "I'm sure we will continue to be a global sourcer.  ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21bc9f493a4557c9bec664d9249db381212d5a53bbc0becec4b9d36890fc2962", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bf16175-4804-4551-b7eb-bac9f100eebc", "node_type": "1", "metadata": {"window": "So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers. ", "original_text": "It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there . "}, "hash": "e3338e2eb248f8b7a1787d3ec2166d69059600027e62365e9673071a27c550f6", "class_name": "RelatedNodeInfo"}}, "text": "We will \nabsolutely take a look at China and how it plays in there. ", "start_char_idx": 789, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bf16175-4804-4551-b7eb-bac9f100eebc": {"__data__": {"id_": "4bf16175-4804-4551-b7eb-bac9f100eebc", "embedding": null, "metadata": {"window": "So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers. ", "original_text": "It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there . ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1a4ed92-0a0b-4917-adf7-96649524f076", "node_type": "1", "metadata": {"window": "But it  \nwasn't all of it.  So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n", "original_text": "We will \nabsolutely take a look at China and how it plays in there. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "762dbae27244ed7319ba07b60851e6b0dc18156915ce73a41479fa5eff283d83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1c5742f-d29f-4620-ab75-abf6a988cd56", "node_type": "1", "metadata": {"window": "I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have. ", "original_text": "But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time. "}, "hash": "fdb0ab4db3154d9490e0e2d2eeb5321a402fa37d87bec1720755b28ba97da7c1", "class_name": "RelatedNodeInfo"}}, "text": "It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there . ", "start_char_idx": 857, "end_char_idx": 1160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1c5742f-d29f-4620-ab75-abf6a988cd56": {"__data__": {"id_": "b1c5742f-d29f-4620-ab75-abf6a988cd56", "embedding": null, "metadata": {"window": "I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have. ", "original_text": "But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bf16175-4804-4551-b7eb-bac9f100eebc", "node_type": "1", "metadata": {"window": "So we were sourcing globally.  I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers. ", "original_text": "It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there . ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bc2d35910c325802c87efde83c6eec74eae88e3f827eb80339cb071f6bb74ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a84526f5-dc8d-49ce-8bd8-17a5c167a449", "node_type": "1", "metadata": {"window": "We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products. ", "original_text": "So absolutely we'll  be taking a look at that.  \n"}, "hash": "1d9bb286ec9c8065a7c6626185a4199c0ad22d7a08da7bd0cd9259abacb40b93", "class_name": "RelatedNodeInfo"}}, "text": "But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time. ", "start_char_idx": 1160, "end_char_idx": 1467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a84526f5-dc8d-49ce-8bd8-17a5c167a449": {"__data__": {"id_": "a84526f5-dc8d-49ce-8bd8-17a5c167a449", "embedding": null, "metadata": {"window": "We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products. ", "original_text": "So absolutely we'll  be taking a look at that.  \n", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1c5742f-d29f-4620-ab75-abf6a988cd56", "node_type": "1", "metadata": {"window": "I'm sure we will continue to be a global sourcer.   We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have. ", "original_text": "But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d9cd9355471c6e64188c0f63b3d3e79bf682cbaf8e6745f59e64756e7cfb2f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9abb7558-0c43-49cd-a389-221c77bcb4a2", "node_type": "1", "metadata": {"window": "It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n", "original_text": "Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers. "}, "hash": "8520c75d5bbd079b3c3dd562622c39b121b5f7db7519f0151c249a4fe03e4715", "class_name": "RelatedNodeInfo"}}, "text": "So absolutely we'll  be taking a look at that.  \n", "start_char_idx": 1467, "end_char_idx": 1516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9abb7558-0c43-49cd-a389-221c77bcb4a2": {"__data__": {"id_": "9abb7558-0c43-49cd-a389-221c77bcb4a2", "embedding": null, "metadata": {"window": "It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n", "original_text": "Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a84526f5-dc8d-49ce-8bd8-17a5c167a449", "node_type": "1", "metadata": {"window": "We will \nabsolutely take a look at China and how it plays in there.  It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products. ", "original_text": "So absolutely we'll  be taking a look at that.  \n", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a88403c148917aff5015cdd174ca6b613f1e85c32ecb40b70f9313f287e4bd95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adad2815-8f2b-4e84-977d-44d507564bb8", "node_type": "1", "metadata": {"window": "But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing. ", "original_text": "They understand \nand have put patients first,  just as we have. "}, "hash": "73daba950c76a83905347f988bdfd071643bb9e0d55ebe49f26dccf30694b54f", "class_name": "RelatedNodeInfo"}}, "text": "Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers. ", "start_char_idx": 1516, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adad2815-8f2b-4e84-977d-44d507564bb8": {"__data__": {"id_": "adad2815-8f2b-4e84-977d-44d507564bb8", "embedding": null, "metadata": {"window": "But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing. ", "original_text": "They understand \nand have put patients first,  just as we have. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9abb7558-0c43-49cd-a389-221c77bcb4a2", "node_type": "1", "metadata": {"window": "It's hard to believe that China won't  be part \nof an  overall global sourcing strategy going forward, but the percentage of the products that are made \nthere and, more  importantly, the type of products that we make in China or that we source in China, \nwe don't have any actual  manufacturing there .  But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n", "original_text": "Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45c7859d8cc970f3bf3d80bb8328f5f0cd3d0849e27726b088331d21f115fa62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edc30575-c408-446b-985f-8b834d4a329a", "node_type": "1", "metadata": {"window": "So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products. "}, "hash": "7e6cf929540f763d4ec0ebca1292125d3b4298bd57a3736c5feb5b171fe38e0f", "class_name": "RelatedNodeInfo"}}, "text": "They understand \nand have put patients first,  just as we have. ", "start_char_idx": 1707, "end_char_idx": 1771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edc30575-c408-446b-985f-8b834d4a329a": {"__data__": {"id_": "edc30575-c408-446b-985f-8b834d4a329a", "embedding": null, "metadata": {"window": "So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adad2815-8f2b-4e84-977d-44d507564bb8", "node_type": "1", "metadata": {"window": "But where we source in China, we're going to take a \nlook at that and make sure that we  have the type of infrastructure that, as we go forward not only in \nthis situation but in future situations, probably is  more diversified and not as dependent as the US  \nwas on certain categories in China this time.  So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing. ", "original_text": "They understand \nand have put patients first,  just as we have. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e4385c8cb990a31219bb3fcc25d346b5a6d2e87efe738ca3a8809be508a18c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e34fd76-d8ab-4f77-958f-d06152b876f5", "node_type": "1", "metadata": {"window": "Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n"}, "hash": "f07dfebdfdba3b1428032e9b815a03d4cd7aeb00247beff56aa8e77b9c18ed2c", "class_name": "RelatedNodeInfo"}}, "text": "And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products. ", "start_char_idx": 1771, "end_char_idx": 1880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e34fd76-d8ab-4f77-958f-d06152b876f5": {"__data__": {"id_": "9e34fd76-d8ab-4f77-958f-d06152b876f5", "embedding": null, "metadata": {"window": "Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edc30575-c408-446b-985f-8b834d4a329a", "node_type": "1", "metadata": {"window": "So absolutely we'll  be taking a look at that.  \n Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d1f68159801fe40c4ba23a9579e9b4e9e35b92902afa0d923c8209681539b69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acae3782-c446-4fb6-987c-f294fe89a60f", "node_type": "1", "metadata": {"window": "They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing. "}, "hash": "bef4e6dac9abe8aa75a7b3152d0d1d8e4fd5de65f7387d71307e6ef576bcd8fa", "class_name": "RelatedNodeInfo"}}, "text": "And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n", "start_char_idx": 1880, "end_char_idx": 2276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acae3782-c446-4fb6-987c-f294fe89a60f": {"__data__": {"id_": "acae3782-c446-4fb6-987c-f294fe89a60f", "embedding": null, "metadata": {"window": "They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e34fd76-d8ab-4f77-958f-d06152b876f5", "node_type": "1", "metadata": {"window": "Your question around cost increases in the channel, it's hard to speak about how that will look going \nforward, but I  will tell you, so far, we've been very transpa rent with our customers.  They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48ce71a9d1ae5ab1315b93b7481e8647a8483ea65713fd337adba2ee51b79efa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4aaa4ad4-9fa7-4e6c-94d1-999c9367fe4e", "node_type": "1", "metadata": {"window": "And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "I believe many of those are temporary for people that are trying to help out and just do "}, "hash": "d1a1cc2a2de7529ec165fc1c9dbceaadd061e654ae140e46c1523601e5db239c", "class_name": "RelatedNodeInfo"}}, "text": "Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing. ", "start_char_idx": 2276, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4aaa4ad4-9fa7-4e6c-94d1-999c9367fe4e": {"__data__": {"id_": "4aaa4ad4-9fa7-4e6c-94d1-999c9367fe4e", "embedding": null, "metadata": {"window": "And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "I believe many of those are temporary for people that are trying to help out and just do ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503aea9981d6c4541bf34d1b119b00d31b70ac07f468e3615af4c6b3e7171b12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acae3782-c446-4fb6-987c-f294fe89a60f", "node_type": "1", "metadata": {"window": "They understand \nand have put patients first,  just as we have.  And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24f0ed17001bf1ec8be4b466a70dfee8ac1df99757297fc9947719fb72774f5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c5b9b83-8e3c-4d0b-a631-59ec44e06f2f", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n", "original_text": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation. "}, "hash": "423f0bc1585c7b69b49a1db55c3188c3b0d112b08df4433c68fbb7712e1790e5", "class_name": "RelatedNodeInfo"}}, "text": "I believe many of those are temporary for people that are trying to help out and just do ", "start_char_idx": 2395, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c5b9b83-8e3c-4d0b-a631-59ec44e06f2f": {"__data__": {"id_": "9c5b9b83-8e3c-4d0b-a631-59ec44e06f2f", "embedding": null, "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n", "original_text": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4aaa4ad4-9fa7-4e6c-94d1-999c9367fe4e", "node_type": "1", "metadata": {"window": "And for us to be able to do that, we've had to change \nwhere we source and how we get certain  PPE products.  And customers have been willing to work \nwith us on those produ cts and work with us on those  higher cost s. And we're going to continue to \nhave those open and transparent conversations, continue to look at  the supply chain going forward \nand determine what's the right and fair way to manage this situation as it goes to  cost increases, \neither on raw materials and those types of things.  \n Overall, over the longer -term, I'm not too worried about new players in the marketplace, in terms of  \nmanufacturing.  I believe many of those are temporary for people that are trying to help out and just do ", "original_text": "I believe many of those are temporary for people that are trying to help out and just do ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0de22c2cce31d48cc0c74999cec0ed7b9a5374d1311b5ab8126f5f05d5b3dc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2784bb5-aab0-4a21-a9d7-1a8db734d9b8", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost. ", "original_text": "And that's great. "}, "hash": "8a09c70819ca1c9cfa6b75ad79422fb5f442556e2aa2035a924a2e0bde1d648d", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation. ", "start_char_idx": 0, "end_char_idx": 45, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2784bb5-aab0-4a21-a9d7-1a8db734d9b8": {"__data__": {"id_": "b2784bb5-aab0-4a21-a9d7-1a8db734d9b8", "embedding": null, "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost. ", "original_text": "And that's great. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c5b9b83-8e3c-4d0b-a631-59ec44e06f2f", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n", "original_text": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f3b7032ae07e000e7b9c7b32e6a63b641b029751bf189e8261e532fed50bb85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7032cfa4-be4c-4cb7-854b-6c39d8cbe477", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost. ", "original_text": "And we really admire and respect the people that are doing \nthat. "}, "hash": "7c51f32f7d868c3168d0abfd316544fea061c7bb0125f224ea8c54501aba6151", "class_name": "RelatedNodeInfo"}}, "text": "And that's great. ", "start_char_idx": 45, "end_char_idx": 63, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7032cfa4-be4c-4cb7-854b-6c39d8cbe477": {"__data__": {"id_": "7032cfa4-be4c-4cb7-854b-6c39d8cbe477", "embedding": null, "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost. ", "original_text": "And we really admire and respect the people that are doing \nthat. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2784bb5-aab0-4a21-a9d7-1a8db734d9b8", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost. ", "original_text": "And that's great. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f899d461e5a74acdbe36d7f58dd6560d93a5b0b50fe6cee4aed9bc13274b0099", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "556863d7-3709-4ca5-963a-07f461385638", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n", "original_text": "I don't think many  of them will stay in the business.  \n"}, "hash": "8f608fe9a432fb3128824619e452c8b2ea7f668bf3cd272396b23ceb5c5fb430", "class_name": "RelatedNodeInfo"}}, "text": "And we really admire and respect the people that are doing \nthat. ", "start_char_idx": 63, "end_char_idx": 129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "556863d7-3709-4ca5-963a-07f461385638": {"__data__": {"id_": "556863d7-3709-4ca5-963a-07f461385638", "embedding": null, "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n", "original_text": "I don't think many  of them will stay in the business.  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7032cfa4-be4c-4cb7-854b-6c39d8cbe477", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost. ", "original_text": "And we really admire and respect the people that are doing \nthat. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5138810eb6f9abbd5ebd2f99fdae735e04e4fc4e1f92134881c7922b90569003", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb4d5433-6547-4ef3-abb9-359d036b4f8e", "node_type": "1", "metadata": {"window": "And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost. "}, "hash": "277767293347c2fbe4467ba213a851e0775de46aa40a135155fba8ea3b302546", "class_name": "RelatedNodeInfo"}}, "text": "I don't think many  of them will stay in the business.  \n", "start_char_idx": 129, "end_char_idx": 186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb4d5433-6547-4ef3-abb9-359d036b4f8e": {"__data__": {"id_": "eb4d5433-6547-4ef3-abb9-359d036b4f8e", "embedding": null, "metadata": {"window": "And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "556863d7-3709-4ca5-963a-07f461385638", "node_type": "1", "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n", "original_text": "I don't think many  of them will stay in the business.  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f540286c4f669efb941a547889c93f5018130ce61857fd11e6ed9883c4879bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c491e913-7df4-48eb-bc44-4da8f5759bac", "node_type": "1", "metadata": {"window": "And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n", "original_text": "So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost. "}, "hash": "717384241480d293f6b54fb74b29daea5995a4b07079a6446c93a259cf2c86ca", "class_name": "RelatedNodeInfo"}}, "text": "And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost. ", "start_char_idx": 186, "end_char_idx": 421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c491e913-7df4-48eb-bc44-4da8f5759bac": {"__data__": {"id_": "c491e913-7df4-48eb-bc44-4da8f5759bac", "embedding": null, "metadata": {"window": "And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n", "original_text": "So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb4d5433-6547-4ef3-abb9-359d036b4f8e", "node_type": "1", "metadata": {"window": "And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b49eee58fc78e9fb25ab9406e25ac823279194965427296718f59be48f26597", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9055c2d1-de00-4dae-9223-04a27cd44bdc", "node_type": "1", "metadata": {"window": "I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much. ", "original_text": "And we' ll come back  with more color when it's appropriate.  \n  \n"}, "hash": "f89e43b841b2d444b0f0c1bc990150dd38b98f35d47c3f23df210d9980cbeb93", "class_name": "RelatedNodeInfo"}}, "text": "So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost. ", "start_char_idx": 421, "end_char_idx": 519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9055c2d1-de00-4dae-9223-04a27cd44bdc": {"__data__": {"id_": "9055c2d1-de00-4dae-9223-04a27cd44bdc", "embedding": null, "metadata": {"window": "I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much. ", "original_text": "And we' ll come back  with more color when it's appropriate.  \n  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c491e913-7df4-48eb-bc44-4da8f5759bac", "node_type": "1", "metadata": {"window": "And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n", "original_text": "So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81afc21aeacf88fb4c531cd04752b48f19e71c3a9c73bcafdea6d3ba13513fc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf0d08e0-c8df-4256-87fd-6afaf0f54ef0", "node_type": "1", "metadata": {"window": "And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n"}, "hash": "574b432c1d1f3872a914a02c726f2c210f51c5c3d6a2a70bac61689664bee38e", "class_name": "RelatedNodeInfo"}}, "text": "And we' ll come back  with more color when it's appropriate.  \n  \n", "start_char_idx": 519, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf0d08e0-c8df-4256-87fd-6afaf0f54ef0": {"__data__": {"id_": "cf0d08e0-c8df-4256-87fd-6afaf0f54ef0", "embedding": null, "metadata": {"window": "And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9055c2d1-de00-4dae-9223-04a27cd44bdc", "node_type": "1", "metadata": {"window": "I don't think many  of them will stay in the business.  \n And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much. ", "original_text": "And we' ll come back  with more color when it's appropriate.  \n  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dcbcfeb0420247959aafbef04fe0ed68a86c7a8bf3c727f21d71a5f55a4468f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05b5735e-1d9f-402e-abde-ccb0e6e7e853", "node_type": "1", "metadata": {"window": "So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about. ", "original_text": "Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n"}, "hash": "89b747c534f4b9d75aab13ba3ac467868059796f7ae8953b83f659fe7769e0ae", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext question, please.  \n  \n", "start_char_idx": 585, "end_char_idx": 628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05b5735e-1d9f-402e-abde-ccb0e6e7e853": {"__data__": {"id_": "05b5735e-1d9f-402e-abde-ccb0e6e7e853", "embedding": null, "metadata": {"window": "So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about. ", "original_text": "Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf0d08e0-c8df-4256-87fd-6afaf0f54ef0", "node_type": "1", "metadata": {"window": "And for those that will, that have the high -quality type of products that we' re looking for, we think it \ncould give us  some opportunity to continue to look at our overall number of sourcing partners and the \nability to drive cost.  So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d99ecc8032eee3625dbaddef829bb4b9a032974a990d6b46bf85a2c589f52132", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4b9f46d-61af-4188-ad55-49ba4fcc444f", "node_type": "1", "metadata": {"window": "And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n", "original_text": "Lisa C. Gill:  \nThanks very much. "}, "hash": "9697cbe1742d81f42b4abb495d00d8018eafa48a38034e77f9d89bc31ad277d4", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n", "start_char_idx": 628, "end_char_idx": 692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4b9f46d-61af-4188-ad55-49ba4fcc444f": {"__data__": {"id_": "f4b9f46d-61af-4188-ad55-49ba4fcc444f", "embedding": null, "metadata": {"window": "And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n", "original_text": "Lisa C. Gill:  \nThanks very much. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05b5735e-1d9f-402e-abde-ccb0e6e7e853", "node_type": "1", "metadata": {"window": "So  that is going to be a key area for us in FY 2021, is going to be managing \nsupply chain cost.  And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about. ", "original_text": "Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e33662eb58b2d73d963613ad8f0d3ba35007f75dcbaf7b4a2250f925c56643a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88e31e6d-2d27-457c-b017-5e84b6623258", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n", "original_text": "Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline. "}, "hash": "8090f7034582c8e5f253245c3ecaa4db5511580edd33d207550dfbac8cb94258", "class_name": "RelatedNodeInfo"}}, "text": "Lisa C. Gill:  \nThanks very much. ", "start_char_idx": 692, "end_char_idx": 726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88e31e6d-2d27-457c-b017-5e84b6623258": {"__data__": {"id_": "88e31e6d-2d27-457c-b017-5e84b6623258", "embedding": null, "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n", "original_text": "Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4b9f46d-61af-4188-ad55-49ba4fcc444f", "node_type": "1", "metadata": {"window": "And we' ll come back  with more color when it's appropriate.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n", "original_text": "Lisa C. Gill:  \nThanks very much. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b046c6526fc6260baaf9929223a0cc85317580e58834943dd1c3e95ffe4292bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f92f9ab-905e-4fd0-b006-d38cd01b5fdc", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer. ", "original_text": "I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about. "}, "hash": "8d85c3c5f8bb27c3ec5cf8464810daafc6e35b272df17c26b0e57e6fd3d2043e", "class_name": "RelatedNodeInfo"}}, "text": "Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline. ", "start_char_idx": 726, "end_char_idx": 839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f92f9ab-905e-4fd0-b006-d38cd01b5fdc": {"__data__": {"id_": "1f92f9ab-905e-4fd0-b006-d38cd01b5fdc", "embedding": null, "metadata": {"window": "Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer. ", "original_text": "I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88e31e6d-2d27-457c-b017-5e84b6623258", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n", "original_text": "Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "058f8e93ad43ff6916d81d242251a4ee953c93e224c75ec73c3ceb512dc55c08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "740c41d9-355c-41a4-864d-272fc7bf63b1", "node_type": "1", "metadata": {"window": "Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections? ", "original_text": "Do you see near -term opportunities to take cost out of your system? \n"}, "hash": "427e80b71f99f1a67c4fb94e1f251bb5c1fa8da8e4768af29a1256bb51835471", "class_name": "RelatedNodeInfo"}}, "text": "I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about. ", "start_char_idx": 839, "end_char_idx": 948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "740c41d9-355c-41a4-864d-272fc7bf63b1": {"__data__": {"id_": "740c41d9-355c-41a4-864d-272fc7bf63b1", "embedding": null, "metadata": {"window": "Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections? ", "original_text": "Do you see near -term opportunities to take cost out of your system? \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f92f9ab-905e-4fd0-b006-d38cd01b5fdc", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Lisa Gill of JPMorgan.  \n  \n Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer. ", "original_text": "I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03cfbc86be4c0fed6ef4c38b6f27c7af65acb3d393dbf98eef0269fa3b9b7f16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5ea0769-e2c8-43ef-b80b-60b5a55a70b4", "node_type": "1", "metadata": {"window": "Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n", "original_text": "So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n"}, "hash": "ba48fa314213a64e6ed837edd3a64422ada4192f1012f3c8e1f3dabfcf42fdf2", "class_name": "RelatedNodeInfo"}}, "text": "Do you see near -term opportunities to take cost out of your system? \n", "start_char_idx": 948, "end_char_idx": 1018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5ea0769-e2c8-43ef-b80b-60b5a55a70b4": {"__data__": {"id_": "f5ea0769-e2c8-43ef-b80b-60b5a55a70b4", "embedding": null, "metadata": {"window": "Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n", "original_text": "So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "740c41d9-355c-41a4-864d-272fc7bf63b1", "node_type": "1", "metadata": {"window": "Lisa C. Gill:  \nThanks very much.  Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections? ", "original_text": "Do you see near -term opportunities to take cost out of your system? \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8bdaa5a4f009655e041bc19e28f6c47e4188df82a7a9d9263b38c58ecd7bdcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "687ad6df-08db-41f3-92cc-0efa9598a413", "node_type": "1", "metadata": {"window": "I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "And then, secondly, I just want to  understand the health of your customer. "}, "hash": "f65720c8867da1ab92c065b0998899f1bede92d57f0413465473c66c0277c8d0", "class_name": "RelatedNodeInfo"}}, "text": "So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n", "start_char_idx": 1018, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "687ad6df-08db-41f3-92cc-0efa9598a413": {"__data__": {"id_": "687ad6df-08db-41f3-92cc-0efa9598a413", "embedding": null, "metadata": {"window": "I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "And then, secondly, I just want to  understand the health of your customer. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5ea0769-e2c8-43ef-b80b-60b5a55a70b4", "node_type": "1", "metadata": {"window": "Good morning and thanks, Mike, to everyone on the Cardinal team, helping  with \nall this PP&E  on the frontline.  I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n", "original_text": "So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fc79724c77a2152eaa5a1c4ca00fb2ae26dc432eacbf13037a3558e6f41402d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51435e71-27f2-473e-bbf3-92721735198b", "node_type": "1", "metadata": {"window": "Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "Have you had any issues \nwith collections? "}, "hash": "91fb5bc4a9b5a816c48d416535aabf6e0539aafd8fb085094b07e7a8e6a2766c", "class_name": "RelatedNodeInfo"}}, "text": "And then, secondly, I just want to  understand the health of your customer. ", "start_char_idx": 1140, "end_char_idx": 1216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51435e71-27f2-473e-bbf3-92721735198b": {"__data__": {"id_": "51435e71-27f2-473e-bbf3-92721735198b", "embedding": null, "metadata": {"window": "Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "Have you had any issues \nwith collections? ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "687ad6df-08db-41f3-92cc-0efa9598a413", "node_type": "1", "metadata": {"window": "I just really want to understand two things, one, just kind of dovetailing \nto what you were talking  about.  Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "And then, secondly, I just want to  understand the health of your customer. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "026973a1fccd6e52116c60000c1278c1ab4552bb3c05a50a3126a72eb5bc97dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a5617b1-547d-4a64-858b-12272044541a", "node_type": "1", "metadata": {"window": "So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n"}, "hash": "fb625f83b2f97fa6790a0d11d441c0e7de1825ff92ccc0bc95cd49d1a831d6fb", "class_name": "RelatedNodeInfo"}}, "text": "Have you had any issues \nwith collections? ", "start_char_idx": 1216, "end_char_idx": 1259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a5617b1-547d-4a64-858b-12272044541a": {"__data__": {"id_": "6a5617b1-547d-4a64-858b-12272044541a", "embedding": null, "metadata": {"window": "So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51435e71-27f2-473e-bbf3-92721735198b", "node_type": "1", "metadata": {"window": "Do you see near -term opportunities to take cost out of your system? \n So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "Have you had any issues \nwith collections? ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dfe19bf9001f57babd4a6d73bfbd1372d04c7df93063512ed38b0de6da2d80a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d502349c-610d-43b4-a282-c230bc1eb15c", "node_type": "1", "metadata": {"window": "And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "Michael C. Kaufmann:  "}, "hash": "99976c3848cfb1d23bb9701533eb18db655f872ac2f44054c2159d7e0bf18988", "class_name": "RelatedNodeInfo"}}, "text": "You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n", "start_char_idx": 1259, "end_char_idx": 1537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d502349c-610d-43b4-a282-c230bc1eb15c": {"__data__": {"id_": "d502349c-610d-43b4-a282-c230bc1eb15c", "embedding": null, "metadata": {"window": "And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "Michael C. Kaufmann:  ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba2305b32b465da6714abc4b9a10f5a2369a7a03981c58b771ca36cc7d61f77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a5617b1-547d-4a64-858b-12272044541a", "node_type": "1", "metadata": {"window": "So, as you look at the ecosystem, you  look at where your costs are today, do you see any cost -\ncutting opportunities?  \n And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9d1b5879ec3e9fdef3a77bb4c7cda1fe74600c8104e3d17013908cfb86e7f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e68d38e-f314-4140-8a56-152eb2beff20", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.  ", "original_text": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n"}, "hash": "ef6a7bed16dc12050570c5495ef9237f7f7c914deaf11e323cad2ea41d8a0b5b", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  ", "start_char_idx": 1537, "end_char_idx": 1559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e68d38e-f314-4140-8a56-152eb2beff20": {"__data__": {"id_": "1e68d38e-f314-4140-8a56-152eb2beff20", "embedding": null, "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.  ", "original_text": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d502349c-610d-43b4-a282-c230bc1eb15c", "node_type": "1", "metadata": {"window": "And then, secondly, I just want to  understand the health of your customer.  Have you had any issues \nwith collections?  You talked about the fact that  you believe there will be con solidation and you're well -\npositioned because you're with the larger players, but how  about some of the smaller, independent \npharmacies or smaller hospitals, are you seeing anything on the  collection side?  \n  \n Michael C. Kaufmann:  ", "original_text": "Michael C. Kaufmann:  ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32785a40dd9f46c7fa8948eafccf3cc58ee42817b9da010c90fb43537f41c511", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d899d8cd-471a-4361-90a1-0f039a2aad2a", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter. ", "original_text": "David C. Evans:  \nYeah. "}, "hash": "6abb49a489c2d16c6a36ff14bc5586c9245b8a16dbe96a6d9d682ce82d4ee997", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n", "start_char_idx": 0, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d899d8cd-471a-4361-90a1-0f039a2aad2a": {"__data__": {"id_": "d899d8cd-471a-4361-90a1-0f039a2aad2a", "embedding": null, "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter. ", "original_text": "David C. Evans:  \nYeah. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e68d38e-f314-4140-8a56-152eb2beff20", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.  ", "original_text": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f562318fccb550bae7af668c3b98f2190695f9d6fc9e4b4d082e385c0b80220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72197b0c-5868-41e2-9f2f-ce0aa40e1853", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road. ", "original_text": "So, on the balance sheet side, collections. "}, "hash": "cf40f6adb357d36cf3ef448c944d3088c79dba148f990ec89a63c7821fc1ddb8", "class_name": "RelatedNodeInfo"}}, "text": "David C. Evans:  \nYeah. ", "start_char_idx": 187, "end_char_idx": 211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72197b0c-5868-41e2-9f2f-ce0aa40e1853": {"__data__": {"id_": "72197b0c-5868-41e2-9f2f-ce0aa40e1853", "embedding": null, "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road. ", "original_text": "So, on the balance sheet side, collections. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d899d8cd-471a-4361-90a1-0f039a2aad2a", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter. ", "original_text": "David C. Evans:  \nYeah. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f2680c5cb00ca9d1d03554e254bcb1a9f60131682dcdbc733550892b49f28fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae662b44-74d9-416a-9d90-018eb67fa7f1", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some. ", "original_text": "Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.  "}, "hash": "2edd7cf775f4d8e7a393f641899991beedeaf9761937b8ba9c89ed2c57508ba2", "class_name": "RelatedNodeInfo"}}, "text": "So, on the balance sheet side, collections. ", "start_char_idx": 211, "end_char_idx": 255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae662b44-74d9-416a-9d90-018eb67fa7f1": {"__data__": {"id_": "ae662b44-74d9-416a-9d90-018eb67fa7f1", "embedding": null, "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some. ", "original_text": "Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.  ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72197b0c-5868-41e2-9f2f-ce0aa40e1853", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road. ", "original_text": "So, on the balance sheet side, collections. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d68e9344d412eac2cc5d2875f29b6928ab8571f653f0a5071c379cf73f3bd7a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0291470-179d-4062-9a0f-b017ab03ae5d", "node_type": "1", "metadata": {"window": "David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n", "original_text": "And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter. "}, "hash": "2bb018ee6e2adc89731cb6b9f392fc37e6e2e1bae402dd3c0b04a80c1d44b86f", "class_name": "RelatedNodeInfo"}}, "text": "Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.  ", "start_char_idx": 255, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0291470-179d-4062-9a0f-b017ab03ae5d": {"__data__": {"id_": "d0291470-179d-4062-9a0f-b017ab03ae5d", "embedding": null, "metadata": {"window": "David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n", "original_text": "And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae662b44-74d9-416a-9d90-018eb67fa7f1", "node_type": "1", "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some. ", "original_text": "Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.  ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93fc4a138f1c1f74cb32b357eb2b04d116db2c462ec4f162500602bc55e78408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "663e87ef-974b-4239-9f47-115a976c1b44", "node_type": "1", "metadata": {"window": "So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road. "}, "hash": "7b4138ef0553f1b8ea9191ce52ff3c45ef7288625857af915f1c660bb9f092c6", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter. ", "start_char_idx": 326, "end_char_idx": 426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "663e87ef-974b-4239-9f47-115a976c1b44": {"__data__": {"id_": "663e87ef-974b-4239-9f47-115a976c1b44", "embedding": null, "metadata": {"window": "So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0291470-179d-4062-9a0f-b017ab03ae5d", "node_type": "1", "metadata": {"window": "David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n", "original_text": "And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "695676505bcb9820435cd155a55d743fba214c74053d3b9d1ac2f9ab12944598", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5d6e34b-2c05-483e-9066-a6716b9fefd5", "node_type": "1", "metadata": {"window": "Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that. ", "original_text": "We'r e anticipating some. "}, "hash": "a5e69afbc2f0d6488d661fbcfb61543a9ca8d2b08e7f02c00cda35f7b724b012", "class_name": "RelatedNodeInfo"}}, "text": "We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road. ", "start_char_idx": 426, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5d6e34b-2c05-483e-9066-a6716b9fefd5": {"__data__": {"id_": "f5d6e34b-2c05-483e-9066-a6716b9fefd5", "embedding": null, "metadata": {"window": "Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that. ", "original_text": "We'r e anticipating some. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "663e87ef-974b-4239-9f47-115a976c1b44", "node_type": "1", "metadata": {"window": "So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah. ", "original_text": "We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e92a86b2773f22adb15c38160535fa2f32cc29d60bfda66f55b5c3185087b950", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15c404c5-b520-4d88-af01-ecbc7cfa2df7", "node_type": "1", "metadata": {"window": "And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing. ", "original_text": "We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n"}, "hash": "aeb9bd979260282befbf6af74a0b3626f62b3e273c902a41a058437a43aaae10", "class_name": "RelatedNodeInfo"}}, "text": "We'r e anticipating some. ", "start_char_idx": 568, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15c404c5-b520-4d88-af01-ecbc7cfa2df7": {"__data__": {"id_": "15c404c5-b520-4d88-af01-ecbc7cfa2df7", "embedding": null, "metadata": {"window": "And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing. ", "original_text": "We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5d6e34b-2c05-483e-9066-a6716b9fefd5", "node_type": "1", "metadata": {"window": "Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.   And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that. ", "original_text": "We'r e anticipating some. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8337babb94c50cf8675339d5bfb2cd68f380a040769f8721a8d84a18130462a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3292f247-1c4c-4cb0-8892-88f26fee903d", "node_type": "1", "metadata": {"window": "We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things. ", "original_text": "Michael C. Kaufmann:  \nYeah. "}, "hash": "cad4dfea85c41675de7a0133b9791dc9567568352b62a5263400454851e7b111", "class_name": "RelatedNodeInfo"}}, "text": "We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n", "start_char_idx": 594, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3292f247-1c4c-4cb0-8892-88f26fee903d": {"__data__": {"id_": "3292f247-1c4c-4cb0-8892-88f26fee903d", "embedding": null, "metadata": {"window": "We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things. ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15c404c5-b520-4d88-af01-ecbc7cfa2df7", "node_type": "1", "metadata": {"window": "And we continue to see fairly consistent trends in terms of cash flow early in the \nfourth quarter.  We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing. ", "original_text": "We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af51abbc152320c18a9e9db3b596473fd369d7ed15fc11dd9b30ddc8ae75574f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c9bfa81-0a16-419c-8d65-fe9ba1a2a0c4", "node_type": "1", "metadata": {"window": "We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs. ", "original_text": "And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that. "}, "hash": "3783364cf510a22bc2972628a71a52e61ba1d04efd9faf6b5c193afe23774c87", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufmann:  \nYeah. ", "start_char_idx": 667, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c9bfa81-0a16-419c-8d65-fe9ba1a2a0c4": {"__data__": {"id_": "3c9bfa81-0a16-419c-8d65-fe9ba1a2a0c4", "embedding": null, "metadata": {"window": "We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs. ", "original_text": "And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3292f247-1c4c-4cb0-8892-88f26fee903d", "node_type": "1", "metadata": {"window": "We're not  oblivious to the fact, as Mike mentioned, the economic health of our \necosystem will likely have some implications  down the road.  We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things. ", "original_text": "Michael C. Kaufmann:  \nYeah. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67b6652d11336d3b276671836ae0563aaafe8b016e90d9d71d09a8723a8ecf67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "733b17ed-a662-49d3-a711-b41a376e405e", "node_type": "1", "metadata": {"window": "We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n", "original_text": "And  from a cost -cutting standpoint,  though, this is something that we're always doing. "}, "hash": "9c35145cd60af0f4973cb99b3970356849127afed84a9aefc982217812eeb75f", "class_name": "RelatedNodeInfo"}}, "text": "And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that. ", "start_char_idx": 696, "end_char_idx": 801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "733b17ed-a662-49d3-a711-b41a376e405e": {"__data__": {"id_": "733b17ed-a662-49d3-a711-b41a376e405e", "embedding": null, "metadata": {"window": "We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n", "original_text": "And  from a cost -cutting standpoint,  though, this is something that we're always doing. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c9bfa81-0a16-419c-8d65-fe9ba1a2a0c4", "node_type": "1", "metadata": {"window": "We'r e anticipating some.  We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs. ", "original_text": "And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3fe782643d95199a4ee96887f80934b0a0ae270d9f9387ce21a35fe32e72a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d12c7274-3b2a-4422-ba69-1508d9bc5627", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative. ", "original_text": "We're \nalways taking a look at  things. "}, "hash": "153ae21b79f88d9e70c93728b9a13bac95279367728681914776cda87bbc65df", "class_name": "RelatedNodeInfo"}}, "text": "And  from a cost -cutting standpoint,  though, this is something that we're always doing. ", "start_char_idx": 801, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d12c7274-3b2a-4422-ba69-1508d9bc5627": {"__data__": {"id_": "d12c7274-3b2a-4422-ba69-1508d9bc5627", "embedding": null, "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative. ", "original_text": "We're \nalways taking a look at  things. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "733b17ed-a662-49d3-a711-b41a376e405e", "node_type": "1", "metadata": {"window": "We expect \nthose to be fairly modest in the grand scheme of things.  \n  \n Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n", "original_text": "And  from a cost -cutting standpoint,  though, this is something that we're always doing. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e89ef45218d9d996efe68cfb8c8d60cf43e4147e179a07395479a6be0cf42a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9e0799f-53a3-4f10-94a3-9a5567f2116b", "node_type": "1", "metadata": {"window": "And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n", "original_text": "And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs. "}, "hash": "9a191292b838bfaad9ede6a59d816511b7bba2d9a81582dae1315d7401e6dca7", "class_name": "RelatedNodeInfo"}}, "text": "We're \nalways taking a look at  things. ", "start_char_idx": 891, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9e0799f-53a3-4f10-94a3-9a5567f2116b": {"__data__": {"id_": "c9e0799f-53a3-4f10-94a3-9a5567f2116b", "embedding": null, "metadata": {"window": "And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n", "original_text": "And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d12c7274-3b2a-4422-ba69-1508d9bc5627", "node_type": "1", "metadata": {"window": "Michael C. Kaufmann:  \nYeah.  And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative. ", "original_text": "We're \nalways taking a look at  things. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3738d867764e2c8e036e995c8e941c3904a13b479578dab8641c4a5ad6b3264d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f974d92-a8d8-4ad5-9140-bfeb5e88760f", "node_type": "1", "metadata": {"window": "And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost. ", "original_text": "It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n"}, "hash": "0a83cf5edfbf327e668f9bbd94c100be68ae636348a8c28dd0a3ebd224e71c1d", "class_name": "RelatedNodeInfo"}}, "text": "And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs. ", "start_char_idx": 931, "end_char_idx": 1033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f974d92-a8d8-4ad5-9140-bfeb5e88760f": {"__data__": {"id_": "8f974d92-a8d8-4ad5-9140-bfeb5e88760f", "embedding": null, "metadata": {"window": "And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost. ", "original_text": "It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9e0799f-53a3-4f10-94a3-9a5567f2116b", "node_type": "1", "metadata": {"window": "And then, as again, I mentioned that as one of the three key areas so we will continue to look \nat that.  And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n", "original_text": "And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a02fd582f973d721957c45a24df14e5276d850fcc560cf2c94b5085d3c7d01c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac3e170c-9a64-42d0-a09f-17c79d77efd4", "node_type": "1", "metadata": {"window": "We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things. ", "original_text": "So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative. "}, "hash": "111294c9af52c0214fe2fe8ef265135feee5b07e227cfcf23b0dbb1823cdec91", "class_name": "RelatedNodeInfo"}}, "text": "It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n", "start_char_idx": 1033, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac3e170c-9a64-42d0-a09f-17c79d77efd4": {"__data__": {"id_": "ac3e170c-9a64-42d0-a09f-17c79d77efd4", "embedding": null, "metadata": {"window": "We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things. ", "original_text": "So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f974d92-a8d8-4ad5-9140-bfeb5e88760f", "node_type": "1", "metadata": {"window": "And  from a cost -cutting standpoint,  though, this is something that we're always doing.  We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost. ", "original_text": "It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e17278cf27a3f7c1c4f0c7692df5d3361fd7231fcff9a7365d6b2ab3571016a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8637706e-79a1-4cca-8f25-f83d7ffaa520", "node_type": "1", "metadata": {"window": "And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n"}, "hash": "3befeca36de8fa875068c359c7b4c0c3ae029529761d1fc6e8dd50dd1f6ff4d9", "class_name": "RelatedNodeInfo"}}, "text": "So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative. ", "start_char_idx": 1134, "end_char_idx": 1258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8637706e-79a1-4cca-8f25-f83d7ffaa520": {"__data__": {"id_": "8637706e-79a1-4cca-8f25-f83d7ffaa520", "embedding": null, "metadata": {"window": "And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac3e170c-9a64-42d0-a09f-17c79d77efd4", "node_type": "1", "metadata": {"window": "We're \nalways taking a look at  things.  And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things. ", "original_text": "So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "527a50ee56c0257cc7dd6757ba896535ab978f1e760106c0a31dc9589fe65308", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdd323ad-665e-437a-90aa-54ee755dc683", "node_type": "1", "metadata": {"window": "It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost. "}, "hash": "0dad8409c2dd4e0c0bc9f37fcb04ce02acb2d49ee4e67f3f33a3afb0e7d57d78", "class_name": "RelatedNodeInfo"}}, "text": "That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n", "start_char_idx": 1258, "end_char_idx": 1629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdd323ad-665e-437a-90aa-54ee755dc683": {"__data__": {"id_": "cdd323ad-665e-437a-90aa-54ee755dc683", "embedding": null, "metadata": {"window": "It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8637706e-79a1-4cca-8f25-f83d7ffaa520", "node_type": "1", "metadata": {"window": "And I wouldn't call it cost -cutting, maybe in the sense that we're just \ncutting costs to cut costs.  It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff91401e6e3eff535ca5e453343e0471584668a982dcc6aea1955e3d06afed48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b0c86c4-32e0-47b9-939e-d58b3ab03b63", "node_type": "1", "metadata": {"window": "So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things. "}, "hash": "ec515053149f13846f761927151b83fee37b1ff7076666e8aae8a3d17916ce68", "class_name": "RelatedNodeInfo"}}, "text": "So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost. ", "start_char_idx": 1629, "end_char_idx": 1792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b0c86c4-32e0-47b9-939e-d58b3ab03b63": {"__data__": {"id_": "1b0c86c4-32e0-47b9-939e-d58b3ab03b63", "embedding": null, "metadata": {"window": "So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdd323ad-665e-437a-90aa-54ee755dc683", "node_type": "1", "metadata": {"window": "It's really  been about prioritizing what's important and finding b etter ways to \nthink about it.  \n So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e04d211bbf9ebe9cd5481c10fe02bf1300c0bf2805b83059d9a8d646c2b7d766", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d45b00c-a111-4b39-bd22-8b862ad5ef6d", "node_type": "1", "metadata": {"window": "That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "And \nyou'll also find a way I think to be faster than you  normally would.  "}, "hash": "2e049831f572918bc3224c4f01d85125b9867b6db015437976f2042ca7a8f774", "class_name": "RelatedNodeInfo"}}, "text": "I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things. ", "start_char_idx": 1792, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d45b00c-a111-4b39-bd22-8b862ad5ef6d": {"__data__": {"id_": "4d45b00c-a111-4b39-bd22-8b862ad5ef6d", "embedding": null, "metadata": {"window": "That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "And \nyou'll also find a way I think to be faster than you  normally would.  ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8efaf885-126c-4769-986e-760b572504a4", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "167f62a883acbdfeeb58462c036165d754c50723e8c38c88e69c3fbed95b5abd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b0c86c4-32e0-47b9-939e-d58b3ab03b63", "node_type": "1", "metadata": {"window": "So if I think about when we announced what we were doing in finance last quarter, that wasn't a cost -\ncutting  initiative.  That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things. ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8211871b8fe730e940f6d5e6b9e86e3f83ecb8e61a405bbd9ffef2c832b8eb2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04192fb9-d023-4d30-acbf-efca301f27c2", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n", "original_text": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things. "}, "hash": "881f644eda03ad2787419ea79b789d34f580c921f4737cfbc74b20a1f1df7575", "class_name": "RelatedNodeInfo"}}, "text": "And \nyou'll also find a way I think to be faster than you  normally would.  ", "start_char_idx": 2038, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04192fb9-d023-4d30-acbf-efca301f27c2": {"__data__": {"id_": "04192fb9-d023-4d30-acbf-efca301f27c2", "embedding": null, "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n", "original_text": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d45b00c-a111-4b39-bd22-8b862ad5ef6d", "node_type": "1", "metadata": {"window": "That was an initiative that saved a lot of money and reduced our overall cost, but it \nwas really about  being more efficient, taking out \u2013 putting in the right locations, using AI, using robotic \nautomations; all those types  of things to really drive the right types of behaviors to have ongoing \ncapabilities and use our skill sets at the  highest levels o f folks.  \n So those are the types of things we're really looking for; like how do we do things smarter and take \nadvantage of  technology and efficiencies to get after cost.  I will say one thing about the COVID \nsituation, when we all get forced  to work -from-home, you do find ability to prioritize what is really, \nreally important and what is not so important  when you're dealing with all of these types of things.  And \nyou'll also find a way I think to be faster than you  normally would.  ", "original_text": "And \nyou'll also find a way I think to be faster than you  normally would.  ", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ced3aaed057b6d04b3dcd3aca40b6554c5687b32747df00abc70d736691bbfea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf3bcf85-cec9-48cc-b63e-a7b1915d0a99", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks. ", "original_text": "So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n"}, "hash": "a2997820be8a12f74e83c3dad080b25c6ad9cb57cd5a071867c28f42c074fa84", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things. ", "start_char_idx": 0, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf3bcf85-cec9-48cc-b63e-a7b1915d0a99": {"__data__": {"id_": "bf3bcf85-cec9-48cc-b63e-a7b1915d0a99", "embedding": null, "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks. ", "original_text": "So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04192fb9-d023-4d30-acbf-efca301f27c2", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n", "original_text": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f30407dcc52e4d7c98b25e8b8795fe30d7d1e2c2f7050d6efdf8454c438b55b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a66898ff-d70c-4cc9-b2d4-71bb80ef53c7", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n"}, "hash": "522ffc8cce25d75111764470fff71e94c755cbb2802fd9189415c37e85b1d96c", "class_name": "RelatedNodeInfo"}}, "text": "So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n", "start_char_idx": 174, "end_char_idx": 445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a66898ff-d70c-4cc9-b2d4-71bb80ef53c7": {"__data__": {"id_": "a66898ff-d70c-4cc9-b2d4-71bb80ef53c7", "embedding": null, "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf3bcf85-cec9-48cc-b63e-a7b1915d0a99", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks. ", "original_text": "So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1edc8cef5251917f5deaba504b40f2e3151eaa1457a139227dac089ec267b5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bf6461d-e574-4283-b186-d0a096762bba", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually. ", "original_text": "Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n"}, "hash": "643bdb1f3b39f3169f120ca7487dc96ffdf4527119ae5563be1786d7d76ed8e5", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext question, please.  \n  \n", "start_char_idx": 445, "end_char_idx": 488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bf6461d-e574-4283-b186-d0a096762bba": {"__data__": {"id_": "7bf6461d-e574-4283-b186-d0a096762bba", "embedding": null, "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually. ", "original_text": "Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a66898ff-d70c-4cc9-b2d4-71bb80ef53c7", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b5c2c35038029eebf424d8e8d9a965c65f9d7f5a80731902c0476d503cc8df1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4586523-4513-427d-abfa-932cc86ade8e", "node_type": "1", "metadata": {"window": "So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears. ", "original_text": "Steven Valiquett e: \nGreat, thanks. "}, "hash": "2d0cb8262f180122ef187a3b7f3110d54f5dae112ad182ffb33023da327ebe51", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n", "start_char_idx": 488, "end_char_idx": 566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4586523-4513-427d-abfa-932cc86ade8e": {"__data__": {"id_": "f4586523-4513-427d-abfa-932cc86ade8e", "embedding": null, "metadata": {"window": "So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears. ", "original_text": "Steven Valiquett e: \nGreat, thanks. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bf6461d-e574-4283-b186-d0a096762bba", "node_type": "1", "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually. ", "original_text": "Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62826caf1239997b7f3e5ce1078856c644f3529527769ea3b4660d52ac6c3360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5727480-b94f-4a67-a61c-4fa57de1c584", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment? ", "original_text": "Good morning, everyone, hope you're staying safe. "}, "hash": "a87e2a09c2d14dc71a7e38212c1066fa38f6dcd298a21263b4b81de312e34a1a", "class_name": "RelatedNodeInfo"}}, "text": "Steven Valiquett e: \nGreat, thanks. ", "start_char_idx": 566, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5727480-b94f-4a67-a61c-4fa57de1c584": {"__data__": {"id_": "d5727480-b94f-4a67-a61c-4fa57de1c584", "embedding": null, "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment? ", "original_text": "Good morning, everyone, hope you're staying safe. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4586523-4513-427d-abfa-932cc86ade8e", "node_type": "1", "metadata": {"window": "So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears. ", "original_text": "Steven Valiquett e: \nGreat, thanks. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "697d1b8f01cd424096404f09dccf27614cc0b95159b523d5c757babc0ab810ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eed0695c-e6ac-42d7-b656-442cc1d02c89", "node_type": "1", "metadata": {"window": "Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so? ", "original_text": "So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually. "}, "hash": "f88f02a024aacd36d8498cf42b322b25a3a05affa1a5d91933fd09e00ca97e3e", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, everyone, hope you're staying safe. ", "start_char_idx": 602, "end_char_idx": 652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eed0695c-e6ac-42d7-b656-442cc1d02c89": {"__data__": {"id_": "eed0695c-e6ac-42d7-b656-442cc1d02c89", "embedding": null, "metadata": {"window": "Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so? ", "original_text": "So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5727480-b94f-4a67-a61c-4fa57de1c584", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment? ", "original_text": "Good morning, everyone, hope you're staying safe. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ed2d951dfb24b68f79e615ae21ce4b31e427826b73640b08f67ec150cb8c82d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5976ff01-ad7e-431c-a24c-7d88660cbac8", "node_type": "1", "metadata": {"window": "Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n", "original_text": "And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears. "}, "hash": "e71dbf69457994897412a51ca20746c1eb062781f0cb865a68cf79da60c0204c", "class_name": "RelatedNodeInfo"}}, "text": "So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually. ", "start_char_idx": 652, "end_char_idx": 985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5976ff01-ad7e-431c-a24c-7d88660cbac8": {"__data__": {"id_": "5976ff01-ad7e-431c-a24c-7d88660cbac8", "embedding": null, "metadata": {"window": "Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n", "original_text": "And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eed0695c-e6ac-42d7-b656-442cc1d02c89", "node_type": "1", "metadata": {"window": "Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so? ", "original_text": "So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb9ce93e9ef82e7948872ad051972238bf66107163cb9c5ced299dcc5311804", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "708e0bc6-0a0c-4396-9408-baef66f8ecff", "node_type": "1", "metadata": {"window": "Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it. ", "original_text": "Can you remind us about any seasonality in the  profits of the Medical segment? "}, "hash": "f139384ca100acb381c7303a9ad81b9b4c3ee009ff20d1dac579a9adb4a9aac2", "class_name": "RelatedNodeInfo"}}, "text": "And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears. ", "start_char_idx": 985, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "708e0bc6-0a0c-4396-9408-baef66f8ecff": {"__data__": {"id_": "708e0bc6-0a0c-4396-9408-baef66f8ecff", "embedding": null, "metadata": {"window": "Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it. ", "original_text": "Can you remind us about any seasonality in the  profits of the Medical segment? ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5976ff01-ad7e-431c-a24c-7d88660cbac8", "node_type": "1", "metadata": {"window": "Steven Valiquett e: \nGreat, thanks.  Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n", "original_text": "And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "747a5281e84ed811b4370d92a0e9f36fb5ce9a67744353315c678fe4e95eed09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3016efc5-b28e-424d-9369-6b45a1f13b03", "node_type": "1", "metadata": {"window": "So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here. ", "original_text": "Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so? "}, "hash": "1b31a46b5949c91ba088a9cddfe313224fb12eec26c350ab9cbbfd2203198a89", "class_name": "RelatedNodeInfo"}}, "text": "Can you remind us about any seasonality in the  profits of the Medical segment? ", "start_char_idx": 1084, "end_char_idx": 1164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3016efc5-b28e-424d-9369-6b45a1f13b03": {"__data__": {"id_": "3016efc5-b28e-424d-9369-6b45a1f13b03", "embedding": null, "metadata": {"window": "So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here. ", "original_text": "Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so? ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "708e0bc6-0a0c-4396-9408-baef66f8ecff", "node_type": "1", "metadata": {"window": "Good morning, everyone, hope you're staying safe.  So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it. ", "original_text": "Can you remind us about any seasonality in the  profits of the Medical segment? ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c06d7aefe026a5486ee0bea6c5fb5b2a3006d51bd58865539019d39f4bcb3da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eee912d2-4da4-4e33-ac71-092bbac2af28", "node_type": "1", "metadata": {"window": "And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "Thanks.  \n  \n"}, "hash": "06d5fb563374984d785ab6d82477f4bdf2a0384d87a794524bc456d3bc724e6a", "class_name": "RelatedNodeInfo"}}, "text": "Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so? ", "start_char_idx": 1164, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eee912d2-4da4-4e33-ac71-092bbac2af28": {"__data__": {"id_": "eee912d2-4da4-4e33-ac71-092bbac2af28", "embedding": null, "metadata": {"window": "And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "Thanks.  \n  \n", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3016efc5-b28e-424d-9369-6b45a1f13b03", "node_type": "1", "metadata": {"window": "So just regarding the comment in \nyour prepared remarks about the mask and gown demand spiking up, just curious if you can give us a \nsense for just  what percent of your Medical segment profits roughly came from PPE just in the \nreported 3Q, just to give us some  context around that because the profits were announced \neventually.  And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here. ", "original_text": "Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so? ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3246db6bfd888bf9a15a994749c8516db654e20957e75424b8bb97697cfae456", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e1bb2e8-2220-44d3-9415-a8630e34caf8", "node_type": "1", "metadata": {"window": "Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "Michael C. Kaufma nn: \nI'll chat briefly about it. "}, "hash": "2ffafaf1c5b338bdb6dfeceec3320bab5af7b2012e533577712f39b1d1cc1c54", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n  \n", "start_char_idx": 1325, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e1bb2e8-2220-44d3-9415-a8630e34caf8": {"__data__": {"id_": "3e1bb2e8-2220-44d3-9415-a8630e34caf8", "embedding": null, "metadata": {"window": "Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "Michael C. Kaufma nn: \nI'll chat briefly about it. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eee912d2-4da4-4e33-ac71-092bbac2af28", "node_type": "1", "metadata": {"window": "And actually just speaking to that  quickly, following some of your acquisitions in recent \nyears.  Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "Thanks.  \n  \n", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be12d5490e7ecbc0470284a80147ee691c6063cc2fc5be41bdb9b2e0c8aff5d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b328229-1f43-478e-b956-e41827ca1fc1", "node_type": "1", "metadata": {"window": "Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "If I miss anything, Dave, feel free to jump in here. "}, "hash": "d434ba4937f5ddfb17e69761868443adf32e8745b97e6c2316db2c8642e6c5a9", "class_name": "RelatedNodeInfo"}}, "text": "Michael C. Kaufma nn: \nI'll chat briefly about it. ", "start_char_idx": 1338, "end_char_idx": 1389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b328229-1f43-478e-b956-e41827ca1fc1": {"__data__": {"id_": "7b328229-1f43-478e-b956-e41827ca1fc1", "embedding": null, "metadata": {"window": "Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "If I miss anything, Dave, feel free to jump in here. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e1bb2e8-2220-44d3-9415-a8630e34caf8", "node_type": "1", "metadata": {"window": "Can you remind us about any seasonality in the  profits of the Medical segment?  Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "Michael C. Kaufma nn: \nI'll chat briefly about it. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977f8d141726c91f46ae177ca4ea0e5ef6d8cbab846a6f65657db3ecfdade8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a662c49b-d51d-4633-8a8b-f32ce26008e1", "node_type": "1", "metadata": {"window": "Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had "}, "hash": "ab9dae5840b56428c152a30dd5b40896c0383afb53cf5ecf1b3fc0dd9118bd2b", "class_name": "RelatedNodeInfo"}}, "text": "If I miss anything, Dave, feel free to jump in here. ", "start_char_idx": 1389, "end_char_idx": 1442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a662c49b-d51d-4633-8a8b-f32ce26008e1": {"__data__": {"id_": "a662c49b-d51d-4633-8a8b-f32ce26008e1", "embedding": null, "metadata": {"window": "Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e87294fcd00cfcfef76fe3891a5d63f9f39d9b1a8e9a498fb4ae903bfe60ee0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b328229-1f43-478e-b956-e41827ca1fc1", "node_type": "1", "metadata": {"window": "Is there a \nfactor that normally drives profits down sequentially in fiscal 3Q versus  fiscal 2Q because that was \nkind of the trend the last three years or so?  Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "If I miss anything, Dave, feel free to jump in here. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30f77aa6101db90840f234dd947cf82c9706e30911b1c672b0a66db440fdcfb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e4224ec-ed2c-4ae4-8f0c-b84cc38b415d", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.  ", "original_text": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products. "}, "hash": "a4430f229b214ed4c199c4ee5b2674a0396fe37f243932695025f24cdab160a6", "class_name": "RelatedNodeInfo"}}, "text": "We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "start_char_idx": 1442, "end_char_idx": 1684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e4224ec-ed2c-4ae4-8f0c-b84cc38b415d": {"__data__": {"id_": "9e4224ec-ed2c-4ae4-8f0c-b84cc38b415d", "embedding": null, "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.  ", "original_text": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a662c49b-d51d-4633-8a8b-f32ce26008e1", "node_type": "1", "metadata": {"window": "Thanks.  \n  \n Michael C. Kaufma nn: \nI'll chat briefly about it.  If I miss anything, Dave, feel free to jump in here.  We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "original_text": "We don't really break out the \nPPE as a  percentage, plus you get into a lot of definitional issues around exactly what's PPE and not, \nbut what we can tell  you is that it di d \u2013 we did see a little bit of a surge in Q3 on that where we had ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb74bc90f78598d89d4740011715e0b3b05a0681fe3031983aa8e1c3097b6ac0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "394ae4fe-e4a1-4c83-aca6-35e5de9f4712", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems. ", "original_text": "We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental. "}, "hash": "cb7c94f72005625744b710ce267b63d51af6863b19508b85e1a6a8416b92900a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products. ", "start_char_idx": 0, "end_char_idx": 98, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "394ae4fe-e4a1-4c83-aca6-35e5de9f4712": {"__data__": {"id_": "394ae4fe-e4a1-4c83-aca6-35e5de9f4712", "embedding": null, "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems. ", "original_text": "We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e4224ec-ed2c-4ae4-8f0c-b84cc38b415d", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.  ", "original_text": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d45507718a4f6fb63c140ec4d5eacdc36ddbfa3c8d6da5e25b06357dfb306c6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "173ffcc9-b0c5-46bd-82af-5b5ef74b61d5", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n", "original_text": "It's wor th \ntalking about. "}, "hash": "69331eda4e858bd7ac023426d2bba3f0ae22cbf865c4e7c08f3efb94036f248c", "class_name": "RelatedNodeInfo"}}, "text": "We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental. ", "start_char_idx": 98, "end_char_idx": 204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "173ffcc9-b0c5-46bd-82af-5b5ef74b61d5": {"__data__": {"id_": "173ffcc9-b0c5-46bd-82af-5b5ef74b61d5", "embedding": null, "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n", "original_text": "It's wor th \ntalking about. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "394ae4fe-e4a1-4c83-aca6-35e5de9f4712", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems. ", "original_text": "We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f640dac0d469c512c6d1b3306d5cc7595ef5b48b3ea45caae96e22e8f90bc528", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b3711e1-f308-479c-8142-1fa1cba3ce77", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical. ", "original_text": "I wouldn't say it's a lot of our other higher margin.  "}, "hash": "cf6d154da8f49a2903ba74c571d1d38a18e22bd2a22cac2c7cb5d8662dc868fd", "class_name": "RelatedNodeInfo"}}, "text": "It's wor th \ntalking about. ", "start_char_idx": 204, "end_char_idx": 232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b3711e1-f308-479c-8142-1fa1cba3ce77": {"__data__": {"id_": "2b3711e1-f308-479c-8142-1fa1cba3ce77", "embedding": null, "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical. ", "original_text": "I wouldn't say it's a lot of our other higher margin.  ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "173ffcc9-b0c5-46bd-82af-5b5ef74b61d5", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n", "original_text": "It's wor th \ntalking about. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "662a78350255697d113de371ebd0aeafa90c96ec833d5192734888e8963d9eb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a21089-36af-4e95-a0a3-45a8558a8eef", "node_type": "1", "metadata": {"window": "We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization. ", "original_text": "Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems. "}, "hash": "1c05ca00bb22cadc9c658f4369c11da7e84dadef53dc87060ae6842907bd34e4", "class_name": "RelatedNodeInfo"}}, "text": "I wouldn't say it's a lot of our other higher margin.  ", "start_char_idx": 232, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a21089-36af-4e95-a0a3-45a8558a8eef": {"__data__": {"id_": "54a21089-36af-4e95-a0a3-45a8558a8eef", "embedding": null, "metadata": {"window": "We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization. ", "original_text": "Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b3711e1-f308-479c-8142-1fa1cba3ce77", "node_type": "1", "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical. ", "original_text": "I wouldn't say it's a lot of our other higher margin.  ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0cc29bd91b52905f954fae322338436bce7cb7aa237db3666ebab0ae9d29b8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43bf6719-efd2-4a9e-8ae3-e4bdbea73e70", "node_type": "1", "metadata": {"window": "It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.  ", "original_text": "But it was important enough to mention from that standpoint.  \n"}, "hash": "34d434093ef33f96ea6eb3e8370d1055a23d6fed03a53d307b4b5d4de9510ec2", "class_name": "RelatedNodeInfo"}}, "text": "Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems. ", "start_char_idx": 287, "end_char_idx": 435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43bf6719-efd2-4a9e-8ae3-e4bdbea73e70": {"__data__": {"id_": "43bf6719-efd2-4a9e-8ae3-e4bdbea73e70", "embedding": null, "metadata": {"window": "It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.  ", "original_text": "But it was important enough to mention from that standpoint.  \n", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a21089-36af-4e95-a0a3-45a8558a8eef", "node_type": "1", "metadata": {"window": "We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization. ", "original_text": "Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a78e46c295c6afef38d7586e4c4c1ced72e50de31e6638bc1fc5beaf15745963", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c3750b2-b1ef-4bed-a1d9-93faaa84d1c1", "node_type": "1", "metadata": {"window": "I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n", "original_text": "And so I would say that as far as seasonality, flu can be a seasonality item for Medical. "}, "hash": "1bd2c2159f537c53b668dd506fb5943064cfb8bf3db1a5406eebf67fcb7a7a08", "class_name": "RelatedNodeInfo"}}, "text": "But it was important enough to mention from that standpoint.  \n", "start_char_idx": 435, "end_char_idx": 498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c3750b2-b1ef-4bed-a1d9-93faaa84d1c1": {"__data__": {"id_": "1c3750b2-b1ef-4bed-a1d9-93faaa84d1c1", "embedding": null, "metadata": {"window": "I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n", "original_text": "And so I would say that as far as seasonality, flu can be a seasonality item for Medical. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43bf6719-efd2-4a9e-8ae3-e4bdbea73e70", "node_type": "1", "metadata": {"window": "It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.  ", "original_text": "But it was important enough to mention from that standpoint.  \n", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dd81f02ad971cb5c5fc96037631825782c8fc10805f8b83817c300e4ba74f00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc2365cd-e4dc-4f54-a23d-845031a60dca", "node_type": "1", "metadata": {"window": "Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization. "}, "hash": "7f332ea643a6ac89d1af743e7f3cce71f7639982a04bc6bb2d412de6e781c626", "class_name": "RelatedNodeInfo"}}, "text": "And so I would say that as far as seasonality, flu can be a seasonality item for Medical. ", "start_char_idx": 498, "end_char_idx": 588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc2365cd-e4dc-4f54-a23d-845031a60dca": {"__data__": {"id_": "fc2365cd-e4dc-4f54-a23d-845031a60dca", "embedding": null, "metadata": {"window": "Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c3750b2-b1ef-4bed-a1d9-93faaa84d1c1", "node_type": "1", "metadata": {"window": "I wouldn't say it's a lot of our other higher margin.   Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n", "original_text": "And so I would say that as far as seasonality, flu can be a seasonality item for Medical. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb92ca7ac40f99de5518d5441e47c8a47ed285e940866387785a54a86a5dfc36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e476980-1418-4514-9df4-dfa95774a425", "node_type": "1", "metadata": {"window": "But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n", "original_text": "And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.  "}, "hash": "66769288c9e50294d14797387e729bcebf74e95177d5bd5e7777c9d99fb0a5c2", "class_name": "RelatedNodeInfo"}}, "text": "We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization. ", "start_char_idx": 588, "end_char_idx": 776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e476980-1418-4514-9df4-dfa95774a425": {"__data__": {"id_": "7e476980-1418-4514-9df4-dfa95774a425", "embedding": null, "metadata": {"window": "But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n", "original_text": "And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.  ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc2365cd-e4dc-4f54-a23d-845031a60dca", "node_type": "1", "metadata": {"window": "Kitting and surgical businesses are \ngoing to be more important type of product lines to us than the lower margin,  lower value PPE type of \nitems.  But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n", "original_text": "We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f13f646d9bdb1a37a05962309291734c4976aca32bbe594f9031022661cb893", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a87d4aa-c0df-4eb8-bfcb-d58185847f7c", "node_type": "1", "metadata": {"window": "And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question. ", "original_text": "So, hopefully, those are two \npieces of helpful information.  \n  \n"}, "hash": "77f92eeee0680dbc85b5b6756ab53f5c4952feda5996cfe0a4b01eebd72280e0", "class_name": "RelatedNodeInfo"}}, "text": "And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.  ", "start_char_idx": 776, "end_char_idx": 1073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a87d4aa-c0df-4eb8-bfcb-d58185847f7c": {"__data__": {"id_": "2a87d4aa-c0df-4eb8-bfcb-d58185847f7c", "embedding": null, "metadata": {"window": "And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question. ", "original_text": "So, hopefully, those are two \npieces of helpful information.  \n  \n", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e476980-1418-4514-9df4-dfa95774a425", "node_type": "1", "metadata": {"window": "But it was important enough to mention from that standpoint.  \n And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n", "original_text": "And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.  ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08042f9c51e75856417e89b7c160e91d04e27f9ddc9a6b0614deb2abdf09d816", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1732082-d25a-4756-96cd-8d5f47351b14", "node_type": "1", "metadata": {"window": "We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n"}, "hash": "42edc9ee7fcf055ecb8ae577cf7d2b6e8e796d1a8cc2525bb837f7345388ad86", "class_name": "RelatedNodeInfo"}}, "text": "So, hopefully, those are two \npieces of helpful information.  \n  \n", "start_char_idx": 1073, "end_char_idx": 1139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1732082-d25a-4756-96cd-8d5f47351b14": {"__data__": {"id_": "d1732082-d25a-4756-96cd-8d5f47351b14", "embedding": null, "metadata": {"window": "We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a87d4aa-c0df-4eb8-bfcb-d58185847f7c", "node_type": "1", "metadata": {"window": "And so I would say that as far as seasonality, flu can be a seasonality item for Medical.  We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question. ", "original_text": "So, hopefully, those are two \npieces of helpful information.  \n  \n", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8f93814e91aea6a125b4d9203a557b1949dd121673c27d1c499f6dd865c54eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b82d5b76-44c4-4a5f-b4e9-fb7c98553472", "node_type": "1", "metadata": {"window": "And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3? ", "original_text": "Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n"}, "hash": "7ac38c30da1283cf8bd7cb5a0b8e8aa1e1aec38a68fee269b7580b892656da66", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nNext question, please.  \n  \n", "start_char_idx": 1139, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b82d5b76-44c4-4a5f-b4e9-fb7c98553472": {"__data__": {"id_": "b82d5b76-44c4-4a5f-b4e9-fb7c98553472", "embedding": null, "metadata": {"window": "And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3? ", "original_text": "Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1732082-d25a-4756-96cd-8d5f47351b14", "node_type": "1", "metadata": {"window": "We have \nseen in the past  when flu ramps up in a Q, either, Q2 or Q3; we see some increases in our Med \nbusiness and in some of our sales  because there tends to be some hospitalization.  And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well. ", "original_text": "Kevin Moran:  \nNext question, please.  \n  \n", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe31a85add0baa255159b04274b86423da21977d18337d1e533fc270f5d4e486", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b2052ed-444c-4afe-8016-a828aee027fe", "node_type": "1", "metadata": {"window": "So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line. ", "original_text": "Stephen B axter:  \nHey, thanks for the question. "}, "hash": "0913b250a36478ae8c1f322f6fb6ef54d4b0ee91b8a77de976ab224622679ae7", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n", "start_char_idx": 1182, "end_char_idx": 1259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b2052ed-444c-4afe-8016-a828aee027fe": {"__data__": {"id_": "1b2052ed-444c-4afe-8016-a828aee027fe", "embedding": null, "metadata": {"window": "So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line. ", "original_text": "Stephen B axter:  \nHey, thanks for the question. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b82d5b76-44c4-4a5f-b4e9-fb7c98553472", "node_type": "1", "metadata": {"window": "And usually also \nin Q2, Med tends to be a little bit strong er as people kind of rush to get some of their year -end type of \ninsurance procedures done and we tend to see some  increase in electives in those types of \nprocedures in Q2, which leads to a little bit stronger Q2 in general for us.   So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3? ", "original_text": "Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd574f36ab6d7202fd28c20f38f85959a2eb72e8d77455e751799c18a801c430", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea115c27-aa9c-473b-9d3a-a8442571f97c", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected. ", "original_text": "Hope you're all doing well. "}, "hash": "8f9d1556483e21d762d8b843605301f2309b178f995faba88a0450910737e7ec", "class_name": "RelatedNodeInfo"}}, "text": "Stephen B axter:  \nHey, thanks for the question. ", "start_char_idx": 1259, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea115c27-aa9c-473b-9d3a-a8442571f97c": {"__data__": {"id_": "ea115c27-aa9c-473b-9d3a-a8442571f97c", "embedding": null, "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected. ", "original_text": "Hope you're all doing well. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b2052ed-444c-4afe-8016-a828aee027fe", "node_type": "1", "metadata": {"window": "So, hopefully, those are two \npieces of helpful information.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line. ", "original_text": "Stephen B axter:  \nHey, thanks for the question. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3305449bfec4c3915c97f99b7602373c90be0fab92322b6fb92760d359fa853", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e71d759c-58ab-418c-8134-cb79b839f50a", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there? ", "original_text": "I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3? "}, "hash": "d9732e52995535e030a93e06b4224812159a334e6ba23c1144065fec755e4719", "class_name": "RelatedNodeInfo"}}, "text": "Hope you're all doing well. ", "start_char_idx": 1308, "end_char_idx": 1336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e71d759c-58ab-418c-8134-cb79b839f50a": {"__data__": {"id_": "e71d759c-58ab-418c-8134-cb79b839f50a", "embedding": null, "metadata": {"window": "Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there? ", "original_text": "I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3? ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea115c27-aa9c-473b-9d3a-a8442571f97c", "node_type": "1", "metadata": {"window": "Kevin Moran:  \nNext question, please.  \n  \n Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected. ", "original_text": "Hope you're all doing well. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d387749a6fee96c441eb61f981170a318ebc3a5f6fd6f1fc689819669b3432ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d60b52d-3496-4edb-84f6-2d7cca977d72", "node_type": "1", "metadata": {"window": "Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison? ", "original_text": "We had seen three quarters of relative stability on that line. "}, "hash": "26fe8a9ca748f3c35e3667c7353e06db3ee8396d1f0317dd74bf2fa91cacc8e6", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3? ", "start_char_idx": 1336, "end_char_idx": 1415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d60b52d-3496-4edb-84f6-2d7cca977d72": {"__data__": {"id_": "8d60b52d-3496-4edb-84f6-2d7cca977d72", "embedding": null, "metadata": {"window": "Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison? ", "original_text": "We had seen three quarters of relative stability on that line. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e71d759c-58ab-418c-8134-cb79b839f50a", "node_type": "1", "metadata": {"window": "Operator : Next question comes from Stephen Baxter with Wolfe Research.  \n  \n Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there? ", "original_text": "I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3? ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734d8c36c6c44c783dbc78888f744701b3386c9c5f4cfbe6e9ef3bc8284b873f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1313c107-70b5-467d-a969-a962217ae362", "node_type": "1", "metadata": {"window": "Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "And then \nthis quarter, it was down  a little bit mor e than maybe I had expected. "}, "hash": "3175ea435b9ffbbb04d989a0c2cb4c717e78eee16567ef54d284654d95f4b1ea", "class_name": "RelatedNodeInfo"}}, "text": "We had seen three quarters of relative stability on that line. ", "start_char_idx": 1415, "end_char_idx": 1478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1313c107-70b5-467d-a969-a962217ae362": {"__data__": {"id_": "1313c107-70b5-467d-a969-a962217ae362", "embedding": null, "metadata": {"window": "Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "And then \nthis quarter, it was down  a little bit mor e than maybe I had expected. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d60b52d-3496-4edb-84f6-2d7cca977d72", "node_type": "1", "metadata": {"window": "Stephen B axter:  \nHey, thanks for the question.  Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison? ", "original_text": "We had seen three quarters of relative stability on that line. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3ec9c09873c54af1703f8e9e077c7af833e61f6c2cbef7eede58ccdb8be74dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bacf09f8-fb77-4600-aa89-5380928f85d2", "node_type": "1", "metadata": {"window": "I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "I was hoping you could talk \nabout the drivers impacting the  comparison there? "}, "hash": "a330afb88af9b8691e83177d9859fc4ea4e0a68363d659ae56024799237f5ad3", "class_name": "RelatedNodeInfo"}}, "text": "And then \nthis quarter, it was down  a little bit mor e than maybe I had expected. ", "start_char_idx": 1478, "end_char_idx": 1561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bacf09f8-fb77-4600-aa89-5380928f85d2": {"__data__": {"id_": "bacf09f8-fb77-4600-aa89-5380928f85d2", "embedding": null, "metadata": {"window": "I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "I was hoping you could talk \nabout the drivers impacting the  comparison there? ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1313c107-70b5-467d-a969-a962217ae362", "node_type": "1", "metadata": {"window": "Hope you're all doing well.  I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "And then \nthis quarter, it was down  a little bit mor e than maybe I had expected. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a40fda713c89bf4056112d062987a51fe015182e524242765db35bbab892f996", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e844fd4-1850-44c7-b68a-aefff70a78b2", "node_type": "1", "metadata": {"window": "We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison? "}, "hash": "a0c138579c477ad63a5c64c9459d81c1fc4e4887b48e7d0620dcb5bc5f774471", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could talk \nabout the drivers impacting the  comparison there? ", "start_char_idx": 1561, "end_char_idx": 1641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e844fd4-1850-44c7-b68a-aefff70a78b2": {"__data__": {"id_": "6e844fd4-1850-44c7-b68a-aefff70a78b2", "embedding": null, "metadata": {"window": "We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison? ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bacf09f8-fb77-4600-aa89-5380928f85d2", "node_type": "1", "metadata": {"window": "I was hoping you could talk a little bit about \nthe Pharma  margin rate in Q3?  We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "I was hoping you could talk \nabout the drivers impacting the  comparison there? ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c514fdbaa223af01f259f1f84ba327eed24a89418a9dc046040920f8d527a602", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4cc5d36-d608-4425-bbd1-27a21ba8fd1a", "node_type": "1", "metadata": {"window": "And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "Thanks.  \n  "}, "hash": "000801817a5405181323c1943c6232f615eec10043b7c9027c7e2b3121f1c456", "class_name": "RelatedNodeInfo"}}, "text": "And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison? ", "start_char_idx": 1641, "end_char_idx": 1781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4cc5d36-d608-4425-bbd1-27a21ba8fd1a": {"__data__": {"id_": "f4cc5d36-d608-4425-bbd1-27a21ba8fd1a", "embedding": null, "metadata": {"window": "And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "Thanks.  \n  ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b97570e5c91ffa9e84284f15b69cc9b93ec7a3e95d72c05677fe3a0fc6b6a9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e844fd4-1850-44c7-b68a-aefff70a78b2", "node_type": "1", "metadata": {"window": "We had seen three quarters of relative stability on that line.  And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison? ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab7536672003eb31cafb5c8497438dea714e4c17487be1e0a61cbab2e5b7d951", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "010fa9eb-7118-4a3f-82b4-27d590fdceed", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics. ", "original_text": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah. "}, "hash": "1eb48e24c5ee7e6d9ffcaac3c60ed15444eee937f020accbd58da730b38de8e0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n  ", "start_char_idx": 1781, "end_char_idx": 1793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "010fa9eb-7118-4a3f-82b4-27d590fdceed": {"__data__": {"id_": "010fa9eb-7118-4a3f-82b4-27d590fdceed", "embedding": null, "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics. ", "original_text": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4cc5d36-d608-4425-bbd1-27a21ba8fd1a", "node_type": "1", "metadata": {"window": "And then \nthis quarter, it was down  a little bit mor e than maybe I had expected.  I was hoping you could talk \nabout the drivers impacting the  comparison there?  And also you might have touched on this but any \ninsight into how the March pull -forward  volumes may have impacted the margin comparison?  Thanks.  \n  ", "original_text": "Thanks.  \n  ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13f6124ba5abf0409a3dba7bec1d8be7182ab880442c4096d096fc5003f09b49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee9e730d-4746-4d4e-a16f-e4a0c0309ad9", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out. ", "original_text": "That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.  "}, "hash": "f300f8ee5f1d143eaa7aa4c4bb73fcb573a1c94d6fb6500cbb39d26959e13ea4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee9e730d-4746-4d4e-a16f-e4a0c0309ad9": {"__data__": {"id_": "ee9e730d-4746-4d4e-a16f-e4a0c0309ad9", "embedding": null, "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out. ", "original_text": "That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.  ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "010fa9eb-7118-4a3f-82b4-27d590fdceed", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics. ", "original_text": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb55b73245d9cc98c6ceec0d6ccdd9b17b943d18a4b865e2ee08048de85ae289", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7203d72e-921c-47b4-8b2d-82f34e883283", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't. ", "original_text": "I would say this: There's nothing going on that's unusual in there. "}, "hash": "1b796762f0619a311580d488da327eac877a55ca132dfc140cd4977d6034f5c9", "class_name": "RelatedNodeInfo"}}, "text": "That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.  ", "start_char_idx": 48, "end_char_idx": 161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7203d72e-921c-47b4-8b2d-82f34e883283": {"__data__": {"id_": "7203d72e-921c-47b4-8b2d-82f34e883283", "embedding": null, "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't. ", "original_text": "I would say this: There's nothing going on that's unusual in there. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee9e730d-4746-4d4e-a16f-e4a0c0309ad9", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out. ", "original_text": "That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.  ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac9f99d23748c4370db56af73a7aaf389475e546bcd9de2d1cf6ae2c0bf39531", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3230326-7cd8-49e6-9149-8ce9e41a7fb2", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n", "original_text": "You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics. "}, "hash": "dcb848bd2b4bed76fca02fe61e57f040965cbd5a36266bc99fb869635aa8b0ac", "class_name": "RelatedNodeInfo"}}, "text": "I would say this: There's nothing going on that's unusual in there. ", "start_char_idx": 161, "end_char_idx": 229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3230326-7cd8-49e6-9149-8ce9e41a7fb2": {"__data__": {"id_": "f3230326-7cd8-49e6-9149-8ce9e41a7fb2", "embedding": null, "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n", "original_text": "You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7203d72e-921c-47b4-8b2d-82f34e883283", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't. ", "original_text": "I would say this: There's nothing going on that's unusual in there. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a43080a453e498a67b45942a1cc20141af4faca9cd644fc1de55087a3b08cfec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03c6c29b-67b2-4337-bef0-971fe2927a63", "node_type": "1", "metadata": {"window": "That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n", "original_text": "I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out. "}, "hash": "c8ab86de445c3bcfc81c74dae535854578a1538f07aed7639f5e3158b64586aa", "class_name": "RelatedNodeInfo"}}, "text": "You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics. ", "start_char_idx": 229, "end_char_idx": 405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03c6c29b-67b2-4337-bef0-971fe2927a63": {"__data__": {"id_": "03c6c29b-67b2-4337-bef0-971fe2927a63", "embedding": null, "metadata": {"window": "That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n", "original_text": "I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3230326-7cd8-49e6-9149-8ce9e41a7fb2", "node_type": "1", "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n", "original_text": "You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9944dd2af40c1a80b749f54807e4ab1f2e7ebcd1f2b01f963f7e2e53a7a534b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66a1c82f-fee8-4131-a34f-70871c26a516", "node_type": "1", "metadata": {"window": "I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n", "original_text": "I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't. "}, "hash": "064026f09eb17b0c90e57817884fcf13b63cb1ee72bdd9234e879cfe5be88a89", "class_name": "RelatedNodeInfo"}}, "text": "I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out. ", "start_char_idx": 405, "end_char_idx": 567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66a1c82f-fee8-4131-a34f-70871c26a516": {"__data__": {"id_": "66a1c82f-fee8-4131-a34f-70871c26a516", "embedding": null, "metadata": {"window": "I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n", "original_text": "I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03c6c29b-67b2-4337-bef0-971fe2927a63", "node_type": "1", "metadata": {"window": "That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n", "original_text": "I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdf9a5998279ade6c684fe0563d34ed7f356982f3a1fef23898accb3413a51c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fbea452-7b67-4d2b-a228-ad41616f04ec", "node_type": "1", "metadata": {"window": "You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much. ", "original_text": "So I wouldn't \ncall out anything unusual there.  \n  \n"}, "hash": "e55b4abd474c7ba049479bd4ee0ce83d47d352fa85fc9bf6f9abc7cbaa9cdf1c", "class_name": "RelatedNodeInfo"}}, "text": "I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't. ", "start_char_idx": 567, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fbea452-7b67-4d2b-a228-ad41616f04ec": {"__data__": {"id_": "0fbea452-7b67-4d2b-a228-ad41616f04ec", "embedding": null, "metadata": {"window": "You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much. ", "original_text": "So I wouldn't \ncall out anything unusual there.  \n  \n", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66a1c82f-fee8-4131-a34f-70871c26a516", "node_type": "1", "metadata": {"window": "I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n", "original_text": "I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fe9fe4c48898c6cfe29565562972fd2273d5e169e36970ae1435f4e7ab9bcb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d2f34f2-08a6-411c-9d11-fe5680083ce9", "node_type": "1", "metadata": {"window": "I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine. ", "original_text": "Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n"}, "hash": "0b131069d3b3bd37f6ae0a247f83011e66a79827ccdfda5cbf27e94d5442a367", "class_name": "RelatedNodeInfo"}}, "text": "So I wouldn't \ncall out anything unusual there.  \n  \n", "start_char_idx": 746, "end_char_idx": 799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d2f34f2-08a6-411c-9d11-fe5680083ce9": {"__data__": {"id_": "6d2f34f2-08a6-411c-9d11-fe5680083ce9", "embedding": null, "metadata": {"window": "I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine. ", "original_text": "Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fbea452-7b67-4d2b-a228-ad41616f04ec", "node_type": "1", "metadata": {"window": "You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics.  I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much. ", "original_text": "So I wouldn't \ncall out anything unusual there.  \n  \n", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08cb85ad6b67f02d4d6b82616e58b9255c392a7d96fd6bf915592ef7cda69da0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc6ce35a-9813-4b8d-98ab-89cefd110c6b", "node_type": "1", "metadata": {"window": "I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical. ", "original_text": "Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n"}, "hash": "0115049294b6fb27bb639b970a51ff549e81705eacca9357684ade9928574f93", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n", "start_char_idx": 799, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc6ce35a-9813-4b8d-98ab-89cefd110c6b": {"__data__": {"id_": "bc6ce35a-9813-4b8d-98ab-89cefd110c6b", "embedding": null, "metadata": {"window": "I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical. ", "original_text": "Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d2f34f2-08a6-411c-9d11-fe5680083ce9", "node_type": "1", "metadata": {"window": "I wouldn't call out \u2013 there's nothing as we dug \nthrough the margin change  that I would tell you tell you is some type of unique change th at I would \ncall out.  I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine. ", "original_text": "Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98c1d5360c6b1ac69b6501a841309129b4c3031377a2d3d4d6160a5f80a8354c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6237c741-5cab-440c-bc1d-3f5148c33ff7", "node_type": "1", "metadata": {"window": "So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases. ", "original_text": "Eric White Coldwell : \nThanks very much. "}, "hash": "3a519e63884d28e3063e47b002cc21e9f7867a6616048ea411f05667d7930589", "class_name": "RelatedNodeInfo"}}, "text": "Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n", "start_char_idx": 881, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6237c741-5cab-440c-bc1d-3f5148c33ff7": {"__data__": {"id_": "6237c741-5cab-440c-bc1d-3f5148c33ff7", "embedding": null, "metadata": {"window": "So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases. ", "original_text": "Eric White Coldwell : \nThanks very much. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc6ce35a-9813-4b8d-98ab-89cefd110c6b", "node_type": "1", "metadata": {"window": "I think it's just a lot of noise in the  quarter because of the pull -forward and some of the \ndynamics of what items had extra demand on them and other  items that maybe didn't.  So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical. ", "original_text": "Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cf0fb7a525f1fb4892494b278cf2ae967282475212fcd57ebcc02d577e99e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02386e1c-7b9c-4921-a712-5ee247c7645b", "node_type": "1", "metadata": {"window": "Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward? ", "original_text": "Ricky's question and I think you started to hit on mine. "}, "hash": "6766e445e51320dee06cdc476d82d6d8c1e6c8b786e838b72652f258511abff1", "class_name": "RelatedNodeInfo"}}, "text": "Eric White Coldwell : \nThanks very much. ", "start_char_idx": 952, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02386e1c-7b9c-4921-a712-5ee247c7645b": {"__data__": {"id_": "02386e1c-7b9c-4921-a712-5ee247c7645b", "embedding": null, "metadata": {"window": "Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward? ", "original_text": "Ricky's question and I think you started to hit on mine. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6237c741-5cab-440c-bc1d-3f5148c33ff7", "node_type": "1", "metadata": {"window": "So I wouldn't \ncall out anything unusual there.  \n  \n Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases. ", "original_text": "Eric White Coldwell : \nThanks very much. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2c064e5c9f19f1755fcb5ac6d0c90b04aaffc395c37827ad6ac94f24b0f8403", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f35fe5d6-a392-4ebf-a3d6-fdda26b10513", "node_type": "1", "metadata": {"window": "Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera. ", "original_text": "It's about Medical. "}, "hash": "980c2e4a0c6a9c3f2234ad495fdd9b332efe6415b599b6d732fb9d9d67301298", "class_name": "RelatedNodeInfo"}}, "text": "Ricky's question and I think you started to hit on mine. ", "start_char_idx": 993, "end_char_idx": 1050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f35fe5d6-a392-4ebf-a3d6-fdda26b10513": {"__data__": {"id_": "f35fe5d6-a392-4ebf-a3d6-fdda26b10513", "embedding": null, "metadata": {"window": "Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera. ", "original_text": "It's about Medical. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02386e1c-7b9c-4921-a712-5ee247c7645b", "node_type": "1", "metadata": {"window": "Kevin Moran : \nOperator, I think we have time for one last question, please.  \n  \n Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward? ", "original_text": "Ricky's question and I think you started to hit on mine. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3bf87c2a5c9ff0cb170a9f68fda31bf53ae8035719beda549db34c53dbfd804", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91fcbb18-6a00-42c0-b620-0a6a344f4a7f", "node_type": "1", "metadata": {"window": "Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward. ", "original_text": "We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases. "}, "hash": "54ebd371b6f17562dc16793ce481b8001c8059a406b634dc000abeba0f237264", "class_name": "RelatedNodeInfo"}}, "text": "It's about Medical. ", "start_char_idx": 1050, "end_char_idx": 1070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91fcbb18-6a00-42c0-b620-0a6a344f4a7f": {"__data__": {"id_": "91fcbb18-6a00-42c0-b620-0a6a344f4a7f", "embedding": null, "metadata": {"window": "Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward. ", "original_text": "We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f35fe5d6-a392-4ebf-a3d6-fdda26b10513", "node_type": "1", "metadata": {"window": "Operator : Our last question comes from Eric Coldwell with Baird.  \n  \n Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera. ", "original_text": "It's about Medical. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cc42722b852086b213aad131dce6a41dfdd26a77b6718a4d81f4ef8e636ee04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ca9bdee-0ad5-468e-8543-a27bd2cc95fe", "node_type": "1", "metadata": {"window": "Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward? ", "original_text": "I'm just curious what is the potential to \nrevisit contracts and pricing moving forward? "}, "hash": "fbfba9106145ff7035330cc6ed1144ebdef46e96747198e06e62994f4258b4b0", "class_name": "RelatedNodeInfo"}}, "text": "We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases. ", "start_char_idx": 1070, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ca9bdee-0ad5-468e-8543-a27bd2cc95fe": {"__data__": {"id_": "6ca9bdee-0ad5-468e-8543-a27bd2cc95fe", "embedding": null, "metadata": {"window": "Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward? ", "original_text": "I'm just curious what is the potential to \nrevisit contracts and pricing moving forward? ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91fcbb18-6a00-42c0-b620-0a6a344f4a7f", "node_type": "1", "metadata": {"window": "Eric White Coldwell : \nThanks very much.  Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward. ", "original_text": "We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c8c089b68f583d871b28896bf8ffa6a9d46545009d684695375df8350e3433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ae60b8f-804b-4432-87d9-d3fdebaaa5e0", "node_type": "1", "metadata": {"window": "It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera. "}, "hash": "8a2b6e96c52b306ba97551ca22a59044025851c7cde7ad7aebc57a6174eda893", "class_name": "RelatedNodeInfo"}}, "text": "I'm just curious what is the potential to \nrevisit contracts and pricing moving forward? ", "start_char_idx": 1328, "end_char_idx": 1417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ae60b8f-804b-4432-87d9-d3fdebaaa5e0": {"__data__": {"id_": "7ae60b8f-804b-4432-87d9-d3fdebaaa5e0", "embedding": null, "metadata": {"window": "It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ca9bdee-0ad5-468e-8543-a27bd2cc95fe", "node_type": "1", "metadata": {"window": "Ricky's question and I think you started to hit on mine.  It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward? ", "original_text": "I'm just curious what is the potential to \nrevisit contracts and pricing moving forward? ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04929e9bfa9114039dda3c4a12e38d6210f8fc63669b60e473aca47612b0b8c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65ce5407-d5ba-4978-8ade-7bf9d3cab911", "node_type": "1", "metadata": {"window": "We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward. "}, "hash": "dc02289d720d5d216270ec517f648fa355410693391e0f5cfd344e603244932d", "class_name": "RelatedNodeInfo"}}, "text": "I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera. ", "start_char_idx": 1417, "end_char_idx": 1537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65ce5407-d5ba-4978-8ade-7bf9d3cab911": {"__data__": {"id_": "65ce5407-d5ba-4978-8ade-7bf9d3cab911", "embedding": null, "metadata": {"window": "We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ae60b8f-804b-4432-87d9-d3fdebaaa5e0", "node_type": "1", "metadata": {"window": "It's about Medical.  We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc2d5e379a8db64c23f7e878dd0c73e690c7e426bb7f334cce5a49991f543c42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "663bf507-9390-48bd-ab47-e3cf43643005", "node_type": "1", "metadata": {"window": "I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward? "}, "hash": "616395aa6b238856cbbb7c413b1ddc69c08b9285c9864e9e22b6b662169e4bf9", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward. ", "start_char_idx": 1537, "end_char_idx": 1622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "663bf507-9390-48bd-ab47-e3cf43643005": {"__data__": {"id_": "663bf507-9390-48bd-ab47-e3cf43643005", "embedding": null, "metadata": {"window": "I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward? ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65ce5407-d5ba-4978-8ade-7bf9d3cab911", "node_type": "1", "metadata": {"window": "We've \nbeen  hearing that mature suppliers like Cardinal, with their existing customers have generally \ncommitted to GPO and  customer contractual prices, whereas off -contract spot prices have spiked \nanywhere from as much as 15% \u2013 5% to 15% in some cases.  I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b97cd2e522768b5ad865195930dc1c352b39e45cc880d71dfc70cd54ecfe9e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3586da76-53a8-4278-8e5d-b17ec42e994f", "node_type": "1", "metadata": {"window": "I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "Thanks very much.  \n  "}, "hash": "70e46f91a0f250b20d2815922764b72afb7d79c1ddde467904c5d46beda904b6", "class_name": "RelatedNodeInfo"}}, "text": "So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward? ", "start_char_idx": 1622, "end_char_idx": 1745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3586da76-53a8-4278-8e5d-b17ec42e994f": {"__data__": {"id_": "3586da76-53a8-4278-8e5d-b17ec42e994f", "embedding": null, "metadata": {"window": "I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "Thanks very much.  \n  ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55cb6674bdda4ee00bd1d76595d24dc84bf9abaff89ace0de7ef46181e6f9deb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "663bf507-9390-48bd-ab47-e3cf43643005", "node_type": "1", "metadata": {"window": "I'm just curious what is the potential to \nrevisit contracts and pricing moving forward?  I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward? ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25ec020f5c9283b28822ef06e9e74b4dd7caabc70714d0ed838d4a8715ad41a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "986a80c6-5db8-44b9-9145-47404a9df481", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.  ", "original_text": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah. "}, "hash": "da63972961ec8d536103156bf88219de5982934dbdd4d07802a3cf391beb5de3", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much.  \n  ", "start_char_idx": 1745, "end_char_idx": 1767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "986a80c6-5db8-44b9-9145-47404a9df481": {"__data__": {"id_": "986a80c6-5db8-44b9-9145-47404a9df481", "embedding": null, "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.  ", "original_text": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3586da76-53a8-4278-8e5d-b17ec42e994f", "node_type": "1", "metadata": {"window": "I  mean I think we're going to have a sustained demand \nspike in certain Medical items, the PPE, the swabs, et  cetera.  Clearly, a lot of supply chain integrity, \nservice and a ccess demand going forward.  So I'm just curious, any  thoughts on ability to maybe \nrevisit pricing and margin in certain Medical items going forward?  Thanks very much.  \n  ", "original_text": "Thanks very much.  \n  ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c16a000df8381607002ceec4acdde12eeacfd8343b383d173a38b4047d9e3abe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5d7eb8c-b5ce-4f3c-a811-7b71a6e8f28b", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time. ", "original_text": "Thanks for the question. "}, "hash": "48e3f9ae4dffb7e8980b34defedd1ddee0f71c09aacc2d2be64d774ad8c81d86", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5d7eb8c-b5ce-4f3c-a811-7b71a6e8f28b": {"__data__": {"id_": "e5d7eb8c-b5ce-4f3c-a811-7b71a6e8f28b", "embedding": null, "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time. ", "original_text": "Thanks for the question. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "986a80c6-5db8-44b9-9145-47404a9df481", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.  ", "original_text": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b38ea32db13368a189931a07b9cac932f839d33e5926275d45478033ace1f271", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70147e78-86ca-4295-973b-98c20ae89dd5", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm. ", "original_text": "A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country. "}, "hash": "a5d33f9333be4c8c31ddcac7f66541c83613db69857f3269d271eb7b39f70a33", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 48, "end_char_idx": 73, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70147e78-86ca-4295-973b-98c20ae89dd5": {"__data__": {"id_": "70147e78-86ca-4295-973b-98c20ae89dd5", "embedding": null, "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm. ", "original_text": "A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5d7eb8c-b5ce-4f3c-a811-7b71a6e8f28b", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time. ", "original_text": "Thanks for the question. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51a761dab0c66cee1f7748e4bb6e57853aed50235b30253af20ff62a990a5642", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45cd1e2e-63f1-4346-b4bc-adb2fc4538cf", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will. ", "original_text": "So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.  "}, "hash": "c972248a5cad903c1d3bf9a0725e3c0d243e19ceca3ba6b856dc85268027101b", "class_name": "RelatedNodeInfo"}}, "text": "A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country. ", "start_char_idx": 73, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45cd1e2e-63f1-4346-b4bc-adb2fc4538cf": {"__data__": {"id_": "45cd1e2e-63f1-4346-b4bc-adb2fc4538cf", "embedding": null, "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will. ", "original_text": "So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.  ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70147e78-86ca-4295-973b-98c20ae89dd5", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm. ", "original_text": "A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d9de2e9705c7f7216b81330b66ff47fa31ac69652a260f442cb347aac50519e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7bb6762-d654-4eb5-be8a-b8b199b60614", "node_type": "1", "metadata": {"window": "Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal. ", "original_text": "So that being said, there  are a lot of \ndisruptions at this point in time. "}, "hash": "69ed80f50e079a1a7f4f9b85887cee9d186eac6b3ecaed49f6e8616492c4bd7b", "class_name": "RelatedNodeInfo"}}, "text": "So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.  ", "start_char_idx": 306, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7bb6762-d654-4eb5-be8a-b8b199b60614": {"__data__": {"id_": "f7bb6762-d654-4eb5-be8a-b8b199b60614", "embedding": null, "metadata": {"window": "Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal. ", "original_text": "So that being said, there  are a lot of \ndisruptions at this point in time. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45cd1e2e-63f1-4346-b4bc-adb2fc4538cf", "node_type": "1", "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will. ", "original_text": "So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.  ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6504e60ae1828488fd4af7a0a7463af99489ab5a125d8a4ceeff3cfeb8eccf5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98863776-feb1-4d26-bbdf-ce833af2853b", "node_type": "1", "metadata": {"window": "A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers. ", "original_text": "And so it's really hard to comment on what  we see of the overall long -\nterm. "}, "hash": "fc6a03fe4b638ed15084163ddd2183457a69325577f2696f212e8d863db1dd56", "class_name": "RelatedNodeInfo"}}, "text": "So that being said, there  are a lot of \ndisruptions at this point in time. ", "start_char_idx": 607, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98863776-feb1-4d26-bbdf-ce833af2853b": {"__data__": {"id_": "98863776-feb1-4d26-bbdf-ce833af2853b", "embedding": null, "metadata": {"window": "A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers. ", "original_text": "And so it's really hard to comment on what  we see of the overall long -\nterm. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7bb6762-d654-4eb5-be8a-b8b199b60614", "node_type": "1", "metadata": {"window": "Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal. ", "original_text": "So that being said, there  are a lot of \ndisruptions at this point in time. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44304f071cb42d3cd4ce43594e188cde8806b5770431a6185f9ba5dc96d4a45c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07ae171c-75e6-4eaa-972f-413d3a0122a2", "node_type": "1", "metadata": {"window": "So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n", "original_text": "We continue to want to work with our customers and will. "}, "hash": "e698b4390a9abee6eb3fc1871504351cd4d4b34388ad6e1a86959a475f939b2d", "class_name": "RelatedNodeInfo"}}, "text": "And so it's really hard to comment on what  we see of the overall long -\nterm. ", "start_char_idx": 683, "end_char_idx": 762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07ae171c-75e6-4eaa-972f-413d3a0122a2": {"__data__": {"id_": "07ae171c-75e6-4eaa-972f-413d3a0122a2", "embedding": null, "metadata": {"window": "So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n", "original_text": "We continue to want to work with our customers and will. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98863776-feb1-4d26-bbdf-ce833af2853b", "node_type": "1", "metadata": {"window": "A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers. ", "original_text": "And so it's really hard to comment on what  we see of the overall long -\nterm. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9ef5775822c9e466333cdf341d5a5dd8e9f71cdae6f92c146cc944fbe7f8dbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d826be8-ebdb-4250-82c3-ff42c866f89b", "node_type": "1", "metadata": {"window": "So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd. ", "original_text": "They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal. "}, "hash": "aeb078038600f586a0085dac77550dd93ad7b22c93fc81fe99c8d11b886520a1", "class_name": "RelatedNodeInfo"}}, "text": "We continue to want to work with our customers and will. ", "start_char_idx": 762, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d826be8-ebdb-4250-82c3-ff42c866f89b": {"__data__": {"id_": "3d826be8-ebdb-4250-82c3-ff42c866f89b", "embedding": null, "metadata": {"window": "So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd. ", "original_text": "They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07ae171c-75e6-4eaa-972f-413d3a0122a2", "node_type": "1", "metadata": {"window": "So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.   So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n", "original_text": "We continue to want to work with our customers and will. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f13eb1409eaf3490f8b35f8c2341a650a4c696945d75601207e61fca6d15b17f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d962ba6-231a-4516-b4fc-7c4f2f65c32d", "node_type": "1", "metadata": {"window": "And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost. ", "original_text": "That's the way we like to  \nwork with our customers. "}, "hash": "6c9b1fa43d72211904784fb48d40333849b939c9c40256949d084c9857471807", "class_name": "RelatedNodeInfo"}}, "text": "They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal. ", "start_char_idx": 819, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d962ba6-231a-4516-b4fc-7c4f2f65c32d": {"__data__": {"id_": "0d962ba6-231a-4516-b4fc-7c4f2f65c32d", "embedding": null, "metadata": {"window": "And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost. ", "original_text": "That's the way we like to  \nwork with our customers. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d826be8-ebdb-4250-82c3-ff42c866f89b", "node_type": "1", "metadata": {"window": "So that being said, there  are a lot of \ndisruptions at this point in time.  And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd. ", "original_text": "They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27324b05f3043345d6cb6c3ec827dadbd4ea566ab263a173400df1e475fd46be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29ac19c6-72fc-4ddc-966a-d41c10233da8", "node_type": "1", "metadata": {"window": "We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them. ", "original_text": "We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n"}, "hash": "3c3c7a5d0bca3227e4b3f3f4e0b6ecef93f797bb8f71a1ad1c08b22775ab240b", "class_name": "RelatedNodeInfo"}}, "text": "That's the way we like to  \nwork with our customers. ", "start_char_idx": 931, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29ac19c6-72fc-4ddc-966a-d41c10233da8": {"__data__": {"id_": "29ac19c6-72fc-4ddc-966a-d41c10233da8", "embedding": null, "metadata": {"window": "We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them. ", "original_text": "We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d962ba6-231a-4516-b4fc-7c4f2f65c32d", "node_type": "1", "metadata": {"window": "And so it's really hard to comment on what  we see of the overall long -\nterm.  We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost. ", "original_text": "That's the way we like to  \nwork with our customers. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fd6a0673fe1cbbaa174d1b01ed02f0a5e73cc4b4c6cc9a7d646da8ae902ebbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a990f897-5d19-4dbd-a4d1-c98f54edf15f", "node_type": "1", "metadata": {"window": "They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure. ", "original_text": "So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd. "}, "hash": "41766d6fdc32b47cae5945df7997b704dd3fc3c4806cc09817f5b1bc1f09dfe3", "class_name": "RelatedNodeInfo"}}, "text": "We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n", "start_char_idx": 984, "end_char_idx": 1297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a990f897-5d19-4dbd-a4d1-c98f54edf15f": {"__data__": {"id_": "a990f897-5d19-4dbd-a4d1-c98f54edf15f", "embedding": null, "metadata": {"window": "They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure. ", "original_text": "So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29ac19c6-72fc-4ddc-966a-d41c10233da8", "node_type": "1", "metadata": {"window": "We continue to want to work with our customers and will.  They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them. ", "original_text": "We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1659d975390200ef59e0af5a66ec5b9af6dadc6fcb37d1fcf280ab33743280a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2319a48-9425-45fb-a879-a632a58625ad", "node_type": "1", "metadata": {"window": "That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things. ", "original_text": "And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost. "}, "hash": "3f7acbfeaa06f2f56aec79e3524603489f24509e00bdf834a91b1583a386bdb1", "class_name": "RelatedNodeInfo"}}, "text": "So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd. ", "start_char_idx": 1297, "end_char_idx": 1425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2319a48-9425-45fb-a879-a632a58625ad": {"__data__": {"id_": "b2319a48-9425-45fb-a879-a632a58625ad", "embedding": null, "metadata": {"window": "That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things. ", "original_text": "And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a990f897-5d19-4dbd-a4d1-c98f54edf15f", "node_type": "1", "metadata": {"window": "They have been great,  and we're \ngoing to continue to have very transparent  conversations for us at Cardinal.  That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure. ", "original_text": "So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43aa6b780ba789d4f974f1854200bd69709780208291c71852c59c057e57c7fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf20797f-66cd-405c-8b2d-aa4b662a165e", "node_type": "1", "metadata": {"window": "We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n", "original_text": "We're going to continue to work with them. "}, "hash": "8399d67a84097fce371d9527c4a9bb206411e3848a2b8afbc1a6626df27cbe1e", "class_name": "RelatedNodeInfo"}}, "text": "And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost. ", "start_char_idx": 1425, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf20797f-66cd-405c-8b2d-aa4b662a165e": {"__data__": {"id_": "bf20797f-66cd-405c-8b2d-aa4b662a165e", "embedding": null, "metadata": {"window": "We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n", "original_text": "We're going to continue to work with them. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2319a48-9425-45fb-a879-a632a58625ad", "node_type": "1", "metadata": {"window": "That's the way we like to  \nwork with our customers.  We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things. ", "original_text": "And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7b143ab7407dd8013299fc3cff60d18ca2041a19aad85c8324600214d6532ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7fccdcb-963e-403b-ad6b-d3946f03d00c", "node_type": "1", "metadata": {"window": "So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n", "original_text": "On our own \nproducts that we manufacture ourselves, we  can control the cost structure. "}, "hash": "282bcff37f88dde55fe1de24eca5182f0afd40cc48f4af4c020d1b5fb5fba20a", "class_name": "RelatedNodeInfo"}}, "text": "We're going to continue to work with them. ", "start_char_idx": 1541, "end_char_idx": 1584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7fccdcb-963e-403b-ad6b-d3946f03d00c": {"__data__": {"id_": "b7fccdcb-963e-403b-ad6b-d3946f03d00c", "embedding": null, "metadata": {"window": "So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n", "original_text": "On our own \nproducts that we manufacture ourselves, we  can control the cost structure. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf20797f-66cd-405c-8b2d-aa4b662a165e", "node_type": "1", "metadata": {"window": "We're not afraid to tell them bad news or give them information or whatever \nto help them  understand how things are going because we think having open and transparent \nconv ersations around the supply  constraints and those types of things is important and they've been \nappreciative and working with us well.  \n So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n", "original_text": "We're going to continue to work with them. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a23c63714f5e17926e9f303f3ea8c3365b0bd5d5f0ca8a421a0b00f6a59da0ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56a89531-3e5b-446b-a788-55a51ab6dd2b", "node_type": "1", "metadata": {"window": "And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session. ", "original_text": "Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things. "}, "hash": "d169ec1e64d813573237550114d451f485ebc20cda790eebc5fdc6098b0a54b6", "class_name": "RelatedNodeInfo"}}, "text": "On our own \nproducts that we manufacture ourselves, we  can control the cost structure. ", "start_char_idx": 1584, "end_char_idx": 1672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56a89531-3e5b-446b-a788-55a51ab6dd2b": {"__data__": {"id_": "56a89531-3e5b-446b-a788-55a51ab6dd2b", "embedding": null, "metadata": {"window": "And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session. ", "original_text": "Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7fccdcb-963e-403b-ad6b-d3946f03d00c", "node_type": "1", "metadata": {"window": "So we're going to continue to have those and where we're seeing challenges in certain PPE items \nthat have super  high dema nd.  And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n", "original_text": "On our own \nproducts that we manufacture ourselves, we  can control the cost structure. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c8c9ed27c099dad832e005544a5240a1d38fd4c18ef9d8e23d0c3f9eea1ae34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "820fae66-3fb5-45b6-b062-d93bffca2558", "node_type": "1", "metadata": {"window": "We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n"}, "hash": "56cb2ec9ae7ef81c645ef51a74078ace3d7f472676e1c266380c6b0ecbe196d4", "class_name": "RelatedNodeInfo"}}, "text": "Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things. ", "start_char_idx": 1672, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "820fae66-3fb5-45b6-b062-d93bffca2558": {"__data__": {"id_": "820fae66-3fb5-45b6-b062-d93bffca2558", "embedding": null, "metadata": {"window": "We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56a89531-3e5b-446b-a788-55a51ab6dd2b", "node_type": "1", "metadata": {"window": "And the only way you can get extra supply is to bring in alternative \nsuppliers and those might be at  higher cost.  We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session. ", "original_text": "Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c764ad9f6d2e7d492581bee35b1090c8206584ed229ac9ceec165892173e5ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d43f5c9c-4237-4f56-a98b-c41ac0139eda", "node_type": "1", "metadata": {"window": "On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "Kevin Moran:  \nOperator?  \n  \n"}, "hash": "2cca5c84616264c6c72764b6b93e188fb118532954f7b7f149f22e740da3f46e", "class_name": "RelatedNodeInfo"}}, "text": "But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n", "start_char_idx": 1796, "end_char_idx": 1982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d43f5c9c-4237-4f56-a98b-c41ac0139eda": {"__data__": {"id_": "d43f5c9c-4237-4f56-a98b-c41ac0139eda", "embedding": null, "metadata": {"window": "On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "Kevin Moran:  \nOperator?  \n  \n", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "820fae66-3fb5-45b6-b062-d93bffca2558", "node_type": "1", "metadata": {"window": "We're going to continue to work with them.  On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acec329ac3630851ab8e6ec19f5f97777d36307aee0db658553e5c3313e0605c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c051a89-c021-4c46-ae11-9415e3465488", "node_type": "1", "metadata": {"window": "Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "Operator : And that concludes our question -and-answer session. "}, "hash": "349a31d6b49f41c5d0137f511bd3c276a86828d19d5f76e3653f5f426e86d4d3", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  \nOperator?  \n  \n", "start_char_idx": 1982, "end_char_idx": 2012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c051a89-c021-4c46-ae11-9415e3465488": {"__data__": {"id_": "6c051a89-c021-4c46-ae11-9415e3465488", "embedding": null, "metadata": {"window": "Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "Operator : And that concludes our question -and-answer session. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d43f5c9c-4237-4f56-a98b-c41ac0139eda", "node_type": "1", "metadata": {"window": "On our own \nproducts that we manufacture ourselves, we  can control the cost structure.  Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "Kevin Moran:  \nOperator?  \n  \n", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d14191758625a681d1076bb7b109b6ac053300989056a1bc87fc21e7ff956505", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bf81211-ff71-4a4e-b94d-0c9c574b12f8", "node_type": "1", "metadata": {"window": "But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  "}, "hash": "eb27670abb7210796c93b4ba7f2c5912b2b9b2076c2a6a79f26a387a03b00b98", "class_name": "RelatedNodeInfo"}}, "text": "Operator : And that concludes our question -and-answer session. ", "start_char_idx": 2012, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bf81211-ff71-4a4e-b94d-0c9c574b12f8": {"__data__": {"id_": "5bf81211-ff71-4a4e-b94d-0c9c574b12f8", "embedding": null, "metadata": {"window": "But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeaa5a49ae53dd209cb1e0d76d0159d896ca7f7d38f24677929e3ff56c22a63b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c051a89-c021-4c46-ae11-9415e3465488", "node_type": "1", "metadata": {"window": "Obviously , we're going to \nbe able to work with them a way to maintain our contract  pricing and do those types of things.  But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "Operator : And that concludes our question -and-answer session. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e16a2893b2511116e94e066456f14c6188c059a0e0ff5c4813ad8d23a319b23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40f15b5f-2a47-49d2-b596-8822764a58a0", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n", "original_text": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah. "}, "hash": "044b12c4ad98e06d979084645f0768c3c5e609c09d3b5f346f2f5cae03771966", "class_name": "RelatedNodeInfo"}}, "text": "I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "start_char_idx": 2076, "end_char_idx": 2174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40f15b5f-2a47-49d2-b596-8822764a58a0": {"__data__": {"id_": "40f15b5f-2a47-49d2-b596-8822764a58a0", "embedding": null, "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n", "original_text": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b71f2fa0cc3c2e48211edfa7924ae0335ea49857e5d1f89f5136a91ae0ab0802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bf81211-ff71-4a4e-b94d-0c9c574b12f8", "node_type": "1", "metadata": {"window": "But as \nyou said, in the spot market buys to be able to take care of patients,  which is what everybody wants \nto do more than anything else, it's going to be incredibly important.  \n  \n Kevin Moran:  \nOperator?  \n  \n Operator : And that concludes our question -and-answer session.  I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "original_text": "I would now like to turn the call back \nto Mike  Kaufmann for any additional or closing remarks.  ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9efb9f2b56c20bda8dde6f165a03be5db9a3d287e2fdc654f9cde4a84f23cb4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0114d4a-bfd5-4966-954d-c84140a6ddc8", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation. ", "original_text": "I just wa nt to thank everyone for joining us this morning. "}, "hash": "67e57a2db4db03d9d3bbfe34c8f76a49bd53a7bc824b93e3d1b2e4b6057e0a95", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah. ", "start_char_idx": 0, "end_char_idx": 51, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0114d4a-bfd5-4966-954d-c84140a6ddc8": {"__data__": {"id_": "c0114d4a-bfd5-4966-954d-c84140a6ddc8", "embedding": null, "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation. ", "original_text": "I just wa nt to thank everyone for joining us this morning. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b71f2fa0cc3c2e48211edfa7924ae0335ea49857e5d1f89f5136a91ae0ab0802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40f15b5f-2a47-49d2-b596-8822764a58a0", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n", "original_text": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9a07fc7804fb3663cdae96e8fd3b1c0144e17ddf39cbb66ceef6a64bf65098b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f80a6b50-eb39-4b9d-90e4-8e683336acc6", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation. ", "original_text": "On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n"}, "hash": "7ea0e080e89abf6f53964cce4d91fdc3d0f414f5be9a664d33cd69a99b782491", "class_name": "RelatedNodeInfo"}}, "text": "I just wa nt to thank everyone for joining us this morning. ", "start_char_idx": 51, "end_char_idx": 111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f80a6b50-eb39-4b9d-90e4-8e683336acc6": {"__data__": {"id_": "f80a6b50-eb39-4b9d-90e4-8e683336acc6", "embedding": null, "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation. ", "original_text": "On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b71f2fa0cc3c2e48211edfa7924ae0335ea49857e5d1f89f5136a91ae0ab0802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0114d4a-bfd5-4966-954d-c84140a6ddc8", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation. ", "original_text": "I just wa nt to thank everyone for joining us this morning. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbdcf7f58c63bc9e9ef0cb41da8d7879c48f58080eb28b4285559e1db51c28a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6e7052b-5faf-498d-b658-a8fc1ae69a7d", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Take care, everybody.  \n  \n"}, "hash": "dbf58a0878508caa3ba3dd19b204958d135f8767384913c1842c9a9b895f6fe0", "class_name": "RelatedNodeInfo"}}, "text": "On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n", "start_char_idx": 111, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6e7052b-5faf-498d-b658-a8fc1ae69a7d": {"__data__": {"id_": "c6e7052b-5faf-498d-b658-a8fc1ae69a7d", "embedding": null, "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Take care, everybody.  \n  \n", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b71f2fa0cc3c2e48211edfa7924ae0335ea49857e5d1f89f5136a91ae0ab0802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f80a6b50-eb39-4b9d-90e4-8e683336acc6", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation. ", "original_text": "On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e86d97555d207bdd02ab5d7cde1f8caa89acfd80a8e2c613256ddcb5ec411c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bf673d3-136a-444c-995b-833769147e25", "node_type": "1", "metadata": {"window": "I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Operator : That concludes  today's presentation. "}, "hash": "031928ddac2eedea6a0260684dcc8fb26c7695cbece6d18b6d3613ca305d6e94", "class_name": "RelatedNodeInfo"}}, "text": "Take care, everybody.  \n  \n", "start_char_idx": 274, "end_char_idx": 301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bf673d3-136a-444c-995b-833769147e25": {"__data__": {"id_": "3bf673d3-136a-444c-995b-833769147e25", "embedding": null, "metadata": {"window": "I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Operator : That concludes  today's presentation. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b71f2fa0cc3c2e48211edfa7924ae0335ea49857e5d1f89f5136a91ae0ab0802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6e7052b-5faf-498d-b658-a8fc1ae69a7d", "node_type": "1", "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Take care, everybody.  \n  \n", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "505b42d44856c559249a33d4d9072d3d2715161540b90b74aefcba52dadda1c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f284577-e492-4002-9da3-52af726590a0", "node_type": "1", "metadata": {"window": "On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Thank you for your participation. "}, "hash": "c93f1c1485fd287c4dc57688d21464ebd922d5c09298557bc082ec702d142b16", "class_name": "RelatedNodeInfo"}}, "text": "Operator : That concludes  today's presentation. ", "start_char_idx": 301, "end_char_idx": 350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f284577-e492-4002-9da3-52af726590a0": {"__data__": {"id_": "5f284577-e492-4002-9da3-52af726590a0", "embedding": null, "metadata": {"window": "On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Thank you for your participation. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b71f2fa0cc3c2e48211edfa7924ae0335ea49857e5d1f89f5136a91ae0ab0802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bf673d3-136a-444c-995b-833769147e25", "node_type": "1", "metadata": {"window": "I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Operator : That concludes  today's presentation. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcaf6962c20a74c0d26401f6e3f30f26a6c11886da45b54e82d0cf58bb4bc03d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8475d5f3-8d1b-45a0-8d8d-a4453e412a5c", "node_type": "1", "metadata": {"window": "Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "You may now \ndisconnect.  \n \n "}, "hash": "023b30a74cd6bcbaaf76ca3ad4c308b11f849ef76c47f31597124bd1025f8319", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your participation. ", "start_char_idx": 350, "end_char_idx": 384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8475d5f3-8d1b-45a0-8d8d-a4453e412a5c": {"__data__": {"id_": "8475d5f3-8d1b-45a0-8d8d-a4453e412a5c", "embedding": null, "metadata": {"window": "Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "You may now \ndisconnect.  \n \n ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1", "node_type": "4", "metadata": {"page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b71f2fa0cc3c2e48211edfa7924ae0335ea49857e5d1f89f5136a91ae0ab0802", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f284577-e492-4002-9da3-52af726590a0", "node_type": "1", "metadata": {"window": "On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n Operator : That concludes  today's presentation.  Thank you for your participation.  You may now \ndisconnect.  \n \n ", "original_text": "Thank you for your participation. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e9785ccc6c0b26eec686972d16020349211e9b7459cb6d48105b2438c9207d8", "class_name": "RelatedNodeInfo"}}, "text": "You may now \ndisconnect.  \n \n ", "start_char_idx": 384, "end_char_idx": 414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"47c5a99a-eb44-46ea-ac60-14415645b32e": {"doc_hash": "5a03f69c792074093642c2d54b062f1089271cb9b7daf0b718461876bd19d328", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "690cb2ea-4aa0-4966-ac82-c080e8951c0a": {"doc_hash": "f1cb8720fca82247380983d9c97aa248e15f894b25d342e3ee4751cc7b469d7f", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "8e59078f-2bfe-4211-a07a-fad3fb6ac28a": {"doc_hash": "fd6844e6ab5d544a2afed0fbf69bc76ac302af5ae60991c9c255ef8b269813eb", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "ff1ed46f-c758-4be5-9c81-9be58ae9827f": {"doc_hash": "9d3987d617d6cdbbb5beb490c1940218c133ba346398866c3cc18d3bc7eea51b", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "846764b5-7124-4336-b239-b506e1d38ee1": {"doc_hash": "db129dcbefc451cb23c345bd517f4b53dc20ff0c77f38e5403c0c583c5ecf6b0", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "711bf7b3-b259-486f-a475-6f5f76afe506": {"doc_hash": "d83c21a370b84e5409be4394bf7ee50931fcc87add215def34ff9c0a20cfa3c2", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "52be385d-b5a3-42e8-a979-3ae8790f7bfd": {"doc_hash": "b254d771a40f93c89fc1840b88001912cd3f140a7713c98506a3000ae903e2b8", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "5a1e5e52-3282-49be-9335-dca9c048d947": {"doc_hash": "92e3cb2772f1f93a48987bf00481a526698797d4478032f7f6516adc6372682b", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "ccf7ff9f-485f-4413-a386-121b695907c7": {"doc_hash": "ff207533d2a14074d19ded80ad70b747e16ad1825a91790441be6d8736ba834e", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "b69904dc-6f3c-45f0-b520-87c090fffd81": {"doc_hash": "abf4cf002edc93fa561640fa33e1eb1bf24034f7196ae9ebf7eef1f6d2bcfdc3", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "c97f1a92-7662-4a4c-8806-6d479f641aed": {"doc_hash": "700bf56d7f2b64f763f88987912250362ca92cf49691162cd2856e9d5d56d4b9", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "e53f4588-d725-437c-b0b4-7a03999a1a0f": {"doc_hash": "7c419bb7ce7307c9c914d33f2ac96047ed03c2104f34b4f071578f449408f7ac", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "829525ed-a150-4bf8-8a40-690985afc94c": {"doc_hash": "be24707443c6b2b219ce53571328ce6b75d07949c928938e151c5d58363464dd", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "aede73da-2713-45b4-ac7b-bd7b4d482f32": {"doc_hash": "50ca68165a49a538dd1250432de8b90ed0b4199f9a9b39fb283bf472b9ff6570", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "c85ef088-5d3c-4786-ab59-831cf32fb740": {"doc_hash": "bb8f6d5e830ff4b2b4f611fc438980834bb27f2934789efe68c62fea00eaac5a", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "b147ee21-1125-42d9-9a6a-05f027b4eb28": {"doc_hash": "c9613915f9154cc624cdcaa2511c215e8a3cf2ff76f4319060036e50a26a58fc", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "a7bec4fc-bcfe-4225-907e-67b54d91a775": {"doc_hash": "193d091e0cb0ba2f2e5cfa6d6ec31653e570d3062a59491745717d8a697596c5", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "dc8c5def-8e00-47a3-bb82-4417b92bdd25": {"doc_hash": "11021bcf40eb026eeee6c4c1215a454d7771551bf5fa662f7ab1e0b5c4647188", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "829e6ccb-219e-46c9-9210-bebb656a458f": {"doc_hash": "b0c8c2f5b66525037d78475bb41365dde0b6c58f089d7617925c0294e47fddd2", "ref_doc_id": "eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7"}, "26a36ef8-9269-49a2-8276-9e68c12a6dc4": {"doc_hash": "1bc0646630845ea0125e544ba3b858340d59a2ab6d3390fc61fff515218ebfcc", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "9adda905-9082-4ad4-895b-307be315f9d1": {"doc_hash": "52c7664826b5416e8124d892a8bac43bc9729a66c463fc9e045ff478b8d4850b", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "578a5c69-c3ac-4b4b-b6de-035d7c802a5e": {"doc_hash": "4a9d94794c5beec10e3b67920f46b7ff14740fa28cd71caf4c836a0c16b41aba", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "aa852383-154e-4103-8aec-9250751934dd": {"doc_hash": "0869626e35c3399e4898c67b430177e0f3b4ffaee2f6eede57cfa5094570a58e", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "9f2e560a-3b20-44aa-87ae-3dc576fef4c4": {"doc_hash": "02fe48edaaa3c9821753a9e8e383e43106eccd1f2a4f40255c131a905ad4b7ee", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "fa3158aa-2327-4d81-9765-545930f325c1": {"doc_hash": "dad528543fe40b84242a00f1d5eff7fbd673d38645b381ab93e1b820b3352b4e", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "25465d55-1aaf-4e1a-a402-d046f474555b": {"doc_hash": "ce389dd08e175a8b9215811510f592908f138ef4daf8e88e5895bd03d7087ba1", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "d70d74e5-3107-4c2d-9446-7ac770a55bd7": {"doc_hash": "6e8ae634b7e0b1e79a98a68c81cabbbf45682f5e00ddd3066e0f9285b2d6e4fe", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "da97ab2b-20bb-43b3-8c62-9fad83a36a12": {"doc_hash": "f5e768155d955684da32cd0fa37184ba2091a25bebe300370dd25f0de73513d7", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "de6748f0-1b20-45db-90be-6c6872dc0e4f": {"doc_hash": "6d2769ee77afb0c1cbf933ae46da15f3b269e53ecd9f20e8d3a0673da1de3d61", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "e9affa75-974a-4844-a58d-cb7b6c6bd627": {"doc_hash": "ea77e235bc95b1f290fcef0fe2c27b7170726e7b5187c8d9267f4943c43dacf1", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "207a37e8-a96e-4e47-810c-fa232779d0dc": {"doc_hash": "27c952bc3cb13d5bef1a30a63e540984b0aee66b2d3bcb4aa936f8373a540bee", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "e61107d1-d8a3-4908-aa57-1604cff2243c": {"doc_hash": "41a95271710bbaae879b4f01e3b87329496124d87e686cb41527aecfec36baf3", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "f5aad3ca-7a3b-4709-8a5d-6b565b993c7b": {"doc_hash": "0d636212d4fbfdaf2a75c85aaca619ad157a5fae2fbcc2c30c29b0796ca10a43", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "e206fcab-c20f-41b6-bfcc-694ce27776b1": {"doc_hash": "edb3f0a821cf92fcdca0ccf811732731ee4fa3c564680b5a306da6edffe99556", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "eecdc177-1450-4ef1-804e-bfdfd4a6496b": {"doc_hash": "8d846258199f2751f6118444f425f289db3850e56370e1cdc1cf36ff46bdb09d", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "7834ebb6-79a3-4bf8-9e7c-3727d40a7619": {"doc_hash": "86e1e17a6e64bc9470e2a379a5d29f8a8915c007e96d19050b562a48e912d784", "ref_doc_id": "3ed1993c-fee9-4dec-b0df-2f592cde3328"}, "96293e33-04ef-46d5-9572-fbed3bf95574": {"doc_hash": "592b2e724df5a6eb16ad529b0dbacacde8ecfa4ad51f04876b372882a3c7541b", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "81a335f0-8d41-4892-8aef-835c9a9ae8be": {"doc_hash": "62c63977f2b5c95b97e53a7677262310a04490e7c8e646906f13fa2ad1d3e7a1", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "33a41ec0-f22e-4122-9fca-eef39a56634c": {"doc_hash": "db335f855931c2827824a3417904578f5da8d696d04fd42159b978edb11550e8", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "5fabbe10-7bfa-466d-b864-21f74db00518": {"doc_hash": "2313c49b9e80b60dbfeecaa7a88849439ca5e998c5d77ec3ff93d6f68dd8bf9c", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "f7ea531b-4f77-44e6-9bf1-3a6c1496ccff": {"doc_hash": "f53ade038896f34b2da248bd0d6d2675ebf6a2c454c05a18f9ec7aa7c1ce982e", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "8fefc8c4-a858-49dc-890f-2b5293c9a505": {"doc_hash": "9007083164e447f770a1cca507838c58e121dcc887f8857a2fe25a3a429cfd8e", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "dc97964e-9abd-47bb-83fe-8d8f25686de0": {"doc_hash": "5fde43490a1fe390a628e43ff16773e11245acdcf16d885bc4262c9e014740b6", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "62f46d5f-b627-4300-9f04-b4ecaf3fa6d0": {"doc_hash": "dd96fca04db90c3d252060c9d43f6ce72c507651a45eb067852dbc00a604df34", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "0e2bad4d-a489-4723-b840-cb5100fac882": {"doc_hash": "de1d9d3b6e7ae7cbad2f964b47505181a6a4f54654d63ba23ad9cad9158f43ca", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "7b7691ce-1b60-4174-8820-63c9b5573e0d": {"doc_hash": "4344eddd546b124c853bcfa7e3b5429067f18be90010b092d7b31a30ffce1fe1", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "361a28e5-5844-4f7c-a889-4a5f0e61b5f5": {"doc_hash": "d0bce7b838a5912cd88867b056950c9dc7cd40ffe71bc1265c0b522f0bc0e14e", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "ec7eb97e-ba38-4b60-a9c4-b8d11c624883": {"doc_hash": "86200b2fad7d0b1880719ac7c9acab82b291e750639677ce5ee983a40ba36c68", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "b0190f7f-0553-4324-a3a9-dc99a4f24f7e": {"doc_hash": "4e58ef5b5d059b4fc49ba319cc836d5f22df02da5dc3577dada7dd54c7cd79ee", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "b1f5f981-f85a-4de7-aa64-20ca449e0333": {"doc_hash": "77d9ba153babd17e217d24ce27a383eee87b71a3878bf925a68d210ce5009ded", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "5760f66b-59a8-4b86-9ad2-08f0898dd9c2": {"doc_hash": "e634b4a39045b1d941e1862b55070d6d4d9ba4854b3b8d84807f3cced8ad6f9f", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "98b89f69-cb8b-4b08-a1c6-7c80e9c453e6": {"doc_hash": "da1bee18a830b9afc57b903003f97a62a1242b51e60b4fbe856eaa2deb8f2a19", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "8a213664-a73f-4bfc-8c64-bf2cde3e19d1": {"doc_hash": "02706a65422f81ebdfd44c0c62eb01397ce753af0701a88eaf9b0aab1973ff18", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "3c85234a-e6e6-4866-8009-84a41e0b0b9e": {"doc_hash": "fd9cdc804a4522970d0456b2e78e478f83a1fd2cee70d9dd2e27bb546d6d4895", "ref_doc_id": "203d7831-9a1e-4994-ad7b-38359fb616ae"}, "30e2e3dd-3dfc-4587-82e6-93c06053dd8a": {"doc_hash": "b513cf08d719958b71394b5a1120f534de56113ff78c9b087660abdc8cc254a8", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "92b489fb-4e54-4944-adf5-8fa74c0fa3b1": {"doc_hash": "bc2e8a86f2da577892c2a78ae773c98fd04f60207c2843b28c21d21246cb4380", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "94df387e-fc74-41e8-8ec5-d901d461606c": {"doc_hash": "3df441aec13872551504ba9fcbc03117415369ce92a3bab457b025518c4cc4cf", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "9aebccdd-a4c4-4624-8528-8ead929185a3": {"doc_hash": "0b505d9fc9fcb9372ae36fd99d8f512dc8aa1fea45e134ec9c09708e3213ab9d", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "42799e2f-1243-447b-aafe-6b0c1ce1836c": {"doc_hash": "da8a79ad6d0e30dbc44001ba56a2839aae6b215e2c506986b773a75c89e1f379", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "098a5eb5-2e31-404b-ae34-f8c207a202d2": {"doc_hash": "d12c35203dd742642bd7722be4876f26660a5105c45f86eab1cc25abe423dbe8", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "e51f8497-c080-4b48-8dec-012ab4a4ad2e": {"doc_hash": "1e74dcaf5a9a4d98a5136674841933021a33cb95c59f623a96be722ab5a801ea", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "1c6c1516-d044-4b9d-9d78-c5866fbb09c1": {"doc_hash": "8dad2f1df003d5d5fbc3005b4933cd14886d2d43e91243af0600047d8479ff92", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "aa88b5bf-7242-4b40-a623-d31421a2ca77": {"doc_hash": "f5df8e72a6976525488c722fbfecd316cb4062b2308a002df374f9cbef6f005a", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "28293a30-5966-435a-8444-7181fd190b54": {"doc_hash": "93298034180573ee1d63a77407f4a0c084737eaa2071722bacec4989ec301e88", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "36cbbb52-e410-49fb-b3c9-8342799920e4": {"doc_hash": "fde82f6ad3feeb7c8f1afbba0e0f2bf327de4d4aedb932447797a65d7eff1911", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "2a77a687-4ca1-470a-b09d-036fdc30cdf1": {"doc_hash": "bd627532edabf3b97ff72cd3129ee88d747a7a3d4cf06ba3aef9a24f7f93a5f3", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "9b15b3f2-3ebf-4fcd-a7a0-bfa99684ab3f": {"doc_hash": "d9e05130de49bf966617ad0f7c07f5a17656c2c804744aa0a0f44a80f50facd5", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "634cdeb9-3570-4b44-94af-f60a3aea64cd": {"doc_hash": "ecb943e97237563482cd5f899ee448dcc83ad94d20c044e308eaae04228d7ee5", "ref_doc_id": "749249e8-6903-4e13-875f-1cd11e6d2165"}, "4152882d-6b49-4bc8-aa8d-68622a4004d5": {"doc_hash": "84c4c87e1d8b9738fd567c51c4d293f08b5033ecff70a0bbdbba3d3e625c51a2", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "75efbcfd-48cb-49c7-a0af-aeff075fbf4f": {"doc_hash": "aa58d6ded217377fe5d9907e9b377d975a588df17a970213681959efd1152a10", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "af051180-8157-4b17-93b9-0980d2158c13": {"doc_hash": "45e7d274904c8695598607cdb3453e409c0a5b0f6fa0b9d212c4a1c266465d0d", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "ae18e658-6f18-4dfb-8bef-d3f062814da6": {"doc_hash": "5678d7926c6cf47bf3fd203012761ba1d8d456989d3a10622c0b2408649a69a7", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "aa8a91b7-2825-4834-8883-25af351ff4bc": {"doc_hash": "32468116ae05072852605caf2f634b18efa22674e4d26b578492b82da2574a48", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "b5a30577-7ea7-445d-af1e-7f4c4db88116": {"doc_hash": "d6ffe829ed2d8e05b97e23053bb866317e9b9e5508f2d2163749002e661f3056", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "8bc5d0c3-9f40-4da5-a990-f2cdc4b014dd": {"doc_hash": "74f790f09236db99cefc82bf50925f5bd9f0c4101fc29864ef0ebb1139077c06", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "22f4960d-f503-4e65-b960-8faf257b5282": {"doc_hash": "3fe53877aaf5874f9014b9fbba5e7361e89f7bee9c2458f7bc57917198df7281", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "79c63d20-9bee-4afe-9cad-ddce8c200e24": {"doc_hash": "0b871f48d22e12b4bdea7b89e5a6595457a5550abe9efd96f8d52036289bcf40", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "14cdd861-8fbb-47f3-813f-bef194e623f6": {"doc_hash": "ba12a08121a6126e702cfc992bd3621f782ae9a531444bbcb598f0603150a1bd", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "44cb5d2a-f234-494e-991d-148b2e55f4fb": {"doc_hash": "584977290216c1c47986594ee6e5ea3afe3b1675dd795c4e6a3b1fc0efd37ef2", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "71458cf0-b4ad-4a67-8594-9e5d88b8b6b5": {"doc_hash": "4e6fa29a97d107da5b43051e4cf45231396a414f950c02e07a41f64c1c059af7", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "db548959-ce87-4f23-95ea-7cb25513f129": {"doc_hash": "1b00a3e08522961493e858106795c6bafee3d6fa49be14551866c62950fb98f7", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "db542f41-5869-49d5-8108-88e273f9f670": {"doc_hash": "31292636b06969bc2fe898da162f2f598d64c9788ab226ad8e5ee15e37f14d4b", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "860d13e7-24db-48b0-b69b-c81fdbd74e51": {"doc_hash": "2768b7691a099451f608f43e09e95fdfb4f85c28c9c414375f922a3c21b1a57e", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "5cbf9a44-c7ab-47c7-9a23-4ecf95b2d421": {"doc_hash": "3e53990c6f8681ef507dbc01d57f238087394595783a6d040cc6d2ada83ab441", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "0be642c0-4f5d-437f-99b5-7d5027184dca": {"doc_hash": "f458027a40f91690a2559b8087c68bd924e12ca1ae1f2bd59bafcb33f2e4858a", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "3e5a6ec7-d85e-4752-ba53-4fc24e66c4ae": {"doc_hash": "e9a7d238365e5a3099f42c2dfb85c49ab6a026b887aaaa5a2a91bf6a491b8afe", "ref_doc_id": "73f715b5-f5ff-4941-80cd-2e28207cdeac"}, "d636f73e-d9e9-424c-8ec3-fa613ec66a47": {"doc_hash": "6b412412655db3f2aab784ae2f3e896c1afc6aaa2b99fc3f32866902fa061eb1", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "e88910ab-474b-465d-973f-1a2a8c3e48cf": {"doc_hash": "feceddfd16cfad9159e6155482a6807d6b98d2956bf01ca84f68617531eceab0", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "e085bd20-8625-4761-92b7-dfa6cbc823a7": {"doc_hash": "f53bc77fd1d9df030c4d1423b731382012856dc101b664dc4f6fbb4543fcea02", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "fa34f45b-6b4f-42ff-8711-a72c7ae3c763": {"doc_hash": "f8954a29326ea25d1b617909ac07368e43a0aaf9446146183715ab26f7a9e796", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "8ee6df7d-f160-4a9e-a834-e41289f11c47": {"doc_hash": "888debff7c8961f91cff9dda15f7396b759ab49276f0b1a1648cb5958cb69c53", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "9996967f-a582-4417-816f-48e788724bef": {"doc_hash": "fa6656dce9764d5d47c1c2b587a52a62b36e4e52c1a26689c93f3deeb66377e1", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "2231776a-b253-4843-a8d2-6d70963969d3": {"doc_hash": "f2c745a66b37f2644e7f7607479f946e91e451bc12ec680803adbdf2c39260ae", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "8a4d179c-b36e-449b-bee1-6750b0a4def8": {"doc_hash": "2b8533eb8f4ddedcb3c5eb79402373fc5f7ed582d0ebe19ccd612c865290145d", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "dffa1ad6-375a-481d-8d43-4e15be89a0f3": {"doc_hash": "890263880df6265d6c7d564216d14dab6002cd45ea5f92507b3581bfd5ed8763", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "eaa97317-79bd-4c18-bbce-2a58362131ca": {"doc_hash": "93fd4737b9ed5c53e4ed5964a76125c314c568dbda527d4770896e17f67d1d5e", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "1f661a2f-38e9-4ec0-8471-20417d966356": {"doc_hash": "b90e40d2ef92985a325d22d304e8faafbde36b120c04ef36719a1cd0641ba564", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "4e07078a-677a-4135-b15c-ac1702539d69": {"doc_hash": "59e8b4d4e964d141f381590333973c483f1d58559abe2fcd7004d76b87f86345", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "45d1c651-ac2c-42f9-9099-69165d1fb620": {"doc_hash": "cf084b83d5e600d1435cd6933c2c587e533e5e4aee5bfa4b4839911466af3830", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "c26159d7-6a9f-4e8e-97fa-95d63ff99051": {"doc_hash": "e0ee6aa29c082e82278c64e77e58e5f71f9469b612cc05946dfeb546e544fb82", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "52ba60ff-f304-4c4a-94c1-dfd324baf341": {"doc_hash": "670fd95c0302c6c26d16e7a059bcd9c3eaed9b5f43347d75ed299c99ffd1cdaa", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "b320b0eb-c56a-4bc1-bee8-47d26b245d27": {"doc_hash": "d83dd2a57a2760faf16607a7f505ae374123855e6467cc84faa9de7710a4d4ba", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "07f6a125-6228-4382-8fb8-603b093135f1": {"doc_hash": "c9b3606475d3eac0cf9cc135ba84dea57e54d4973a596dff8e25b9e0c74ded30", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "f4f2ef7b-de1c-458d-bbe1-c48bc20de7ba": {"doc_hash": "89f51b0060102f292dc7efc865aa5fbf7b84bcac2d9ae22fc25914b210b8cb1f", "ref_doc_id": "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7"}, "582b5cdd-d86f-48b6-ba87-8601003b5935": {"doc_hash": "8c5b59f0a4998c9720894200d2a2d6d53016643543c4f17ab5d1f37fd8e5811f", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "db374b57-1515-46d0-91ff-0a1f79bf0fea": {"doc_hash": "ebd2e799dfa29660b9f32332752acbf345ed8bb0d896f9efbce5f746da2e59aa", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "5ac16330-f3d9-4dca-8906-96fb652b7338": {"doc_hash": "1be870f07e4cc0113f27ca86eed6a7a4b95553b3c426ca029e9cc5d985c11818", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "3407171b-87ef-4b76-9d3a-29cd41580a3f": {"doc_hash": "edbb842b9116817523355f500ec061622dfa94b7b3b0d6357b512898bf0f32e3", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "9d4d0bbd-b912-44b4-a1db-5a5a892b63bd": {"doc_hash": "d88928fbfc0571a006f41d437c09f7c6d451babcecfae7ed31ba3c9919524765", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "0db27ef7-e234-4451-b45e-fe7e630bf68e": {"doc_hash": "cec93184b1f4ba71f19e8f544ec84e491d7665d9db762dde3e7ca20841616e23", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "2e7351b6-7c80-4455-bddd-f624606f7984": {"doc_hash": "87a9aabb3e4218c87a0670a63f8182ff109e2707b344ece9f876049f64981130", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "f03a22d6-7d2a-4a10-869c-e4e3adb7ec56": {"doc_hash": "d25bd6a43fd89585940452b5c8f5af8ec07493b3bb1065aac6998727f6b1fb8d", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "ddbc55aa-8b21-48d7-8f47-ead88f7ee0e2": {"doc_hash": "22031c992c682603522044c9cf90a8932a2aaf58dd72c84b9e12209ea8e3a5bc", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "9828afcb-3180-4346-ab32-c964ccdb8061": {"doc_hash": "8ceae3ccbef07f0a7bd1322abfd85e598e2aba0028399035e329a1a28085aaa9", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "4a51ed7b-8e98-4aa3-a996-8b8b252f4801": {"doc_hash": "00b8e90d1ca3aef9df0a21de8fdf6cd8b7501ad749235b4807e9601931d3dfc6", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "afc2e198-e2e8-41c2-bc01-632f70681657": {"doc_hash": "7f0f5c1c21120fa3840f0bf24a1b8593d9e2a971c7ba0556df616960e7ce7341", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "bd87ec13-ae44-4ec2-872e-8ab5bb42b3b0": {"doc_hash": "5b476991a094565e71243c886c62793b1edf1841500b7985623f06e4dc0ce028", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "17c38b86-b821-4105-963b-3eaa3ad53a15": {"doc_hash": "d8a8174d719b7ea2e7e89bff6c85c7dcad3ea4a82ef271b49d4260a54a3f52c9", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "85b38c9d-8354-4bd8-b912-e41aeb3729fb": {"doc_hash": "3fedc688a467c30886a7a0b919b7692e613aae755f4e47fdc087ee4955e7de28", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "2580da52-0a87-4c41-9169-ae65f47e3849": {"doc_hash": "0492775456a91f49f5157ab4fdfa92b40eab4f152e490d6433792c0687461a24", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "3d995c8f-b301-4432-bb9d-251746f6cdb0": {"doc_hash": "ef3c5fd8fe92f71508527749e274000832132d6a1db5a3fd64ae5e55615597de", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "d22990ed-d09d-4e4b-ab01-2193a3cd9740": {"doc_hash": "5f4ee6ba843fce1f1fb34a02224f7e6e421298ef4d9831aaa4dc6dff96373484", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "3c336615-c783-4ccd-b2c0-174a6d29bbe9": {"doc_hash": "fd614f94de00a4b7b170f4127a7a52691bcefb3bfb413bc09a6df056d270f9a8", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "f203f410-cd4c-4139-ace2-99a4d2d6c82a": {"doc_hash": "f1547086295ef22242f697ea29b607e9063a01fe9fc650cdb632713c5a73f718", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "ff85b395-e1e2-4afc-a6ae-3b3e9c1b8530": {"doc_hash": "646354ba7af54b712e8276f9750e1afed035179132f71bc17dbad37f5aebf987", "ref_doc_id": "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5"}, "d3007680-b3b7-44ec-bbcc-5205e5586f3d": {"doc_hash": "3f9dbaf74ad80f10258b313f8b6365915f1d8d98509623fac1eac616297a8278", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "4af601d1-be99-483e-b139-56a28239ef1c": {"doc_hash": "e2251f5dfcc9b0ece5d1b987c5e949aa44c24254c3307f732e56735b09b1e2aa", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "73f4f911-ca1d-4a5f-ae5c-7a6629da8c4a": {"doc_hash": "281b8197574be11c1c3d88c9c77ccf6b728279160ca099d504a8ef3e368a6cdf", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "ab7a0fb1-d89e-454f-bafe-ac95aab90574": {"doc_hash": "73a6821c7aa29b817bcf9ae66bb3a6bc2d081b6158bcee4236979e840be56a83", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "e6cd5125-1b30-4d45-8c78-6f86e91ec3a8": {"doc_hash": "17f4d926c18ef772be2fd1f118647c454ddc77dc6b7b020cfae76895daa620d0", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "97ac17e6-c08d-49df-ac67-fab9b0c7b1f7": {"doc_hash": "5ff74ff8da850102b75a3a7db5322c1eb1eb352ec074b1c190f5ce4cbbe2aa9a", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "563930c4-7de4-4f8c-9d6c-aeff4e013c49": {"doc_hash": "793d99bd244c83c354816f43fa8f7e5421c91ac522e3416c3363336a58d120b6", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "5ad20631-e557-4e2e-87d3-48a7456c9c48": {"doc_hash": "a1327562e64fb841ad833a8451896cf413f8e36a60df3c188e1eb475abbd32f9", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "c5a02dd9-a1bb-4882-b9fd-dcff6ea25947": {"doc_hash": "ebf9bb65544bda7b2379fbe8b470449f689f08ebeb6f9ee588057ff458e035a7", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "09b7b9ff-6b1c-445b-a556-13e66650174d": {"doc_hash": "c6fe4dcd79d7b415a9963b61df3c09bf499c672c0c8b17327cef7561e71ccfe4", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "add8066b-de6d-4c13-8384-2a4c06de1854": {"doc_hash": "e75b7e4e2bef6764a278b1429f1ee4f6ee09a7fd00ec9cd47ca289634005f62b", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "5de87ed0-742c-4de1-9ebd-3cc25b949c94": {"doc_hash": "23a88bf9438ec5dc809a1df565e601ed2966297b46e4d3bb9006093c67139773", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "2673e92f-d667-4498-95c8-6e0d64b6668d": {"doc_hash": "ad9111946c98a8e1b64cb92edff9f6c6800627f5d936b1d334331fa161c014e2", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "2bd3e19f-ee49-4b69-8dcb-d9d0675beecf": {"doc_hash": "ba728935a85b581da579fc20ee5bd7aef1723ae189c0f9a8bf3a9264f7ac41db", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "d75a3ed8-5561-43e5-9fe6-dae4863dfd05": {"doc_hash": "3dc689b5e66e0088506d771e230a50fc41e06a4f45f8f74f56c0b10cae747675", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "b962b2dc-d2ac-4c45-a1a6-58d0f774553d": {"doc_hash": "f81fdc54287855dafe8665021338f80e9a47484dd96ad05a0bad03474b62f074", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "71d31f4d-2002-4849-94b1-c2f23a7df5c4": {"doc_hash": "6bde2a2fd6b7fc0612418a8e7952bb32027f485293d4862b45d905453f5c4520", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "42cc6cb9-465a-4970-abfe-2e41ce42b3fe": {"doc_hash": "efa246481f4a0f7b1b914ee796e4c02313277512c56f03bf5b981b800d724224", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "278d3c37-7560-4e58-9eb6-ffb5b5bcc51d": {"doc_hash": "4a7441b2ae36a71143190cbaeea3e4aadf84df3d81212df076e2c226c273b504", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "bcf5ad57-eef0-4e4b-85c5-cdeb4c45b123": {"doc_hash": "6a1f89de2f08cb87f8904d9d24cf58a475e41a854021bc1f90e65f200f786c29", "ref_doc_id": "45c3b7c8-e177-4ff1-ac8e-eb7277b50464"}, "d271b624-ccd9-4633-b8f5-909defc99c9f": {"doc_hash": "257eb9c2d63babf5108c23f27b6542c2fc80db3cbdd376d0a8bf3b0008e98cf1", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "710069eb-ffa5-4728-a7b3-498ba5a860dc": {"doc_hash": "d2d9348a15bfab90c1c83db3d46edf7faf511cb1045800e4c673de6c9fdb929c", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "e085cbf5-9c24-4e47-86c8-20196f656065": {"doc_hash": "1ba8ed04297183e6be35af703b5385021ce124ad8e88bf625f6b1695d46cc020", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "892bebc3-1d24-4cd7-9908-9dc2cd8f5874": {"doc_hash": "c4b578b21b1d0959abb827f1bbaedaf9ef8c0a2065d13502132e62b92021eabe", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "52a3c95c-487f-47cd-a461-4f0bb4269423": {"doc_hash": "e71771ca6eecf66bc1db1d538456ab185e8d641c024bd85da4ef0e058ce4d42d", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "6088d735-1f1e-4546-8f1c-883d17cb1517": {"doc_hash": "ce86394f59ed8fd3a9f2b7bcfdf96f69c29acd3232568b3dc6061d5834a2bf0d", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "d0a2b6da-96a4-4fd0-ba91-c417c890f5b6": {"doc_hash": "f3d08ae2fb8d6ac7613f4709cadae861834e528d2a03b4c4b753f53dbae5ea7f", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "f0bc9290-f02d-4b48-897a-79db89a3b67c": {"doc_hash": "b91e1ed278ecb091db2fe754607a5b138ee339584f2d99aa13eef1e9338c3399", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "6629fb00-3ea5-4b60-bede-255e8642e393": {"doc_hash": "3393c3b981e9f7e313f252c6974a1a24111610646813a2b8c0b2f9c1e0b5651c", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "73afc2e0-14fc-4349-bc62-1e461145a4e3": {"doc_hash": "82930cd45ad184694da188566af0c4f065f2bef21aca7977e27f2f88acc0ba60", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "fdb5dc83-2bc1-44c1-a707-725a01ab1154": {"doc_hash": "a3892983642784415a98b886ba7b9e45ce09fc7f46109af96b4ad6cbe0e1aa3c", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "c96c0cda-e0a3-43c1-85c4-6f55331e24c7": {"doc_hash": "e5dd4f4f7ffe24352fa71e89ef5c81d966933a0ae4c377716fde8d1fb9b79ad3", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "24bbf2d6-9761-4bd0-b972-69351fb0fcb3": {"doc_hash": "f024c838e65b6404d369d9d31805393b4ce0599db2197384fe27321d2f001b6c", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "6b321fb9-94c2-4524-aa6a-e1bfa727591d": {"doc_hash": "59eed11aebd5777b4bc0a96d064e1a4857f8fd11f94650e9d4a6bf66037cc3ba", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "00f02eaa-813e-4971-903c-07d8791a08c3": {"doc_hash": "75f30713b2febfc5786f74b3392c6c41c4652c8b7148ab6563209f73572563f7", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "bc577726-2b7f-468b-82b9-4536bfc7ecd7": {"doc_hash": "49849bae5720935b628dda44aac8b78c21c55e3cd0ff4dc3363831d704030999", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "c265e83f-5927-4651-ae83-b6feba8c4a9f": {"doc_hash": "a0aba88b6704536589f8ee6efca5058214851ad27f5d8210b05a6eaa2b944559", "ref_doc_id": "d644f729-545e-41d5-abe8-fd0f5acd8f83"}, "89de6a7c-2c3b-42d3-b50a-b5b099498361": {"doc_hash": "64dcfd43aa206465c058484f780fd141746a8db8bb7b32e202b1e542dee37fe6", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "c63123f1-7f39-4ddc-a297-812b84e5496b": {"doc_hash": "4ab8bbd350181bf0783f2e709dab74ec979f218d9ebb60faa6c683febb6db35d", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "822a17fc-a4d5-4509-b5fe-4f3e837ab5b6": {"doc_hash": "d0e1d260091c178ea5f0239a39e984bbe52279b83273982cacd189899bca67bc", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "930fc1e2-44b4-4e1d-b093-0ddc2ff5db2b": {"doc_hash": "48b5265211abd1df662b4b830944828386c975eb7c752f803500d39d59292556", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "63100f90-1753-449d-958a-1677ea6eb6ac": {"doc_hash": "f5dcc5a633e165b62543db2aada442ecc30967cb763866434b4b503c24f2af4f", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "657f7e60-0917-4307-a889-13c344593a9b": {"doc_hash": "b9deb2f0dec469453e99d911723757a0a3d0357b1188e1757f7f900e4360e090", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "3804f37c-73be-4382-9d97-a121e17477b7": {"doc_hash": "926ee1b085b3c5f747c0c2f068625f5169e2f0c4017aca2603a5aed02687029b", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "333a88c0-fa9e-4c12-959b-6ef93f9a48d4": {"doc_hash": "5fed4b2f717f22e1ecff8816cf5c4e0d5f2ef9578fb566abefe0666417e3c0b4", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "af596633-cc2c-4019-b9db-c660dc332cc8": {"doc_hash": "f9df326d0f4cd2758f7069df81db7329759d67468d55e50e33d88fbfc872cbc3", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "9cf21122-2b83-46a3-9030-e3a08763a5d6": {"doc_hash": "a8f6e06585c06874c1f4a254033c73fd133e263f61fe1bb4311287415476264e", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "a2c1a310-03d5-4b3b-94cb-7518d4dd506e": {"doc_hash": "6a0edb998c9362e176635e500e0069ab6453f158853267c6de2d9e5c5937482d", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "1c8e4e2e-cf4e-47a4-9315-964de1feb705": {"doc_hash": "ad09f050df9e6fac1ed58d92bad24ac1ad327249a962784fc4ae4e31251a63d8", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "cce6acd8-68aa-45ae-bfbc-ec77c3ecf3de": {"doc_hash": "e619033267d8416134e541390b08e3b5b44074bbd5c013d76c23255c7a679901", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "006d845d-fb74-47ad-b2d3-cfd002ddad66": {"doc_hash": "3196a7fa4e3e5e755df8e944206d31e96869e9216ee946418b634e2e019aa663", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "00ab13ba-d369-4303-96de-c2c21e2a0ff6": {"doc_hash": "81638253ab43415b1e71d48ad87f798724c67d9fc60f89f7220a600815a5f8e6", "ref_doc_id": "6fa0c02d-c316-411c-b922-52f8188b521d"}, "0b28b522-08ea-48eb-813a-1b8dceadf5b2": {"doc_hash": "b7712f36107de6b590827033fe0bca76c20a34f1b309889149eb21245d1e19d2", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "06995ff8-e152-4920-bd38-f7549104a8b0": {"doc_hash": "7dc46eaf1a02a4b5abaa0c5e433340e911bd23ac8362f6b9f2a6d831c2974229", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "da607590-e0d9-48dc-b388-0735c301dc23": {"doc_hash": "ad24a0dd051e93ebebfeb63aea752804b41e6ba0adaa3000413ab5e9d45ddf2f", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "7736ba52-bab6-4141-9941-a927692c579a": {"doc_hash": "64d36fe600272ea45b1227425ef1c078d0522d6f1d7739a375ad1fbaa52d4d59", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "649c388a-3d4c-4b08-a2d8-60f144fca0fc": {"doc_hash": "9bf2a4cd729595c7a5883bdb9bbbb932abaff6a26894857cd00fdcad132c2961", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "77e4c049-5b2f-4c11-92e2-20f9cdfff8a8": {"doc_hash": "a5e801d4df50e5aefd74b4f427a0d62eebd925ff7734874e76371072968cf457", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "c0ddb713-1f49-4773-ac88-c7112cd8dc87": {"doc_hash": "ca9039cf3b9c6d2ddad2582dbeab8dc5cc090b5cc2c1b9a812137891a047ba61", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "a211a202-0e29-4747-9b4c-948fc940f742": {"doc_hash": "514a3fbbdcf1442c5c091a3510397ed9be98481cebaa9206f14f7ab107a27220", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "3a46f34e-3e2b-4009-920e-37c084d4abf8": {"doc_hash": "5a550f73af0d63b352b7ef08e32ec9195a71fdd669ae03d1f9d15651311c3d1a", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "91e3c0ca-4ebc-442a-a766-a88ec32f7128": {"doc_hash": "2505797d020dfa2fe93253f38dacc313d48529b028ee3d7c8a48b16a903552d2", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "02164be0-07a3-45ae-ae5e-42f3d3bbab3d": {"doc_hash": "3c3205689dba0cd8c6cc957c82fc1efbe59cf2d22b6a469f809969d58803f2f7", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "2ee92a5e-4001-4f79-93ac-97e5b9cc91b9": {"doc_hash": "7b0f685e3b966c0a8b8be4185ecdaf9346044e62219dde2c6f4a378eed81c6dc", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "a3a8fa65-591a-4aab-be98-e88c47a3ae25": {"doc_hash": "d4746c6839b23b990b2555df464635fd6573f4c0900ca6563bd1cd8f57844be6", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "adb60a02-0f07-43fb-a60c-4d71d1844471": {"doc_hash": "7aa6b7ac98fe27d63ff1f692d1825835733aab42397d001eb2ff282d1715c96f", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "2a15b0ed-39b9-4db4-9ccd-13d8a8556d18": {"doc_hash": "b25f32b034e5c17d4c7452addea9b3fa293ccbfd1b0b39eed30343dbb67e8edd", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "dc101d1a-7bc5-4b2d-a5b0-4b9209a54039": {"doc_hash": "92b6460372a9a17897fdad480e62f12c8c59b9347c8603cc5e2dea5665939d52", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "047fd61d-ce6a-4c47-b42d-b1f85a963dbe": {"doc_hash": "1a7ed48731b873aba95b6cf868449249de6e88af86da84dbc1504ef00c19f208", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "446d4d8b-b072-4f64-8a31-ab3d307ea1ca": {"doc_hash": "1a8e554e49ffa5da8adecd319d846e2edc2669cfb2a25aab3042ae6dfcbb81b6", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "8b4d3123-c02a-4c3b-8bac-55631259eee8": {"doc_hash": "6f57064fb67476d2c00b1f9ccd3169b587294e8d88081ab1c5a0a98e72e04d37", "ref_doc_id": "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7"}, "1a516d43-ffe9-4025-86e3-9479991119ca": {"doc_hash": "461a1549eb300cce475ea842d291be74ebb4eefc9e2700babdcfe6ad8a74bbd1", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "352f4fd6-d6aa-4ab6-850f-ca9664748831": {"doc_hash": "cf7e1d53f36a6b3f69f97a3bacdd44e33e1e50db659c5ce84cf983622fd6465f", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "264e33bb-5543-461c-a7ea-571d621234b5": {"doc_hash": "40ec138b7e72c849dfca91387cc6cce55617bff3fbc7667acffe7ec8e43dcc66", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "a1a818e8-dc95-4de2-b248-0dacab932c49": {"doc_hash": "8abbefcdfb64492052e75289c5d0fc9dadfa11eff3e35bcd8c9ab043c24c805a", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "15e3f369-f085-4640-be41-a100a2e2d5c5": {"doc_hash": "8aca2cc6533555096284085c9d12ae7d89dbf3b553b627ca1ec80d07a4299640", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "9c8ab6c7-7569-4d34-a53c-b2890dfe8aee": {"doc_hash": "de78c8f075017121802ad857d70580a1c3151be24050974f4d7143bdb6262bb2", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "72b8aedc-2336-4656-b687-a0f1fff8f838": {"doc_hash": "140a2514f44cc6964ca59d4498cfc86e44ac35ba1f831e13b3f7767e0bd03835", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "c3d12beb-a0d3-46f8-8279-b6e461e61f2f": {"doc_hash": "b9f6eab09d9d70196b9d6ac75e7688e9d9bc96f9458b5404ecfcb65a05c8e2b2", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "877c0743-d9ea-46ba-a9ec-9a73232e5a54": {"doc_hash": "852640d9def27078b02f21b66b0277d7da3718894ea84108258856065a4d681c", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "4359e524-5d0f-4215-a0e5-58140ef628a5": {"doc_hash": "770c59744f802614282af27bc31c4993c73c9aa37c00d467f5bff3f2cafc13f7", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "3d1bab7b-22c0-42f9-a214-8f08638701ea": {"doc_hash": "012c2aba71afb9ceff581225188885fccbafc49b549e41d3ff16761c79f13d5b", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "86b89665-ca8a-4ec4-be41-34ee0bbe380d": {"doc_hash": "326ceb07a74b36f4989936b988fdb6dea63f31580823154a756500a2b8548db4", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "9855f5e0-47f5-414b-b1db-55bfb84fe3ef": {"doc_hash": "bd64310f73dab21fa630df454e7f2131be0a80da5e4fa843eb67027258743335", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "744cb3ad-6258-4d1a-b1f5-416261b51c7f": {"doc_hash": "6c64780221fdd0771497c1cc37b19f3c985bc5f1f25b0fc17cd6d80ad7c80e58", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "47af2890-d7fa-444a-9ab9-3e516e81bfab": {"doc_hash": "301acd8dcf4fb1a5ed6bf9d466bde1e0316a0ac51ce6a5e79305e8ce2c0ef15c", "ref_doc_id": "a7d281bd-578c-45ca-906e-b9c0ec6d02f2"}, "5ea0c74b-db93-4a59-ad8b-b1cb3449ddd4": {"doc_hash": "7d55147edb9cab505881de4080f7fb10c2bdea8d09824ed5745e247b7d826296", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "b49b04b0-bcd1-4b39-8917-4573cdf148b3": {"doc_hash": "ed0902e84ef6ba5e5f75af255031754a48b3944687f0d8412b1e09438cb19e95", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "9c3a57e9-bc09-42b1-85d8-b9e18239fbf5": {"doc_hash": "290add3ca572639df16d67f4b2510d8b86c6888e910f84188bc5b574018526cc", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "ad38d5a5-95e4-4a7b-9a2c-40f752b54497": {"doc_hash": "412d418d1744a95307097b3a02258444619673906bc09de548eb06939af13b60", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "0cf6391a-661d-4903-adde-a2803dbbe887": {"doc_hash": "89191545914cad8586cbf278ce631b7561591519b1fa84e6f3437a8fdaa099e7", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "43e2d246-f70d-414d-b127-b9ebc4fe4260": {"doc_hash": "eb1e186bc5b3e9c095c89470703894598b2650ef87e361ed95e9cfa73ea6a41e", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "12e5eefc-7b8e-4fd3-b76d-5a63b6f91ae0": {"doc_hash": "88d068418a3b3d23c14bf6e5b89a82aecc42b0386d8fd5e3dfdb76315ea01601", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "e93a299a-7b92-44b3-8fac-c6f7cc75160a": {"doc_hash": "da8737e5be8f01c8d0a58cf69d9008c14e4d08e5bca2157b349750ccf2ce6878", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "1ecc8617-5719-41e3-962b-dd958ceb613b": {"doc_hash": "4566f31350bb84c7884d63d41b52f9141b50f54d69a29ec8ea5593c99d386728", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "873af012-f235-4246-afe6-44635ee0686d": {"doc_hash": "3869700a383cc85d7e408a41e1996812f116c689e2732dbb3ad7e584a2e5d2ff", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "4751fc01-3853-409f-b486-2c138f075294": {"doc_hash": "6f01d7cd70ae60bccffea5f0e6c1b4cb2506a521a48da20363e4140b8d9f3e38", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "9a49cf7d-d0cc-4a34-9b38-7a399ba010bc": {"doc_hash": "f69dbb16cc9a3ab4b3f43c3dbb8fd497c1cf35eca803ff81ca88e325c72f45d0", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "f311b8c4-4d3a-41ff-8081-165f4b004fcc": {"doc_hash": "dcad8bcab52a04161658ebfb7ccab8ecdc6c71889a7bae5bdf51daf415b69386", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "c532b3e3-db96-4b75-9eeb-a4f1e4f80e1e": {"doc_hash": "99cbdb05d82b709896059640ca45fb19bf48bb14d2f07fc5e16d220bda506657", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "bd2b6a05-9b97-484a-b68c-20d57123a569": {"doc_hash": "0d69f871f882926bab8960938453ac31d96db243d5d5874d802bbd0d4f4abaad", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "4372b2dc-c7dc-4ce2-8be4-a502e4913aa6": {"doc_hash": "d669b93af41179d1d063195fe3dc9f892953aeb2931ba1a2d107a38e1f0f5519", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "ab54e2b8-6192-4865-9f38-9b3994d9d260": {"doc_hash": "7e350cc16b7191804107b5e0694060d123dc98c6fdd8cb59b3d0c109581c058c", "ref_doc_id": "cd432e14-6e39-47b9-88fa-2fa321fca7c2"}, "fb573523-e553-4dd9-ba46-17aa28396c71": {"doc_hash": "2aca70f6ca7cc8031cc6e8449b6e6e1155f2b0980f50812cdfa42537043dfc55", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "d30a0feb-15a6-43aa-a179-dba6c28ca67c": {"doc_hash": "75111be4125356c34f800d51bd7e398d45e3bf724456801bee729760b8fce54c", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "c2468c24-5034-49fa-aac5-5acaa56b6d3d": {"doc_hash": "1a45b2c55359b9d7deaef62f0fc734e1b5f056e988eb1571b3c1410390713729", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "7f83d19a-1926-4c4f-948a-181504c1add4": {"doc_hash": "53794076d0adbcbc3694a64756768e0ae7f94b582b8d87d9cb6e330184dc99c2", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "df993d7f-7fc1-43b1-8573-efbf0d3447ca": {"doc_hash": "321d899d822cb68cc0d71e3c851dc3dd73e9ac23af2e497b8fb99fb0aa0129d2", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "4724f829-484b-418d-91ae-dc9f93098701": {"doc_hash": "691dcc4092bba16e057bd207e546615d4946c6067ce4d28de603b09025ad3fe8", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "64e1848b-da30-42c1-aa8c-de09de026e6a": {"doc_hash": "de37dff12a6bbe2289a7cad160c4459ff7dd71efb5f2b1fb22049158afbb52c2", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "b0496584-5380-4a64-9f1d-5abf282465bc": {"doc_hash": "8a17d4294e99190910f133d159dec4a8e7e7c1f25ab71c862747cb3b8f6ff7da", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "0f57243a-a037-4699-a869-702a50ac906d": {"doc_hash": "d5fdc5849870ab4291391c12f4ed3daaa1080bbbff716e875e949a3733f43857", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "f415084f-90bb-45bc-b11c-7e14f1f06f6b": {"doc_hash": "df9111b1fbc889f59fe5e9a990755482b492570426338fa5cdeb21bc84299b4d", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "f12125b4-14f4-4fee-a71a-9cc8f81c0d63": {"doc_hash": "2a9b323ce3748e1cf5739d09ba1dd0f451ec0a02d4635f8a16621f308b7e4150", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "18119403-7a62-40f4-b1cb-663a38b34b9a": {"doc_hash": "f410227588dcf7f0006d4b0dc38ed3b2ab5a5682dacdfe5823d4257b4540396d", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "2bf5233a-3754-42ec-b624-52bc36407ebf": {"doc_hash": "33df30c29704e8d91cbfd39180ab3f0e23177b1d43a62d2020c68aa416066b2e", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "f86b732a-bc6f-4701-bd75-d31ca09e9bb6": {"doc_hash": "6d5829d17926583e3587f8526cea24a12829d921336152be047c7f27cec9d126", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "8314f892-6b71-4a09-b2b6-c10c270f84f4": {"doc_hash": "fc2392a37f1d863e5ca5d56e57e2f337412d6852ec55a5766f31b62e10684f9c", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "fb281b36-5c5d-4add-b1d8-033fbec81fab": {"doc_hash": "ee637aa4a502f04cc557c3aff3e603942c3a5d1a52042925802d89bf9e86b824", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "1aacc820-955a-4257-a784-1d523c18369b": {"doc_hash": "837893328bc55e079cce736e0cebc817c1bb030bfca6ed2b2741a01606aa3037", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "ac22d7c4-eef1-4bf8-8d39-08779184b92c": {"doc_hash": "d4fe3044b771bf87338ee6129ead95771a3f3ade16c513e86fa75b42249ab3c8", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "a8abadbf-12e9-4bf1-a6ef-9c30d0fa94be": {"doc_hash": "24c2ae1da4914d9a4131ba79429ae8af2338af5cf8a3a3e71701f8362281eb61", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "5cef8176-765c-4e04-a9d1-debacb7b2a99": {"doc_hash": "98494ab0865da5e19971a4197efba3f17f16ded779397b4836f0057ca00b783e", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "ed3b5309-5b3a-4f86-bd53-2af31cb2291a": {"doc_hash": "9df7ad0098c29afe270093da2c8eeb27527cc79f277a4c0f3bc8af5feda6a199", "ref_doc_id": "e3dabdd8-5aad-433f-9038-bd228a38d7f0"}, "42245d64-a55d-4b90-bf2d-a3b4cc4060f2": {"doc_hash": "bd49fab7ca891a7a031c082269eaaa7b7bfd67115ba1498cf503a653322bbee2", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "efd5d409-2dfe-4233-b199-e52a776a84c0": {"doc_hash": "51756e3686cbd20085e649d8b044bebcca362ec02e7de140ec36fcdbd806cb74", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "49bd4eb6-a94f-4427-90ea-32f470786c3d": {"doc_hash": "0d2c914c9ce89474e3d8d2473d92f677bff1821d179d63907802cf2acda6d22f", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "b2953fe2-adf2-43b0-844f-6476a7b70bad": {"doc_hash": "dddbf40c09d008a369b48d1da535fee991ac81f5c0354130d683ffbdc9f90c5c", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "e9b38bbf-853b-400d-966e-a1d44d3acda0": {"doc_hash": "ca8b83290fc278fa01528035f0b11452e1f9b863940551ec8ecc1f0f889eeb55", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "e89674c9-3bca-486e-bb46-995d44cfae3a": {"doc_hash": "2107b40b92cd88051d9d47fd5d9e5a147b4376a07c323f2a883e6e76de18570c", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "48d1ee29-1c8c-4305-9322-6cf80f2416a1": {"doc_hash": "9bbbcee3ea014d379e29ef63e35e38f207f6289080168994b0801fbd695ae63a", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "8cd73546-7cd9-4a9c-8b52-633cf9b0e823": {"doc_hash": "f3b5274649bf6add9762b3d7d262275cb15c29699f3f63edc51aa740de8c8ef0", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "497ce74c-3b9a-481c-aa5a-76a96f0f812d": {"doc_hash": "6ebe96f30169d73e347031d996cf22a3be5b143735a73c4fc077fc823b321649", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "f0a97a85-6525-423f-8728-a8ea560db9d3": {"doc_hash": "6197cf1c0f17e6713e765968ba252c80486b2f4c5390c21033eac7cb7283eb03", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "2482b5f5-c155-46cb-83df-fbe7c177e78d": {"doc_hash": "22000df43fccf425c7fed0bdcce808c9c6326dfaeca0d1e7354c68c00ba53cfd", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "27fc0892-a5ec-4715-b091-684c47640808": {"doc_hash": "82f10fa101789b8ecb3a9c2335ffa9f53e6200e0c43c21e35f97485ae39d7468", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "c260a7d7-2292-4879-8a50-95a7b2752637": {"doc_hash": "55714a59c3a6be4c31effae797a87ad1f47f1a0e2c72ed4b4c37726134210ca4", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "30786cf3-9dec-4dd8-b651-39dc7f9352f7": {"doc_hash": "320ef80b03fab84c7f4c3f8a07f6faee71aca038484830b775b239c6e8db05ac", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "882d2d84-eea5-4338-901b-906f5411791c": {"doc_hash": "dbd8ebe66354d03238c4d8f26fa5da491aa681a1589e60f02aca894213d2a686", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "5baaa71a-ac23-4756-a430-470b69ddb90f": {"doc_hash": "64933d039a5edec9469c11258180656fd80c7d6fb82f7d57d87e2ff3e89003ce", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "04af0390-afce-4f47-ae80-44143f2d00ed": {"doc_hash": "6d98de787941f993fb08fe31410afd8a7bc2cdb75da0c149d7486c9d6e5ba8be", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "7c29078f-0b9c-42aa-b8b1-9763b18afa0e": {"doc_hash": "a22a1580fb27d9ae6bba12abc74dc75fd8be19d78a93e1e965b7dad86cbcc288", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "47913828-89e8-4816-9f74-d9add8b27729": {"doc_hash": "5bdee1908ff9adad8a24e501309df644f3f4ba6b29607cf95080ba35d3e7d884", "ref_doc_id": "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252"}, "21455c87-6eff-4b11-b87d-ca0f653af770": {"doc_hash": "185af9b25da021c0aef7a74c2c34881b099ffd81b297c7cf0e372b41725e287e", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "bd4ff66e-54c0-46a5-b819-554c56007aa4": {"doc_hash": "2143db9a7039db5c195edf80ae7b876617d1ef304c5c4bf7c594532e8c79b5a8", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "f25be417-2a78-4e8b-8626-bf41669292f6": {"doc_hash": "f643f549835246e605cef148b42df251fd8de4ef8d634806bd294a2e0ce79525", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "b3db26af-84f0-4b1b-b924-53c60ade9477": {"doc_hash": "2602cb7f11481cdaca71f3d33f7b2de3b4ee3fa5b664ce2d03abbddbf2542eb0", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "a0ec53c9-d436-4072-b46b-84a06ad9202a": {"doc_hash": "e1667df5b5a0b23c64ab739a406b482b5c4aacf1b16d382360243291eeeb227b", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "bca1875c-5182-4e40-9725-0ef8af8ccc15": {"doc_hash": "5c441444bbdf3e943d9bdc79f38175cd3f356a9e1d6527873454b4ead3c7ba27", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "e9e8bdb0-c25c-4fd0-a992-36103013afe0": {"doc_hash": "3a54a7de26705c52506802a5dc9455a369d340efbcebc275244ef854cb6c3f08", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "69ed922f-4896-4f4a-bd21-0f9ccf1fb1a8": {"doc_hash": "6659e801c7a212905476775723386195684ba39ffe8106de3fa95532be6cd0c7", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "454dd7f4-6244-41d2-834c-4177a59def4b": {"doc_hash": "89d08a5edfbd55bc5e3a2888cfbd9d9da53ab259b5a461731f4db3c9c6ac4ea8", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "b18e9ca4-2c32-4d3d-b7ef-437025187992": {"doc_hash": "59165aa59f3e7f3a97161c54f084e825891ac3099d437c5bbe28f752ce31e766", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "b54f6165-4740-404d-bbc2-63f4742181a8": {"doc_hash": "578afb1ca14cb0e53bd6b19916caadd4075c505b089a1f71ef2c068eafe466ed", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "237391d0-7f76-4026-8577-62b18ed8f8f3": {"doc_hash": "e726fcd64556b83810d844b2cb4be652b2392ceb0f6050826a4e98a71511a12e", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "0413ad28-e5d4-4f44-9437-d850e05b30ef": {"doc_hash": "9f797af27e5aa6fc3f70a5aa93231230dcafb86c946902b4c5e1b851bbd2723c", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "074aad28-3129-4127-a7de-0233f141e54f": {"doc_hash": "91fe3c0669f3238fa14841865b2f30c33503a7d19da9397780492138c3de7cd5", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "e4f83654-18cc-4b27-90b4-45efaa9c5129": {"doc_hash": "b4dbba60832aa09789e76bb9a730949bc0210a3d68c60311136c0424ec7a93d3", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "ab21c85f-6222-4725-bea0-adf87782eb88": {"doc_hash": "128e1211a6b0fbacd40659d7f948420b8aee5c6d2d38890bbdaab397cf808a76", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "1725c2bc-7fe0-4eb2-abd4-7ba8e18271bc": {"doc_hash": "501c8c190fa85b98ce55e02512b0d5295bb3fb453bb5324847b4dbbbf8c97276", "ref_doc_id": "2dfb3a05-26da-4478-a3a7-94617c67271c"}, "43b284d8-6b27-4d0b-9f61-739fd80d9a25": {"doc_hash": "9733bcb9ceb7417f1ee91350d4fcc05fee670e1584bb943ab858ee7a59d6d460", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "cdc41274-c4a9-4beb-9cf7-f279da071d87": {"doc_hash": "3cf4170a9907001b8ecc14dd4db04bcd68bad0ec78c685eeff01f6af0bbb0cde", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "7439a986-f98d-4304-9209-54997c0db3a0": {"doc_hash": "75a405c7b88267869b6e315038b9cc9f9255702a1d12bc5afbcab3fb6c3ef957", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "3774e732-5fdf-481a-905a-977452468483": {"doc_hash": "d083c0521dcf3d0bf5dc696b13806c7ed3bf978525e9c057f7abd469a73ded12", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "69489ca9-f47f-4b69-a373-9ce0d9c38a48": {"doc_hash": "297b134152ca0a7c3dd2010c098559b126c3373bb969ecd841ae5f3739df168e", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "2a4b8114-a257-42b7-bdae-89836d41b0b3": {"doc_hash": "b2fe50309292e4e29ae4ea39f4a7ce5c046d20c09769f654f0e4f62d119b65a7", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "2106419f-e98f-417b-aab0-46ed02f273b3": {"doc_hash": "3baad82b97b455d837d2bbc5915808289761cbfc23bc8e20611490559d7f779d", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "0ae1bd7f-08ec-4b29-933b-9a2ab013a7fd": {"doc_hash": "017e20faf8d188f04ad9707b9c45219503bd1f6465f9398a0558eb3316fc88ea", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "69656d43-f6f1-4d2d-b462-ade11e3b1ff0": {"doc_hash": "e30bc870df5cb3bfb4a9c1edb35bac8a0315e4ab930009da521140e1ba61a6a5", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "461ba17c-e075-4b2c-a12e-ce2485bc7d3f": {"doc_hash": "5169308a73703b9eb83b1487a0690b241ec4efa5d8a908b59578de55a3325588", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "22619191-4ca7-4e8b-b273-a331eab41384": {"doc_hash": "d5abb7555b20b1cc819773436496e611c65ea9fc33cc0006bb9d69ed677ee5df", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "0a3e22b6-534e-4cda-8f02-d56b3a4135fd": {"doc_hash": "0c2c01620eb64594392a2b084dc65c19e9e456a19c0eaac5f9cdbe42e10c2e10", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "3a126231-57d1-4db7-b51a-06fe46249ecc": {"doc_hash": "2866ee48779ee061c1c01d13688e35c9b74115b775fc646b39ce7adaad178611", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "c743fa55-3b22-4245-a82e-d77f1cfda0b4": {"doc_hash": "8b1e90b31fb0992d4a9c55a5df53f063d181e67d6976b20dc05e861f08a50ed6", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "514f28bb-0dc1-4ef0-84f8-b74abbd09376": {"doc_hash": "6ce5fd3c0cbff5536d5b95c1e0becaad6f65969c4e7ce4a0387b6ad99bbed715", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "41827d0f-b5c3-43ce-aa06-051f18381a80": {"doc_hash": "bb4834e448a0afd389726d4e0ab2f774b475410a7f6c01eb72674d54d9a22b13", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "81c28042-17bb-40ec-9e35-87a3eb53d0ca": {"doc_hash": "bce253164c90494a945861079a3827c9618bae718d31a0c7d652eb2592b4b2ba", "ref_doc_id": "7bb52ad1-2922-4458-84b3-a1c9eea4d572"}, "f3ead348-569b-4155-ba93-d492960a9f0b": {"doc_hash": "65eace8ae6a74726833058af38247b56d30d6184e6bb30c728d314f866f4e90e", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "7b4137ab-abc8-4718-8c2a-cc08895b735a": {"doc_hash": "af982efae855c8fed1307f66846aebbda75fd0083ad9c0770ac3f6c40475a859", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "c3b8d24e-4da7-4f9c-b571-6618fb935d75": {"doc_hash": "2c91a2669738ba9e3081536a53498a04cc54a5a6e4e23732d3176a826d193d10", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "4d1a79c3-932c-44ba-9212-d3744d3403cd": {"doc_hash": "0176ae0bc40d3eaa5d12a21a5aabc507487aa43b1d20236f070181d538c06c89", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "2a68887e-86a2-4c42-895e-c44a52b4b266": {"doc_hash": "a9b9f19fe6834694803db1aa2a58f5289d11ab02f95d397b799ef77e21e6662c", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "540b244d-5bd5-4d50-bac9-ded7692de678": {"doc_hash": "6bd5fca675d4a8c9370e6d40217dccd1d04210d4de01a15645a6b3d424e3cbbc", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "58775dc0-40fe-4c10-8f53-64bd99c33939": {"doc_hash": "5da534ab6083ca0215c3891cc5a919e7873246e7de75d0f7c9cb98d6c00d4c9f", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "660389fc-1a3d-4a74-8546-d2fb473fa5a2": {"doc_hash": "8a658600ea5c93bc41a563ef0fd06e74b52117e70e1b4db0502578ce241672fa", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "a612802e-5ee3-46ad-becc-b16089dd7c7b": {"doc_hash": "5c740aa1778a67a666eccf0bf6c31c30914485e8e37b5bf951c89419e11690f4", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "dc27d7ce-74cb-44da-b797-4d4c69d65c7d": {"doc_hash": "d0fcf086078e829400dd57bf94a43545aec58b3fdc569e8a9af79bd7afff4078", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "561623fa-9a36-4a3c-98b1-cec0c61222c8": {"doc_hash": "d4c9b83a6217d8ccac96f16bf5de9a8bcb5632064e1c7688191e8564d0312209", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "857b438a-71bb-475e-90b6-454b7e4c42e6": {"doc_hash": "457170fc10c50b5e28e33821dd833e64ff4e2ef79b15614479670beead31f850", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "b65e98f9-55e3-4403-82af-38022bc7cc7d": {"doc_hash": "2b472267fed44171c61a1c25297c733b45ace5a7d0271e15b82835161c7f3e13", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "7ab1f55b-1b55-45d3-9779-146542b4260f": {"doc_hash": "c01694a9672e842e2eb917e7618bca591b1b35fe9fb50e417382eddbbdf77fa9", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "a627f41a-17df-4f8f-b11a-0335b71f9fe5": {"doc_hash": "714fec90b121f8c5300ccea94e8172ecedf5c4201c2968e8e9132132479cc559", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "f1cea348-2749-46e7-8296-423ba887349e": {"doc_hash": "8685ae0908aba7cdcd580383b7c49cbabc0dd451f5bf6d252b426ed0b53f9993", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "b7bcb8ff-d23b-4442-a661-8ab5716ac7e1": {"doc_hash": "fe7bc6465b31141322976a366f0c0b1548a65520c07918a826b1d6a002fa170a", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "4f89fd6f-0369-465f-bef6-0d2b0095978b": {"doc_hash": "a7732af9d51b67349cb4c49a424277303e891229c9958afa433d98a28cd73296", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "d164f2ed-1b10-4c1e-821e-f49ffeba1c74": {"doc_hash": "7330df3f83fecf0c669d35df2000bb98ce1ccdd79e79cefb6897887ef875ff28", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "3b7ab8ce-5781-4798-89bb-e552417836f3": {"doc_hash": "ec02b96e81c11ba6e7ee0ff276d5b87c5dce0eb660f37a1d9d1720ee5c7ce6d2", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "afba3be8-d9cc-48fd-af98-96bc2c050cff": {"doc_hash": "6db517f65f75e8fe4267536f8f280e8f3de8b099b0fc200bf1af260fe536d516", "ref_doc_id": "7113bdf5-385f-4ee7-aa48-4766ed2853e8"}, "eb500f35-3c0e-4b92-9f4f-9417aedad024": {"doc_hash": "c3d07c6621b7693c4a6bb61fb9ac051a41caac9e2b72233b1687a25e20ed52d2", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "85ad8cab-bc38-4275-8f73-8e8e07a3f921": {"doc_hash": "508adb65744ffcb2e2a82d3956c9b417cd436a19a475ea8920d743508f60c89e", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "a6b65184-8e52-41d5-a27d-56fc3d442c16": {"doc_hash": "74f611342eec65147199db51ad631390a0babbe9cfbc9e81cb1dd3ea908e39eb", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "73fe196b-b0d7-4fba-86ae-3e01aae760a6": {"doc_hash": "7708af525df42c0945659e0bddd9e5a0a02d4f388e8775c219f058ca4f0ec292", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "f63b88e6-b643-48dd-807a-e240e50fa93b": {"doc_hash": "83ce35cc0cef38edfe896f4226f05c90a0665b11675ad29abc1dc095b8e3354d", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "223f5381-6e99-4c6d-8c48-7b8a35cf00fe": {"doc_hash": "e6169fafdaa94ba92eaf310c46daecb576094ebfdeff883c25beefab0e52238e", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "d905754d-a061-412d-9eb4-59f136ffcd9a": {"doc_hash": "d50967949a662e90f01a5fd3aee95e9434ee0f7bdd74ac7c21720149f24f7a4b", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "0d3e173e-eff0-4cd2-bc6b-47ecafafd94e": {"doc_hash": "015c0169e6645fc2174d06555541b90d20561a5b1957c6f82523fe94abc27901", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "241255c5-98ce-4207-a1c7-b7f8f19c55d1": {"doc_hash": "6da14e9956ae055883cd984bcf03417b3ba68b06061e1b0f3a3e44810719fdf2", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "b1d786f1-fb6f-469d-8a88-c0bf4c93c0e9": {"doc_hash": "6e691710922b50c60a00b438bed1c81e5994177a2d74c37268846d334a4e7435", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "7bf05e53-ed2a-4656-a6d6-cbd8cb20dc63": {"doc_hash": "a423735c47900f18607e25f16cac198c905b412b4bfd18ffb7213fb89d636c68", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "8a15bb20-3c94-4df6-a186-5dc8f58846e2": {"doc_hash": "91d772d920a568c129e2cf835b8beeffdecfddf13c86b0c49ce838afaec0da2e", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "e4981fd4-ce4c-4168-9512-46f9580a470e": {"doc_hash": "7891038813841807982ac142e699cb7e8213b6fdb2eab8ec5f69d86437fc57bf", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "5f260dc1-2265-4436-890f-39f453509aa0": {"doc_hash": "757a5ae1292cbc07aac8d60d065369d46fa4916041cd9898f6e020ffac2517bb", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "f27cdd8c-96ab-4276-ac18-fbb48cd884fe": {"doc_hash": "f4b16e38d4e0e77d6aab66f67cd1e7f0eaa171b781c2baa3c1d2631953d3e437", "ref_doc_id": "c81f6e92-223c-40b9-a4c6-2061bdf770de"}, "f0de7f71-b31f-490d-b438-3f34db9ee514": {"doc_hash": "46bc8a97206bd93a9b19eb2a86e244367bb6bbddf261f20eb0612f43dd20c9a6", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "d9dc1854-6934-4ce8-9a2c-44175342c586": {"doc_hash": "d1be9fe8b238ecf2ab51996f3dd56bf511bd73c023370b0321f5e0576288d658", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "360774ff-6388-4974-b4fa-7a879845851d": {"doc_hash": "2af3ea16d014794d563db74599ae36d9b1ae4ce86c043d921bf76963afa3fc72", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "f7d5c0dd-3a97-46c1-b546-8dd0d1904c70": {"doc_hash": "7f30455cff571d52489c6aea1a55d128c0d430b4fd22e4184706ebad870ea7f1", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "2ce4f9d3-06df-45ab-8ae0-3be5242c5323": {"doc_hash": "ba01bc663d891e99afa22001579ab50848b8e2168bd43109a2c8beb41c9fd007", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "129ea801-ddd4-4360-9645-dfdc65758741": {"doc_hash": "1e5b9efdda7a3f6e9817b73318203b7cb40010099a724a89724d570535797794", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "3c8f8758-7f3d-4434-91e2-6bc32c429dc2": {"doc_hash": "b6a297998a63d60a765b90814f9d093242eb5e78335a5ec0f8886320e1bf9cc1", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "7915ebc7-fae5-46e6-8ac6-ecfd38e29f31": {"doc_hash": "523f0d7a896306a63626dba4e1d599eb7361b452bcc312af082db758f7e11489", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "8636d026-5c95-4caf-89d4-f263cea8b114": {"doc_hash": "847a4c3828b58fe22ea8fac7408d3dc81efd80330234c346e6a9a0a2c751c17b", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "5b347cda-fb3a-4d55-98f7-0018509822a6": {"doc_hash": "21e41bd398f34dce3b78ff625987a21206b3ea693667836f527dbaec1657c80a", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "32da04e4-b779-4d0d-8da4-fb99086dacd5": {"doc_hash": "ef551af27e2232e09993d1acb3ad3ab32c8f017ab50742a68045d2004c1a8bf6", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "9c13633e-7ccb-4314-a25f-f0a0d04f9af2": {"doc_hash": "7833e2407f736a8fad14885e3036e880a071a3085ad8279682f5c8d8062d33a2", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "02fd0e88-481b-47d4-8941-7605ce06583b": {"doc_hash": "c2a37256d3a7e7e7566f85eb6a2d51ea612853381c686676039920baa6f48834", "ref_doc_id": "c0850b0e-196f-49b6-8d0d-75fa79b6c813"}, "f419adfd-3ba5-45c9-b60e-f8f23247ce2d": {"doc_hash": "8ff09d33ad00dbae4581429768ff2de91fcccafea2a247f405d8a45f50d4f100", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "134cf7bc-7833-483f-9b2f-abb4f764cb8e": {"doc_hash": "643d168d191230ca8829ef52eb5fc4e6a7011c648189f37f8880eb1a32c6aca1", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "66e31c2d-7343-4aa9-a2b2-ec37fabf6c91": {"doc_hash": "c84b755fbc2e3c9564d3508380e867bd0960e3f7cfefb7c0c425f0250c85db8f", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "458a603f-3872-4068-9fc3-8dc4b7453fd8": {"doc_hash": "5596150b3aca4d1a87f809002cf1eec037a8d8af4cac64461774fd648ec75a6f", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "502b1bbc-9259-44a8-b24a-fc4f77bc0729": {"doc_hash": "76640937b86e77e0e4058f32590071a57b6c4aef4792e8b5554f3e03f82ebab5", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "db445ba8-52f2-49d3-a3c2-39f5f3c026f4": {"doc_hash": "07643cea2f9fcd12fe5589601b9daf15f55a2900262b71e72deff3db5a37b543", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "9a293bee-6635-4a99-9920-f7234a3a1268": {"doc_hash": "0c1ad7a422ae40fcb388acfda4b0ea07f10edbd617f27944b1aac18eefc611b8", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "0c3e0308-c183-48de-9288-f906ecb0211e": {"doc_hash": "1296a5a34f6516d296716f16eb7ac6ce04e691a7db93c98cb822b75f97c4dfef", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "a3d731c2-9047-40a1-b9fe-163097b9e735": {"doc_hash": "a69bc11a142338587fc85fa30745201f478a97051a0bae51eb2b52daae0b4799", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "64d52d44-cfa9-4bc9-9a47-362eca8f2485": {"doc_hash": "68a350968ac897bc04faa28c56fd0f1e43f295fe156527db566af99df11b92e9", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "066b5237-6b40-47c5-af49-62354a1b877f": {"doc_hash": "a4b9f9e64a4b7416fbccf97db666d5fef9fba71d3a331020e81e857035ef9550", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "2aa5a554-22cd-42cc-8041-483b311c6ac3": {"doc_hash": "31f44d4cb8a84e0c4e41cfbb425467afbbbcb0450214021d616ddf4e3a6b1bbc", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "9f537312-c6a6-4e96-aba3-f69d39b7ab23": {"doc_hash": "49876dba7257da1db02dc89f0a9a699fe93f0efa948ec6b6deb69d0a449e5809", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "2ce9e252-b553-46c2-9381-433d8244c48f": {"doc_hash": "57e1889b11c5d5c5cdd9fadbfbd402af394f796086fd635fde4ea1a99282cdf5", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "fa1e6c17-8194-4668-9d0b-77dd1dbddbda": {"doc_hash": "f90599bd4807c6d9ef7707212806bc0a6d04c60431bb967563d4305e0bb5022f", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "a1b18211-8e50-4abc-8822-55dfc5ab5aef": {"doc_hash": "ae54bfb067ad458c1d15c9fc2ecb2bb71c8f68705cd784c1c9e9b50c85d1913a", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "31ce54a6-5319-4edd-ac16-74f55bb4db23": {"doc_hash": "d0c7a8f90b610cfb06ee73454c74c9a7e0d247c27c71b0195ae488949c2468fc", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "8826e3f6-3b19-45df-9694-f991745d989a": {"doc_hash": "908f8ac33cbda7d82927ffdfcbe9d5ea335df5f2fcf7686c310d2311757e091a", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "9cd13924-535d-44da-9e1e-5a49bf960d36": {"doc_hash": "0f9d465ba9ef30c01d654d4f38a0336ef57cf114cebe9c062393f11206ffa3b0", "ref_doc_id": "66268ab9-4892-43da-9f34-91db9bd2d796"}, "704e3bc9-e426-4f23-808d-1c5b8820881c": {"doc_hash": "d84db9bdf99dc0eea10356afa8569858c1fbb9b4efe7cc910cb1a1a0da53c7f3", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "fbc15012-3ac8-49be-9f8d-6ccf4f8ef00a": {"doc_hash": "c4809067c911d87e55302f2e3229b7163906ccda1f13a08f5e74fad2e1d5ebb2", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "ccab591d-4dd1-49e6-aac5-cb94e78f95e0": {"doc_hash": "b059f0360759f5ea7f3c3da0e37ca6a217f67c599c556c70cf09a33bb6405e62", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "1646407b-5691-4f92-a576-cc7361435313": {"doc_hash": "207f115b1075b99fbf4b9f3978c2f39dc4304a908e2a422807d22aae0af89ac6", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "6d2026d9-9e8d-463b-ab71-684cc8a51d7e": {"doc_hash": "5a9cd3e1fcfffcdd3459d81682aaf449aada199f38d9d22aee2dcebf7e7975a5", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "934020f6-5de0-412b-927e-14cf6c3f0248": {"doc_hash": "874b2a0a5236003dd8e1c9666e3435dddacecfd0cfc9f96be3a0cde57bed7780", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "68b994fd-9e7b-489c-b050-61f0b2b498bc": {"doc_hash": "c9ccf6726a4b3952b23087fe908372e1e98da227cd908baffe4d91fc16d9b939", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "e5a8132c-0fc0-46d8-be8e-10635881664a": {"doc_hash": "17618604a42a933c34c3cf0bb09eccf7488a681fffd558081116b1892181ea82", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "7c4ffc91-fa3f-4dee-8aad-2217d9c09eb7": {"doc_hash": "332bb7b1f4d01cce683899c3bf94c51491064d75834f88c2029b37453c2fb4ef", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "98bbcb90-bbd3-4cd5-a1c3-692a2b21b7cc": {"doc_hash": "e446ff343e48bb0753a946c32e5abd6c4cbbd8e79c9c55277f0d0428daf205bd", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "c54d93d5-b2a0-42fa-9f47-b4b56543eac7": {"doc_hash": "89aeaa7454faa379b7dffc389508efa1087acb9f13ad7ea60a5247a9a9d9e1a3", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "086340db-14ee-41e5-8912-a5bd30feae6a": {"doc_hash": "4be0e7bb4846a4a5536af0a8030f1648cac0fa41d9ac6eb16d68b516c02d0346", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "8cead0a4-b126-4da8-883c-e82a8ae6a170": {"doc_hash": "1697c24476dcbe3b1ccde0960e47581ada7de001970a00e44e0c6049a0e54bd4", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "e0241a46-9312-4459-a096-4386280cbb92": {"doc_hash": "aed3366263539fd4fffb00caa12a960eb01d1c6e456c9d73b449c192586cc074", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "5aa66390-7154-468e-bf6c-555268d33b17": {"doc_hash": "da2ee6abf7a610bc201cd49504099a3d911be1070b16983fbc46df93f3ece88b", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "ff4d1feb-5381-4bd1-baff-69ecc403a68d": {"doc_hash": "82bc9db2a28b2e30dcaafd9606755804e3553e642e95f07bcfb43b64d666443b", "ref_doc_id": "5a074724-3e88-4807-8a0f-59f5fa5107d5"}, "9823a5ea-960a-40cd-87d2-12de295413c5": {"doc_hash": "c65541bc724740a0f24778dac414ef6d1873665661d06e0c647eed7372667b19", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "c9606c4c-2543-4396-8625-a44e2edb2073": {"doc_hash": "52046009614c831cce8a60a84d93093e4fde477f18b09b5be0ad73bfc2caf80d", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "b759f92f-ee34-4db0-8008-d4b2a8c50a56": {"doc_hash": "02d42658171a2af4815c90e5567d6fe9b8ae97bc28b5074061a17c38415bac4b", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "dcb59bcb-92bc-4ad5-99a3-f692bc93ea1e": {"doc_hash": "cea7190ddaf07533022e2c775135fa5cbab4c95420a605e5c6640e8b2a5ddba0", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "9b4a5066-b73d-45c3-ae21-ce9286163943": {"doc_hash": "12e83c9e7a69a8f313a5822a5f5725db8c1fd95a3ff57092f621d29cdf95802b", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "74cc3092-f13a-4894-8823-a266ef554235": {"doc_hash": "9dd83fe0ef288f93872e6fd26f717e929b2391c7a86573778689339d9570813e", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "3314f7b9-3704-46a6-9581-5601b8e4c345": {"doc_hash": "62de1c0e2757da715f1e522da7f778e3f0892b1fb7f288d36313295a0f7f12e5", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "dbffaf0c-230d-4a4d-ae0f-7502a25e69bc": {"doc_hash": "f3b14b312824e819cbb763203583a82cf914c37c02ab8691e130e724435c6c6a", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "efdb9dc0-6108-48f5-9706-c06bd683271c": {"doc_hash": "00d1e607d1853f0a818fd16ce4d7f22b41863e0bddeca6c1859c61bf6669dae9", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "4706add1-4082-46d2-838b-f0cd016e92fb": {"doc_hash": "eec12ddcf4fa59b6328042f77d8880708de2f2c6ecbfa17906a192a71aed46d9", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "ddec4dd9-7362-4e27-9738-a619c7c5cd73": {"doc_hash": "249e53e63ec845fc0077fc553cc9b8331e2ae8a29244e7f0f924ebc12168aa6f", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "5b4fca0b-2f2a-4914-974e-97da58b7de65": {"doc_hash": "d5d8ace9e0e4faa5d5434e9591a6021b071d4fb074c6574295f70e114c1c9c08", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "b2ae76ac-1461-4015-b43b-db153311bfcc": {"doc_hash": "aa99194e074184f5ebc2e5bfd84e9643fa4d0344d44966755b371c5de37ff545", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "12c5c56d-3f0d-4838-b122-fec3a1e16946": {"doc_hash": "5d6902d51fd76144c51056051872eebbc428694be108fcb2a93e3abc3579e237", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "0b343946-72f1-4986-8a70-5bbec30c61e8": {"doc_hash": "a61a4bd1735c32423c1c860f9b923e08d9a2169d6d3eac6d2bdb34edce42d918", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "0a21ec32-ce14-471f-8985-fdcdce685ebd": {"doc_hash": "e9f5a3b65ac2850cf30608d8ff0aa7dda4de483df9f2b0487a5ebce75c631e69", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "82c1ece9-f24a-4377-b3d4-f9bd496cf318": {"doc_hash": "fd0aa9bc8d5f77b394b5bc747e8c47afd384f789e43b46bf27a59f70ad202c7c", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "d1ef331a-ebd2-4174-9e2c-73824652a44c": {"doc_hash": "db2f30d3e970a631c51281a2b7b028242defae7fb9523c1e185adc72ce6e9291", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "18666948-8150-42e1-a699-cc72d821aa80": {"doc_hash": "daafb587120f3b05eb6a777f194950c332642eca9aba58fedb02f0fed4b4df1c", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "40087d2c-0acc-4d04-85e3-a8a1ad0d6292": {"doc_hash": "4e12b1c4d3247f859d43fc256441c9a87a3f99917c00c033cec325bdd3e95072", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "c4ff466a-736d-400d-8aba-7c65c526a7be": {"doc_hash": "06d8005861e4a276ca57eb6e35e1d56d51113c3c1108f062f10c709444768eb6", "ref_doc_id": "01a32722-91b0-499f-aeac-be881aa19ee6"}, "288c1ba1-9618-48b1-8045-cc9b2d18faab": {"doc_hash": "f71b6cb3180f84ee851dc235cdc48464a77ad3fd31d4e410a4a061276588cc92", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "aa250749-ade5-4767-b16f-38232adbb12f": {"doc_hash": "3348f0828ec99b65874452271090712b25d0c9d7a62a32f7996b1edfdab17873", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "3390fa2d-16f2-44b1-86b9-a48fbd8790f3": {"doc_hash": "94700379e941491d41e0cdbd01038fe2a99851a10d6d89dd2cd7fbabe179f780", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "25a8b9fd-f101-4677-b28d-ba42f66996bb": {"doc_hash": "652bd3f2fc14f3d275c1703422942ae8415043bc762e783c94cb90567d1d4a96", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "619bf745-c673-45d9-a329-36e4919764f5": {"doc_hash": "c41027f99fe253ad2a7a1acafdb8b179e81fae5b841604e839f9730d01ff5320", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "3be44112-77f8-4691-8603-ddaafcfd6838": {"doc_hash": "b26d20bb69e9afe698e57ff35656ea17b5c87b318c4108cdd0fe8963f465e426", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "2ddd95c8-a18e-4484-a2ca-e58f3c0d370f": {"doc_hash": "b222e5926e3cf9644d61056e9993f3b9a4acbcd116bf33c29a54a5114deb4590", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "cf4fcfe8-ca0a-4200-b77a-01e73e31e000": {"doc_hash": "d3fbcb498cb8e99aee7a1bebc1787b7b924876d962e34c323cb24178b245fb74", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "4259711b-620c-403d-93db-8de01cccaf42": {"doc_hash": "ddea8e2c02874d1fd7693839bd09fd906cbb76615817a6bd9c520c98ef434420", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "9024357f-6ec6-4f97-8f0e-4d1601536b14": {"doc_hash": "16ecaf9892328e3c7f6c0a9c93ff727a4e6424ac3addfc6a5f620463a09349b2", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "9d181847-42d3-43a2-bd54-3883c44a68ff": {"doc_hash": "21bc9f493a4557c9bec664d9249db381212d5a53bbc0becec4b9d36890fc2962", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "c1a4ed92-0a0b-4917-adf7-96649524f076": {"doc_hash": "762dbae27244ed7319ba07b60851e6b0dc18156915ce73a41479fa5eff283d83", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "4bf16175-4804-4551-b7eb-bac9f100eebc": {"doc_hash": "7bc2d35910c325802c87efde83c6eec74eae88e3f827eb80339cb071f6bb74ef", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "b1c5742f-d29f-4620-ab75-abf6a988cd56": {"doc_hash": "0d9cd9355471c6e64188c0f63b3d3e79bf682cbaf8e6745f59e64756e7cfb2f8", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "a84526f5-dc8d-49ce-8bd8-17a5c167a449": {"doc_hash": "a88403c148917aff5015cdd174ca6b613f1e85c32ecb40b70f9313f287e4bd95", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "9abb7558-0c43-49cd-a389-221c77bcb4a2": {"doc_hash": "45c7859d8cc970f3bf3d80bb8328f5f0cd3d0849e27726b088331d21f115fa62", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "adad2815-8f2b-4e84-977d-44d507564bb8": {"doc_hash": "2e4385c8cb990a31219bb3fcc25d346b5a6d2e87efe738ca3a8809be508a18c8", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "edc30575-c408-446b-985f-8b834d4a329a": {"doc_hash": "0d1f68159801fe40c4ba23a9579e9b4e9e35b92902afa0d923c8209681539b69", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "9e34fd76-d8ab-4f77-958f-d06152b876f5": {"doc_hash": "48ce71a9d1ae5ab1315b93b7481e8647a8483ea65713fd337adba2ee51b79efa", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "acae3782-c446-4fb6-987c-f294fe89a60f": {"doc_hash": "24f0ed17001bf1ec8be4b466a70dfee8ac1df99757297fc9947719fb72774f5f", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "4aaa4ad4-9fa7-4e6c-94d1-999c9367fe4e": {"doc_hash": "b0de22c2cce31d48cc0c74999cec0ed7b9a5374d1311b5ab8126f5f05d5b3dc2", "ref_doc_id": "3ab088d2-9dd1-4aa1-bd82-b30544e415ac"}, "9c5b9b83-8e3c-4d0b-a631-59ec44e06f2f": {"doc_hash": "0f3b7032ae07e000e7b9c7b32e6a63b641b029751bf189e8261e532fed50bb85", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "b2784bb5-aab0-4a21-a9d7-1a8db734d9b8": {"doc_hash": "f899d461e5a74acdbe36d7f58dd6560d93a5b0b50fe6cee4aed9bc13274b0099", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "7032cfa4-be4c-4cb7-854b-6c39d8cbe477": {"doc_hash": "5138810eb6f9abbd5ebd2f99fdae735e04e4fc4e1f92134881c7922b90569003", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "556863d7-3709-4ca5-963a-07f461385638": {"doc_hash": "4f540286c4f669efb941a547889c93f5018130ce61857fd11e6ed9883c4879bf", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "eb4d5433-6547-4ef3-abb9-359d036b4f8e": {"doc_hash": "4b49eee58fc78e9fb25ab9406e25ac823279194965427296718f59be48f26597", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "c491e913-7df4-48eb-bc44-4da8f5759bac": {"doc_hash": "81afc21aeacf88fb4c531cd04752b48f19e71c3a9c73bcafdea6d3ba13513fc2", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "9055c2d1-de00-4dae-9223-04a27cd44bdc": {"doc_hash": "3dcbcfeb0420247959aafbef04fe0ed68a86c7a8bf3c727f21d71a5f55a4468f", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "cf0d08e0-c8df-4256-87fd-6afaf0f54ef0": {"doc_hash": "d99ecc8032eee3625dbaddef829bb4b9a032974a990d6b46bf85a2c589f52132", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "05b5735e-1d9f-402e-abde-ccb0e6e7e853": {"doc_hash": "e33662eb58b2d73d963613ad8f0d3ba35007f75dcbaf7b4a2250f925c56643a0", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "f4b9f46d-61af-4188-ad55-49ba4fcc444f": {"doc_hash": "b046c6526fc6260baaf9929223a0cc85317580e58834943dd1c3e95ffe4292bb", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "88e31e6d-2d27-457c-b017-5e84b6623258": {"doc_hash": "058f8e93ad43ff6916d81d242251a4ee953c93e224c75ec73c3ceb512dc55c08", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "1f92f9ab-905e-4fd0-b006-d38cd01b5fdc": {"doc_hash": "03cfbc86be4c0fed6ef4c38b6f27c7af65acb3d393dbf98eef0269fa3b9b7f16", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "740c41d9-355c-41a4-864d-272fc7bf63b1": {"doc_hash": "a8bdaa5a4f009655e041bc19e28f6c47e4188df82a7a9d9263b38c58ecd7bdcb", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "f5ea0769-e2c8-43ef-b80b-60b5a55a70b4": {"doc_hash": "1fc79724c77a2152eaa5a1c4ca00fb2ae26dc432eacbf13037a3558e6f41402d", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "687ad6df-08db-41f3-92cc-0efa9598a413": {"doc_hash": "026973a1fccd6e52116c60000c1278c1ab4552bb3c05a50a3126a72eb5bc97dc", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "51435e71-27f2-473e-bbf3-92721735198b": {"doc_hash": "3dfe19bf9001f57babd4a6d73bfbd1372d04c7df93063512ed38b0de6da2d80a", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "6a5617b1-547d-4a64-858b-12272044541a": {"doc_hash": "f9d1b5879ec3e9fdef3a77bb4c7cda1fe74600c8104e3d17013908cfb86e7f42", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "d502349c-610d-43b4-a282-c230bc1eb15c": {"doc_hash": "32785a40dd9f46c7fa8948eafccf3cc58ee42817b9da010c90fb43537f41c511", "ref_doc_id": "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f"}, "1e68d38e-f314-4140-8a56-152eb2beff20": {"doc_hash": "3f562318fccb550bae7af668c3b98f2190695f9d6fc9e4b4d082e385c0b80220", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "d899d8cd-471a-4361-90a1-0f039a2aad2a": {"doc_hash": "0f2680c5cb00ca9d1d03554e254bcb1a9f60131682dcdbc733550892b49f28fb", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "72197b0c-5868-41e2-9f2f-ce0aa40e1853": {"doc_hash": "d68e9344d412eac2cc5d2875f29b6928ab8571f653f0a5071c379cf73f3bd7a0", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "ae662b44-74d9-416a-9d90-018eb67fa7f1": {"doc_hash": "93fc4a138f1c1f74cb32b357eb2b04d116db2c462ec4f162500602bc55e78408", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "d0291470-179d-4062-9a0f-b017ab03ae5d": {"doc_hash": "695676505bcb9820435cd155a55d743fba214c74053d3b9d1ac2f9ab12944598", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "663e87ef-974b-4239-9f47-115a976c1b44": {"doc_hash": "e92a86b2773f22adb15c38160535fa2f32cc29d60bfda66f55b5c3185087b950", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "f5d6e34b-2c05-483e-9066-a6716b9fefd5": {"doc_hash": "8337babb94c50cf8675339d5bfb2cd68f380a040769f8721a8d84a18130462a4", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "15c404c5-b520-4d88-af01-ecbc7cfa2df7": {"doc_hash": "af51abbc152320c18a9e9db3b596473fd369d7ed15fc11dd9b30ddc8ae75574f", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "3292f247-1c4c-4cb0-8892-88f26fee903d": {"doc_hash": "67b6652d11336d3b276671836ae0563aaafe8b016e90d9d71d09a8723a8ecf67", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "3c9bfa81-0a16-419c-8d65-fe9ba1a2a0c4": {"doc_hash": "d3fe782643d95199a4ee96887f80934b0a0ae270d9f9387ce21a35fe32e72a62", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "733b17ed-a662-49d3-a711-b41a376e405e": {"doc_hash": "9e89ef45218d9d996efe68cfb8c8d60cf43e4147e179a07395479a6be0cf42a4", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "d12c7274-3b2a-4422-ba69-1508d9bc5627": {"doc_hash": "3738d867764e2c8e036e995c8e941c3904a13b479578dab8641c4a5ad6b3264d", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "c9e0799f-53a3-4f10-94a3-9a5567f2116b": {"doc_hash": "8a02fd582f973d721957c45a24df14e5276d850fcc560cf2c94b5085d3c7d01c", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "8f974d92-a8d8-4ad5-9140-bfeb5e88760f": {"doc_hash": "9e17278cf27a3f7c1c4f0c7692df5d3361fd7231fcff9a7365d6b2ab3571016a", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "ac3e170c-9a64-42d0-a09f-17c79d77efd4": {"doc_hash": "527a50ee56c0257cc7dd6757ba896535ab978f1e760106c0a31dc9589fe65308", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "8637706e-79a1-4cca-8f25-f83d7ffaa520": {"doc_hash": "ff91401e6e3eff535ca5e453343e0471584668a982dcc6aea1955e3d06afed48", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "cdd323ad-665e-437a-90aa-54ee755dc683": {"doc_hash": "e04d211bbf9ebe9cd5481c10fe02bf1300c0bf2805b83059d9a8d646c2b7d766", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "1b0c86c4-32e0-47b9-939e-d58b3ab03b63": {"doc_hash": "8211871b8fe730e940f6d5e6b9e86e3f83ecb8e61a405bbd9ffef2c832b8eb2d", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "4d45b00c-a111-4b39-bd22-8b862ad5ef6d": {"doc_hash": "ced3aaed057b6d04b3dcd3aca40b6554c5687b32747df00abc70d736691bbfea", "ref_doc_id": "8efaf885-126c-4769-986e-760b572504a4"}, "04192fb9-d023-4d30-acbf-efca301f27c2": {"doc_hash": "6f30407dcc52e4d7c98b25e8b8795fe30d7d1e2c2f7050d6efdf8454c438b55b", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "bf3bcf85-cec9-48cc-b63e-a7b1915d0a99": {"doc_hash": "c1edc8cef5251917f5deaba504b40f2e3151eaa1457a139227dac089ec267b5e", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "a66898ff-d70c-4cc9-b2d4-71bb80ef53c7": {"doc_hash": "6b5c2c35038029eebf424d8e8d9a965c65f9d7f5a80731902c0476d503cc8df1", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "7bf6461d-e574-4283-b186-d0a096762bba": {"doc_hash": "62826caf1239997b7f3e5ce1078856c644f3529527769ea3b4660d52ac6c3360", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "f4586523-4513-427d-abfa-932cc86ade8e": {"doc_hash": "697d1b8f01cd424096404f09dccf27614cc0b95159b523d5c757babc0ab810ed", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "d5727480-b94f-4a67-a61c-4fa57de1c584": {"doc_hash": "3ed2d951dfb24b68f79e615ae21ce4b31e427826b73640b08f67ec150cb8c82d", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "eed0695c-e6ac-42d7-b656-442cc1d02c89": {"doc_hash": "8eb9ce93e9ef82e7948872ad051972238bf66107163cb9c5ced299dcc5311804", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "5976ff01-ad7e-431c-a24c-7d88660cbac8": {"doc_hash": "747a5281e84ed811b4370d92a0e9f36fb5ce9a67744353315c678fe4e95eed09", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "708e0bc6-0a0c-4396-9408-baef66f8ecff": {"doc_hash": "3c06d7aefe026a5486ee0bea6c5fb5b2a3006d51bd58865539019d39f4bcb3da", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "3016efc5-b28e-424d-9369-6b45a1f13b03": {"doc_hash": "3246db6bfd888bf9a15a994749c8516db654e20957e75424b8bb97697cfae456", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "eee912d2-4da4-4e33-ac71-092bbac2af28": {"doc_hash": "be12d5490e7ecbc0470284a80147ee691c6063cc2fc5be41bdb9b2e0c8aff5d7", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "3e1bb2e8-2220-44d3-9415-a8630e34caf8": {"doc_hash": "28977f8d141726c91f46ae177ca4ea0e5ef6d8cbab846a6f65657db3ecfdade8", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "7b328229-1f43-478e-b956-e41827ca1fc1": {"doc_hash": "30f77aa6101db90840f234dd947cf82c9706e30911b1c672b0a66db440fdcfb6", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "a662c49b-d51d-4633-8a8b-f32ce26008e1": {"doc_hash": "cb74bc90f78598d89d4740011715e0b3b05a0681fe3031983aa8e1c3097b6ac0", "ref_doc_id": "6fd30564-e52b-49f5-94c4-a793a22dbf92"}, "9e4224ec-ed2c-4ae4-8f0c-b84cc38b415d": {"doc_hash": "d45507718a4f6fb63c140ec4d5eacdc36ddbfa3c8d6da5e25b06357dfb306c6b", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "394ae4fe-e4a1-4c83-aca6-35e5de9f4712": {"doc_hash": "f640dac0d469c512c6d1b3306d5cc7595ef5b48b3ea45caae96e22e8f90bc528", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "173ffcc9-b0c5-46bd-82af-5b5ef74b61d5": {"doc_hash": "662a78350255697d113de371ebd0aeafa90c96ec833d5192734888e8963d9eb2", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "2b3711e1-f308-479c-8142-1fa1cba3ce77": {"doc_hash": "f0cc29bd91b52905f954fae322338436bce7cb7aa237db3666ebab0ae9d29b8e", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "54a21089-36af-4e95-a0a3-45a8558a8eef": {"doc_hash": "a78e46c295c6afef38d7586e4c4c1ced72e50de31e6638bc1fc5beaf15745963", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "43bf6719-efd2-4a9e-8ae3-e4bdbea73e70": {"doc_hash": "5dd81f02ad971cb5c5fc96037631825782c8fc10805f8b83817c300e4ba74f00", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "1c3750b2-b1ef-4bed-a1d9-93faaa84d1c1": {"doc_hash": "bb92ca7ac40f99de5518d5441e47c8a47ed285e940866387785a54a86a5dfc36", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "fc2365cd-e4dc-4f54-a23d-845031a60dca": {"doc_hash": "1f13f646d9bdb1a37a05962309291734c4976aca32bbe594f9031022661cb893", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "7e476980-1418-4514-9df4-dfa95774a425": {"doc_hash": "08042f9c51e75856417e89b7c160e91d04e27f9ddc9a6b0614deb2abdf09d816", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "2a87d4aa-c0df-4eb8-bfcb-d58185847f7c": {"doc_hash": "b8f93814e91aea6a125b4d9203a557b1949dd121673c27d1c499f6dd865c54eb", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "d1732082-d25a-4756-96cd-8d5f47351b14": {"doc_hash": "fe31a85add0baa255159b04274b86423da21977d18337d1e533fc270f5d4e486", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "b82d5b76-44c4-4a5f-b4e9-fb7c98553472": {"doc_hash": "bd574f36ab6d7202fd28c20f38f85959a2eb72e8d77455e751799c18a801c430", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "1b2052ed-444c-4afe-8016-a828aee027fe": {"doc_hash": "b3305449bfec4c3915c97f99b7602373c90be0fab92322b6fb92760d359fa853", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "ea115c27-aa9c-473b-9d3a-a8442571f97c": {"doc_hash": "d387749a6fee96c441eb61f981170a318ebc3a5f6fd6f1fc689819669b3432ac", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "e71d759c-58ab-418c-8134-cb79b839f50a": {"doc_hash": "734d8c36c6c44c783dbc78888f744701b3386c9c5f4cfbe6e9ef3bc8284b873f", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "8d60b52d-3496-4edb-84f6-2d7cca977d72": {"doc_hash": "b3ec9c09873c54af1703f8e9e077c7af833e61f6c2cbef7eede58ccdb8be74dd", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "1313c107-70b5-467d-a969-a962217ae362": {"doc_hash": "a40fda713c89bf4056112d062987a51fe015182e524242765db35bbab892f996", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "bacf09f8-fb77-4600-aa89-5380928f85d2": {"doc_hash": "c514fdbaa223af01f259f1f84ba327eed24a89418a9dc046040920f8d527a602", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "6e844fd4-1850-44c7-b68a-aefff70a78b2": {"doc_hash": "ab7536672003eb31cafb5c8497438dea714e4c17487be1e0a61cbab2e5b7d951", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "f4cc5d36-d608-4425-bbd1-27a21ba8fd1a": {"doc_hash": "13f6124ba5abf0409a3dba7bec1d8be7182ab880442c4096d096fc5003f09b49", "ref_doc_id": "c086ab6f-1018-4098-8c6f-3f9cf8fa7839"}, "010fa9eb-7118-4a3f-82b4-27d590fdceed": {"doc_hash": "eb55b73245d9cc98c6ceec0d6ccdd9b17b943d18a4b865e2ee08048de85ae289", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "ee9e730d-4746-4d4e-a16f-e4a0c0309ad9": {"doc_hash": "ac9f99d23748c4370db56af73a7aaf389475e546bcd9de2d1cf6ae2c0bf39531", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "7203d72e-921c-47b4-8b2d-82f34e883283": {"doc_hash": "a43080a453e498a67b45942a1cc20141af4faca9cd644fc1de55087a3b08cfec", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "f3230326-7cd8-49e6-9149-8ce9e41a7fb2": {"doc_hash": "9944dd2af40c1a80b749f54807e4ab1f2e7ebcd1f2b01f963f7e2e53a7a534b9", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "03c6c29b-67b2-4337-bef0-971fe2927a63": {"doc_hash": "fdf9a5998279ade6c684fe0563d34ed7f356982f3a1fef23898accb3413a51c4", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "66a1c82f-fee8-4131-a34f-70871c26a516": {"doc_hash": "6fe9fe4c48898c6cfe29565562972fd2273d5e169e36970ae1435f4e7ab9bcb2", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "0fbea452-7b67-4d2b-a228-ad41616f04ec": {"doc_hash": "08cb85ad6b67f02d4d6b82616e58b9255c392a7d96fd6bf915592ef7cda69da0", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "6d2f34f2-08a6-411c-9d11-fe5680083ce9": {"doc_hash": "98c1d5360c6b1ac69b6501a841309129b4c3031377a2d3d4d6160a5f80a8354c", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "bc6ce35a-9813-4b8d-98ab-89cefd110c6b": {"doc_hash": "c9cf0fb7a525f1fb4892494b278cf2ae967282475212fcd57ebcc02d577e99e3", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "6237c741-5cab-440c-bc1d-3f5148c33ff7": {"doc_hash": "c2c064e5c9f19f1755fcb5ac6d0c90b04aaffc395c37827ad6ac94f24b0f8403", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "02386e1c-7b9c-4921-a712-5ee247c7645b": {"doc_hash": "a3bf87c2a5c9ff0cb170a9f68fda31bf53ae8035719beda549db34c53dbfd804", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "f35fe5d6-a392-4ebf-a3d6-fdda26b10513": {"doc_hash": "4cc42722b852086b213aad131dce6a41dfdd26a77b6718a4d81f4ef8e636ee04", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "91fcbb18-6a00-42c0-b620-0a6a344f4a7f": {"doc_hash": "a8c8c089b68f583d871b28896bf8ffa6a9d46545009d684695375df8350e3433", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "6ca9bdee-0ad5-468e-8543-a27bd2cc95fe": {"doc_hash": "04929e9bfa9114039dda3c4a12e38d6210f8fc63669b60e473aca47612b0b8c9", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "7ae60b8f-804b-4432-87d9-d3fdebaaa5e0": {"doc_hash": "dc2d5e379a8db64c23f7e878dd0c73e690c7e426bb7f334cce5a49991f543c42", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "65ce5407-d5ba-4978-8ade-7bf9d3cab911": {"doc_hash": "9b97cd2e522768b5ad865195930dc1c352b39e45cc880d71dfc70cd54ecfe9e0", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "663bf507-9390-48bd-ab47-e3cf43643005": {"doc_hash": "25ec020f5c9283b28822ef06e9e74b4dd7caabc70714d0ed838d4a8715ad41a0", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "3586da76-53a8-4278-8e5d-b17ec42e994f": {"doc_hash": "c16a000df8381607002ceec4acdde12eeacfd8343b383d173a38b4047d9e3abe", "ref_doc_id": "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5"}, "986a80c6-5db8-44b9-9145-47404a9df481": {"doc_hash": "b38ea32db13368a189931a07b9cac932f839d33e5926275d45478033ace1f271", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "e5d7eb8c-b5ce-4f3c-a811-7b71a6e8f28b": {"doc_hash": "51a761dab0c66cee1f7748e4bb6e57853aed50235b30253af20ff62a990a5642", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "70147e78-86ca-4295-973b-98c20ae89dd5": {"doc_hash": "1d9de2e9705c7f7216b81330b66ff47fa31ac69652a260f442cb347aac50519e", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "45cd1e2e-63f1-4346-b4bc-adb2fc4538cf": {"doc_hash": "6504e60ae1828488fd4af7a0a7463af99489ab5a125d8a4ceeff3cfeb8eccf5d", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "f7bb6762-d654-4eb5-be8a-b8b199b60614": {"doc_hash": "44304f071cb42d3cd4ce43594e188cde8806b5770431a6185f9ba5dc96d4a45c", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "98863776-feb1-4d26-bbdf-ce833af2853b": {"doc_hash": "c9ef5775822c9e466333cdf341d5a5dd8e9f71cdae6f92c146cc944fbe7f8dbd", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "07ae171c-75e6-4eaa-972f-413d3a0122a2": {"doc_hash": "f13eb1409eaf3490f8b35f8c2341a650a4c696945d75601207e61fca6d15b17f", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "3d826be8-ebdb-4250-82c3-ff42c866f89b": {"doc_hash": "27324b05f3043345d6cb6c3ec827dadbd4ea566ab263a173400df1e475fd46be", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "0d962ba6-231a-4516-b4fc-7c4f2f65c32d": {"doc_hash": "9fd6a0673fe1cbbaa174d1b01ed02f0a5e73cc4b4c6cc9a7d646da8ae902ebbd", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "29ac19c6-72fc-4ddc-966a-d41c10233da8": {"doc_hash": "c1659d975390200ef59e0af5a66ec5b9af6dadc6fcb37d1fcf280ab33743280a", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "a990f897-5d19-4dbd-a4d1-c98f54edf15f": {"doc_hash": "43aa6b780ba789d4f974f1854200bd69709780208291c71852c59c057e57c7fc", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "b2319a48-9425-45fb-a879-a632a58625ad": {"doc_hash": "b7b143ab7407dd8013299fc3cff60d18ca2041a19aad85c8324600214d6532ae", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "bf20797f-66cd-405c-8b2d-aa4b662a165e": {"doc_hash": "a23c63714f5e17926e9f303f3ea8c3365b0bd5d5f0ca8a421a0b00f6a59da0ae", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "b7fccdcb-963e-403b-ad6b-d3946f03d00c": {"doc_hash": "6c8c9ed27c099dad832e005544a5240a1d38fd4c18ef9d8e23d0c3f9eea1ae34", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "56a89531-3e5b-446b-a788-55a51ab6dd2b": {"doc_hash": "8c764ad9f6d2e7d492581bee35b1090c8206584ed229ac9ceec165892173e5ee", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "820fae66-3fb5-45b6-b062-d93bffca2558": {"doc_hash": "acec329ac3630851ab8e6ec19f5f97777d36307aee0db658553e5c3313e0605c", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "d43f5c9c-4237-4f56-a98b-c41ac0139eda": {"doc_hash": "d14191758625a681d1076bb7b109b6ac053300989056a1bc87fc21e7ff956505", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "6c051a89-c021-4c46-ae11-9415e3465488": {"doc_hash": "8e16a2893b2511116e94e066456f14c6188c059a0e0ff5c4813ad8d23a319b23", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "5bf81211-ff71-4a4e-b94d-0c9c574b12f8": {"doc_hash": "9efb9f2b56c20bda8dde6f165a03be5db9a3d287e2fdc654f9cde4a84f23cb4f", "ref_doc_id": "3d1064ee-30db-4c5e-953e-ac4a7b131106"}, "40f15b5f-2a47-49d2-b596-8822764a58a0": {"doc_hash": "a9a07fc7804fb3663cdae96e8fd3b1c0144e17ddf39cbb66ceef6a64bf65098b", "ref_doc_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1"}, "c0114d4a-bfd5-4966-954d-c84140a6ddc8": {"doc_hash": "dbdcf7f58c63bc9e9ef0cb41da8d7879c48f58080eb28b4285559e1db51c28a0", "ref_doc_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1"}, "f80a6b50-eb39-4b9d-90e4-8e683336acc6": {"doc_hash": "9e86d97555d207bdd02ab5d7cde1f8caa89acfd80a8e2c613256ddcb5ec411c3", "ref_doc_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1"}, "c6e7052b-5faf-498d-b658-a8fc1ae69a7d": {"doc_hash": "505b42d44856c559249a33d4d9072d3d2715161540b90b74aefcba52dadda1c5", "ref_doc_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1"}, "3bf673d3-136a-444c-995b-833769147e25": {"doc_hash": "dcaf6962c20a74c0d26401f6e3f30f26a6c11886da45b54e82d0cf58bb4bc03d", "ref_doc_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1"}, "5f284577-e492-4002-9da3-52af726590a0": {"doc_hash": "0e9785ccc6c0b26eec686972d16020349211e9b7459cb6d48105b2438c9207d8", "ref_doc_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1"}, "8475d5f3-8d1b-45a0-8d8d-a4453e412a5c": {"doc_hash": "c13fd0f74f9ceb3f5706355970be8c7accb8e26d15aac75e01de5dfd34393eb9", "ref_doc_id": "eeaf206e-018c-4d02-8891-33ac0bee35e1"}}, "docstore/ref_doc_info": {"eb4ef4a4-74e1-44e8-91cc-41bbf4f704a7": {"node_ids": ["47c5a99a-eb44-46ea-ac60-14415645b32e", "690cb2ea-4aa0-4966-ac82-c080e8951c0a", "8e59078f-2bfe-4211-a07a-fad3fb6ac28a", "ff1ed46f-c758-4be5-9c81-9be58ae9827f", "846764b5-7124-4336-b239-b506e1d38ee1", "711bf7b3-b259-486f-a475-6f5f76afe506", "52be385d-b5a3-42e8-a979-3ae8790f7bfd", "5a1e5e52-3282-49be-9335-dca9c048d947", "ccf7ff9f-485f-4413-a386-121b695907c7", "b69904dc-6f3c-45f0-b520-87c090fffd81", "c97f1a92-7662-4a4c-8806-6d479f641aed", "e53f4588-d725-437c-b0b4-7a03999a1a0f", "829525ed-a150-4bf8-8a40-690985afc94c", "aede73da-2713-45b4-ac7b-bd7b4d482f32", "c85ef088-5d3c-4786-ab59-831cf32fb740", "b147ee21-1125-42d9-9a6a-05f027b4eb28", "a7bec4fc-bcfe-4225-907e-67b54d91a775", "dc8c5def-8e00-47a3-bb82-4417b92bdd25", "829e6ccb-219e-46c9-9210-bebb656a458f"], "metadata": {"window": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 11th , 201 9 8:30AM Eastern  \n \nOperator : Good day, and welcome to the Cardinal Health, Inc.  Third Quarter Fiscal Year 2020 \nEarnings  Conference Call.  Today's conference is being recorded. ", "original_text": " \nPage 1 of 31 \n \nQ3 FY20 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3ed1993c-fee9-4dec-b0df-2f592cde3328": {"node_ids": ["26a36ef8-9269-49a2-8276-9e68c12a6dc4", "9adda905-9082-4ad4-895b-307be315f9d1", "578a5c69-c3ac-4b4b-b6de-035d7c802a5e", "aa852383-154e-4103-8aec-9250751934dd", "9f2e560a-3b20-44aa-87ae-3dc576fef4c4", "fa3158aa-2327-4d81-9765-545930f325c1", "25465d55-1aaf-4e1a-a402-d046f474555b", "d70d74e5-3107-4c2d-9446-7ac770a55bd7", "da97ab2b-20bb-43b3-8c62-9fad83a36a12", "de6748f0-1b20-45db-90be-6c6872dc0e4f", "e9affa75-974a-4844-a58d-cb7b6c6bd627", "207a37e8-a96e-4e47-810c-fa232779d0dc", "e61107d1-d8a3-4908-aa57-1604cff2243c", "f5aad3ca-7a3b-4709-8a5d-6b565b993c7b", "e206fcab-c20f-41b6-bfcc-694ce27776b1", "eecdc177-1450-4ef1-804e-bfdfd4a6496b", "7834ebb6-79a3-4bf8-9e7c-3727d40a7619"], "metadata": {"window": " \nPage 2 of 31 \n \nyour questions.  During the Q&A, we kindly ask that  you try and limit y ourself to one question, so that \nwe can try and give everyone an opportunity.  \n With that, I'll now turn the call over to Mike.  \n  \n Michael C. Kaufmann:  \nThanks, Kevin. ", "original_text": " \nPage 2 of 31 \n \nyour questions. ", "page_label": "2", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "203d7831-9a1e-4994-ad7b-38359fb616ae": {"node_ids": ["96293e33-04ef-46d5-9572-fbed3bf95574", "81a335f0-8d41-4892-8aef-835c9a9ae8be", "33a41ec0-f22e-4122-9fca-eef39a56634c", "5fabbe10-7bfa-466d-b864-21f74db00518", "f7ea531b-4f77-44e6-9bf1-3a6c1496ccff", "8fefc8c4-a858-49dc-890f-2b5293c9a505", "dc97964e-9abd-47bb-83fe-8d8f25686de0", "62f46d5f-b627-4300-9f04-b4ecaf3fa6d0", "0e2bad4d-a489-4723-b840-cb5100fac882", "7b7691ce-1b60-4174-8820-63c9b5573e0d", "361a28e5-5844-4f7c-a889-4a5f0e61b5f5", "ec7eb97e-ba38-4b60-a9c4-b8d11c624883", "b0190f7f-0553-4324-a3a9-dc99a4f24f7e", "b1f5f981-f85a-4de7-aa64-20ca449e0333", "5760f66b-59a8-4b86-9ad2-08f0898dd9c2", "98b89f69-cb8b-4b08-a1c6-7c80e9c453e6", "8a213664-a73f-4bfc-8c64-bf2cde3e19d1", "3c85234a-e6e6-4866-8009-84a41e0b0b9e"], "metadata": {"window": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days.  Supporting the delivery of these critical products is a priority for us and we \nwill continue to do all we  can to address these increases in demand.  I will share more about how we \nwill continue to navigate this  challenging environment to pe rform our essential role in healthcare.  \n Now, I'll turn to Dave to discuss the financials.  \n \n", "original_text": " \nPage 3 of 31 \n \nDemand for mask s and other facial protection, gowns and gloves have spiked 2 to 12 times normal \nlevels in t he last 90 days. ", "page_label": "3", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "749249e8-6903-4e13-875f-1cd11e6d2165": {"node_ids": ["30e2e3dd-3dfc-4587-82e6-93c06053dd8a", "92b489fb-4e54-4944-adf5-8fa74c0fa3b1", "94df387e-fc74-41e8-8ec5-d901d461606c", "9aebccdd-a4c4-4624-8528-8ead929185a3", "42799e2f-1243-447b-aafe-6b0c1ce1836c", "098a5eb5-2e31-404b-ae34-f8c207a202d2", "e51f8497-c080-4b48-8dec-012ab4a4ad2e", "1c6c1516-d044-4b9d-9d78-c5866fbb09c1", "aa88b5bf-7242-4b40-a623-d31421a2ca77", "28293a30-5966-435a-8444-7181fd190b54", "36cbbb52-e410-49fb-b3c9-8342799920e4", "2a77a687-4ca1-470a-b09d-036fdc30cdf1", "9b15b3f2-3ebf-4fcd-a7a0-bfa99684ab3f", "634cdeb9-3570-4b44-94af-f60a3aea64cd"], "metadata": {"window": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.   In Q3, we paid down approximately \n$90 million of long-term debt and have now paid down approximately $880  million through the first \nnine months of fiscal 2020.  \n Our effective tax rate for the quarter was 25.7%, approximately 4 percentage points higher than the \nprior year,  which included some net favorable  discrete tax items.  Average diluted shares outstanding \nwere 294 million, about  5 million fewer than the prior year quarter, reflecting the $350 million \naccelerated share repurchase program  completed in our second fiscal quarter.  \n", "original_text": " \nPage 4 of 31 \n \nWe continue to place a high priority on reducing debt leverage.  ", "page_label": "4", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "73f715b5-f5ff-4941-80cd-2e28207cdeac": {"node_ids": ["4152882d-6b49-4bc8-aa8d-68622a4004d5", "75efbcfd-48cb-49c7-a0af-aeff075fbf4f", "af051180-8157-4b17-93b9-0980d2158c13", "ae18e658-6f18-4dfb-8bef-d3f062814da6", "aa8a91b7-2825-4834-8883-25af351ff4bc", "b5a30577-7ea7-445d-af1e-7f4c4db88116", "8bc5d0c3-9f40-4da5-a990-f2cdc4b014dd", "22f4960d-f503-4e65-b960-8faf257b5282", "79c63d20-9bee-4afe-9cad-ddce8c200e24", "14cdd861-8fbb-47f3-813f-bef194e623f6", "44cb5d2a-f234-494e-991d-148b2e55f4fb", "71458cf0-b4ad-4a67-8594-9e5d88b8b6b5", "db548959-ce87-4f23-95ea-7cb25513f129", "db542f41-5869-49d5-8108-88e273f9f670", "860d13e7-24db-48b0-b69b-c81fdbd74e51", "5cbf9a44-c7ab-47c7-9a23-4ecf95b2d421", "0be642c0-4f5d-437f-99b5-7d5027184dca", "3e5a6ec7-d85e-4752-ba53-4fc24e66c4ae"], "metadata": {"window": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics.  We were encouraged to see another quarter \nof consistent dynamics within the generics market.  Recall, we first began to see th is in the fourth of \nour fiscal 2019.   If these dynamics remain consistent going forward, we don't expect a year -over-year \ncomparison to be as  beneficial. ", "original_text": " \nPage 5 of 31 \n \nBefore closing out on Pharma, a quick note on generics. ", "page_label": "5", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4eb46ca5-47bd-4ea9-898a-d3dff4f722d7": {"node_ids": ["d636f73e-d9e9-424c-8ec3-fa613ec66a47", "e88910ab-474b-465d-973f-1a2a8c3e48cf", "e085bd20-8625-4761-92b7-dfa6cbc823a7", "fa34f45b-6b4f-42ff-8711-a72c7ae3c763", "8ee6df7d-f160-4a9e-a834-e41289f11c47", "9996967f-a582-4417-816f-48e788724bef", "2231776a-b253-4843-a8d2-6d70963969d3", "8a4d179c-b36e-449b-bee1-6750b0a4def8", "dffa1ad6-375a-481d-8d43-4e15be89a0f3", "eaa97317-79bd-4c18-bbce-2a58362131ca", "1f661a2f-38e9-4ec0-8471-20417d966356", "4e07078a-677a-4135-b15c-ac1702539d69", "45d1c651-ac2c-42f9-9099-69165d1fb620", "c26159d7-6a9f-4e8e-97fa-95d63ff99051", "52ba60ff-f304-4c4a-94c1-dfd324baf341", "b320b0eb-c56a-4bc1-bee8-47d26b245d27", "07f6a125-6228-4382-8fb8-603b093135f1", "f4f2ef7b-de1c-458d-bbe1-c48bc20de7ba"], "metadata": {"window": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n We're also reaffirming assumptions provided last quarter for the Medical segment and corporate.  We \nare, however, making one update to our Pharma segment assumptions.   Given expected Q4 COVID -\nrelated impacts, Pharma segment profits could now decline as much as mid -single  digits for the year.  \n", "original_text": " \nPage 6 of 31 \n \nWith this perform ance and with only a few months of COVID -19 related impacts, at this time, we are \nreaffirming  our fiscal 2020 EPS guidance range of $5.20 to $5.40.  \n", "page_label": "6", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ac484e74-d7e9-4fe7-bc71-e39e8dcc3ed5": {"node_ids": ["582b5cdd-d86f-48b6-ba87-8601003b5935", "db374b57-1515-46d0-91ff-0a1f79bf0fea", "5ac16330-f3d9-4dca-8906-96fb652b7338", "3407171b-87ef-4b76-9d3a-29cd41580a3f", "9d4d0bbd-b912-44b4-a1db-5a5a892b63bd", "0db27ef7-e234-4451-b45e-fe7e630bf68e", "2e7351b6-7c80-4455-bddd-f624606f7984", "f03a22d6-7d2a-4a10-869c-e4e3adb7ec56", "ddbc55aa-8b21-48d7-8f47-ead88f7ee0e2", "9828afcb-3180-4346-ab32-c964ccdb8061", "4a51ed7b-8e98-4aa3-a996-8b8b252f4801", "afc2e198-e2e8-41c2-bc01-632f70681657", "bd87ec13-ae44-4ec2-872e-8ab5bb42b3b0", "17c38b86-b821-4105-963b-3eaa3ad53a15", "85b38c9d-8354-4bd8-b912-e41aeb3729fb", "2580da52-0a87-4c41-9169-ae65f47e3849", "3d995c8f-b301-4432-bb9d-251746f6cdb0", "d22990ed-d09d-4e4b-ab01-2193a3cd9740", "3c336615-c783-4ccd-b2c0-174a6d29bbe9", "f203f410-cd4c-4139-ace2-99a4d2d6c82a", "ff85b395-e1e2-4afc-a6ae-3b3e9c1b8530"], "metadata": {"window": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n Jason M. Hollar:  \nThanks, Mike, and thanks to Dave as well.  I've appreciated the partnership from both of you as I get \nup to speed.   I'm really excit ed to join the team. ", "original_text": " \nPage 7 of 31 \n \nJason, I'll turn it to you to briefly share a few thoughts.  \n  \n", "page_label": "7", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "45c3b7c8-e177-4ff1-ac8e-eb7277b50464": {"node_ids": ["d3007680-b3b7-44ec-bbcc-5205e5586f3d", "4af601d1-be99-483e-b139-56a28239ef1c", "73f4f911-ca1d-4a5f-ae5c-7a6629da8c4a", "ab7a0fb1-d89e-454f-bafe-ac95aab90574", "e6cd5125-1b30-4d45-8c78-6f86e91ec3a8", "97ac17e6-c08d-49df-ac67-fab9b0c7b1f7", "563930c4-7de4-4f8c-9d6c-aeff4e013c49", "5ad20631-e557-4e2e-87d3-48a7456c9c48", "c5a02dd9-a1bb-4882-b9fd-dcff6ea25947", "09b7b9ff-6b1c-445b-a556-13e66650174d", "add8066b-de6d-4c13-8384-2a4c06de1854", "5de87ed0-742c-4de1-9ebd-3cc25b949c94", "2673e92f-d667-4498-95c8-6e0d64b6668d", "2bd3e19f-ee49-4b69-8dcb-d9d0675beecf", "d75a3ed8-5561-43e5-9fe6-dae4863dfd05", "b962b2dc-d2ac-4c45-a1a6-58d0f774553d", "71d31f4d-2002-4849-94b1-c2f23a7df5c4", "42cc6cb9-465a-4970-abfe-2e41ce42b3fe", "278d3c37-7560-4e58-9eb6-ffb5b5bcc51d", "bcf5ad57-eef0-4e4b-85c5-cdeb4c45b123"], "metadata": {"window": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand.  We are  doing everything we can to remain prepared \nto meet this demand and we will continue to best position these  businesses for the future.  \n Second, generics availability and pricing.  Our sourcing teams and our partners at Red Oak are \nworking directly  with supplie rs to understand any potential disruptions and resulting changes in \npricing that could emerge. ", "original_text": " \nPage 8 of 31 \n \nsurge in some areas related to pent -up demand. ", "page_label": "8", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d644f729-545e-41d5-abe8-fd0f5acd8f83": {"node_ids": ["d271b624-ccd9-4633-b8f5-909defc99c9f", "710069eb-ffa5-4728-a7b3-498ba5a860dc", "e085cbf5-9c24-4e47-86c8-20196f656065", "892bebc3-1d24-4cd7-9908-9dc2cd8f5874", "52a3c95c-487f-47cd-a461-4f0bb4269423", "6088d735-1f1e-4546-8f1c-883d17cb1517", "d0a2b6da-96a4-4fd0-ba91-c417c890f5b6", "f0bc9290-f02d-4b48-897a-79db89a3b67c", "6629fb00-3ea5-4b60-bede-255e8642e393", "73afc2e0-14fc-4349-bc62-1e461145a4e3", "fdb5dc83-2bc1-44c1-a707-725a01ab1154", "c96c0cda-e0a3-43c1-85c4-6f55331e24c7", "24bbf2d6-9761-4bd0-b972-69351fb0fcb3", "6b321fb9-94c2-4524-aa6a-e1bfa727591d", "00f02eaa-813e-4971-903c-07d8791a08c3", "bc577726-2b7f-468b-82b9-4536bfc7ecd7", "c265e83f-5927-4651-ae83-b6feba8c4a9f"], "metadata": {"window": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n Second, we're remaining and flexible and adaptable.  COVID -19 will have long -lasting and broad -\nreaching  implications and we are thinking about how to modify o ur strategies accordingly.  For \nexample, we recognize that  our sales team plays a critical role in supporting our customers and we \nrecognize there could be changes to how  these teams will interact with customers going forward. ", "original_text": " \nPage 9 of 31 \n \nto partner and identify  additi onal collaborative opportunities which will be critical as we collectively \nnavigate this pandemic.  \n", "page_label": "9", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6fa0c02d-c316-411c-b922-52f8188b521d": {"node_ids": ["89de6a7c-2c3b-42d3-b50a-b5b099498361", "c63123f1-7f39-4ddc-a297-812b84e5496b", "822a17fc-a4d5-4509-b5fe-4f3e837ab5b6", "930fc1e2-44b4-4e1d-b093-0ddc2ff5db2b", "63100f90-1753-449d-958a-1677ea6eb6ac", "657f7e60-0917-4307-a889-13c344593a9b", "3804f37c-73be-4382-9d97-a121e17477b7", "333a88c0-fa9e-4c12-959b-6ef93f9a48d4", "af596633-cc2c-4019-b9db-c660dc332cc8", "9cf21122-2b83-46a3-9030-e3a08763a5d6", "a2c1a310-03d5-4b3b-94cb-7518d4dd506e", "1c8e4e2e-cf4e-47a4-9315-964de1feb705", "cce6acd8-68aa-45ae-bfbc-ec77c3ecf3de", "006d845d-fb74-47ad-b2d3-cfd002ddad66", "00ab13ba-d369-4303-96de-c2c21e2a0ff6"], "metadata": {"window": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases.  But in the near -term, \nour other  capital allocation priorities take precedence.  \n To close, we are focused on supporting the healthcare system now and into the future.  We play a \ncritical role in  helping our customers combat many of the challenges this pandemic has presented.  \n", "original_text": " \nPage 10 of 31 \n \nFinally, going forward, we will continue to evaluate M&A and share repurchases. ", "page_label": "10", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b4cbd6a3-a0a6-4b00-a605-f65db916c0c7": {"node_ids": ["0b28b522-08ea-48eb-813a-1b8dceadf5b2", "06995ff8-e152-4920-bd38-f7549104a8b0", "da607590-e0d9-48dc-b388-0735c301dc23", "7736ba52-bab6-4141-9941-a927692c579a", "649c388a-3d4c-4b08-a2d8-60f144fca0fc", "77e4c049-5b2f-4c11-92e2-20f9cdfff8a8", "c0ddb713-1f49-4773-ac88-c7112cd8dc87", "a211a202-0e29-4747-9b4c-948fc940f742", "3a46f34e-3e2b-4009-920e-37c084d4abf8", "91e3c0ca-4ebc-442a-a766-a88ec32f7128", "02164be0-07a3-45ae-ae5e-42f3d3bbab3d", "2ee92a5e-4001-4f79-93ac-97e5b9cc91b9", "a3a8fa65-591a-4aab-be98-e88c47a3ae25", "adb60a02-0f07-43fb-a60c-4d71d1844471", "2a15b0ed-39b9-4db4-9ccd-13d8a8556d18", "dc101d1a-7bc5-4b2d-a5b0-4b9209a54039", "047fd61d-ce6a-4c47-b42d-b1f85a963dbe", "446d4d8b-b072-4f64-8a31-ab3d307ea1ca", "8b4d3123-c02a-4c3b-8bac-55631259eee8"], "metadata": {"window": " \nPage 11 of 31 \n \nSo Michael, this is Dave.  Why don't I start and then Mike can add more of the kind of the qualitative \ncolor to your  question.  \n With respect to the fourth quarter, I think the way you need to think of it on a year -over-year basis is \nthat this  slowdown in elective procedures is impacting our Pharma business in the form of our \nNuclear business, which  tends to be our higher margin product lines with higher fixed costs.  So the \nNuclear business itself is the biggest  impact year -over-year.  \n", "original_text": " \nPage 11 of 31 \n \nSo Michael, this is Dave. ", "page_label": "11", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a7d281bd-578c-45ca-906e-b9c0ec6d02f2": {"node_ids": ["1a516d43-ffe9-4025-86e3-9479991119ca", "352f4fd6-d6aa-4ab6-850f-ca9664748831", "264e33bb-5543-461c-a7ea-571d621234b5", "a1a818e8-dc95-4de2-b248-0dacab932c49", "15e3f369-f085-4640-be41-a100a2e2d5c5", "9c8ab6c7-7569-4d34-a53c-b2890dfe8aee", "72b8aedc-2336-4656-b687-a0f1fff8f838", "c3d12beb-a0d3-46f8-8279-b6e461e61f2f", "877c0743-d9ea-46ba-a9ec-9a73232e5a54", "4359e524-5d0f-4215-a0e5-58140ef628a5", "3d1bab7b-22c0-42f9-a214-8f08638701ea", "86b89665-ca8a-4ec4-be41-34ee0bbe380d", "9855f5e0-47f5-414b-b1db-55bfb84fe3ef", "744cb3ad-6258-4d1a-b1f5-416261b51c7f", "47af2890-d7fa-444a-9ab9-3e516e81bfab"], "metadata": {"window": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n Operator : Next question comes from Glen Santangelo with Guggenheim.  \n  \n Glen Santa ngelo:  \nOh, yeah.  Thanks for taking the question. ", "original_text": " \nPage 12 of 31 \n \n  \nKevin Moran:  \nNext question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cd432e14-6e39-47b9-88fa-2fa321fca7c2": {"node_ids": ["5ea0c74b-db93-4a59-ad8b-b1cb3449ddd4", "b49b04b0-bcd1-4b39-8917-4573cdf148b3", "9c3a57e9-bc09-42b1-85d8-b9e18239fbf5", "ad38d5a5-95e4-4a7b-9a2c-40f752b54497", "0cf6391a-661d-4903-adde-a2803dbbe887", "43e2d246-f70d-414d-b127-b9ebc4fe4260", "12e5eefc-7b8e-4fd3-b76d-5a63b6f91ae0", "e93a299a-7b92-44b3-8fac-c6f7cc75160a", "1ecc8617-5719-41e3-962b-dd958ceb613b", "873af012-f235-4246-afe6-44635ee0686d", "4751fc01-3853-409f-b486-2c138f075294", "9a49cf7d-d0cc-4a34-9b38-7a399ba010bc", "f311b8c4-4d3a-41ff-8081-165f4b004fcc", "c532b3e3-db96-4b75-9eeb-a4f1e4f80e1e", "bd2b6a05-9b97-484a-b68c-20d57123a569", "4372b2dc-c7dc-4ce2-8be4-a502e4913aa6", "ab54e2b8-6192-4865-9f38-9b3994d9d260"], "metadata": {"window": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1.  So we're \njust going to keep our eye on it and  we'll be ready to react accordingly.  And if we do see price \nincreases, obviously our goal would be able to at least  keep our margin per unit similar going forward.  \n On the Medical side, when it comes to the PPE, the really biggest thing to think about is that we work \nthrough our  safety stock. ", "original_text": " \nPage 13 of 31 \n \nCOVID -19 that we think  could have an impact either in Q4 or possibly going forward in Q1. ", "page_label": "13", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e3dabdd8-5aad-433f-9038-bd228a38d7f0": {"node_ids": ["fb573523-e553-4dd9-ba46-17aa28396c71", "d30a0feb-15a6-43aa-a179-dba6c28ca67c", "c2468c24-5034-49fa-aac5-5acaa56b6d3d", "7f83d19a-1926-4c4f-948a-181504c1add4", "df993d7f-7fc1-43b1-8573-efbf0d3447ca", "4724f829-484b-418d-91ae-dc9f93098701", "64e1848b-da30-42c1-aa8c-de09de026e6a", "b0496584-5380-4a64-9f1d-5abf282465bc", "0f57243a-a037-4699-a869-702a50ac906d", "f415084f-90bb-45bc-b11c-7e14f1f06f6b", "f12125b4-14f4-4fee-a71a-9cc8f81c0d63", "18119403-7a62-40f4-b1cb-663a38b34b9a", "2bf5233a-3754-42ec-b624-52bc36407ebf", "f86b732a-bc6f-4701-bd75-d31ca09e9bb6", "8314f892-6b71-4a09-b2b6-c10c270f84f4", "fb281b36-5c5d-4add-b1d8-033fbec81fab", "1aacc820-955a-4257-a784-1d523c18369b", "ac22d7c4-eef1-4bf8-8d39-08779184b92c", "a8abadbf-12e9-4bf1-a6ef-9c30d0fa94be", "5cef8176-765c-4e04-a9d1-debacb7b2a99", "ed3b5309-5b3a-4f86-bd53-2af31cb2291a"], "metadata": {"window": " \nPage 14 of 31 \n \nYeah.  Thanks for the question.  A couple of things.  Remember, we have two really big things that are \nthe drivers  for us when it comes to Medical from the positive side, and number one is going to be the \nyear-over-year benefit  of not having that charge that we had last year. ", "original_text": " \nPage 14 of 31 \n \nYeah. ", "page_label": "14", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4030ac1c-f91a-4e98-8cb9-d2e3fcaa5252": {"node_ids": ["42245d64-a55d-4b90-bf2d-a3b4cc4060f2", "efd5d409-2dfe-4233-b199-e52a776a84c0", "49bd4eb6-a94f-4427-90ea-32f470786c3d", "b2953fe2-adf2-43b0-844f-6476a7b70bad", "e9b38bbf-853b-400d-966e-a1d44d3acda0", "e89674c9-3bca-486e-bb46-995d44cfae3a", "48d1ee29-1c8c-4305-9322-6cf80f2416a1", "8cd73546-7cd9-4a9c-8b52-633cf9b0e823", "497ce74c-3b9a-481c-aa5a-76a96f0f812d", "f0a97a85-6525-423f-8728-a8ea560db9d3", "2482b5f5-c155-46cb-83df-fbe7c177e78d", "27fc0892-a5ec-4715-b091-684c47640808", "c260a7d7-2292-4879-8a50-95a7b2752637", "30786cf3-9dec-4dd8-b651-39dc7f9352f7", "882d2d84-eea5-4338-901b-906f5411791c", "5baaa71a-ac23-4756-a430-470b69ddb90f", "04af0390-afce-4f47-ae80-44143f2d00ed", "7c29078f-0b9c-42aa-b8b1-9763b18afa0e", "47913828-89e8-4816-9f74-d9add8b27729"], "metadata": {"window": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business?  Thanks.  \n  \n Michael C. Kaufmann:  \nYes.  So from a core business standpoint, what we saw was a surge in our Q3. ", "original_text": " \nPage 15 of 31 \n \nAnd then, I guess ju st the one other question is, the assumption on the core business, the kind of \nsmall molecule  specialty channels, is the assumption that what you're seeing kind of late in the \nquarter, early this quarter, just  kind of run rated through 4Q or is there a lit tle bit more complexity \naround how you're thinking about forecasting  the core business? ", "page_label": "15", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2dfb3a05-26da-4478-a3a7-94617c67271c": {"node_ids": ["21455c87-6eff-4b11-b87d-ca0f653af770", "bd4ff66e-54c0-46a5-b819-554c56007aa4", "f25be417-2a78-4e8b-8626-bf41669292f6", "b3db26af-84f0-4b1b-b924-53c60ade9477", "a0ec53c9-d436-4072-b46b-84a06ad9202a", "bca1875c-5182-4e40-9725-0ef8af8ccc15", "e9e8bdb0-c25c-4fd0-a992-36103013afe0", "69ed922f-4896-4f4a-bd21-0f9ccf1fb1a8", "454dd7f4-6244-41d2-834c-4177a59def4b", "b18e9ca4-2c32-4d3d-b7ef-437025187992", "b54f6165-4740-404d-bbc2-63f4742181a8", "237391d0-7f76-4026-8577-62b18ed8f8f3", "0413ad28-e5d4-4f44-9437-d850e05b30ef", "074aad28-3129-4127-a7de-0233f141e54f", "e4f83654-18cc-4b27-90b4-45efaa9c5129", "ab21c85f-6222-4725-bea0-adf87782eb88", "1725c2bc-7fe0-4eb2-abd4-7ba8e18271bc"], "metadata": {"window": " \nPage 16 of 31 \n \nfor the mid to long -term.  So we remain  committed to it.  And as we start to see electives ramp up, \nwe're going to be ready to go to take advantage of that.  \n  \n Kevin Moran:  \nNext question,  please.  \n  \n", "original_text": " \nPage 16 of 31 \n \nfor the mid to long -term. ", "page_label": "16", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7bb52ad1-2922-4458-84b3-a1c9eea4d572": {"node_ids": ["43b284d8-6b27-4d0b-9f61-739fd80d9a25", "cdc41274-c4a9-4beb-9cf7-f279da071d87", "7439a986-f98d-4304-9209-54997c0db3a0", "3774e732-5fdf-481a-905a-977452468483", "69489ca9-f47f-4b69-a373-9ce0d9c38a48", "2a4b8114-a257-42b7-bdae-89836d41b0b3", "2106419f-e98f-417b-aab0-46ed02f273b3", "0ae1bd7f-08ec-4b29-933b-9a2ab013a7fd", "69656d43-f6f1-4d2d-b462-ade11e3b1ff0", "461ba17c-e075-4b2c-a12e-ce2485bc7d3f", "22619191-4ca7-4e8b-b273-a331eab41384", "0a3e22b6-534e-4cda-8f02-d56b3a4135fd", "3a126231-57d1-4db7-b51a-06fe46249ecc", "c743fa55-3b22-4245-a82e-d77f1cfda0b4", "514f28bb-0dc1-4ef0-84f8-b74abbd09376", "41827d0f-b5c3-43ce-aa06-051f18381a80", "81c28042-17bb-40ec-9e35-87a3eb53d0ca"], "metadata": {"window": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years.  That's generally running about \nas expected.  And so putting those  four together, we're very pleased to say last quarter we now expect \nour gene rics program to be a net tailwind for  the year versus at the beginning of the year.  We thought \nit would be a net headwind and we still expect it to be a  net tailwind for the year. ", "original_text": " \nPage 17 of 31 \n \nSo our goal is to maintain that margin per unit and then hopefully continue to see volume increases \nwhich we  have seen and some new item launches, which we said from beginning of the year we \nexpected those to be  relatively small over these next couple of years. ", "page_label": "17", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7113bdf5-385f-4ee7-aa48-4766ed2853e8": {"node_ids": ["f3ead348-569b-4155-ba93-d492960a9f0b", "7b4137ab-abc8-4718-8c2a-cc08895b735a", "c3b8d24e-4da7-4f9c-b571-6618fb935d75", "4d1a79c3-932c-44ba-9212-d3744d3403cd", "2a68887e-86a2-4c42-895e-c44a52b4b266", "540b244d-5bd5-4d50-bac9-ded7692de678", "58775dc0-40fe-4c10-8f53-64bd99c33939", "660389fc-1a3d-4a74-8546-d2fb473fa5a2", "a612802e-5ee3-46ad-becc-b16089dd7c7b", "dc27d7ce-74cb-44da-b797-4d4c69d65c7d", "561623fa-9a36-4a3c-98b1-cec0c61222c8", "857b438a-71bb-475e-90b6-454b7e4c42e6", "b65e98f9-55e3-4403-82af-38022bc7cc7d", "7ab1f55b-1b55-45d3-9779-146542b4260f", "a627f41a-17df-4f8f-b11a-0335b71f9fe5", "f1cea348-2749-46e7-8296-423ba887349e", "b7bcb8ff-d23b-4442-a661-8ab5716ac7e1", "4f89fd6f-0369-465f-bef6-0d2b0095978b", "d164f2ed-1b10-4c1e-821e-f49ffeba1c74", "3b7ab8ce-5781-4798-89bb-e552417836f3", "afba3be8-d9cc-48fd-af98-96bc2c050cff"], "metadata": {"window": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah.  I'll start with that then I'll go back to the other.  We do feel really good about how our at -Home \nbusiness is  positioned .  This has been a trend we've been seeing for a while now, we've been calling \nout. ", "original_text": " \nPage 18 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "18", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c81f6e92-223c-40b9-a4c6-2061bdf770de": {"node_ids": ["eb500f35-3c0e-4b92-9f4f-9417aedad024", "85ad8cab-bc38-4275-8f73-8e8e07a3f921", "a6b65184-8e52-41d5-a27d-56fc3d442c16", "73fe196b-b0d7-4fba-86ae-3e01aae760a6", "f63b88e6-b643-48dd-807a-e240e50fa93b", "223f5381-6e99-4c6d-8c48-7b8a35cf00fe", "d905754d-a061-412d-9eb4-59f136ffcd9a", "0d3e173e-eff0-4cd2-bc6b-47ecafafd94e", "241255c5-98ce-4207-a1c7-b7f8f19c55d1", "b1d786f1-fb6f-469d-8a88-c0bf4c93c0e9", "7bf05e53-ed2a-4656-a6d6-cbd8cb20dc63", "8a15bb20-3c94-4df6-a186-5dc8f58846e2", "e4981fd4-ce4c-4168-9512-46f9580a470e", "5f260dc1-2265-4436-890f-39f453509aa0", "f27cdd8c-96ab-4276-ac18-fbb48cd884fe"], "metadata": {"window": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n Operator : Next question comes from Eric Percher with Nephron Research.  \n  \n Eric Percher:  \nThank you and thanks for the efforts alongside the commentary.  A question on Medical and I'm \nthinkin g what you  provided on Nuclear was very helpful. ", "original_text": " \nPage 19 of 31 \n \n  \nKevin Moran:  \nNext question please.  \n  \n", "page_label": "19", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c0850b0e-196f-49b6-8d0d-75fa79b6c813": {"node_ids": ["f0de7f71-b31f-490d-b438-3f34db9ee514", "d9dc1854-6934-4ce8-9a2c-44175342c586", "360774ff-6388-4974-b4fa-7a879845851d", "f7d5c0dd-3a97-46c1-b546-8dd0d1904c70", "2ce4f9d3-06df-45ab-8ae0-3be5242c5323", "129ea801-ddd4-4360-9645-dfdc65758741", "3c8f8758-7f3d-4434-91e2-6bc32c429dc2", "7915ebc7-fae5-46e6-8ac6-ecfd38e29f31", "8636d026-5c95-4caf-89d4-f263cea8b114", "5b347cda-fb3a-4d55-98f7-0018509822a6", "32da04e4-b779-4d0d-8da4-fb99086dacd5", "9c13633e-7ccb-4314-a25f-f0a0d04f9af2", "02fd0e88-481b-47d4-8941-7605ce06583b"], "metadata": {"window": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver.  And then the \nbiggest negative which is why we'll still have some challenges in Q4 is  going to be related to overall \nelective procedures where our core businesses, with the  biggest one being our  products business, in \nour OR, our kitting, our Cordis business, those businesses are going to see significant  declines and \nhave seen significant declines related to COVID.  \n  \n David C. Evans:  \nYeah, Eric, the Med is, it is a bit of a complex story for Q4.  The way I'd distill it down is you have this \ncharge from  last year. ", "original_text": " \nPage 20 of 31 \n \ndrivers in Medical for Q4 will be the  year-over-year impact of not having the charge last year related \nto the Cordis exclusive distribution agreement;  expenses will be number two, and then the other three \nsmaller businesses, combined together, would be like the  third largest positive driver. ", "page_label": "20", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "66268ab9-4892-43da-9f34-91db9bd2d796": {"node_ids": ["f419adfd-3ba5-45c9-b60e-f8f23247ce2d", "134cf7bc-7833-483f-9b2f-abb4f764cb8e", "66e31c2d-7343-4aa9-a2b2-ec37fabf6c91", "458a603f-3872-4068-9fc3-8dc4b7453fd8", "502b1bbc-9259-44a8-b24a-fc4f77bc0729", "db445ba8-52f2-49d3-a3c2-39f5f3c026f4", "9a293bee-6635-4a99-9920-f7234a3a1268", "0c3e0308-c183-48de-9288-f906ecb0211e", "a3d731c2-9047-40a1-b9fe-163097b9e735", "64d52d44-cfa9-4bc9-9a47-362eca8f2485", "066b5237-6b40-47c5-af49-62354a1b877f", "2aa5a554-22cd-42cc-8041-483b311c6ac3", "9f537312-c6a6-4e96-aba3-f69d39b7ab23", "2ce9e252-b553-46c2-9381-433d8244c48f", "fa1e6c17-8194-4668-9d0b-77dd1dbddbda", "a1b18211-8e50-4abc-8822-55dfc5ab5aef", "31ce54a6-5319-4edd-ac16-74f55bb4db23", "8826e3f6-3b19-45df-9694-f991745d989a", "9cd13924-535d-44da-9e1e-5a49bf960d36"], "metadata": {"window": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi.  Good morning.  Thanks everyone.  I was wondering if you guys can provide any color around if \nthere was any  margin impact in the third quarter from the shift from retail to mail channel we have \nseen and, additionally, once  we are out of COVID -19, do you see this mix returning to pre -COVID \nlevels or do you think this is going to be a  new norm, just curious on you r thoughts on the trend \nmoving forward?  \n \n", "original_text": " \nPage 21 of 31 \n \n  \nJailendra Singh:  \nHi. ", "page_label": "21", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5a074724-3e88-4807-8a0f-59f5fa5107d5": {"node_ids": ["704e3bc9-e426-4f23-808d-1c5b8820881c", "fbc15012-3ac8-49be-9f8d-6ccf4f8ef00a", "ccab591d-4dd1-49e6-aac5-cb94e78f95e0", "1646407b-5691-4f92-a576-cc7361435313", "6d2026d9-9e8d-463b-ab71-684cc8a51d7e", "934020f6-5de0-412b-927e-14cf6c3f0248", "68b994fd-9e7b-489c-b050-61f0b2b498bc", "e5a8132c-0fc0-46d8-be8e-10635881664a", "7c4ffc91-fa3f-4dee-8aad-2217d9c09eb7", "98bbcb90-bbd3-4cd5-a1c3-692a2b21b7cc", "c54d93d5-b2a0-42fa-9f47-b4b56543eac7", "086340db-14ee-41e5-8912-a5bd30feae6a", "8cead0a4-b126-4da8-883c-e82a8ae6a170", "e0241a46-9312-4459-a096-4386280cbb92", "5aa66390-7154-468e-bf6c-555268d33b17", "ff4d1feb-5381-4bd1-baff-69ecc403a68d"], "metadata": {"window": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n Elizabeth Anderson:  \nHi.  Good morning, guys.  Thanks for the question. ", "original_text": " \nPage 22 of 31 \n \nOperator : Our next question comes from Elizabeth Anderson with Evercore.  \n  \n", "page_label": "22", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "01a32722-91b0-499f-aeac-be881aa19ee6": {"node_ids": ["9823a5ea-960a-40cd-87d2-12de295413c5", "c9606c4c-2543-4396-8625-a44e2edb2073", "b759f92f-ee34-4db0-8008-d4b2a8c50a56", "dcb59bcb-92bc-4ad5-99a3-f692bc93ea1e", "9b4a5066-b73d-45c3-ae21-ce9286163943", "74cc3092-f13a-4894-8823-a266ef554235", "3314f7b9-3704-46a6-9581-5601b8e4c345", "dbffaf0c-230d-4a4d-ae0f-7502a25e69bc", "efdb9dc0-6108-48f5-9706-c06bd683271c", "4706add1-4082-46d2-838b-f0cd016e92fb", "ddec4dd9-7362-4e27-9738-a619c7c5cd73", "5b4fca0b-2f2a-4914-974e-97da58b7de65", "b2ae76ac-1461-4015-b43b-db153311bfcc", "12c5c56d-3f0d-4838-b122-fec3a1e16946", "0b343946-72f1-4986-8a70-5bbec30c61e8", "0a21ec32-ce14-471f-8985-fdcdce685ebd", "82c1ece9-f24a-4377-b3d4-f9bd496cf318", "d1ef331a-ebd2-4174-9e2c-73824652a44c", "18666948-8150-42e1-a699-cc72d821aa80", "40087d2c-0acc-4d04-85e3-a8a1ad0d6292", "c4ff466a-736d-400d-8aba-7c65c526a7be"], "metadata": {"window": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah.  Hi, good morning.  I have one follow -up on Nuclear and then my question.  So, just that we \nunderstand on  Nuclear. ", "original_text": " \nPage 23 of 31 \n \nRicky R. Goldwa sser:  \nYeah. ", "page_label": "23", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3ab088d2-9dd1-4aa1-bd82-b30544e415ac": {"node_ids": ["288c1ba1-9618-48b1-8045-cc9b2d18faab", "aa250749-ade5-4767-b16f-38232adbb12f", "3390fa2d-16f2-44b1-86b9-a48fbd8790f3", "25a8b9fd-f101-4677-b28d-ba42f66996bb", "619bf745-c673-45d9-a329-36e4919764f5", "3be44112-77f8-4691-8603-ddaafcfd6838", "2ddd95c8-a18e-4484-a2ca-e58f3c0d370f", "cf4fcfe8-ca0a-4200-b77a-01e73e31e000", "4259711b-620c-403d-93db-8de01cccaf42", "9024357f-6ec6-4f97-8f0e-4d1601536b14", "9d181847-42d3-43a2-bd54-3883c44a68ff", "c1a4ed92-0a0b-4917-adf7-96649524f076", "4bf16175-4804-4551-b7eb-bac9f100eebc", "b1c5742f-d29f-4620-ab75-abf6a988cd56", "a84526f5-dc8d-49ce-8bd8-17a5c167a449", "9abb7558-0c43-49cd-a389-221c77bcb4a2", "adad2815-8f2b-4e84-977d-44d507564bb8", "edc30575-c408-446b-985f-8b834d4a329a", "9e34fd76-d8ab-4f77-958f-d06152b876f5", "acae3782-c446-4fb6-987c-f294fe89a60f", "4aaa4ad4-9fa7-4e6c-94d1-999c9367fe4e"], "metadata": {"window": " \nPage 24 of 31 \n \nhealthy way.  This slowdown of elective procedures is really going to  negate some of t hat growth.  So, \nRicky, those would be the major items characterizing our fourth quarter COVID  impact.  \n \n Michael C. Kaufmann : \nYeah. ", "original_text": " \nPage 24 of 31 \n \nhealthy way. ", "page_label": "24", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4d13848c-ecfa-4c4b-b0d0-5d7970488e3f": {"node_ids": ["9c5b9b83-8e3c-4d0b-a631-59ec44e06f2f", "b2784bb5-aab0-4a21-a9d7-1a8db734d9b8", "7032cfa4-be4c-4cb7-854b-6c39d8cbe477", "556863d7-3709-4ca5-963a-07f461385638", "eb4d5433-6547-4ef3-abb9-359d036b4f8e", "c491e913-7df4-48eb-bc44-4da8f5759bac", "9055c2d1-de00-4dae-9223-04a27cd44bdc", "cf0d08e0-c8df-4256-87fd-6afaf0f54ef0", "05b5735e-1d9f-402e-abde-ccb0e6e7e853", "f4b9f46d-61af-4188-ad55-49ba4fcc444f", "88e31e6d-2d27-457c-b017-5e84b6623258", "1f92f9ab-905e-4fd0-b006-d38cd01b5fdc", "740c41d9-355c-41a4-864d-272fc7bf63b1", "f5ea0769-e2c8-43ef-b80b-60b5a55a70b4", "687ad6df-08db-41f3-92cc-0efa9598a413", "51435e71-27f2-473e-bbf3-92721735198b", "6a5617b1-547d-4a64-858b-12272044541a", "d502349c-610d-43b4-a282-c230bc1eb15c"], "metadata": {"window": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation.  And that's great.  And we really admire and respect the people that are doing \nthat.  I don't think many  of them will stay in the business.  \n", "original_text": " \nPage 25 of 31 \n \nthe \u2013 feel an obligation. ", "page_label": "25", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8efaf885-126c-4769-986e-760b572504a4": {"node_ids": ["1e68d38e-f314-4140-8a56-152eb2beff20", "d899d8cd-471a-4361-90a1-0f039a2aad2a", "72197b0c-5868-41e2-9f2f-ce0aa40e1853", "ae662b44-74d9-416a-9d90-018eb67fa7f1", "d0291470-179d-4062-9a0f-b017ab03ae5d", "663e87ef-974b-4239-9f47-115a976c1b44", "f5d6e34b-2c05-483e-9066-a6716b9fefd5", "15c404c5-b520-4d88-af01-ecbc7cfa2df7", "3292f247-1c4c-4cb0-8892-88f26fee903d", "3c9bfa81-0a16-419c-8d65-fe9ba1a2a0c4", "733b17ed-a662-49d3-a711-b41a376e405e", "d12c7274-3b2a-4422-ba69-1508d9bc5627", "c9e0799f-53a3-4f10-94a3-9a5567f2116b", "8f974d92-a8d8-4ad5-9140-bfeb5e88760f", "ac3e170c-9a64-42d0-a09f-17c79d77efd4", "8637706e-79a1-4cca-8f25-f83d7ffaa520", "cdd323ad-665e-437a-90aa-54ee755dc683", "1b0c86c4-32e0-47b9-939e-d58b3ab03b63", "4d45b00c-a111-4b39-bd22-8b862ad5ef6d"], "metadata": {"window": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n David C. Evans:  \nYeah.  So, on the balance sheet side, collections.  Lisa, we've seen liquidity, as you saw in the third \nquarter, strong.  ", "original_text": " \nPage 26 of 31 \n \nYeah, I'll have Dave talk a  little bit about what we're seeing on the collection side and the balance \nsheet and then  I'll talk about a few of the other things.  \n  \n", "page_label": "26", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6fd30564-e52b-49f5-94c4-a793a22dbf92": {"node_ids": ["04192fb9-d023-4d30-acbf-efca301f27c2", "bf3bcf85-cec9-48cc-b63e-a7b1915d0a99", "a66898ff-d70c-4cc9-b2d4-71bb80ef53c7", "7bf6461d-e574-4283-b186-d0a096762bba", "f4586523-4513-427d-abfa-932cc86ade8e", "d5727480-b94f-4a67-a61c-4fa57de1c584", "eed0695c-e6ac-42d7-b656-442cc1d02c89", "5976ff01-ad7e-431c-a24c-7d88660cbac8", "708e0bc6-0a0c-4396-9408-baef66f8ecff", "3016efc5-b28e-424d-9369-6b45a1f13b03", "eee912d2-4da4-4e33-ac71-092bbac2af28", "3e1bb2e8-2220-44d3-9415-a8630e34caf8", "7b328229-1f43-478e-b956-e41827ca1fc1", "a662c49b-d51d-4633-8a8b-f32ce26008e1"], "metadata": {"window": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things.  So the ability to which we have flipped \nmanufacturing plants, added  capacity, work ed through different types of things, I do think w e will find \nsome additional cost -cutting opportunities  through prioritization, technology and just being faster as a \ncompany.  \n  \n Kevin Moran:  \nNext question, please.  \n  \n Operator : Our next question comes from Steven Valiquette with Barclays.  \n  \n", "original_text": " \nPage 27 of 31 \n \nAnd I've seen our teams work  at speeds that are just outstanding because there's such a deep \ncommitment to  patients and healthcare to get after things. ", "page_label": "27", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c086ab6f-1018-4098-8c6f-3f9cf8fa7839": {"node_ids": ["9e4224ec-ed2c-4ae4-8f0c-b84cc38b415d", "394ae4fe-e4a1-4c83-aca6-35e5de9f4712", "173ffcc9-b0c5-46bd-82af-5b5ef74b61d5", "2b3711e1-f308-479c-8142-1fa1cba3ce77", "54a21089-36af-4e95-a0a3-45a8558a8eef", "43bf6719-efd2-4a9e-8ae3-e4bdbea73e70", "1c3750b2-b1ef-4bed-a1d9-93faaa84d1c1", "fc2365cd-e4dc-4f54-a23d-845031a60dca", "7e476980-1418-4514-9df4-dfa95774a425", "2a87d4aa-c0df-4eb8-bfcb-d58185847f7c", "d1732082-d25a-4756-96cd-8d5f47351b14", "b82d5b76-44c4-4a5f-b4e9-fb7c98553472", "1b2052ed-444c-4afe-8016-a828aee027fe", "ea115c27-aa9c-473b-9d3a-a8442571f97c", "e71d759c-58ab-418c-8134-cb79b839f50a", "8d60b52d-3496-4edb-84f6-2d7cca977d72", "1313c107-70b5-467d-a969-a962217ae362", "bacf09f8-fb77-4600-aa89-5380928f85d2", "6e844fd4-1850-44c7-b68a-aefff70a78b2", "f4cc5d36-d608-4425-bbd1-27a21ba8fd1a"], "metadata": {"window": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products.  We did have some \nsafety stock and so we blew through a lot of that,  which drove some extra incremental.  It's wor th \ntalking about.  I wouldn't say it's a lot of our other higher margin.  ", "original_text": " \nPage 28 of 31 \n \nsignificantly increased demand, as  I've said, 2 to 12 times on some products. ", "page_label": "28", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5d3a8ad7-c00d-4068-bd98-bea4e40ec2f5": {"node_ids": ["010fa9eb-7118-4a3f-82b4-27d590fdceed", "ee9e730d-4746-4d4e-a16f-e4a0c0309ad9", "7203d72e-921c-47b4-8b2d-82f34e883283", "f3230326-7cd8-49e6-9149-8ce9e41a7fb2", "03c6c29b-67b2-4337-bef0-971fe2927a63", "66a1c82f-fee8-4131-a34f-70871c26a516", "0fbea452-7b67-4d2b-a228-ad41616f04ec", "6d2f34f2-08a6-411c-9d11-fe5680083ce9", "bc6ce35a-9813-4b8d-98ab-89cefd110c6b", "6237c741-5cab-440c-bc1d-3f5148c33ff7", "02386e1c-7b9c-4921-a712-5ee247c7645b", "f35fe5d6-a392-4ebf-a3d6-fdda26b10513", "91fcbb18-6a00-42c0-b620-0a6a344f4a7f", "6ca9bdee-0ad5-468e-8543-a27bd2cc95fe", "7ae60b8f-804b-4432-87d9-d3fdebaaa5e0", "65ce5407-d5ba-4978-8ade-7bf9d3cab911", "663bf507-9390-48bd-ab47-e3cf43643005", "3586da76-53a8-4278-8e5d-b17ec42e994f"], "metadata": {"window": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah.  That margin profile gets a little complicated because there was a significant uptick in the surge \nin products.   I would say this: There's nothing going on that's unusual in there.  You probably just have \nsome  mix of certain generics,  certain branded products that were higher and some lower because \nthere were some  shortages, some mix within generics. ", "original_text": " \nPage 29 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "29", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3d1064ee-30db-4c5e-953e-ac4a7b131106": {"node_ids": ["986a80c6-5db8-44b9-9145-47404a9df481", "e5d7eb8c-b5ce-4f3c-a811-7b71a6e8f28b", "70147e78-86ca-4295-973b-98c20ae89dd5", "45cd1e2e-63f1-4346-b4bc-adb2fc4538cf", "f7bb6762-d654-4eb5-be8a-b8b199b60614", "98863776-feb1-4d26-bbdf-ce833af2853b", "07ae171c-75e6-4eaa-972f-413d3a0122a2", "3d826be8-ebdb-4250-82c3-ff42c866f89b", "0d962ba6-231a-4516-b4fc-7c4f2f65c32d", "29ac19c6-72fc-4ddc-966a-d41c10233da8", "a990f897-5d19-4dbd-a4d1-c98f54edf15f", "b2319a48-9425-45fb-a879-a632a58625ad", "bf20797f-66cd-405c-8b2d-aa4b662a165e", "b7fccdcb-963e-403b-ad6b-d3946f03d00c", "56a89531-3e5b-446b-a788-55a51ab6dd2b", "820fae66-3fb5-45b6-b062-d93bffca2558", "d43f5c9c-4237-4f56-a98b-c41ac0139eda", "6c051a89-c021-4c46-ae11-9415e3465488", "5bf81211-ff71-4a4e-b94d-0c9c574b12f8"], "metadata": {"window": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah.  Thanks for the question.  A couple of things: First and forem ost, we are absolutely committed to \nkeeping  cost as low as possible for our customers and doing everything we can to help to be part of \nreducing the overall  cost of healthcare in this country.  So we're always looking at our sourcing \nstrategies and our own expense  structures in order to get after those types of things, so we can \naggressively help our customers lower their cost,  either by how much they  buy \u2013 the price of the \nproduct, how they utilize it and all those types of things.  ", "original_text": " \nPage 30 of 31 \n \nMichael C. Kaufmann:  \nYeah. ", "page_label": "30", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "eeaf206e-018c-4d02-8891-33ac0bee35e1": {"node_ids": ["40f15b5f-2a47-49d2-b596-8822764a58a0", "c0114d4a-bfd5-4966-954d-c84140a6ddc8", "f80a6b50-eb39-4b9d-90e4-8e683336acc6", "c6e7052b-5faf-498d-b658-a8fc1ae69a7d", "3bf673d3-136a-444c-995b-833769147e25", "5f284577-e492-4002-9da3-52af726590a0", "8475d5f3-8d1b-45a0-8d8d-a4453e412a5c"], "metadata": {"window": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah.  I just wa nt to thank everyone for joining us this morning.  On behalf of the entire Cardinal Health \nfamily, we  hope you and your families stay safe and well, and we look forward to speaking to you \nagain sometime soon.  \n Take care, everybody.  \n  \n", "original_text": " \nPage 31 of 31 \n \n  \nMichael C. Kaufmann:  \nYeah. ", "page_label": "31", "file_name": "CAH-Q3-FY20-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 206151, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}